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Abstract
This thesis examines the use quality adjusted life years (QALY’S) in the 
allocation of health care resources. It is divided into three broad sections. The 
first section discusses how health status measurement techniques can be used 
to derive the utility values incorporated into QALY'S. The second section 
uses one health status measurement instrument, the Rosser-Kind 
Classification of Illness States, to estimate the QALY'S gained by patients who 
have undergone hip and knee joint replacement surgery. It is shown that the 
Rosser-Kind Classification of Illness States is as effective in measuring the 
health-related quality of life of these patients as more detailed questionnaires. 
In addition, it is found that further research is required before any 
generalisations concerning the acceptability of retrospective data can be made. 
A third important result is that there are significant improvements in health- 
related quality of life following both types of surgery, with the highest Rosser- 
Kind rating scores achieved after the first year following knee replacement 
surgery and after the second year following hip replacement surgery. The 
third section of the thesis performs an extensive sensitivity analysis on the 
widely-quoted cost utility estimates for seven medical procedures, calculated 
by Gudex (1986). The estimates are shown to be sensitive to Gudex's 
conversion of health outcome data into the Rosser-Kind Classification, her 
assumptions concerning the survival period I life expectancy following each 
of the medical procedures and the selected discount rate. A more in depth 
analysis is then performed on the cost utility estimate for one of the seven 
procedures, ceftazidime treatment of cystic fibrosis. It is demonstrated that the 
health outcome and cost assumptions underlying the cost utility estimate for 
this procedure are not supported by the medical literature. Finally, the thesis 
raises a number of issues for discussion.
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1CHAPTER 1
INTRODUCTION
CHAPTER 1 2
Health economics is a relatively modern science. Mooney (1986) defined it 
as the discipline of economics applied to the topic of health. Since the ethical 
bases of these two subjects are distinct, one may argue that they are 
incompatible. However, with scarce resources available to meet the infinite 
demand for health care, the importance of a subject which attempts to tackle 
resource allocation problems within the health sector is in little doubt. 
Indeed, the importance of health economics is likely to increase in the future 
as a result of the changing demographic structures of Western populations 
and the high levels of modem medical technology costs in the world market.1
Within health economics, the forms of analysis which have been applied 
to health programmes tend to fall into five categories [Drummond et al. 
(1987)]. Cost analysis is the simplest of these techniques. It only deals with the 
costs of programmes and ignores their consequences. The costs incorporated 
into such analyses include direct costs, which cover labour costs, drug costs 
and other health care costs and indirect costs which cover the costs of lost 
production. A third category of costs, intangible costs, or the monetary value 
placed on the pain and suffering resulting from an illness, is usually ignored 
because of the difficulties involved in its calculation.* 2 Cost minimization 
analysis compares the costs of two or more programmes whose consequences 
are shown to be identical. Cost effectiveness analysis compares the costs of a 
programme to its consequences, which are measured in natural or physical 
units, such as life years saved or hospital days saved. Cost benefit analysis 
compares the costs of a programme to its consequences which are valued in 
monetary terms. As in the case of costs, the economic consequences of a 
programme fall into three groups: direct benefits, which are the savings to the 
health sector because the health programme avoids a lower consequential use 
of resources; indirect benefits, which represent the production gains to society
Financial Times, Friday January 24,1986.
A detailed discussion of the cost components of health programmes is presented in Chapter 6.
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as a result of people returning to work; and intangible benefits, which 
represent the monetary benefits resulting from a reduction in pain and 
suffering. The latter category is usually ignored by studies because of its 
complexity. Cost utility analysis is a form of cost effectiveness analysis which 
measures the consequences of programmes in terms of utility-weighted time 
units.
The form of analysis selected by health economists depends on the 
information available to them and the viewpoint of the study. If no 
information on the consequences of a health programme is available, then 
only a cost analysis can be performed. If the benefits of a programme are 
expressed in physical units, then either a cost minimization analysis or a cost 
effectiveness analysis can be performed. More often than not, the former 
form of analysis is restricted to comparisons within specialized clinical fields. 
The latter can be applied in any clinical field, but is not very helpful in 
assessing single programmes, or in comparing disparate alternatives whose 
consequences are measured in alternative physical units. Cost benefit and cost 
utility analyses are sophisticated techniques in that they allow all 
programmes to be compared using a common denominator. However in 
practice, cost benefit analysis is usually restricted to calculating a limited range 
of costs and benefits [Drummond et al. (1987)1. Cost utility analysis is the most 
exciting technique in health economics in that it allows all health 
programmes to be compared in terms of their costs and the health 
improvements they procure. These health improvements are usually 
measured in terms of a single weighted measure, quality adjusted life years or 
QALY's which combine the survival periods and health-related quality of life 
states accruing from medical programmes.
This thesis is concerned with the increasing use of quality adjusted life 
years in deciding how health care resources should be allocated within the 
cost utility framework. It endeavours to examine how the utility values
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incorporated into quality adjusted life years are derived using health status 
measurement techniques, how they could be used to estimate the relative cost 
effectiveness3 of medical procedures and how they have been used (in 
perhaps inadvertently a misleading manner).
Chapter 2 provides a detailed synopsis and exposition of the techniques 
which have been used to measure health status. Five broad approaches are 
outlined: the willingness to pay approach, decision analytic techniques, the 
use of existing utility values available in the medical literature, a range of 
measurement techniques (the rating scale technique, the standard gamble 
approach, the time trade-off approach, the equivalence method and ratio 
scaling) and the use of health status indices. Examples are provided to 
illustrate how these techniques are used in practice. Particular attention is 
focussed on one health status index, the Rosser-Kind Classification of Illness 
States [Rosser and Kind (1978), Kind et al. (1982)], primarily due to its 
prominence in the field of Health Economics and its relevance to this thesis. 
The latter part of Chapter 2 explains how cardinal4 utility values have been 
derived from these health status measurement techniques, and how these 
utility values have been used as a method of assessing preferences for 
alternative health states within the quality adjusted life year unit.
In Chapter 3, the Rosser-Kind Classification of Illness is tested as a health 
status index on a selected group of patients. It is used to estimate the 
preoperative and postoperative health-related quality of life of patients who 
had undergone hip and knee joint replacement surgery. This chapter has four 
main aims. First, to compare the use of the Rosser-Kind Classification of 
Illness States with detailed questionnaires as tools of measurement in health- 
related quality of life estimates. Second, to test for the reliability of using
3 In this context, the term cost effectiveness is used as an adjective.
4 Cardinal scales are sets of numbers which allow the strength of the preference for each 
number to be compared. They will be discussed in Chapter 2 and, in detail, in Chapter 7.
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retrospective data as opposed to prospective data when estimating the 
improvements in health-related quality of life in patients who had 
undergone hip and knee joint replacement surgery. Third, to calculate the 
scale of change in health-related quality of life in these two groups of patients, 
with QALY’s used as the method of estimation. Fourth, to use the results to 
estimate the time period over which the maximum improvements in health- 
related quality of life are achieved.
Chapters 4 to 6 consider the use of QALY’s by Gudex (1986), as means of 
determining the efficient allocation of scarce health care resources, and 
illustrate how the approach may inadvertently be used to present misleading 
results. These chapters should be read in conjunction with each other. 
Chapter 4 performs an extensive sensitivity analysis5 of Gudex's cost utility 
calculations for seven medical procedures: continuous ambulatory peritoneal 
dialysis (CAPD), haemodialysis, treatment of cystic fibrosis with ceftazidime, 
kidney transplantation, shoulder joint replacement surgery, scoliosis surgery 
for idiopathic adolescents and scoliosis surgery for neuromuscular illness. 
Gudex's main arguments are outlined and the underlying assumptions of her 
study discussed. The chapter then performs a sensitivity analysis of Gudex's 
conversion of the health outcome data (she had obtained from the medical 
literature for each of the seven procedures), into the Rosser-Kind 
Classification. In addition, sensitivity analyses are also performed on her 
assumptions concerning the survival period / life expectancy following each 
of the seven medical procedures and the chosen discount rate6.
Chapter 5 conducts a more in depth analysis of Gudex's cost utility estimate 
for one of the seven medical procedures, cystic fibrosis treatment with 
ceftazidime. After a detailed sensitivity analysis of Gudex's assumptions
5 A sensitivity analysis varies parameters over plausible ranges to determine the robustness of 
one's results.
6 The discount rate reduces future costs and benefits to present values. This concept will be 
discussed in more detail in Chapter 4.
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concerning the procedure, the chapter then proceeds to analyse the validity of 
these assumptions in relation to clinical evidence. In particular, the efficacy of 
antibiotic treatment of cystic fibrosis patients, as revealed by ten placebo 
controlled antibiotic trials, is used to test Gudex's assumptions with respect to 
patient distress, patient disability and survival.
Chapter 6 focuses on the cost assumptions in Gudex's study. A case study is 
presented of the costs of hospital acquired infection to illustrate the cost 
components that can be calculated in economic evaluations. The chapter then 
follows on from Chapter 5 by analysing Gudex's cost estimate for ceftazidime 
treatment of cystic fibrosis. Using the same placebo controlled antibiotic trials 
that were analysed in Chapter 5, the cost structures of the different modes of 
antibiotic treatment are revealed and compared to Gudex's result.
Finally, Chapter 7 presents a summary of the main results of the thesis and 
considers a number of topics for discussion. These fall into four main 
categories. First, the use of health status indices, disease-specific and generic, 
in economic evaluations. Second, the implications of discounting future costs 
and benefits to present values. Third, the use and abuse of the QALY concept 
for allocating health care resources and fourth, the problems that arise in the 
collection of original data. The thesis ends with a presentation of a number of 
suggestions which are felt would assist health care evaluators and decision 
makers.
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2.1 Introduction
Much of the literature in Health Economics has concentrated on 
measuring the costs and benefits of health care programmes. Until recently, 
little attention was paid to measuring health status itself, even though it is a 
major problem in health care evaluations. This chapter will review and 
critically appraise the five broad approaches to the quantitative valuation of 
health improvement which have emerged. They are the willingness to pay 
approach, decision analytic techniques, the use of existing values of health 
status available in the medical literature, a range of measurement techniques 
and the use of health status indices. Particular emphasis shall be placed on 
one health status index, the Rosser-Kind Classification of Illness States. 
Throughout the chapter, it shall be assumed that associated problems, such as 
the selection of the appropriate subjects to make the valuations and the 
comprehensiveness of the descriptions of each health state, have been 
overcome. An annotated bibliography of all the studies referred to in this 
chapter is presented in Appendix 1.
2.2 Willingness to Pay Approach
The first approach to measuring the value of improvements in health 
status can be described as the willingness to pay or willingness to receive 
approach. In this approach, the benefits of a health care programme are 
estimated on the basis of the total amount individuals are willing to pay for 
the health improvement itself. Likewise, compensation for a diminution in 
health status can also be estimated by use of, for example, the calculation of 
pay premiums received by workers in dangerous occupations. One advantage
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of this approach is that people are familiar with answering willingness to pay 
questions for goods or benefits in everyday life.
Willingness to pay estimates can be obtained in a number of ways 
depending on the context. The alternatives include asking consumers 
themselves through the use of questionnaires, directly observing their 
behaviour in the marketplace, inferring from their behaviour and the use of 
models.
A noticeable feature of the health economics literature is the paucity of 
articles which apply the willingness to pay/receive approach. Acton (1973) 
provides the earliest example of the approach by examining the willingness to 
pay for a programme of mobile coronary care units that were designed to 
reduce the risk of death from a heart attack. The sample of 100 respondents 
was made up of citizens of the city of Boston, trade union leaders and upper- 
level city executives. They were asked how much they were willing to pay for 
the programme if it reduced their probability of dying from a heart attack by 
two thousandths (0.002). The average response was $119 (1973 prices), 
implying an average value of life in this sample of $59,000.
A further example of willingness to pay methodology applied to a clinical 
study is that of Thompson et al. (1984). In this study, 184 patients with 
osteoarthritis and rheumatoid arthritis were asked their willingness to pay for 
a hypothetical complete cure of chronic arthritis. Subjects were chosen by 
stratified random sampling from a rheumatology clinic. They were asked 
how much they were willing to pay for the complete cure in terms of US 
dollars each week, as well as a percentage of their family's total weekly 
income. The interviews lasted for an average of 50 minutes. With minimal 
pressure and possibilities for revision of earlier answers, the response rate 
was only 27 percent. The average willingness to pay amongst this group was 
17 percent of family income.
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The paucity of the willingness to pay/receive literature is largely due to the 
practical difficulties involved in measuring willingness to pay. According to 
Thompson et al. (1984), "noncomprehension by subjects, misrepresentation of 
preferences, extraneous determinants of answers, and ethical concerns" (page 
195) deter the use of the approach. Klarman (1982) argues that there are two 
main difficulties with ascertaining willingness to pay estimates in the health 
field. One difficulty is the general free-rider problem "of respondents 
dissembling their true preferences for a public good that is desired by many 
individuals, in the hope that others would pay for it" (page 589). A second 
difficulty is that individuals may not accurately perceive and assess risks and 
benefits. In their survey of 77 senior year undergraduate students, Muller and 
Reutzel (1984) questioned the assumptions "that people employ rational 
considerations when responding to willingness to pay questions and that they 
are capable of matching their responses with the functional relationship 
(proportionality) underlying implied value of life calculations" (page 808). 
One ethical concern is that since willingness to pay estimates are constrained 
by individuals' ability to pay, the wealthy might be given an unproportional 
influence in determining which programmes were carried out. Likewise, the 
underlying values of individuals capable of responding rationally to 
willingness to pay questions might be given an unproportional influence.
2.3 Decision Analysis
A second approach to measuring health status is decision analysis. 
Decision-analytic techniques have been increasingly used in the medical field 
to measure health status. They provide a coherent framework for aiding 
decisions under conditions of uncertainty by replacing complex decisions 
with a series of simpler decisions and by using the maximization of expected
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utility as the criterion for selection. The method deals with difficult problems 
by dividing them into components and structuring these components into 
logical decision trees. Decision makers then attempt to solve them by 
providing values and probabilities to the more manageable components.
Elstein et al. (1986) provide an eloquent summary of the technique: 
"Decision analysis is a formal analytic framework that is increasingly being 
applied to the problem of selecting an action in clinical situations in which 
the optimal choice is not intuitively clear or the judgments of competent 
physicians differ. These situations often involve complex combinations of 
uncertainty, values, risks, and benefits, precisely where human judgment 
may encounter difficulty in reaching an * optimal solution and where a 
decision aid may be useful. The techniques and principles of clinical decision 
analysis constitute a family of tools for the logical analysis of such complex 
clinical situations. Selecting a management plan is accomplished by a detailed 
analysis of the available alternatives and their potential consequences, the 
criterion for selection being the maximization of expected utility, a 
quantitative measure of preference. Clinical decision analysis has been 
applied to a variety of medical problems to determine how to treat or work­
up a specific patient, to analyze management alternatives for certain 
problems, and to assess the value of diagnostic tests" (page 246).
As is clear in the above quote, the use of decision analysis as a tool in 
valuing the health status of individuals with different clinical conditions has 
usually formed only a component of general option appraisal of alternative 
medical procedures. An early example of the application of decision analysis 
to a clinical study was its use by Pauker (1976) as an aid in the management of 
individual patients with chronic ischemic heart disease. Specifically, the 
approach was used to evaluate the choice between coronary artery bypass 
surgery and medical therapy. The study considered a set of 48 prototypical 
analyses. This set was composed of 12 clinical cohorts which were in turn
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subdivided into 4 groups of patient preferences. The model of prognosis 
encompassed many published data about both forms of medical treatment. 
The authors estimated a preference for coronary surgery amongst many 
patients with disabling angina, but it was not found to be the preferred 
therapy in asymptomatic patients. Final decisions were strongly affected by 
patient preferences.
The decision analytic model constructed by Pauker and Pauker (1977) 
allowed prospective parents to make hypothetical decisions concerning mid­
trimester amniocentesis for prenatal diagnosis. The technique was applied to 
the prenatal diagnosis of Down's syndrome, meningomyelocele and 
Duchenne muscular dystrophy. Parents were asked to consider their relative 
preferences for five possible outcomes: an unaffected child, an affected child, 
spontaneous abortion, therapeutic abortion of an unaffected fetus and 
therapeutic abortion of an affected fetus. The parents decisions were aided by 
medical consultation on the likelihood of the birth of a child affected by a 
genetic disorder, the risk of amniocentesis and the probability that the 
diagnoses provided by the amniocentesis will be correct.
Stason and Weinstein (1977) used a decision analysis model to determine 
the efficient use of resources within programmes to treat hypertension. The 
alternative forms of treatment considered were the screening and treatment 
for hypertension versus no organised screening programme. The 
information given concerning the assumed effectiveness of each mode of 
treatment was the number of physician visits, investigations, length of 
hypertension treatment, and the mortality and morbidity benefits. 
Effectiveness was calculated in terms of increased life expectancy, with a 
quality adjustment incorporated in order to reflect treatment side-effects. A 
year of life with side-effects was assumed to be equivalent to 0.99 of a healthy 
year, with this assumption varied in a sensitivity analysis. The authors also 
made three assumptions concerning the reduction of risk of high blood
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pressure. When assumptions concerning the costs of each programme were 
incorporated, the study concluded that improving patient adherence was the 
more cost effective procedure.
The study by Weinstein et al. (1977) used decision analysis methodology to 
develop a structural framework that assists decision makers in deciding 
whether or not to offer coronary artery bypass surgery to patients. The 
framework allows decision makers to incorporate their own subjective 
assessments as well as hard data in reaching their decisions. The authors used 
the information available in the medical literature as well as their own 
subjective judgments to illustrate the probability assessments offerred by the 
model for five hypothetical patients. They argued that the patients typified 
the spectrum of cases that might be presented as surgical candidates. 
Sensitivity analyses were performed on their probability assessments with the 
result that surgical mortality was the parameter with the single most 
important effect. Though the model is limited by the use of subjective data, it 
does illustrate the technique of decision analysis for evaluating clinical 
procedures.
Pliskin et al. (1980) made several assumptions to develop alternative forms 
of bivariate utility functions of life years and health status. The derived utility 
functions were then used in deciding whether or not to apply coronary artery 
bypass graft surgery in patients with coronary artery disease, with the result 
that patient attitudes towards risks on longevity influenced the choice of 
treatment.
The study by Weinstein (1980) incorporated hypothetical subjective 
evaluations of the effects of estrogen use on the health-related quality of life 
of postmenopausal women. Postmenopausal women were defined as women 
aged over fifty years and mostly in whom the uterus was in situ and for 
whom the risk of endometrical cancer thus existed. Based on evidence in the 
medical literature, the author assumed that symptomatic improvement was
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equivalent to 0.01 of a healthy year. The benefits of treatment were shown to 
depend on whether the women had prior hysterectomies or osteoporosis, and 
on the subjective values assigned to symptomatic relief.
Expanding on their study of a year earlier, Pliskin et al. (1981) applied 
decision-analytic techniques to assist them in choosing between an 
autocoronary bypass operation and medical management in fourteen 
hypothetical patients with varying degrees of coronary artery disease. The 
factors incorporated into the decision framework included the physical and 
psychological characteristics of each patient, the availability of operative 
treatment and its quality, and the relative benefits and risks of the alternative 
forms of treatment. The probability estimates for each of the factors 
incorporated into the framework were obtained from two cardiologists and 
one cardiac surgeon, though the study does not reveal what those estimates 
were. Patient preferences were incorporated by assigning utility values to 
alternative trade-offs between life expectancy and health-related quality of life. 
The framework favoured operation for 13 of the 14 hypothetical patients, but 
there were discrepancies between the clinical judgments of the physicians and 
the derived estimates using the decision-analytic techniques. This is 
explained by the absence of angina in selected patients.
Decision analytic techniques were used by Torrance and Zipursky (1984) to 
estimate the effectiveness of antepartum prophylaxis of rhesus (Rh.) 
immunization in the province of Ontario, Canada. By not making quality 
adjustments for the life years gained by a sample of 1,000 pregnant women, 
the authors estimated that a comprehensive antepartum prophylaxis 
programme would be cost effective in comparison with other health care 
expenditures.
Decision analysis methodology was also used by Williams (1985) to 
determine the future level of operations for coronary artery bypass grafting. 
By using the subjective valuations of three cardiologists concerning the
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severity of angina and type of disease in a group of hypothetical patients who 
had or had not undergone surgery, Williams was able to determine the 
relative cost effectiveness of coronary artery bypass graft surgery compared to 
heart transplantation, the treatment of endstage renal failure and hip 
replacement surgery.
Another example of the application of decision analysis in the medical 
literature is a well presented, hypothetical scenario in the study by Weinstein 
(1986). This study uses decision flow diagrams to illustrate the choices 
involved in the alternative treatments for chronic progressive liver failure. 
However, as the author himself indicates, a number of assumptions are 
incorporated into the scenario which may not be appropriate. For example, 
the scenario has been formulated in such a way as to avoid the application of 
value judgments to the alternative outcomes. The issue of resource 
constraints is avoided. Moreover, it is not clear how the probabilities of the 
success or failure of the alternative forms of treatment were obtained. Any 
such probabilities must themselves incorporate the subjective judgments of 
experts.
The advantages of the decision analysis approach are that it is fast and 
relatively inexpensive. Physicians (or other health care evaluators) can use 
their expert knowledge to construct a decision framework which provides 
values for alternative health states. However, one’s results should be 
thoroughly scrutinized by the use of sensitivity analysis. In any health care 
evaluation, the robustness of the final decision should be tested over a range 
of plausible values and probabilities. If large variations in these values or 
probabilities for alternative health states do not significantly alter the results 
of the health care evaluation, then confidence in the results is increased. 
Elstein et al. (1986) question the applicability of the decision analysis approach 
in complex, multivariate environments. They argue that in situations with 
multiple objectives in which it is unclear how to take all of them into
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account, actual decision behaviour will often follow the course of action 
implied by the most important objective because such choices are more easily 
justified. They also argue that decision analysis may not be an adequate 
descriptive theory where issues of responsibility and regret are concerned. 
Weinstein (1986) doubted the widespread acceptance of decision analysis 
methodology by medical practitioners and health care administrators. Possible 
reasons for this are argued to be the limited quality of information about the 
effects of clinical procedures in heterogenous populations, the incomplete 
understanding of the value and preferences of patients and potential users of 
health care, the imperfectly structured incentives for cost effective resource 
use in both the public and private health care systems and the frustrations 
often felt by clinicians at the task of assigning explicit values and probabilities, 
especially when the empirical data base is deficient.
2.4 Medical Literature
A third approach to measuring health status is the use of existing values 
available in the literature. This approach is relatively quick, straightforward 
and inexpensive though it is not as reliable as the utility measurement 
approach since it is difficult to ensure that the health states, subjects and 
measurement instruments used match those of one's own study. A number 
of studies in the medical literature report utility values. The study by Kaplan 
et al. (1976) reports utility values for 36 different health states, ranging from 
no symptoms or problems to a loss of consciousness such as seizures, fainting 
or comas (out cold or knocked out). Sackett and Torrance (1978) present social 
utility values for 10 different health states: depression, home confinement for 
tuberculosis, home confinement for an unnamed contagious disease, hospital 
confinement for tuberculosis, hospital confinement for an unnamed
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contagious disease, hospital dialysis, home dialysis, kidney transplant, 
mastectomy for breast cancer and mastectomy for injury. By contrast, Pliskin 
et al. (1980) presented utility values for varying degrees of angina. A further 
example of a study which presented utility values for a specific illness is that 
of McNeil et al. (1981) who reported utility values for loss of speech due to 
laryngeal cancer. Torrance et al. (1982) presented utility values for different 
combinations of physical activity, role activity, social activity and health 
problems. A more recent example of the presentation of utility values in the 
medical literature is the study by Read et al. (1984) who presented utility 
values for no angina, moderate angina and severe angina.
2..5 Measurement Techniques
The fourth approach to measuring health status is through measurement 
techniques themselves. As Torrance (1986) points out, "this involves the 
identification of health states for which utilities are required, the preparation 
of health state descriptions, the selection of subjects, and the use of a utility 
measurement instrument" (page 11). The most frequently used methods of 
measuring health status have been rating scales, the standard gamble 
approach and the time trade-off approach. Two additional techniques, 
equivalence and ratio scaling, have been used less regularly. These methods 
are described below.
(a) Rating Scale Technique
The rating scale technique is a relatively straightforward method of 
measuring health status. Typically, individuals are offered several case- 
descriptions covering a wide range of health states and are asked to assign
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values to them on a line whose endpoints have already been defined. The 
ratings correspond to the individual's preference values for the alternative 
health states.
Individuals rate the alternative health states such that the interspaces 
between them correspond to their perceived differences in preferences. The 
scale is standardized between 0 and 1 where zero usually represents 'death' 
and unity 'perfect health'. However, some health states have been rated as 
even worse than death [Boyle et al. (1983)]. In this case, death is located on the 
scale between the two endpoints. Preferences for temporary health states can 
also be rated using the same principle. Torrance et al. (1982) have developed 
sophisticated props, such as 'health thermometers', to aid respondents to 
assign values.
Drummond et al. (1987) describe how an individual might use the 
technique to rate a group of health states: "The subject is asked to select the 
best health state of the batch, which presumably would be 'normal healthy 
life' and the worst state, which may or may not be 'death at age of onset'. He 
is then asked to locate the other states on the rating scale relative to each 
other such that the distances between the locations are proportional to his 
preference differences. The rating scale is measured between 0 at one end and 
1 at the other end. If death is judged to be the worst state and placed at the 0 
end of the rating scale, the preference value for each of the other states is 
simply the scale value of its placement. If death is not judged to be the worst 
state but is placed at some intermediate point on the scale, say d, the 
preference values for the other states are given by the formula (x-d)/(l- 
d), where x is the scale placement of the health state" (page 125).
A related procedure to the rating scale technique is category scaling in 
which subjects assign health states to alternative categories rather than to 
points on a line. The same principle applies in terms of the scale value of the 
location of each category. Kaplan et al. (1979) describe this technique as
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efficient, easy to use, and applicable in a large number of laboratory and 
survey settings.
Bush et al. (1973) report the use of the rating scale technique by 11 
nationally recognised phenylketonuria (PKU) authorities for 15 function 
levels of mental retardation. Each consultant used their expert knowledge to 
assign weights to the function levels on a scale which ranged from 0 for death 
to 1 for well. Group consultation allowed the consultants to make revised 
estimates, after which the means were used as the group judgment. A similar 
procedure was also carried out by a group of graduate students in nursing and 
health administration using the category scaling technique.
The development of the Index of Well-being by Kaplan et al. (1976) will be 
discussed on page 32. This study applied the rating scale technique on a 
sample of 867 citizens of San Diego to measure the utility values for 36 
different health states, so as to determine the validity and reliability of their 
classifications into the 43 function levels. Each of the 867 subjects were 
interviewed, as were 370 children and 89 dysfunctional persons later 
identified.
(b) Standard Gamble Approach
The standard gamble approach to measuring health status is derived from 
the axioms of utility theory first conceived by Von Neumann and 
Morgenstern (1947) and later developed by Keeney and Raiffa (1976). It 
basically requires individuals to choose between hypothetical lotteries as a 
means of measuring their utility for specific health states.
The hypothetical lotteries that subjects are asked to consider involve a 
choice between two alternatives; the certain outcome of surviving for a fixed 
period and a chance or gamble with two possible outcomes (death or survival 
for a longer period). The probability of successfully surviving for the longer
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period is varied until the subject is indifferent between the two alternatives at 
which point his utility for the health state can be calculated. Slightly different 
approaches are used to assess states worse than death and temporary health 
states. Because untrained people experience difficulties in understanding 
gambles, the approach is often supplemented with visual aids such as 
'probability wheels'.
Torrance et al. (1972) explained the standard gamble approach as follows: 
"The subject is asked to choose between two alternatives: alternative 1, the 
certainty of good health for time t, then state n-1 for time t, followed by death; 
and alternative 2, the gamble of good health for time t, followed by use of a 
hypothetical drug with a probability p of keeping the subject completely 
asymptomatic for time t, followed by death, and a probability 1-p of causing 
immediate death. The probability p is varied to locate the point at which the 
respondent is indifferent between these two alternatives. At this indifference 
point the utilities of the two alternatives are equal and the utility of state n-1 
may be calculated as follows:
hit + hnqt = hit + hitp + hnt(l- p)
Since by definition hi = 1 and hn = 0, this simplifies to
hn-i = p
The apparently superfluous requirement that in each alternative the 
respondent begins by being healthy for time t is in fact necessary to ensure 
that all times the respondent is dealing with his future death and never with 
his immediate death. This precaution not only improves the reliability of the 
resultant utilities but is also consistent with their eventual use: the utilities 
are to be used in planning decisions concerning future health programs, 
consequently the trade-offs to be evaluated will all be in the future" (pages 
122-123).
As Pauker and McNeil (1981) inform us, if a subject is prepared to accept a 
certain survival time which is less than the average return expected on the
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gamble, he is described as 'risk averse'; if he is prepared to accept a certain 
survival time which is equal to the average return, he is described as 'risk 
neutral'; if he is prepared to accept a certain survival time which is greater 
than the average return, he is described as 'risk seeking'.
An early example of the standard gamble approach in the medical 
literature is its application by McNeil et al. (1978) to 14 patients with operable 
lung cancer. The primary treatment of 6 of these patients had included a 
recent operation, whilst the other 8 patients had received radiation therapy 
only. The standard gamble approach was used to elicit their attitudes towards 
survival for varying periods. This involved offering patients 50:50 choices 
between fixed periods of certain survival and gambles on longer periods of 
survival. It was found that patients were quite risk averse towards the 
probability of immediate death. The data on patient attitudes were then 
combined with survival data for the two types of treatment to obtain a 
relative measure of efficacy, called expected utility. The final results suggested 
a patient preference for radiotherapy with patient age, operative mortality and 
the quality of surgical results all having major effects on the choice of therapy.
Eraker and Sox (1981) used the standard gamble approach to characterize 
patient preferences to drug therapy. The study questioned 523 subjects, all of 
whom were patients at a variety of California clinics, about their attitudes to 
three pairs of therapeutic outcomes. Each scenario offerred patients the choice 
between two drugs with equivalent effects. One drug offerred a certain 
outcome, whilst the other offerred two possible outcomes. The first was a 
large therapeutic effect, and the second was no therapeutic effect at all. Most 
patients tended to be risk averse when a positive therapeutic effect was on 
offer, that is they tended to opt for the certain and intermediate outcome. 
However, when the drug effects were adverse, patients exhibited risk seeking 
behaviour and were willing to take more of a risk in order to have a chance at
experiencing the most positive outcome on offer.
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Breyer and Fuchs (1982) also used the standard gamble approach to 
investigate the risk behaviour of individuals in the health dimension. A 
sample of 325 individuals were questioned about their attitudes to 12 
hypothetical scenarios. In each scenario, the individuals were offerred choices 
between 2 alternative forms of treatment for a supposed illness. One 
treatment offerred a fixed health effect. The other treatment offerred two 
possible outcomes (a more favourable and a less favourable health effect). As 
in the study by Eraker and Sox (1981), the authors found that individuals 
exhibit risk averse behaviour towards positive health outcomes and risk 
seeking behaviour towards negative health outcomes.
Elstein et al. (1986) used the standard gamble, rating scale and category 
scaling approaches in their comparison of physicians' decisions regarding 
estrogen replacement therapy for menopausal women and derived decisions 
from a decision analytic model. Fifty physicians used the rating scale approach 
to indicate the utility values they would place on 12 cases representing 
menopausal women. Their decisions were then compared with a decision 
analytic model that included 5 possible treatment regimens and 3 possible 
treatment outcomes. The subjective probabilities required for the model were 
elicited using the category scaling and standard gamble approaches. The 
results of the study indicated differences between the two types of decisions.
(c) Time Trade-Off Approach
The time trade-off approach was developed by Torrance, Thomas and 
Sackett (1972) to measure health state utilities. Like the standard gamble 
approach, it attempts to elicit subjects' preference values for alternative 
health states in an implicit manner.
The core of the technique involves asking subjects to consider the relative 
amounts of time they would be willing to trade in order to survive in various
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health states. The choice may lie between continuing in a present defined 
state of ill health or moving to a shorter but healthier life. The duration of 
the shorter but healthier state is varied until the subject is indifferent between 
the two alternatives, at which point his utility for the health state can be 
calculated.
Torrance et al. (1972) described the technique as follows: "Here the 
respondent is asked to choose between two alternatives of certainty: 
alternative 1, state n-1 for time t, followed by death; and alternative 2> good 
health for time x less than t, followed by death. The respondent's indifference 
point is located by varying the time x. The average utility for state n-1 over 
time period t, hn-i, is again determined by equating the utilities of the two 
alternatives:
hn_!t = hjx + hn(t-x) 
hn_i - x/t"
(Page 124)
Torrance et al. (1972) also explain the application of this method to any 
state i other than state n-1. "The two certainty alternatives are alternative 1, 
state i for time t, followed by good health; and alternative 2, state i + 1 for time 
x less than t, followed by good health. The required utility is calculated from 
hi= 1 - x/t(l - hi+i)" (page 124).
Slightly different approaches can be used to assess chronic health states 
preferred to death, chronic health states considered worse than death, and 
temporary health states. In addition, props such as laminated boards aid the 
technique.
The time trade-off approach has been incorporated into a number of 
studies. The model developed by Pliskin et al. (1980) was described on page 13. 
Decision-analytic techniques were used to develop alternative forms of 
bivariate utility functions. An empirical assessment of these utility functions 
used the time trade-off and standard gamble approaches to decide whether or
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not to prescribe coronary artery bypass graft surgery in patients with coronary 
artery disease. There were ten subjects whose utility values formed the basis 
of the study results, nine of whom were academics and one of whom was a 
guest. The subjects were asked seven questions in total. The first six questions 
asked subjects the minimum number of years they were willing to trade in 
return for relief from anginal pain. The final question offerred patients a 
lottery by asking them how many additional years of life for certain they 
would value equivalent to a 50:50 chance of living for either 5 or 15 years. 
Five of the subjects exhibited risk neutrality, three exhibited risk proneness 
and two risk aversion, implying real differences in the utility values of the 
respondents. •
Another example of a study which used both the time trade-off and 
standard gamble approaches to measure utility values is that of McNeil et al. 
(1981). As in the earlier study by the authors [McNeil et al. (1978), page 21], the 
expected utility of a sample of subjects was measured to assist in the choice 
between two alternative treatments. The sample was made up of 37 healthy 
volunteers, 25 of whom were middle and upper management executives and 
12 of whom were firemen. The treatment choice was between surgery and 
radiation therapy for laryngeal cancer. To obtain individual preferences for 
the two types of treatment, the subjects were asked a series of questions using 
the standard gamble and time trade off techniques. First they were asked to 
consider their response to a hypothetical choice between an intermediate 
period of certain survival and an equal chance of a much longer period of 
survival and death in a few months. They were then asked a series of 
questions concerning the proportion of certain survival they were willing to 
trade in order to retain their normal speech. When the results on patient 
utilities were combined with data on the results of various treatment 
strategies, the authors obtained a much clearer picture of the relative values 
for the alternative treatments. This study indicated that to maintain their
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voices, approximately 20 percent of volunteers would choose radiation 
therapy instead of surgery even though radiation therapy was associated with 
a lower survival rate.
The multi-attribute model was tested by Torrance et al. (1982) on 112 
parents of school children. In interviews the subjects were asked to value the 
seven different combinations of the 4 attributes between 0 and 1, where 0 
represented death and 1 healthy. They were asked to imagine that they would 
survive in such hypothetical health states for a lifetime. With the aid of 
printed cards and reference levels, the subjects used the time trade off and 
category scaling methods to provide utility values for each of the seven 
health states. Some of the chronic dysfunctional states were rated as worse 
than death. As a result, the range of utility values extended from 1 to -0.39.
Weinstein and Stason (1982) used the time trade off approach in their cost 
effectiveness analysis of coronary artery bypass surgery. Without measuring 
the utilities on a sample of patients, the authors used the information 
available in the medical literature to assume that patients with severe angina 
are willing to trade 1 year of discomfort with 0.7 of a pain-free year. However, 
the cost effectiveness of surgery was shown to be sensitive to the varying of 
this proportion between 0.5 and 1.0.
Buxton et al. (1986) illustrated that the time trade-off approach is practicable 
by testing the method on a group of 114 subjects. In interviews which lasted 
for an average of 20-25 minutes, the subjects were asked to place five 
alternative descriptions of a woman with breast cancer and a description of a 
woman in full health in rank order from the best to the worst situation. 
Then, with the help of visual aid, they were asked how many years of each of 
the five 'post-cancer' health states they were willing to trade in order to 
survive in the full health situation. There was a considerable degree of 
consistency in the rank order of the health states between the subjects.
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However, the results section of the study does not state the average number 
of years subjects were willing to trade.
(d) Other Measurement Techniques
Two additional techniques, equivalence and ratio scaling, have also 
occasionally been used to measure health state utilities. According to the 
equivalence technique, preference values for alternative health states are 
measured by asking subjects to relate groups of people in alternative health 
states. For example, subjects are asked how many sick people in one health 
state are equivalent in total health status to a given number of perfectly 
healthy people. In this way, all health states can be related to each other in 
terms of utilities. Bush et al. (1973) used the equivalence technique in their 
cost effectiveness analysis of a phenylketonuria screening programme.
Ratio scaling, which is very similar to the equivalence method, provides a 
ratio comparison of health states. Here the subject is asked to provide a value 
that represents the ratio of the desirability of each health state to an arbitrarily 
chosen one. The reference state is assigned a random value from which the 
preference values of the other health states can be calculated. In this way the 
preference values for all the health states can be represented on a scale. Ratio 
scaling has only been used in one published study (Rosser and Kind, 1978).
(e) Comparability of Measurement Techniques
Since different measurement techniques may lead people to construct 
diverse preference values for the same health states, it is important to 
question which technique is superior.
The advantages of the rating scale and category scaling techniques are their 
efficiency, straightforwardness, wide applicability and the fact that they are
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quick and inexpensive to employ. However, as Read et al. (1984) inform us, 
there is a temptation for subjects to spread their responses evenly across 
categories. "Experimental evidence indicates that one factor affecting category 
scaling responses is a desire to use all categories of the scale equally often" 
(page 325).
Because the standard gamble approach is derived from the axioms of utility 
theory and introduces risk into the assessment task, it is often argued that it 
has advantages over other methods. Certainly, the introduction of risk into 
the measurement procedure permits a method of combining indices of 
components of the characteristics bundle of 'health' into an over-all index. 
This may prove advantageous in some applications. However, as Culyer 
(1978) points out "...a possible disadvantage is that the health status index is 
itself not merely a function of the characteristics on the axes but also of the 
judges' attitudes to risk...In descriptive studies, where the actual state of 
health is the focus rather than affecting some change in status, attitude to risk 
may distort the 'pure' trade-offs between dimensions of ill-health."
The standard gamble approach is relatively time-consuming and people 
often have difficulties understanding the concept of probabilities. Moreover, 
preference values can be strongly influenced by the way questions are framed 
[Read et al. (1984)].
Despite the fact that the time trade-off approach is reliable, practicable, 
simpler to understand and use than the standard gamble approach, and that it 
can be justified by the axioms of utility theory under certain conditions and 
can provide a relatively cost-effective way of measuring health state utilities, 
it does have some drawbacks. As Rosser and Kind (1978) inform us, the 
approach is based on the assumptions that the perception of time is linear and 
that the perception of the severity of illness is independent of the time spent 
in this state. "This clearly becomes untenable when dealing with states such
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as unconsciousness which are acceptable for short periods but unacceptable 
for very long ones" (page 348).
In addition, the trade-off concept is difficult for many people to 
understand. Does a subject who says that he would be willing to live a shorter 
but healthier life really mean that he would be willing to die earlier ? It may 
be that he hasn't fully considered the consequences of his answers. Moreover, 
Fein (1977) argues that it is unclear what implications the method has in 
questions of choice, when ethical questions are asked.
Studies reported in Torrance (1986) and Read et al. (1984) found the 
reliability of all the measurement techniques to be satisfactory. In addition, 
the standard gamble approach was found to be valid by definition whilst the 
time trade-off technique was relatively valid according to the definition used 
and the rating scale method was not at all valid.
2.6 Health Status Indices
The fifth health status measurement approach involves the use of health 
status indices. These indices or scales are essentially weighting schemes which 
assign weights to each definable health status. The source of these weights is 
ultimately subjective, that is researchers themselves precisely predetermine 
what they consider to be adequate indicators of health status and the relative 
importance of each constituent component of disability and discomfort.
A number of health status indices have been developed based on the 
premise that health status is a complex, multidimensional phenomenon. The 
’Karnofsky Index of Performance Status' [Karnofsky et al. (1948)] is the earliest 
example of a widely-used health status index. Originally developed to classify 
the functional status of patients with cancer, the index interprets a patient's 
health-related quality of life in terms of physical ability. Three criteria were
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used to assess physical ability: patient's ability to work, patient's ability to 
pursue what the authors describe as 'normal activity' and patients' ability to 
care for themselves. The classification was divided into eleven categories 
which covered varying degrees of ability to pursue these activities, ranging 
from 0 representing dead, to 1, representing 'normal'.
A more generic health status index was developed by Grogono and 
Woodgate (1971) with the expressed aim of measuring health and allowing 
severity of disease, efficacy of treatment and costs to be compared. As in the 
example by Karnofsky et al. (1948), the index varied numerically between 0 
and 1. However, in this index, 0 represented 'extreme ill-health' and 1 
'normal'. Patients were assessed with respect to 10 activities which were 
thought of as comprehensive pattern of daily life. The activities were work, 
recreation, physical suffering, mental suffering, communication, sleep, 
dependency on others, feeding, excretion and sexual activity. Each activity 
received a score of either 1, 0.5 or 0, representing normal, impaired, or 
incapacitated respectively. No intermediate points of assessment were used. 
The total was then divided by 10 to yield a final score of between 0 and 1. By 
multiplying any period of time by this weighting factor, the authors argued, 
the benefits resulting from any medical treatment could be expressed in terms 
of 'health-years' gained. Initial observations with the index on 27 patients by 
20 observers (including consultants, registrars, housemen and students) 
produced scores which varied between 0.25 for a man with severe asthma and 
1.0 for a man awaiting admission for excision of a tongue papilloma. There 
was only a slight variation in the scores of the observers.
The 'Harris Index' was developed by Harris et al. (1971) to assess the effects 
of physical, mental and sensory handicap in the British population on the 
ability to obtain work, need for health and welfare support. It was based on 
the results from interviews with 12,738 subjects between October 1968 and 
February 1969. These subjects had been narrowed down from an earlier, much
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larger, sample of 250,000 households. Severity of handicap was classified into 
8 categories, three of which related to those who needed special care and the 
remaining five related to specified dimensions. The degree of severity of each 
function was categorised by the subjects themselves, the interviewers merely 
providing the descriptions.
The 'Ability Index' developed by Izsak and Medalie (1971) provides a wide- 
ranging and comprehensive follow-up assessment of carcinoma patients. The 
index is composed of 15 parameters. Seven parameters measured the 
subjective reactions and feelings of each patient: pain, prosthesis, sleep, 
frequency of visits to physician, everyday self-care ability, sexual relationships 
and the degree of ambulation. Three parameters measured the working 
ability and earning capacity of each patient: actual earnings relative to income 
prior to illness, whether the patient returned to previous work or changed 
occupation and attitude (satisfaction) to work. Five parameters measures the 
social adjustment of each patient: husband-wife relationships, parent-child 
relationships, relationships to other relatives, wider social relationships and 
feeling of well-being. Each of the 15 parameters received a score of either 0, 1, 
2 or 3 points, with 0 representing the worst possible scenario and 3 the best 
possible scenario. The overall scores therefore could vary between 0 and 45 
points. The emphasis is placed on the clinician to perform the scoring.
Breslow (1972) made a brave attempt to apply the World Health 
Organisation definition of health ( a state of physical, mental and social well­
being, not merely the absence of disease or infirmity) to health outcome 
measurement. After an initial survey involving 6,928 adults in Alameda 
County, California, three indices of physical, mental and social well-being 
were constructed. The measure of physical health was a seven-point 
spectrum. The categories in the spectrum ranged from 1, representing severe 
disability, to 7, representing a physical state without any complaints. An 
eight-item index measured health, based on five negative and three positive
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feelings. The measure of social health incorporated employability, marital 
satisfaction, sociability and community involvement. The three indices 
provided independent but complementary indicators of health status.
Patrick et al. (1973) constructed a comprehensive health status index 
incorporating 29 function levels. Using the method of category scaling (to be 
explained later), 31 registered nurses and 31 graduate students without a 
medical background assigned values to health state descriptions. The health 
state descriptions comprised various combinations of physical activity, 
mobility and social activity. The social activity scale comprised 5 components 
which ranged from an ability to perform major and other activities to a 
requirement of assistance with self-care activities. The mobility scale also 
comprised five components, which ranged from an ability to travel freely to a 
state of being restricted to a special unit. The physical activity scale comprised 
four components, ranging from an ability to walk freely to a state of being 
restricted to bed or chair for most or all of the day. The values for the health 
state descriptions were then transformed into a 0-1 scale. Zero represented 
death, whilst one represented optimum function. The study demonstrated 
differences between the two groups of judges and between function levels.
The 'Sickness Impact Profile' [Bergner et al. (1976)] was conceptualized as 
an instrument which would provide a descriptive profile of the responses of 
a given individual in terms of the specific behavioural impacts of sickness. 
After much sorting and grouping of potential items, the instrument was 
reduced to 312 items in 14 categories. The 14 categories were social interaction; 
ambulation or locomotion activity; sleep and rest activity; taking nutrition; 
usual daily work; household management; mobility and confinement; 
movement of the body; communication activity; leisure pastimes and 
recreation; intellectual functioning; interaction with family members; 
emotions, feelings, and sensations; and personal hygiene. Subjects were asked 
to respond only to the items which they felt described them on the day of
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evaluation, and were related to their health. The results of initial pilot studies 
were transformed into 11-point and 15-point scales, which ranged from 
minimally dysfunctional to severely dysfunctional, with high agreement 
amongst judges.
The 'Activities of Daily Living Index', developed by Katz and Akpom 
(1976) is a good example of a health status index created for a variety of 
diagnoses. It measures a patient's health-related quality of life in terms of six 
functions: bathing, dressing, feeding, continence, transfer and toileting. For 
each function, patients are categorised as either independent or dependent, 
independence defined as an ability to perform the function without 
supervision, direction, or active personal assistance. The index summarizes 
overall performance into grades A, B, C, D, E, F. G or 'Other' where A 
represents independence in feeding, continence, transferring, going to the 
toilet, dressing and bathing, and G represents dependence in all six functions. 
The category 'Other' represents dependence in at least two functions, but not 
classifiable as C, D, E or F. The authors argue that this category usually 
includes less than 5% of patients. The ability of each patient to perform each 
function without supervision is decided upon by an observer.
The 'Index of Well-being' was created by Kaplan et al. (1976) to fulfil the 
definition of content validity as it applies to health status measures. It is made 
up of two components, level of well-being and prognosis, the latter 
representing the probability of attaining a level of well-being by a certain time. 
The index classifies individuals into a continuum which ranges from 
optimum function (weighted 1.0) to death (weighted 0.0), using 43 function 
levels which are combinations of mobility, physical activity and social activity 
scales.
Sackett et al. (1977) developed a health status index "designed to measure 
the social, emotional, and physical function of free-living populations" (page 
423). The subjects whose health state valuations formed the basis of the index
CHAPTER 2 33
were family members in the general practice of one of the five investigators. 
There were 296 subjects in total, all aged 15 years or over. All subjects were 
interviewed in their homes for a mean duration time of 40 minutes. They 
responded to detailed questionnaires which contained 64 items related to 
social function, 41 items related to emotional function and 35 items related to 
physical function, as well as questions related to respiratory and joint 
symptoms, cigarette use, and a series of sociodemographic variables. In 
addition to these questionnaires, the family physician of each subject 
completed assessment forms with respect to their physical, social, emotional 
and family function, total health and predicted future health. These clinical 
assessments were based entirely upon reviews of clinical records and the 
memory of each physician. The agreement between subject and physician 
assessments was then calculated. The subjects' responses to the questions 
related to social and emotional function were then standardized into separate 
social and emotional indices which ranged from 0 to 1, where 0 represented 
'extremely poor function' and I 'extremely good function'. It is argued that 
these indices can be used to compare patients with a variety of diseases.
The Spitzer quality of life index or QL-Index [Spitzer et al. (1981)] aims to 
assist physicians in assessing the relative benefits and risks of various medical 
procedures. The authors mention palliative care and hospice care as examples 
of procedures to which the index is suited. They make clear, however, that it 
is not suitable for measuring the health-related quality of life of a healthy 
population. It is composed of five items (activity, daily living, health, support 
and outlook on life) which are transformed into a 0-10 scale. The authors do 
not clarify whether the items are given equal weights in the scale. The index 
was tested by more than 150 physicians on 879 Australian and Canadian 
patients, with high inter-rater correlation coefficients. The median time of 
completion of the index was just one minute.
CHAPTER 2 34
Six years after first constructing the ’Index of Well-being’, Kaplan and Bush 
(1982) were also instrumental in the creation of a new unit of health status, 
the 'Well-Year'. This unit measures health outcome across two dimensions, 
the length of survival and health-related quality of life produced by a health 
programme. The latter is estimated using the 29 function levels constructed 
by Patrick et al. (1973). When balanced against the cost of each programme, the 
'Well-Year' allows cost-utility comparisons to be made. Kaplan and Bush 
(1982) provide one of the earliest examples in the medical literature of the 
importance of such measurements.
Torrance et al. (1982) use the multi-attribute utility method [Keeney and 
Raiffa (1976)] to measure health status. They define health status according to 
a four-attribute health state classification system. The four attributes were 
mobility and physical activity, self-care and role activity, emotional well-being 
and social activity and health problems. The mobility and physical activity 
attribute was subdivided into six levels, ranging from being able to get around 
the house, yard, neighbourhood or community without help from another 
person and having no limitation in physical ability to lift, walk, run, jump or 
bend to needing help from another person in order to get around the house, 
yard, neighbourhood or community and not being able to use or control the 
arms and legs. The self-care and role activity attribute was subdivided into 
five levels, ranging from being able to eat, dress, bathe and go to the toilet 
without help and having no limitations when playing, going to school, 
working or in other activities to needing help to eat, dress, bathe or go to the 
toilet and not being able to play, attend school or work. The emotional well­
being and social attribute was subdivided into four levels, ranging from being 
happy and relaxed most or all of the time and having an average number of
friends and contacts with others to being anxious or depressed some or a good
$
bit of the time and having very few friends and little contact with others. The 
health problem attribute was subdivided into eight levels, ranging from
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having no health problem to being blind or deaf or not able to speak. The 
classification was tested on 112 parents of school children who were asked to 
value seven different combinations of the four attributes between 0 and 1, 
where 0 represented death and 1 healthy (the method of valuation in this 
study shall be explained later in the chapter).
The 'Nottingham Health Profile' was developed by Hunt et al. (1985). It is a 
short and straightforward index which is divided into two parts. Part 1 
comprises 38 statements which fall into six areas: sleep, physical mobility, 
energy, pain, emotional reactions and social isolation. Part 2 comprises 7 
statements which relate to paid employment, jobs around the house, social 
life, personal relationships, sex life, hobbies and interests, and holidays. 
Respondents are required yes to each statement if it applies to them and no if 
it does not. Each statement is weighted to give a maximum score of 100 for 
each part of the index, with a score of 100 representing maximum severity of 
perceived problems in that area. The authors argue that the profile is useful 
in evaluating the outcomes of medical interventions, but it is limited in that 
zero scores for each statement do not necessarily indicate total absence of 
distress. Hence, the profile is not useful in measuring mild forms of distress.
A more recent health status index was developed by Bulpitt and Fletcher 
(1990) to measure the effects of antihypertensive treatment on the health- 
related quality of life of hypertensive patients. The health index measured the 
disability of the patients on a continuum from 0 to 1, where 0 represented 
death and 1 total well-being. The numerical values given to the different 
states of disability were as follows: total well-being (1.0), minor dissatisfaction 
(0.975), discomfort (0.875), minor disability (0.8), major disability (0.75), 
disabled (0.625), confined (0.375), bedridden (0.125), isolated (0.025), comatose 
(0) and dead (0). The measurement techniques used in the derivation of these 
scores were the time trade off and standard gamble techniques which shall be 
explained later.
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Finally, a measure of health status which has not yet been completed is the 
’euroqol instrument’ [Euroqol Group (1990)]. This contains 6 distinct 
dimensions of health: mobility, self-care, main activity, social relationships,
, pain and mood. The mobility dimension has 3 categories: no problems 
walking about, unable to walk about without a stick, crutch or walking frame 
and confined to bed. The self-care dimension has 3 categories: no problems 
with self-care, unable to dress self and unable to feed self. The main activity 
dimension has 2 categories: able to perform main activity (e.g. work, study, 
housework) and unable to perform main activity. The social relationships 
dimension has 2 categories: able to pursue family and leisure activities and 
unable to pursue family and leisure activities. The pain dimension has 3 
categories: no pain or discomfort, moderate pain or discomfort and extreme 
pain or discomfort. The mood dimension has 2 categories: not anxious or 
depressed and anxious or depressed. The instrument was tested on groups of 
patients in pilot studies in the UK, the Netherlands and Sweden by asking 
patients to rate 16 of the 216 possible combinations of the health-related 
quality of life dimensions on a visual analogue scale similar to a 
thermometer. Early results indicate striking similarities between the relative 
valuations attached to the health states.
These scales can be used to measure the health status of individuals and 
can be applied to the economic appraisal of health care programmes. They 
have the advantage that they overcome the mutidimensional nature of 
health-related quality of life. However, Spitzer et al. (1981) outline the 
methodological problems involved in the use of such scales. According to 
this author, they "...are usually lengthy; require specially-trained research 
personnel to administer, code and store the information; were generally 
developed by experts on the basis of their own views of the appropriate 
dimensions to be included; are frequently oriented to physical function with 
insufficient attention to social and emotional aspects of quality of life; have
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often been applied in only one disease or one health problem; have limited 
use outside the original research setting because physicians find them too 
long or complicated for routine, period assessment of patients; and have not 
always been validated, this is especially true of the shorter ones" (pages 586­
587). Drummond (1989) questions their sensitivity in picking up small 
improvements in the health-related quality of life associated with some 
treatments. In their analysis of the Karnofsky Index of Performance Status, 
Hutchinson et al. (1979) found that "the major sources of observer variability 
appeared to be the lack of operational criteria to define the major elements of 
the scale and the nonexhaustive aggregation of the scale's constituent 
elements" (page 661). Moreover, Culyer (1978) argues that these measures 
incorporate value judgments which appear not to be identically shared by 
individuals in the community.
2.7 Rosser-Kind Classification of Illness States
One health status index which has had a major impact on health status 
measurement issues in recent years is the Rosser-Kind Classification of Illness 
States developed by Rosser and Kind (1978) and Kind et al. (1982). Its 
importance, not only for the field of health-related quality of life 
measurement but also for this thesis, merits a separate section and detailed 
explanation.
The Rosser-Kind Classification of Illness States is based on two dimensions 
of health, disability and distress, where disability is defined as the extent to 
which a patient is judged to be unable to pursue the activities of a normal 
person, and distress is defined as a patient's pain and mental suffering in 
relation to disablement, anxiety and depression [Rosser and Watts (1975)]. The 
classification divides the disability dimension into the following eight
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categories: I no disability; II slight social disability; IH severe social disability or 
slight impairment of performance at work, able to do all housework except 
very heavy tasks; IV choice of work or performance at work severely limited, 
housewifes and old people able to do light housework only but able to go out 
shopping; V unable to undertake any paid employment, unable to continue 
any education, old people confined to home except for escorted outings and 
short walks and unable to do shopping, housewifes only able to perform a few 
simple tasks; VI confined to chair or wheelchair or able to move around in 
the home only with support from an assistant; VI confined to bed, and VII 
unconscious (Table 2.1). The classification also divides the distress dimension 
into four categories: none, mild, moderate and severe (Table 2.1). In total, the 
Rosser Classification contains 29 descriptions of health status. The reason for 
29 (rather than 32) categories is that, by definition, unconscious patients 
cannot be in distress. ,
Rosser and Kind (1978) interviewed 70 subjects with the expressed aim of 
allotting utility values to each of the 29 states of illness. The subjects included 
10 patients from medical wards, 10 psychiatric in-patients, 10 experienced state 
registered general nurses, 10 experienced state registered psychiatric nurses, 20 
healthy volunteers and 10 doctors sufficiently experienced to have gained a 
membership or fellowship of at least one Royal College. Each interview began 
with a discussion of the context of the experiment. The subjects were then 
required to make pairwise comparisons of the different combinations of 
disability and distress, using the ratio scaling method. They were assisted with 
the use of typed cards, and were invited to discuss any implications or 
discrepancies associated with their conclusions. The interviews lasted 
between 1.5 and 4.5 hours, with some subjects indicating at the end that they 
found the experience painful and disturbing. Kind et al. (1982) transformed
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the median results of the 70 interviews into an interval scale1. The 
transformed scale had endpoints of 0 and 1 where 0 represented death and 1 
represented fit. The valuations of pairwise combinations of disability and 
distress are listed in Table 2.2. It is noticeable that two of the health states 
(VIID and VIIIA) were rated as worse than death. The results for the different 
groups of subjects were highly variable with doctors, in particular, placing less 
emphasis on the importance of death.
The Rosser-Kind Classification has been criticised on a number of grounds. 
Gudex (1986) argues that the utility values were estimated by too small a 
sample, and that the subjects themselves were unrepresentative of society as a 
whole. In addition, she argues that the disability scale can be construed as 
ambiguous. For example, in which disability category would one place a 
wheelchair-bound patient who is able to work full time and without 
impairment? Further criticisms of the classification include the emphasis 
placed on paid employment, the insufficient descriptions which assess the 
health-related quality of life of children, the mentally handicapped and the 
elderly, and the omission of features of quality of life such as marriage 
satisfaction and role fulfilment.
1 An interval scale has fixed endpoints and tells us that one unit differs by a 
certain amount of a property from another unit.
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TABLE 2.1: ROSSER-KIND CLASSIFICATION OF ILLNESS STATES
DISABILITY DISTRESS
I NO DISABILITY A NO DISTRESS
H SLIGHT SOCIAL DISABILITY B MILD
HI SEVERE SOCIAL DISABILITY AND/OR 
SLIGHT IMPAIRMENT OF 
PERFORMANCE AT WORK.
ABLE TO DO ALL HOUSEWORK ’ 
EXCEPT VERY HEAVY TASKS.
C MODERATE
D SEVERE
IV CHOICE OF WORK OR PERFORMANCE 
AT WORK VERY SEVERELY LIMITED. 
HOUSEWIVES AND OLD PEOPLE 
ABLE TO DO LIGHT HOUSEWORK 
ONLY BUT ABLE TO GO OUT SHOPPING.
V UNABLE TO UNDERTAKE ANY PAID
EMPLOYMENT. UNABLE TO CONTINUE 
ANY EDUCATION. OLD PEOPLE 
CONFINED TO HOME EXCEPT FOR 
ESCORTED OUTINGS AND SHORT 
WALKS AND UNABLE TO DO SHOPPING. 
HOUSEWIVES ABLE ONLY TO PERFORM 
A FEW SIMPLE TASKS.
VI CONFINED TO CHAIR OR TO
WHEELCHAIR OR ABLE TO MOVE 
AROUND IN THE HOUSE ONLY WITH 
SUPPORT FROM AN ASSISTANT
VII CONFINED TO BED
vin UNCONSCIOUS
Source: Kind et al. (1982)
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TABLE 2,2; ROSSER VALUATION MATRIX
DISABILITY DISTRESS RATING
RATING
A B C D.
I 1.000 0.995 0.990 0.967
n 0.990 0.986 0.973 0.932
m. 0.980 0.972 0.956 0.912
IV 0.964 0.956 0.942 0.870
V 0.946 0.935 0.900 0.700
VI 0.875 0.845 0.680 0.000
VII 0.677 0.564 0.000 -1.486
VIII - 1.028
Source: Kind et al. (1982)
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2.8 From Health Status Measurement Techniques to QALY’s
In this chapter, five broad approaches to measuring health status have 
been described and appraised: the willingness of individuals to pay for 
alternative health states, decision-analytic techniques, the use of existing 
values available in the medical literature, a range of measurement techniques 
and health status indices. Special emphasis was placed on one health status 
index, the Rosser-Kind Classification of Illness States, because of its 
importance to the field of health status measurement in general and to this 
thesis in particular.
The willingness to pay approach places monetary values on the perceived 
benefits of a medical procedures. However, the other four approaches allow 
utility values to be placed on alternative health states, that is they allow 
preferences for the alternative health states to be measured on cardinal scales 
and to be meaningfully compared in terms of health state utilities. These 
cardinal scales usually range from 0 to 1 where 0 represents death and 1 
represents full health. This information on the relative preferences for 
alternative health states can be employed in conjunction with survival/life 
expectancy data to give quality adjusted life years [Drummond et al. (1987)].
Quality adjusted life years or QALY’s are single weighted measures which 
combine the survival periods and health-related quality of life states accruing 
from health programmes. The idea can be illustrated with a simple example. 
Let us assume that there are two treatments for an illness. Both treatments 
extend the life expectancy of an individual by 1 year. However, treatment A 
results in the individual surviving the year in full health (usually 
represented by a health-related quality of life score of 1.0 on a cardinal scale), 
whilst treatment B results in the individual surviving the year in a health 
state with a health-related quality of life score of 0.7 (using any of the four 
approaches to obtaining health state utilities). Treatment A has led to a gain
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in QALY's of 1.0 (1 x 1.0), whilst treatment B has led to a gain in QALY's of 0.7 
(1 x 0.7). Benefits accruing beyond the first year are usually discounted to their 
present values (this topic shall be discussed in Chapter 4).
QALY's have been measured for a number of specific illnesses, usually in 
combination with cost data and with the aim of aiding resource allocation 
decisions within specialities. Stason and Weinstein (1977) used QALY data to 
determine how resources could be used most efficiently within programmes 
to treat hypertension (the study was discussed on page 12). The alternatives 
considered were the screening and treatment for hypertension and an 
organised screening programme at all. A year of life with side effects was 
assumed to be equivalent to 0.99 QALY’s. This estimate was not obtained 
using a health status measurement approach, but rather was an adaptation of 
the information available in the Framingham Study [Kannel and Gordon 
(1970)]. Weinstein (1980) incorporated his own subjective evaluations of the 
effects of estrogen use on the health-related quality of life of postmenopausal 
women. By assuming that symptomatic improvement was equivalent to 0.01 
QALY's, the author estimated that treatment was relatively cost effective in 
certain women. However, the subjective values assigned to symptomatic 
relief were critical to the final cost effectiveness results. Weinstein and Stason 
(1982) also used information available in the medical literature to estimate 
that a year of life with severe angina was equivalent to 0.7 QALY's. However, 
once again, their final cost effectiveness estimate for coronary artery bypass 
surgery was very sensitive to their quality weight. Decision analytic 
techniques were used by Boyle et al. (1983) to adjust the costs of neonatal 
intensive care of very low birth weight infants. In this study, costs per life year 
gained of $2,900- $9,300 were adjusted to costs per QALY gained of $3,200- 
$22,400.
A few studies have used QALY data to compare the relative cost 
effectiveness of different health care programmes. In these studies, the health
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outcome data should be obtained using the same measurement techniques, 
thus facilitating across-programme comparisons. Torrance and Zipursky 
(1984) list the costs per QALY gained of 14 health care programme reported in 
the medical literature. The results ranged from a negative figure for PKU 
screening to $54,000 for hospital haemodialysis. All costs had been converted 
to their equivalent 1983 amounts using the US consumer price index for 
medical care. However, methodological differences remained with respect to 
the discount rate, preference weights, method of costing and selection of 
patients used in each of the studies. The decision analysis methodology used 
by Williams (1985) to determine the future level of operations for coronary 
artery bypass grafting was discussed on page 14. This study summarizes the 
costs and benefits of alternative medical treatments in terms of costs per 
QALY gained, ranging from £750 for hip replacement surgery to £14,000 for 
hospital haemodialysis (all costs at 1983-1984 prices). Gudex (1986) used 
information available in the medical literature to estimate the relative cost 
effectiveness of seven medical procedures. The costs per QALY gained for 
these procedures ranged from £194 for surgery for scoliosis secondary to 
neuromuscular illness to £13,434 for CAPD (1986 prices).
4 5
CHAPTER 3
JOINT REPLACEMENT STUDY
3.1 Introduction.............................................................................................. 46
3.2 Methods...............................   46
3.3 Control Group Results.........................................   50
3.31 Control Group: Comparison of Rosser Classification
with Questionnaires.................................................................. 50
(a) Preoperative Stage............................................................. 51
(b) Postoperative Stage........................................................... 53
(c) Retrospective Stage..................   54
(d) All Stages........................................................................... 56
3.32 Control Group: Reliability of Retrospective Data................ 57
(a) Total Control Group......................................................... 58
(b) Hips.................................................................................... 60
(c) Knees................................................................................... 61
(d) Sexes.................................................................................... 63
(e) Total Control Group: Further Test for Bias................. 65
(f) Hips: Further Test for Bias.............................................. 67
(g) Knees: Further Test for Bias............................................. 68
(h) Summary............................................................................ 69
3.33 Control Group: Quality of Life Improvements............ ........ 70
3.331 Control Group: Cost per QALY Gained.................... 71
(a) Hips.......................................................................... 71
(b) Knees....................................................................... 72
3.332 Control Group: Change in Quality of Life
for Individual Functions.............................................. 74
3.4 Retrospective Group Results.................................................................. 77
3.41 Retrospective Group: Comparison of Rosser
Classification with Questionnaires......................................... 78
(a) Postoperative Stage........................................................... 79
(b) Retrospective Stage........................................................... 80
(c) Summary...........................................................................  82
3.42 Retrospective Group: Quality of Life Improvements........... 84
3.421 Retrospective Group: Cost per QALY Gained......... 87
3.422 Retrospective Group: Change in Quality
of Life for Individual Functions................................. 88
3.5 Matched Control Group and Retrospective Group Patients............ 91
CHAPTER 3 46
3.1 Introduction
Our interest in the Rosser-Kind Classification of Illness States led naturally 
to a desire to use the classification to measure the health-related quality of life 
of a specific group of patients. Patients who had undergone hip and knee joint 
replacement surgery were chosen because of their accessibility and because the 
procedure is, at present, frequently performed at a nearby hospital (Dundee 
Royal Infirmary). The aims of the study were fourfold. First, to compare the 
use of the classification with detailed questionnaires as tools of measurement 
in health-related quality of life estimates. Second, to test for the reliability of 
using retrospective data as opposed to prospective data when estimating the 
improvements in health-related quality of life in patients who have 
undergone hip and knee joint replacement surgery. Third, to calculate the 
scale of change in health-related quality of life in these two groups of patients, 
with quality adjusted life years (QALY's) used as the method of estimation. 
Fourth, to use the results to estimate the time period over which the 
maximum improvements in health-related quality of life are achieved.
3.2 Methods
The study was carried out at the Dundee Royal Infirmary between May 
1990 and February 1991 and was divided into two parts. A control sample of 44 
patients were interviewed twice, preoperatively and at three months 
postoperatively. Of the 44 patients, 19 were male, 25 female; 23 had hip 
replacements and 21 knee replacements. Table 3.1 (page 47) shows the number 
of patients who fell into each operation site and sex subgroup. The average 
age of the 44 patients at the time of their operation was 68 (66 for the males, 
70 for the females). At each of the two interviews, the purpose of the study 
was explained verbally and the 44 patients were asked a range of questions
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pertaining to their health-related quality of life at that time. At the 
postoperative interview, the patients were again questioned about their 
health-related quality of life prior to their operation.
Table 3.1: Control Group: Number of Patients by Sex and by Operation Type
Males Females Total
Hips 13 10 23
Knees 6 15 21
Total 19 25 44
The second sample was made up of 159 patients who were interviewed 
retrospectively at three months, one year or two years after their operation. Of 
the 159 patients, 51 were male, 108 female; 116 had hip replacements, 43 knee 
replacements; 30 were interviewed three months after their operation, 71 one 
year after their operation and 58 two years after their operation. Table 3.2 
shows the number of patients who fell into each operation site and sex 
subgroup. The average age of the 159 patients at the time of their operation 
was 66 (65 for males, 66 for females). The 159 retrospective patients were 
interviewed once only, but each interview was divided into two parts. The 
first section asked the patients about their health-related quality of life at that 
point in time; the second about their health-related quality of life prior to 
their operation. Again, the purpose of the study was explained verbally to 
each patient once the interview had commenced.
Table 3.2: Retrospective Group: Number of Patients by Sex and by Operation 
Type / Interview Interval
Males Females Total
Three Month Hips 7 13 20
One Year Hips 12 26 38
Two Year Hips 26 32 58
Three Month Knees 0 10 10
One Year Knees 6 27 33
Total 51 108 159
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A copy of the questionnaires used in the interviews can be found in 
Appendices 2-5. There were four questionnaires in total: a preoperative 
questionnaire for the hip control group patients (Appendix 2), a preoperative 
questionnaire for the knee control group patients (Appendix 3), a 
postoperative and retrospective questionnaire for the patients who had hip 
replacements in both the control and retrospective groups (Appendix 4), and a 
postoperative and retrospective questionnaire for the patients who had knee 
replacements in both the control and retrospective groups (Appendix 5). The 
first two of the four questionnaires (Appendices 2 and 3) were used solely in 
the preoperative interviews of the control group patients. The latter two 
(Appendices 4 and 5) were used in the postoperative interviews of the control 
group patients and all the interviews of the retrospective group patients.
The interviews lasted for an average of 20 minutes and were conducted by 
a single interviewer (the writer). At each stage of every interview, the patient 
was first asked to categorise his or her health-related quality of life according 
to the Classification of Illness States. This involved the patient placing 
himself/herself into one Rosser Disability/Distress Category (or in an overlap 
between two categories) after hearing their descriptions. They were then asked 
a wide range of questions about their ability to undertake everyday functions 
which allowed an assessment to be made by the observer of their health- 
related quality of life using the same classification. The questions related to 
functions which were particularly affected by arthritis (which most of the 
patients were suffering from) and were divided into categories which could 
easily be converted into the Rosser Classification. The response to the 
question regarding pain, stiffness and swelling in the joint, for example, was 
divided into none, slight, moderate and severe categories which could easily 
be converted into Rosser Distress Categories A, B, C and D respectively. The 
response to the question concerning the impairment of performance at work 
or choice of work was divided into none, slight, severe and complete
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categories which could easily be converted into Rosser Disability Categories I­
II, III, IV and V respectively. The five options available to the housework 
question (able to perform all housework, able to perform all housework 
except very heavy tasks, able to perform light housework, able to perform a 
few simple tasks and unable to perform any housework at all) were matched 
to Rosser Disability Categories I-II, in, IV, V and VI-VIII respectively. The 
hobbies and sports questions provided information on the social disability of 
the patients. All the remaining questions helped to build up an overall 
picture of the disability and distress of each patient and also acted as checks on 
the validity of answers to other questions. Where the answers seemed to 
contradict themselves or seemed to place the patient into alternative 
Disability/Distress Categories, a judgment had to be made on the most 
appropriate categorisation of the patient based on the totality of answers.
At the end of each stage of each interview therefore, two assessments of 
each patient's health-related quality of life were available for study. First, the 
patient's own assessment of their health-related quality of life according to 
their placement in the Classification of Illness States and second, an 
observer's assessment of their health-related quality of life based on a 
conversion of their responses to a wide range of questions into the same 
classification. In total, six health-related quality of life scores were derived 
from the two interviews with the control group patients (two health-related 
quality of life scores at each of the three stages of the interviews), and four 
health-related quality of life scores were derived from the one interview with 
the retrospective group patients (two health-related quality of life scores at 
each of the two stages of the interview).
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3.3 Control Group Results
A listing of the characteristics of the 44 control group patients is presented 
in Appendix 6, together with the subject's original prospective Rosser-Kind 
estimate (rating) of his/her health-related quality of life, the derived 
prospective Rosser-Kind estimate (rating) of his/her health-related quality of 
life, the subject's Rosser-Kind estimate (rating) after three months, the 
derived Rosser-Kind estimate (rating) after three months, the subject's 
retrospective Rosser-Kind estimate (rating) of his/her health-related quality 
of life prior to the operation and the derived retrospective Rosser-Kind 
estimate (rating) of his/her health-related quality of life prior to the 
operation. Thus, there were six health-related quality of life scores for each 
control group patient. Three of the scores were derived from the subject's 
own positioning on the Rosser-Kind Classification at the preoperative, 
postoperative and retrospective stages. The other three were derived from an 
assessment of each patient's health-related quality of life at the same stages, 
based on their answers in the interviews.
3.31 Control Group: Comparison of Rosser Classification with Questionnaires
The first aim of the study was to compare the use of the Rosser-Kind 
Classification of Illness States with the questionnaires as tools of 
measurement in health-related quality of life estimates. The most common 
method of comparing two such measurements is to calculate the correlation 
coefficient (r) between them. Considering the detailed nature of the 
questionnaires, one might the expect the two approaches to yield different 
results and the correlation coefficient between them to be quite low. 
However, the correlation coefficients between the patient estimates of their
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health-related quality of life (based on their positioning on the Rosser-Kind 
Disability/Distress Scale) and the derived estimates of their health-related 
quality of life (based on their responses to the questionnaires) were very high 
at every stage of the process: 0.899 at the preoperative stage, 0.972 at the 
postoperative stage and 0.931 at the retrospective stage. In addition, the 
correlation coefficients between the patient estimates and the derived 
estimates were high in every category of the operation site and sex subgroups. 
At the preoperative stage, the correlation coefficients were 0.930 for the hip 
subgroup, 0.788 for the knee subgroup, 0.893 for the male patients and 0.902 
for the female patients. At the postoperative stage, the correlation coefficients 
were 0.953 for the hip subgroup, 0.989 for the knee subgroup, 0.961 for the 
male patients and 0.989 for the female patients. At the retrospective stage, the 
correlation coefficients were 0.947 for the hip subgroup, 0.908 for the knee 
subgroup, 0.938 for the male patients and 0.944 for the female patients. 
Though the correlation coefficient measures the strength of a relation 
between two variables, it does not tell us whether we can reliably use both 
variables interchangeably. As Bland and Altman (1986) inform us, a more 
appropriate method would be to test the agreement between the two variables 
by plotting the difference between them against their mean. Therefore, tests of 
agreement were conducted between the two variables at each of the three 
stages of interviews.
(a) Preoperative Stage
Figure 3.1 (page 52) displays a simple scatter diagram of the subjects' 
prospective rating scores and the derived prospective rating scores, with the 
line of agreement for the two sets of data. Figure 3.2 (page 52) plots the 
difference between the two sets of data against their mean.
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Figure 3.2 shows no clear relationship between the difference and the 
mean; the difference between the two sets of prospective rating scores neither 
increases nor decreases as the average rating score increases. In other words, 
the Test of Agreement does not display any consistent bias over the range of 
average rating scores. The mean difference between the subjects’ prospective 
and the derived prospective rating scores was extremely small, 0.0034, with a 
95% confidence interval of -0.0206 to 0.0273. The limits of agreement were
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0.153, with a 95% confidence interval of 0.1115 to 0.1945, and -0.1462, with a 
95% confidence interval of -0.1877 to -0.1047. The width of these intervals is 
the result of two outliers. The line of best fit between the two sets of data, y = 
-0.21153 + 1.2546x (R2=0.809), conforms quite strongly to the line of agreement. 
Moreover, the mann-whitney test found that the probability that there is no 
difference between the medians of the two sets of prospective scores is 0.2582.
(b) Postoperative Stage
Figures 3.3 and 3.4 (page 54) carry out the same exercise for the relationship 
between the subjects' postoperative and the derived postoperative rating
scores.
Fig. 3.3: Control Group: Relationship between subjects'
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Figure 3.4 displays a very strong agreement between the subjects' 
postoperative and the derived postoperative rating scores. The mean 
difference between the two set of postoperative rating scores was 0.00124, with 
a 95% confidence interval of -0.0009 to 0.0034. The limits of agreement were 
an extremely narrow 0.0138, with a 95% confidence interval of 0.0101 to 
0.0175, and -0.0113, with a 95% confidence interval of -0.0150 to -0.0076. The 
slope and intercept of the line of best fit between the two sets of data (y = 
-8.2909e-2 + 1.0880x, R2= 0.946) and the mann-whitney test of the difference 
between their medians (significance level = 0.5089) illustrate the strength of 
the agreement between them.
(c) Retrospective Stage
The two diagrams on page 55 illustrate the relationship between the 
subjects' retrospective and the derived retrospective rating scores.
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Fig. 3.5: Control Group: Relationship between subjects’
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No consistent bias is obvious over the range of average retrospective rating 
scores. The mean difference between the subject's retrospective and the 
derived retrospective rating scores was -0.0014, with a 95% confidence 
interval of -0.0264 to 0.0236. The limits of agreement were 0.1442, with a 95% 
confidence interval of 0.1009 to 0.1875, and -0.147, with a 95% confidence 
interval of -0.1903 to -0.1037. Moreover, the equation of the line of best fit 
between the two sets of data (y = -0.24529 + 1.3082x, R2 = 0.868) and the mann-
CHAPTER 3 56
whitney test of the differences between their medians (significance level = 
0.8322) again illustrates the agreement between them.
(d) All Stages
Figures 3.1-3.6 illustrate the strength of the agreement between the 
subjects’ estimates and the derived estimates of their health-related quality of 
life at each stage of the process. It seems therefore that the Rosser-Kind 
Classification is an excellent indicator of the health-related quality of life of 
patients who have undergone joint replacement surgery. However, certain 
points of caution should be introduced at this stage. It may be the case that the 
Rosser-Kind Classification provides a comprehensive measure of the health- 
related quality of life of lower limb joint replacement patients. Alternatively, 
it may be that its crude generic nature may be too insensitive to pick up subtle 
changes in the health-related quality of life of these patients. For example, 
most of the patients in this study were elderly and as such, the emphasis in 
the Classification placed on paid employment may have been superfluous. In 
addition, though most patients found it relatively straightforward to identify 
their position on the disability and distress scales, some ambiguity did 
surround the position of working-age patients who felt unable to undertake 
any paid employment but could perform all housework except heavy tasks. In 
such cases, the patient would be placed in the intermediate disability category 
(IV).
The Rosser-Kind Classification of Illness States was used rather than a 
disease-specific scale, because it allows us to compare the improvements in 
health status resulting from joint replacement surgery with those which 
result from other types of medical treatment. Hence, we can use it to calculate 
the relative cost effectiveness of joint replacement surgery vis-a-vis other 
medical procedures. However, its categories may be too broad and general to
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pick up small changes in the health-related quality of life of our groups of 
patients. It may not be surprising therefore that in the conversion process, the 
information in the questionnaires should conform so strongly to the patients' 
own positioning in the Classification. Using an alternative disease-specific 
scale to measure the health-related quality of life of the patients would forgo 
the cross-programme comparison quality of the Rosser Classification. 
Moreover, there is little evidence that the assumptions and value judgments 
underlying alternative scales are any more acceptable than those underlying 
the Rosser Classification. Based on the information available in our study 
however, it does seem that the Rosser-Kind Classification is an acceptable 
basis for measuring the health-related quality of life of patients who have 
undergone hip and knee joint replacement surgery.
3.32 Control Group: Reliability of Retrospective Data
The second aim of the study was to test for the reliability of retrospective 
data as opposed to prospective data when estimating the improvements in 
health-related quality of life in patients who have undergone hip and knee 
joint replacement surgery. If the retrospective rating scores of the control 
group (estimated at the postoperative interview) compare favourably with 
the prospective rating scores from the preoperative interview, then we can 
feel comfortable in our use of retrospective data, and we will be able to extend 
our analyses to the much larger retrospective sample of patients. The 
correlation coefficient between the derived prospective Rosser-Kind rating 
scores (MYPRERKR) and the derived retrospective Rosser-Kind rating scores 
(MYRERKR) is 0.725. Using the subjects' approximations to the Rosser-Kind 
Classification, the correlation coefficient between the prospective and 
retrospective data is 0.832. When the data is broken down into operation site
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and sex subgroups however, very different results emerge. The correlation 
coefficients between the prospective and retrospective sets of data, using the 
derived estimates were as follows (with the correlation coefficients between 
the subject’s estimates in brackets): hips 0.913 (0.948), knees 0.441 (0.404), males 
0.449 (0.309) and females 0.739 (0.890). If the control group is broken down into 
smaller subgroups, a clearer picture emerges. Using the derived estimates, the 
correlation coefficients between the prospective and retrospective sets of data 
were 0.666 for the male hip subgroup, 0.970 for the female hip subgroup, 0.553 
for the male knee subgroup and 0.209 for the female knee subgroup. At first 
sight therefore, the use of retrospective data seems acceptable for patients who 
have undergone hip joint replacement surgery, but should be used with 
caution when analysing the health-related quality of life improvements in 
patients who have undergone knee joint replacement surgery.
(a) Total Control Group
As explained above (page 51), a more appropriate method to decide 
whether we can use prospective and retrospective rating scores 
interchangeably would be to test the agreement between the two variables by 
plotting the difference between them against their mean. Figure 3.7 (page 59) 
shows a simple scatter diagram of the prospective and retrospective rating 
scores of the whole control group, with a line of agreement for the two sets of 
data. Figure 3.8 (page 59) plots the difference between the two sets of data 
against their mean.
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Fig 3.7: Control Group: Relationship between prospective 
and retrospective rating scores for whole group
Derived prospective rating scores
Fig. 3.8: Control Group: Test of Agreement between derived 
prospective rating scores (MYPRERKR) and derived retro­
spective rating scores (MYRERKR) for whole group
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What is not clear in the diagrams is that for many patients, the difference 
between the prospective and retrospective rating scores was zero. 
Unfortunately, many patients overlap at certain points, and only one circle 
appears in the diagram to represent them.
Figure 3.8 shows no clear relationship between the difference and the 
mean; the difference between the rating scores neither increases nor decreases
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as the average rating score increases. In other words, the Test of Agreement 
does not display any consistent bias over the range of average rating scores. 
The mean difference between the prospective and retrospective rating scores 
was 0.035, with a 95% confidence interval of 0.0077 to 0.0623. Thus, the 
retrospective rating scores tended to be lower by between 0.0077 and 0.0623. 
The limits of agreement for the control group data were 0.208 (with a 95% 
confidence interval of 0.1607 to 0.2553) and -0.138 (with a 95% confidence 
interval of -0.1853 to -0.0907). The mann-whitney test resulted in an 
insignificant difference between the medians of the two sets of data 
(significance level = 0.1979). Before commenting on the acceptability of the 
limits of agreement, it is important that the same exercise is first carried out 
on each of the operation site and sex subgroups, so as to obtain a clearer 
picture of where the main differences lie.
Q>) Hips
Figure 3.9 (page 61) displays the difference between the prospective and 
retrospective rating scores against their mean for the patients who had hip 
joint replacements.
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Fig. 3.9: Control Group: Test of Agreement between derived 
prospective rating scores (MYPRERKR) and derived retro-M**X spective rating scores (MYRERKR) for hip subgroup
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Figure 3.9 displays no consistent bias over the range of average rating 
scores. In fact, there is very strong agreement between the two sets of scores. 
Many patients had a mean difference of 0, (though once again they do not all 
appear because of overlaps). The mean difference between the prospective 
and retrospective rating scores was -0.003, with a 95% confidence interval 
of -0.0279 to 0.0220. Hence, in contrast to the control group as a whole, the 
prospective and retrospective rating scores tended to differ by between -0.0279 
to 0.0220. The limits of agreement also are relatively narrow: 0.1094 (with a 
95% confidence interval of 0.0661 to 0.1527) and -0.1154 (with a 95% 
confidence interval of -0.1587 to -0.0721). This is further supported by the very 
low level of significance (0.8007) for the difference between the medians of the 
two sets of data.
(c) Knees
The diagram on page 62 performs the same exercise for the patients who 
had knee joint replacement surgery.
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Fig. 3.10: Control Group: Test of Agreement between derived 
prospective rating scores (MYPRERKR) and derived retro-
Average of rating scores: (MYPRERKR+MYRERKR)/2
It is clear in Figure 3.10 that, though there is no consistent bias over the 
range of average rating scores, the width of the limits of agreement are less 
acceptable than those of the hip replacement subgroup. The mean difference 
between the prospective and retrospective rating scores was 0.0789, with a 95% 
confidence interval of 0.0329 to 0.1250. Thus, the retrospective rating scores 
tended to be lower by between 0.0329 to 0.1250. The relatively wide intervals 
for the limits of agreement [0.2699, with a 95% confidence interval of 0.1903 to 
0.3495, and -0.1121, with a 95% confidence interval of -0.1917 to -0.0325] reflect 
the small sample size, and the fact that a small number of outliers have 
distorted the results of the whole knee replacement subgroup. [Perhaps also a 
learning effect was at work]. Further evidence of the differences between the 
two sets of data is provided by the mann-whitney test which calculated a 
significant difference between the medians of the two sets of data (significance 
level = 0.0357).
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(d) Sexes
Figures 3.11 and 3.12 display the differences between the prospective and 
retrospective rating scores against their means for the male and female 
subgroups respectively.
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Fig. 3.11: Control Group: Test of Agreement between derived 
prospective rating scores (MYPRERKR) and derived retro­
spective rating scores (MYRERKR) for male subgroup
Mean + 2SD
Mean
Mean - 2SD
“T-
0.2
T-
0.4
r
0.6
“T“
0.8
“i
1.0
7—
>
© o
Average of rating scores: (MYPRERKR+MYRERKR)/2
Fig. 3.12: Control Group: Test of Agreement between derived 
prospective rating scores (MYPRERKR) and derived retro-
0.4 -I spective rating scores (MYRERKR) for female subgroup
2
8 £ « 2 
G frl
'2 2 2 > 
§2 8 pkS 2 
*****
,8 w 
4) 2
22 
Q Ci
*33
Q
0.3-
0.2­
0.1"
0.0-
-o.l-
-0.2­
-0.3­
-0.4
<2
°o
Mean + 2SD
Mean
Mean - 2SD
----------,------------ ,---------- ,------------ ,------------ ,
0.0 0.2 0.4 0.6 0.8 1.0
Average of rating scores: (MYPRERKR-MYRERKR)/2
<9
o o
o
CHAPTER 3 64
The mean difference between the prospective and retrospective rating 
scores for the male subgroup was 0.0179, with a 95% confidence interval of 
-0.0203 to 0.0562. The limits of agreement were 0.1767, with a 95% confidence 
interval of 0.1103 to 0.2431, and -0.1409, with a 95% confidence interval of 
-0.2073 to -0.0745. The difference between the medians of the two sets of 
rating scores was insignificant (significance level = 0.5424). For the males who 
had hip joint replacements, the mean difference between the prospective and 
retrospective rating scores was -0.0148, with a 95% confidence interval of 
-0.0527 to 0.0231, and with limits of agreement of 0.1106 and -0.1402. For the 
males who had knee joint replacements, the mean difference between the 
prospective and retrospective rating scores was 0.0890, with a 95% confidence 
interval of 0.0192 to 0.1588, and with limits of agreement of 0.222 and -0.044.
The mean difference between the prospective and retrospective rating 
scores for the female subgroup was 0.0497, with a 95% confidence interval of 
0.0092 to 0.0902. The limits of agreement were 0.2323, with a 95% confidence 
interval of 0.1622 to 0.3024, and -0.1329, with a 95% confidence interval of 
-0.2030 to -0.0628. The significance level of the difference between the medians 
of the two sets of rating scores was calculated by the mann-whitney test to be 
0.0808. For the females who had hip joint replacements, the mean difference 
between the prospective and retrospective rating scores was 0.0142, with a 95% 
confidence interval of -0.0187 to 0.0471, and with limits of agreement of 0.0998 
and -0.0714. For the females who had knee joint replacements, the mean 
difference between the prospective and retrospective rating scores was 0.0743, 
with a 95% confidence interval of 0.0087 to 0.1399, and limits of agreement of 
0.2913 and -0.1427.
An analysis of variance performed on the differences between the 
prospective and retrospective rating scores of the control group patients 
found that surgery type had a significant effect (F=9.71) on the mean 
difference between the two scores. The sex of the patients had an insignificant
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effect (F=0.07) on the mean difference between the two scores. This led us to 
believe that the sex of our group of patients did not have any additional 
explanatory value for the difference between the prospective and 
retrospective rating scores. This may not be the case if the study was 
performed on a much larger sample of patients. However, these results do 
suggest that, in our study, the difference between the two sets of rating scores 
is statistically explained by operation type.
It is becoming evident that, based on the information we have obtained 
from our control group, the use of retrospective data to estimate the health- 
related quality of life of patients who have had hip replacements, seems 
acceptable. The mean difference between the prospective and retrospective 
rating scores for these patients is negligible, and the limits of agreement 
relatively narrow. Moreover, the patients who had hip replacements neither 
underestimated nor overestimated their retrospective rating scores. However, 
when estimating the health-related quality of life of patients who have had 
knee replacements, we should use retrospective data with caution. The 
differences within the limits of agreement are wide enough to suggest 
considerable lack of agreement between prospective and retrospective rating 
scores. Moreover, the evidence presented above suggests that patients who 
have had knee replacements consistently underestimate their retrospective 
rating scores. This suggests that further research is required before any 
generalisations concerning the acceptability of retrospective data can be made.
(e) Total Control Group: Further Test for Bias
It is possible that the level of agreement between the prospective and 
retrospective rating scores is related to the change in health-related quality of 
life of the patients who are making the retrospective assessments. In other 
words, there may be a consistent bias in the retrospective assessments of
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patients who have shown the greatest improvements in health-related 
quality of life following their operations. Alternatively, a bias may exist in the 
retrospective assessments of patients who have shown the smallest 
improvements in health-related quality of life following their operations. 
The following exercise tests the agreement between the prospective and 
retrospective scores of the whole control group when used as a base to assess 
health-related quality of life improvements.
Fig. 3.13: Control Group: Test of Agreement between derived 
prospective and retrospective rating scores when used
0.4 as a base to assess quality of life improvements for whole group
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Figure 3.13 displays no consistent bias over the range of average changes in 
health-related quality of life scores. Amongst patients who achieved little or 
no change in health-related quality of life, the differences between the 
changes in health-related quality of life scores were relatively small. In other 
words, amongst these patients, using either the prospective rating scores or 
the retrospective rating scores to assess health-related quality of life 
improvements made little difference. The same seems to be the case for 
patients who made considerable improvements following their operation. 
The outliers in the diagram are amongst patients who made moderate
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improvements in health-related quality of life. The mean difference between 
the changes in health-related quality of life scores, when either prospective or 
retrospective scores are used as a base, was -0.035, with a 95% confidence 
interval of -0.0823 to 0.0123. Thus, using the retrospective scores as a base 
tended to lead to slightly higher estimates of health-related quality of life 
improvements. The limits of agreement were 0.138, with a 95% confidence 
interval of 0.0907 to 0.1853, and -0.208, with a 95% confidence interval of 
-0.2553 to -0.1607. Before making any inferences from these results, the results 
of the same exercise when the control group is broken down into operation 
site subgroups shall be described.
(f) Hips: Further Test for Bias
Figure 3.14 tests the agreement between the changes in health-related 
quality of life scores amongst patients who had hip replacements.
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Amongst patients who had hip replacements, there was a smaller bias over 
the range of average changes in health-related quality of life scores than 
existed for the control group as a whole. The mean difference between the 
changes in health-related quality of life scores, when either preoperative or 
retrospective scores were used as a base, was 0.003, with a 95% confidence 
interval of -0.022 to 0.0279. Thus, there is no evidence amongst the hip 
subgroup that using either prospective or retrospective scores, distorts the 
results unduly. The limits of agreement were relatively narrow: 0.1154, with a 
95% confidence interval of 0.0721 to 0.1587, and -0.1094, with a 95% confidence 
interval of -0.1527 to -0.0661.
(g) Knees: Further Test for Bias
Figure 3.15 illustrates the same test for the knee subgroup.
Fig. 3.15: Control Group: Test of Agreement between derived 
prospective and retrospective rating scores when used
0,41 as a base to assess quality of life improvements for knee subgroup
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The diagram confirms our earlier inference that, although there is no 
consistent bias over the range of average rating scores, the width of the limits
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of agreement are less acceptable than those of the hip replacement subgroup. 
The mean difference between the changes in health-related quality of life 
scores was -0.0789, with a 95% confidence interval of -0.1250 to -0.0329. Thus, 
using the retrospective score as a base tends to lead to higher estimates of 
health-related quality of life improvements. A comparison of the results in 
Figures 3.10 (page 62) and 3.15 (page 68) illustrates how this is largely a result 
of the lower retrospective rating scores estimated by the knee subgroup. (The 
bias is not related to the scale of health-related quality of life improvements). 
The limits of agreement were 0.1121, with a 95% confidence interval of 0.0324 
to 0.1917, and -0.2699, with a 95% confidence interval of -0.3495 to -0.1903.
(h) Summary
The two Tests of Agreement described above illustrate a degree of 
acceptability in using retrospective data when estimating the health-related 
quality of life of patients who have had hip replacements. For the hip patients 
in the control group, the mean difference between the prospective and 
retrospective rating scores was small and the limits of agreement narrow. 
There was no evidence that the patients either overestimated or 
underestimated their prospective health-related quality of life scores. 
Moreover, the level of agreement between the prospective and retrospective 
rating scores was not related to the scale of change in the health-related 
quality of life of the patients after their operations. The two Tests of 
Agreement, however, also illustrate the caution with which retrospective 
data should be used when estimating the health-related quality of life of 
patients who have had knee replacements. There was strong evidence that 
the knee patients in the control group underestimated their preoperative 
health-related quality of life when making their retrospective assessments. 
This may have been the result of the relatively small sample size, the
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distorting effects of a small group of outliers or even a learning effect. The 
bias was not related to the scale of change in the health-related quality of life 
of the patients after their operations. Section 3.331 (page 73) illustrates the 
differences between prospective and retrospective scores when they are used 
as the basis for estimating the Cost per QALY gained of knee replacement 
surgery. The differences between the prospective and retrospective rating 
scores of the male and female subgroups were shown to be largely the result 
of the distorting effects of the knee patients. It seems fair to conclude therefore 
that further research is required before any wider generalisations concerning 
the acceptability of retrospective data can be made.
3.33 Control Group: Quality of Life Improvements
The third aim of the study, and the final one which could be applied to the 
control group, was to calculate the scale of change in health-related quality of 
life in patients who have undergone joint replacement surgery, and to 
elucidate the functions in which the greatest improvements occur. Table 3.3 
(page 76) summarizes the various health-related quality of life scores at each 
stage of the process, and gives a breakdown of the Rosser-Kind ratings into 
sex/operation site subgroups. As can be seen in the table, there was a marked 
improvement in the health-related quality of life scores between the 
preoperative and three month postoperative interviews. For the control 
group as a whole, the QALY's gained ranged from 0.028 (0.11057/4) to 0.041 
(0.16527/4), depending on which estimates are used. Of the 44 patients, the 
derived estimates showed that 39 improved their rating scores after the three 
month period, 1 patient's score showed no change, 1 patient's score 
deteriorated and 3 patients failed to turn up for their follow-up interviews. 
The respective figures based on the subject's estimates were 36, 2, 3 and 3.
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When the data is broken down into hip and knee subgroups, it is 
immediately noticeable that the improvements in health-related quality of 
life in the patients who had hip replacements lie in a very narrow range 
whichever estimates are used. These improvements convert into 0.034-0.036 
QALY’s gained over the three month period. For the patients who had knee 
replacements however, the improvements vary between 0.021-0.048 QALY’s 
gained depending on the source and stage of estimation. This is the result of 
the underestimation of the retrospective scores by the knee subgroup, which 
was highlighted above. When the data is broken down between the sexes, it is 
evident that the greatest improvements in health-related quality of life were 
amongst the female patients. However, this may be because the female 
subgroup had a lower average prospective rating. At the postoperative stage, 
the differences between the sexes were not significant. Once again, the 
divergences in health-related quality of life improvements for each of the 
sexes were largely the result of the underestimation of the retrospective scores 
by the knee subgroup.
3.331 Control Group: Cost per QALY Gained
To illustrate the differences between the prospective and retrospective 
rating scores of the hip and knee subgroups, the Cost per QALY gained was 
calculated for hip and knee joint replacement surgery, using both sets of 
rating scores as the basis for estimation.
(a) Hips
Figure 3.16 (page 72) illustrates the exercise for hip replacement surgery. 
The joint survival period resulting from this type of surgery was assumed to
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be 10 years. This estimate lies at the lower range of the results calculated by 
Kilgus et al. (1991). The derived estimates from the questionnaires were used 
as the basis of the health-related quality of life information, and the cost of a 
hip replacement was assumed to be £4,426 (Tayside Health Board, April 1991 
prices).
Fig 3.16: Control Group: Difference in Cost per QALY (£)
The figure demonstrates that, when a joint survival period of 10 years is 
assumed, using the two sets of rating scores interchangeably has very little 
effect on the final Cost per QALY estimate for hip replacement surgery. 
Indeed, the curves are so close, they are almost indistinguishable. The 
differences in the Costs per QALY vary between £12 (£3,269 - £3,281) when a 
discount rate of 0 percent is applied and £19 (£5,320 - £5,339) when a discount 
rate of 10 percent is applied.
(b) Knees
Figure 3.17 (page 73) illustrates the same exercise for knee replacement 
surgery. Once again, the survival period of a knee replacement is assumed to
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be 10 years [Bowman et al. (1991)], and the derived estimates from the 
questionnaires are used as the basis of the health-related quality of life 
information. The cost of a knee replacement is assumed to be £5,302 (Tayside 
Health Board, April 1991 prices).
Fig. 3.17: Control Group: Difference in Cost per QALY (£) 
for knee replacement surgery when prospective and
The diagram demonstrates quite clearly that there are large differences in 
the Cost per QALY estimate for knee replacement surgery when prospective 
and retrospective rating scores are used as the basis for estimating health- 
related quality of life improvements. Assuming a 0 percent discount rate and 
a joint survival period of 10 years, the Cost per QALY for knee replacement 
surgery is £5,531 when prospective rating scores are used as the basis for 
estimating health-related quality of life improvements, and £3,208 when 
retrospective rating scores are used as the basis (a difference of £2,323). 
Assuming a 10 percent discount rate, the respective estimates are £9,002 and 
£5,221 (a difference of £3,781).
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3.332 Control Group: Change in Quality of Life for Individual Functions
Appendices 7-11 summarize the change in rating scores for individual 
questions between the preoperative and postoperative stages. The scales to 
each question are listed, as are the number of subjects who fall into each 
category of each scale at the preoperative and postoperative stages. Since we 
are dealing with interval rather than continuous variables, the chisquare test 
is used to test the null hypothesis that no improvement in health-related 
quality of life occur after the operation. Appendix 7 summarizes the results of 
the whole control group; Appendices 8 and 9 summarize the results of the 
hip and knee subgroups respectively, and Appendices 10 and 11 summarize 
the results of the male and female subgroups respectively.
The appendices illustrate significant improvements in the ability to 
undertake everyday functions. There was an extremely significant reduction 
in pain (less than the 0.001 level) in every operation site and sex subgroup. In 
addition, there were significant improvements (at the 0.05 level) in every 
subgroup in the ability to sleep without noticeable discomfort, in the ability to 
walk distances without noticeable discomfort, in the ability to bend knees 
without noticeable discomfort, in the ability to climb stairs without noticeable 
discomfort and in the ability to sit down on and get up off chairs without 
noticeable discomfort. The functions in which the. improvements were not 
significant (greater than the 0.1 level) were largely ones in which the subjects 
already had a high rating prior to their operations (dependence on others for 
activities of daily living, ability to bathe, ability to dress, ability to cook, 
assistance in the home and confinement to a chair). The only exceptions were 
the insignificant improvements in the ability to work and participation in 
sports. This is hardly surprising, since most patients were elderly and were 
not employed or active participants in sport prior to their operations. The 
conclusion here must be that future health status measurements of patients
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who have undergone hip and knee joint replacement surgery need not 
include these functions in their studies, but rather should concentrate on 
measuring changes within areas where our study has shown significant 
improvements (pain, sleeping, walking, bending knees, climbing stairs, 
sitting down on and getting up off chairs).
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Table 3.3 - Control Group: Summary of Rosser-Kind Rating Scores for the Sex 
and Operation Site Subgroups at the Preoperative, Postoperative and 
Retrospective Stages
Overall 
Mean RKR
Mean RKR 
for Males 
(n=19)
Mean RKR 
for Females 
(n=25)
Mean RKR 
for Hips 
(n=23)
Mean RKR 
for Knees 
(n=21)
SUBPRERKR 0.8475 0.9009 0.8038 0.8267 0.8704
MYPRERKR 0.8368 0.8823 0.8022 0.8246 0.8502
SUBPORKR 0.95807 0.95840 0.95783 0.96220 0.95257
MYPORKR 0.95345 0.95445 0.95255 0.95950 0.94606
SUBRERKR 0.7928 . 0.8605 0.7419 0.8173 0.7601
MYRERKR 0.8046 0.8643 0.7506 0.8241 0.7808
SUBPORKR-
SUBPRERKR
0.11057 0.0575 0.15403 0.1355 0.08217
MYPORKR-
MYPRERKR
0.11665 0.07215 0.15035 0.1349 0.09586
SUBPORKR-
SUBRERKR
0.16527 0.0979 0.21593 0.1449 0.19247
MYPORKR-
MYRERKR
0.14885 0.09015 0.20195 0.1354 0.16526
SUBPRERKR-
SUBRERKR
0.0547 0.0404 0.0619 0.0094 0.1103
MYPRERKR-
MYRERKR
0.0322 0.018 0.0516 0.0005 0.0694
Abbreviations :
MYPRERKR : Derived preoperative Rosser-Kind rating score 
MYPORKR : Derived postoperative Rosser-Kind rating score 
MYRERKR : Derived retrospective Rosser-Kind rating score
RKR : Rosser-Kind rating score
SUBPRERKR : Subject's preoperative Rosser-Kind rating score 
SUBPORKR : Subject's postoperative Rosser-Kind rating score 
SUBRERKR : Subject's retrospective Rosser-Kind rating score
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3.4 Retrospective Group Results
Three main lessons were learnt in our analysis of the control group data. 
First, the Rosser-Kind Classification of Illness States is an excellent tool of 
measurement when assessing the health-related quality of life of patients 
who have had (or are about to have) joint replacement surgery. Second, it 
seems that we can use retrospective data with some degree of confidence 
when estimating the improvements in health-related quality of life in 
patients who have had hip replacements. However, retrospective data should 
only be used with caution when estimating the improvements in health- 
related quality of life in patients who have had knee replacements, and 
further research is required before we can make any wider generalisations 
concerning the acceptability of retrospective data. Third, there are significant 
improvements in health-related quality of life following both hip and knee 
joint replacement surgery. The most significant area of improvement is the 
reduction in pain and distress.
With these lessons in mind, we can proceed in our analysis of the 
retrospective group data with the following objectives. First, to compare the 
use of the Rosser-Kind Classification of Illness States with the questionnaires 
as methods of assessing the health-related quality of life of the retrospective 
group patients. Second, to calculate the scale of improvement in health- 
related quality of life in the retrospective group patients, following their 
operations. Quality adjusted life years will be used as the method of 
estimation. The data will then be broken down further, so as to assess the 
changes within the main functions of everyday life. Third, to use the results 
to estimate the time period over which the maximum improvements in 
health-related quality of life are achieved. The most appropriate method of 
approaching such a study would be to follow up patients who have 
undergone joint replacement surgery over a period of time following their
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operations. However, the time constraints of this study meant that it was not 
possible, and that retrospective assessments were necessary.
Appendix 12 lists the characteristics of the 159 retrospective group patients. 
The appendix also tabulates each subject's postoperative Rosser-Kind estimate 
(rating) of his/her health-related quality of life, the derived postoperative 
Rosser-Kind estimate (rating) of his/her health-related quality of life, each 
subject's retrospective Rosser-Kind estimate (rating) of his/her health-related 
quality of life and the derived retrospective Rosser-Kind estimate (rating) of 
his/her health-related quality of life. Thus, for each retrospective group 
patient, four health-related quality of life scores were available for study. Two 
of the scores were derived from the subject's own positioning on the Rosser- 
Kind Classification at the postoperative and retrospective stages. The other 
two were derived estimates of each patient's health-related quality of life at 
the same stages, based on their answers in the interviews.
3.41 Retrospective Group: Comparison of Rosser Classification with 
Questionnaires
The first aim in our analysis of the retrospective group data was to 
compare the use of the Rosser-Kind Classification of Illness States with the 
(much more detailed) questionnaires when estimating the health-related 
quality of life of the retrospective group patients. The correlation coefficients 
between the patient estimates of their health-related quality of life (based on 
their positioning on the Rosser-Kind Disability/Distress Scale) and the 
derived estimates of their health-related quality of life (based on their 
responses to the questionnaires) were high for both stages: 0.970 at the 
postoperative stage and 0.971 at the retrospective stage. Moreover, the 
correlation coefficients between patient estimates and the derived estimates
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were high in every category of the operation site and sex subgroups. At the 
postoperative stage, the correlation coefficients were 0.944 for the hip 
subgroup, 0.816 for the knee subgroup, 0.722 for the male subgroup and 0.979 
for the female subgroup. At the retrospective stage, the correlation coefficients 
were 0.992 for the hip subgroup, 0.840 for the knee subgroup, 0.948 for the 
male subgroup and 0.988 for the female subgroup. However, as was explained 
earlier (page 51), a more appropriate method of testing the agreement between 
two variables is to plot the difference between them against their mean.
(a) Postoperative Stage
Figure 3.18 displays the relation between patient postoperative rating scores 
and the derived postoperative rating scores, whilst Figure 3.19 (page 80) tests 
the agreement between the two variables.
Fig. 3.18: Retrospective Group: Relationship between subjects’ 
postoperative and derived postoperative rating scores
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Fig. 3.19: Retrospective Group: Test of Agreement between 
subjects’ postoperative (SUBPORKR) and derived
postoperative (MYPORKR) rating scores
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The mean difference between the subjects' postoperative and the derived 
postoperative rating scores was extremely small, 0.00595, with a 95% 
confidence interval of 0.00230 to 0.00961. Thus, the derived postoperative 
rating scores tended to be lower by between 0.00230 and 0.00961. The narrow 
limits of agreement (0.05093 and -0.03903) and the line of best fit between the 
two sets of data (y = 6.7085e'2 + 0.93544x, R2 = 0.942) also suggest that we can 
confidently use both methods of estimation interchangeably. Furthermore, 
the difference between the medians of the two sets of postoperative rating 
scores was insignificant (significance level = 0.2897)
(b) Retrospective Stage
Figures 3.20 and 3.21 (page 81) illustrate the same exercise concerning the 
retrospective rating scores of the retrospective group.
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Pig. 3.20: Retrospective Group: Relationship between subjects'
Fig. 3.21: Retrospective Group: Test of Agreement between 
subjects* retrospective (SUBRERKR) and derived
0.41 retrospective (MYRERKR) rating scores
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The two diagrams confirm that not only is there strong relation between 
the patient retrospective rating scores and the derived retrospective rating 
scores, but there is also strong agreement between the two variables. Most of 
the patients are clusterred very close to the mean difference line, and there is
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no consistent bias over the range of average retrospective scores. The mean 
difference between the subjects’ retrospective scores and the derived 
retrospective scores was 0.00804, with a 95% confidence interval of -0.00602 to 
0.02210. The narrow limits of agreement (0.18116, -0.16508) and the line of best 
fit between the two variables (y = 2.6402e_2 + 0.97439x, R2 = 0.942) suggest we 
can use both methods of estimation with confidence. Further support is 
provided by the mann-whitney test which calculated an insignificant 
difference between the medians of the two sets of retrospective rating scores 
(significance level - 0.5587).
(c) Summary
Table 3.4 (page 83) illustrates the strong agreement between the subjects' 
estimates of their health-related quality of life and the derived estimates of 
their health-related quality of life for each of the operation site and 
retrospective period subgroups.
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Table 3.4: Retrospective Group: Descriptive Statistics Comparing Subjects’ and 
Derived Quality of Life Scores for each Retrospective Period and Operation 
Site Subgroup
Number Mean Median 95%
Confidence
Interval
SUBPOTMH 20 0.95180 0.95025 0.94399-0.95961
MYPOTMH 20 0.94383 0.94550 0.92897-0.95868
SUBPOTMK 10 0.9161 0.9385 0.8584-0.9738
MYPOTMK 10 0.8940 0.9280 0.8188-0.9692
SUBPOOYH 37 0.9359 0.9720 0.8809-0.9909
MYPOOYH 38 0.9276 0.9640 0.8725-0.9826
SUBPOOYK 32 0.96691 0.9640 0.95984-0.97398
MYPOOYK 32 0.95840 0.9620 0.94517-0.97162
SUBPOTYH 48 0.96493 0.9720 0.95199-0.97786
MYPOTYH 58 0.95745 0.9720 0.94312-0.97178
SUBRETMH 20 0.6004 0.7000 0.4288-0.7721
MYRETMH 20 0.6254 0.7000 0.4627-0.7881
SUBRETMK 10 0.7922 0.7850 0.7281-0.8563
MYRETMK 10 0.8007 0.7850 0.7408-0.8606
SUBREOYH 37 0.6485 0.8700 0.4604-0.8365
MYREOYH 38 0.6249 0.7850 0.4398-0.8100
SUBREOYK 32 0.7540 0.8700 0.6596-0.8484
MYREOYK 32 0.7189 0.7850 0.6146-0.8232
SUBRETYH 48 0.8035 0.8700 0.7471-0.8600
MYRETYH 58 0.7898 0.8700 0.7408-0.8389
Abbreviations :
MYPO : Derived mean postoperative Rosser-Kind rating score
MYRE : Derived mean retrospective Rosser-Kind rating score
SUBPO : Subjects' mean postoperative Rosser-Kind rating score
SUBRE : Subjects' mean retrospective Rosser-Kind rating score
TMH : Three month hip subgroup
TMK : Three month knee subgroup
OYH: One year hip subgroup
OYK: One year knee subgroup
TYH : Two year hip subgroup
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3.42 Retrospective Group: Quality of Life Improvements
The two remaining aims of the analysis of the retrospective group data 
were to estimate the improvements in health-related quality of life in 
patients who have had hip joint replacements and knee joint replacements, 
and also to calculate the time period over which the maximum 
improvements in health-related quality of life are achieved. Table 3.5 (page 
90) summarizes the mean Rosser-Kind rating scores at the postoperative and 
retrospective stages for the entire retrospective group, the operation site and 
sex subgroups and also the retrospective period subgroups.
It is clear from the table that there were noticeable changes in the health- 
related quality of life scores for the retrospective group as a whole, and for 
every subgroup. Nonparametric statistics were used to compare the 
postoperative health-related quality of life scores of each subgroup because the 
data was discrete, skewed and indicative of rank order. The medians for each 
subgroup were as follows: three month hip subgroup (0.95025), one year hip 
subgroup (0.972), two year hip subgroup (0.972), three month knee subgroup 
(0.9385) and one year knee subgroup (0.964). The mann-whitney test was used 
to compare the difference between the sample medians. The medians of the 
three month and one year hip subgroups were significantly different at the 
0.0039 level. The medians of the three month and two year hip subgroups 
were significantly different at the 0.0014 level. For the one year and two year 
hip subgroups, the significance level of the difference between the medians 
was 0.4539. The medians of the three month and one year knee subgroups 
were significantly different at the 0.005 level.
The average increase in the Rosser-Kind rating score for the 159 patients 
was between 0.228 and 0.230 (Table 3.5, page 90), depending on the source of 
estimation, but this figure tells us little since it does not take into account the 
retrospective periods of estimation. Therefore, it cannot be converted into
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average quality adjusted life years gained. Incorporating the time span 
element allows us to estimate the health-related quality of life improvements 
at fixed points in time following the operations. The results in Table 3.5 (page 
90) are quite interesting. For the knee subgroup, a higher mean Rosser-Kind 
rating score was calculated for the patients who were interviewed one year 
following their operations (0.95840-0.96691, depending on the source of 
estimation) than for the patients who were interviewed three months 
following their operations (0.8940-0.9161, depending on the source of 
estimation). If we accept the retrospective estimates as reliable, the average 
increase in the Rosser-Kind rating scores was between 0.21291 and 0.2395 . 
(equivalent to 0.21291-0.2395 QALY’s) for the one year retrospective knee 
subgroup, compared to an average increase of between 0.0933 and 0.1239 
(equivalent to 0.023325-0.030975 QALY's) for the three month retrospective 
knee subgroup. These results suggest that amongst patients who have 
undergone knee joint replacement surgery, significant improvements in 
health-related quality of life are achieved between three months and one year 
following the operation. In addition, the rate of improvement in health- 
related quality of life suggests that the highest Rosser-Kind rating score is 
achieved after the first year.
Amongst the 116 patients who were interviewed following their hip 
replacements, less consistent improvements are noticeable. The mean Rosser- 
Kind rating scores were 0.94383-0.95180 for the patients who were interviewed 
three months after their hip replacements, 0.9276-0.9359 for the patients who 
were interviewed one year after their hip replacements, and 0.95745-0.96493 
for the patients who were interviewed two years after their hip replacements. 
If we accept the retrospective estimates as reliable, the average increase in the 
Rosser-Kind rating score was between 0.31843 and 0.3514 for the three month 
retrospective hip subgroup (equivalent to 0.0796-0.08785 QALY's gained). This 
compares to an average increase in the Rosser-Kind rating score of between
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0.2874 and 0.3027 for the one year retrospective hip subgroup (equivalent to 
0.2874-0.3027 QALY's gained), and an average increase of between 0.1614 and 
0.1677 for the two year retrospective hip subgroup (equivalent to 0.3229-0.3353 
QALY's gained before discounting). These results suggest that for patients 
who have hip replacements, a higher Rosser-Kind rating score is achieved at 
three months following the operation than at one year following the 
operation. It was probably the case that the overall one year retrospective hip 
sample in Table 3.5 (page 90) included a number of patients with abnormally 
low rating scores (this is supported by the evidence that the mean rating score 
of the sample was lower than the median). However, the Rosser-Kind rating 
score starts to increase again beyond the one year period. The rate of increase 
in the Rosser-Kind rating score between the first and second year following 
the operations suggests that the highest rating score is achieved after the 
second year.
When the retrospective estimates are incorporated into our analysis, it is 
immediately noticeable that the improvements from the retrospective base 
decline after the first three months. This is the result of the higher 
retrospective rating scores estimated by the one year and two year subgroups. 
It may be the case that the one year and two year subgroups overestimated 
their preoperative health-related quality of life (these groups of patients may 
have had greater difficulty in recalling their preoperative health status) and, 
as a result, the true improvements in health-related quality of life have been 
underestimated. Alternatively, it may be the case that the patients within 
these two subgroups were less disabled than the patients in the three month 
hip subgroup. Our analysis of the control group data found the retrospective 
estimates at three months to be reliable indicators of the preoperative health- 
related quality of life of patients who have undergone hip replacement 
surgery. Whether retrospective assessments at one or two years following an 
operation are reliable indicators of preoperative health-related quality of life
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is beyond the scope of this study. However, the analysis in section 3.5 which 
matches the control and retrospective groups of patients may go some way in 
explaining our results.
3.421 Retrospective Group: Cost per QALY Gained
To estimate the QALY’s gained over a joint survival period, the health- 
related quality of life scores for the three month and one year hip and knee 
retrospective subgroups (using the subjects' estimates) were once again 
extrapolated over 10 years. Extrapolating the health-related quality of life 
estimates of the three month hip retrospective subgroup over a 10 year period 
results in 3.514 QALY’s gained (assuming a 0% discount rate), 2.713 QALY’s 
gained (assuming a 5% discount rate) and 2.159 QALY’s gained (assuming a 
10% discount rate). Extrapolating the health-related quality of life estimates of 
the one year hip retrospective subgroup over a 10 year period results in 2.874 
QALY’s gained (assuming a 0% discount rate), 2.219 QALY’s gained (assuming 
a 5% discount rate) and 1.766 QALY’s gained (assuming a 10% discount rate). 
Assuming that the postoperative health-related quality of life score of the 
three month hip subgroup is achieved immediately after the operation and 
that the postoperative health-related quality of life score of the one year hip 
subgroup is achieved immediately after the three month stage results in 3.395 
(0% discount rate), 2.621 (5% discount rate) and 2.086 (10% discount rate) 
QALY’s gained respectively over a 10 year period. If it is assumed that the 
postoperative health-related quality of life score of the three month hip 
subgroup is not achieved until the three month stage after the operation and 
that the postoperative health-related quality of life score of the one year hip 
subgroup is not achieved until the one year stage after the operation, the 
extrapolated QALY’s gained are 2.636, 2.035 and 1.619 respectively over 10
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years. Finally, if it is assumed that the postoperative health-related quality of 
life score of the three month hip subgroup is not achieved until the one and a 
half month stage after the operation and that the postoperative health-related 
quality of life score of the one year hip subgroup is not achieved until the 
seven and a half month stage after the operation, the extrapolated QALY's 
gained are 3.015, 2.328 and 1.853 respectively over 10 years. As a result of these 
assumptions, our results suggest 1.619-3.514 QALY's gained over a 10 year 
period. In terms of the Cost per QALY gained from hip replacement surgery, 
this is equivalent to £2,734-£l,260, using our earlier cost estimate (£4,426, page 
72. Amongst the knee patients, extrapolating the health-related quality of life 
estimates of the one year retrospective subgroup over a 10 year period results 
in 2.129 QALY's gained (assuming a 0% discount rate), 1.644 (assuming a 5% 
discount rate) and 1.308 (assuming a 10% discount rate). This translates into a 
Cost per QALY for knee replacement surgery of £2,490-£4,054, using our 
earlier cost estimate (£5,302, page 72).
3.422 Retrospective Group: Change in Quality of Life for Individual Functions
Appendices 13-17 summarize the change in rating scores for individual 
functions between the retrospective and postoperative stages. The scales to 
each question are listed, as are the number of subjects who fall into each 
category of each scale at the retrospective and postoperative stages. Once 
again, the chisquare test is used to test the null hypothesis that no 
improvements in health-related quality of life occur after the operation. 
Appendix 13 summarizes the results of the three month hip subgroup, 
Appendix 14 the results of the one year hip subgroup and Appendix 15 the 
results of the two year hip subgroup. Appendices 16 and 17 summarize the 
results of the two knee subgroups.
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Significant improvements in the ability to undertake everyday functions 
are evident in every subgroup. There were significant improvements (at the 
0.05 level) in every subgroup in pain reduction, in the ability to sleep without 
noticeable discomfort, in the ability to walk distances without noticeable 
discomfort, in the ability to bend knees without noticeable discomfort, in the 
ability to climb stairs without noticeable discomfort and in the ability to sit 
down on and get up off chairs without noticeable discomfort. The chisquare 
values also reveal some interesting trends. There were consistent 
improvements over the periods of estimation in all categories apart from the 
ability to bathe, the ability to cook, assistance in the home and confinement to 
a chair. This can be accounted for, however, by the high preoperative ratings 
for these functions. As in our discussion of the control group results, our 
conclusion is that future health status measurement studies of patients who 
have undergone hip and knee joint replacement surgery should concentrate 
on measuring changes within the functions most likely to show 
improvements (pain, sleeping, walking, bending knees, climbing stairs and 
sitting down on and getting up off chairs).
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Table 3.5 - Retrospective Group: Summary of Rosser-Kind Rating Scores for 
each Retrospective Period and Operation Site Subgroup at the Postoperative 
and Retrospective Stages of Interview
SUBPORKR MYPORKR SUBRERKR MYRERKR SUBPORKR-
SUBRERKR
MYPORKR-
MYRERKR
TOTAL
GROUP
0.95282 0.94465 0.7251 0.7156 022772 0.22905
TOTAL
HIP
GROUP
0.9522 0.94531 0.7102 0.7074 0.2420 0.23791
HIPS:
THREE
MONTHS
0.95180 0.94383 0.6004 0.6254 0.3514 0.31843
HIPS:
ONE
YEAR
0.9359 0.9276 0.6485 0.6249 0.2874 03027
HIPS:
TWO
YEARS
0.96493 0.95745 0.8035 0.7898 0.16143 0.16765
TOTAL
KNEE
GROUP
0.95435 0.94288 0.7616 0.7375 0.19275 020538
KNEES:
THREE
MONTHS
0.9161 0.8940 0.7922 0.8007 0.1239 0.0933
KNEES:
ONE
YEAR
0.96691 0.95840 0.7540 0.7189 021291 02395
TOTAL
MALE
GROUP
0.97227 0.96868 0.7666 0.7518 020567 0.21688
TOTAL
FEMALE
GROUP
0.9432 0.9333 0.7046 0.6985 0.2386 02348
Abbreviations :
MYPORKR : Derived mean postoperative Rosser-Kind rating score 
MYRERKR : Derived mean retrospective Rosser-Kind rating score 
SUBPORKR : Subjects' mean postoperative Rosser-Kind rating score 
SUBRERKR : Subjects' mean retrospective Rosser-Kind rating score
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3.5 Matched Control Group and Retrospective Group Patients
In order to compare the results from the control group and retrospective 
group analyses, the retrospective group patients have been matched to the 
control group patients in terms of age, sex and operation site. Where possible, 
the matched patients are of the same sex and are within five years of each 
other in terms of age at operation. As can be seen in the two appendices 
(Appendices 18 and 19), an attempt to match each hip patient in the control 
group to one patient in the three month retrospective hip subgroup, two 
patients in the one year retrospective hip subgroup and two patients in the 
two year retrospective hip subgroup has been made (Appendix 18). Likewise, 
an attempt to match each knee patient in the control group to one patient in 
the three month retrospective knee subgroup and two patients in the one 
year retrospective knee subgroup has been made (Appendix 19). The mean 
Rosser Kind rating scores of the matched patients are shown in Tables 3.6 
(page 92) and 3.7 (page 93).
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Table 3.6: Matched Hips Group: Rosser-Kind Rating Scores of the Hip Patients 
Matched Between the Control and Retrospective Groups
Postoperative
Period
Control Hip Patients Retrospective Hip Patients
Three Months MYPRERKR = 0.8246 
MYPORKR = 0.95950 
MYRERKR = 0.8241
MYPORKR = 0.94506 
MYRERKR = 0.6704
One Year Sample 1:
MYPORKR = 0.9572 
MYRERKR = 0.597
Sample 2:
MYPORKR = 0.9401 Z
MYRERKR = 0.7038
Average:
MYPORKR = 0.9505 
MYRERKR = 0.619
Two Years Sample 1:
MYPORKR = 0.97439 
MYRERKR = 0.8379
Sample 2:
MYPORKR = 0.9525 
MYRERKR = 0.7816
Average:
MYPORKR = 0.96343 
MYRERKR =0.8098
Abbreviations :
MYPRERKR : Derived preoperative Rosser-Kind rating score 
MYPORKR : Derived postoperative Rosser-Kind rating score
MYRERKR : Derived retrospective Rosser-Kind rating score
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Table 3.7: Matched Knees Group: Rosser-Kind Rating Scores of the Knee 
Patients Matched Between the Control and Retrospective Groups
Postoperative
Period
Control Knees Patients Retrospective Knees Patients
Three Months MYPRERKR = 0.8502 
MYPORKR = 0.94606 
MYRERKR = 0.7808
MYPORKR = 0.8940 
MYRERKR = 0.8007
One Year Sample 1:
MYPORKR = 0.95204 
MYRERKR = 0.7224
Sample 2:
MYPORKR = 0.96645 
MYRERKR = 0.6790
Average:
MYPORKR = 0.95606 
MYRERKR = 0.7303
Abbreviations :
MYPRERKR : Derived preoperative Rosser-Kind rating score 
MYPORKR : Derived postoperative Rosser-Kind rating score
MYRERKR : Derived retrospective Rosser-Kind rating score
Table 3.6 (page 92) shows that, after the retrospective group patients have 
been matched to the control group patients in terms of age, sex and operation 
type, slightly different results are obtained than the overall retrospective 
group results in Table 3.5 (page 90). Amongst the matched retrospective hip 
samples, the postoperative Rosser-Kind rating scores increase consistently up 
until the second year, confirming our earlier inference that the highest rating 
score is achieved after the second year. Our overall retrospective group result 
in Table 3.5 (page 90) that amongst patients who have hip replacements, a 
higher Rosser-Kind rating score is achieved at three months following the 
operation than at one year following the operation, is not repeated in this 
analysis. As mentioned above, it was probably the case that the overall one 
year retrospective hip sample in Table 3.5 (page 90) included a number of 
patients with abnormally low rating scores (this is supported by the evidence
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that the mean rating score of the sample was lower than the median). Further 
evidence is provided by the mann-whitney test between the matched three 
month hip sample and the average matched one year hip sample. This test 
found the difference between the medians of these two samples (0.951 and 
0.9659 respectively) were significantly different at the 0.0363 level. After the 
patients have been matched therefore, the evidence indicates a continuous 
increase in the Rosser-Kind rating score up until and beyond the second year.
Using the mann-whitney test, there were no significant differences 
between the median retrospective rating score of the control group hip 
patients and the median retrospective rating scores of the matched sample 
patients. The significance levels between the median retrospective rating 
scores of the control group hip patients and the matched three month, one 
year and two year samples were 0.1297, 0.1226 and 0.6662 respectively.
Table 3.7 (page 93) confirms our earlier conclusion that amongst patients 
who have undergone knee joint replacement surgery, significant 
improvements in health-related quality of life are achieved between three 
months and one year following the operation, and that the highest Rosser- 
Kind rating score is achieved after the first year. The median postoperative 
rating scores of the matched three month and matched one year knee samples 
(0.928 and 0.9595 respectively) were significantly different at the 0.0679 level. 
Further, the retrospective estimate of the knee control group was not 
statistically different from those of the matched retrospective groups at three 
months (0.5059 significance level) and at one year (0.8994 significance level). 
This evidence increases the validity of the use of retrospective estimates.
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4.1 Introduction
In this chapter, the attempt by Gudex (1986) to use cost per quality adjusted 
life year (QALY) data as a means of determining the efficient allocation of 
health service resources is analysed. This study was selected for analysis in 
recognition of the fact that it was an early attempt to open up the debate on 
the application of cost utility analysis to health care. The chapter does not 
discuss the theoretical assumptions underlying QALY’s, but rather works 
within a debatable framework and discusses the problems involved in 
calculating and applying QALY's. Specifically, this involves analysing the 
sensitivity of Gudex's cost utility calculations to her underlying assumptions. 
In the first section, Gudex's main arguments are outlined. This is followed by 
a discussion of the underlying assumptions of the study. The main body of 
the chapter then presents an extensive sensitivity analysis of those 
underlying assumptions and will allow us to gauge the confidence with 
which we can use Gudex's results. Finally, some conclusions are offered.
4.2 Summary of Gudex Study
Gudex (1986) incorporates quality-adjusted life-years (QALY's) into Cost per 
QALY data in an attempt to formulate efficient criteria when allocating health 
service resources. Using seven medical programmes as examples, she 
illustrates how both costs and health outcomes should be taken into account 
when determining priorities in the competition for finite resources. The 
seven medical programmes which Gudex focuses on are CAPD, 
haemodialysis, the treatment of cystic fibrosis with ceftazidime, kidney 
transplants, shoulder joint replacements, scoliosis surgery for idiopathic 
adolescents and scoliosis surgery for neuromuscular illness.
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QALY’s are used as the proxy measure of health outcome and are 
calculated using both health-related quality of life estimates and survival 
data. Gudex obtained the health-related quality of life estimates by converting 
the information in the available medical literature into the 'Classification of 
Illness States', developed by Rosser and Kind (1978) and Kind et al. (1982). The 
health-related quality of life estimates for each medical condition were then 
multiplied by ranges of potential survival periods which had been discounted 
by 5% to reflect the subjects' positive marginal rate of time preference. Hence, 
ranges of QALY’s were obtained for each of the seven medical procedures. In 
this way, it is argued, the relative benefits of each of the medical procedures 
could be combined with their relevant costs to formulate efficient resource
allocation decisions.
4.3 Assumptions Underlying Gudex Study
The first major assumption of the study is that the information on patient 
outcome for each of the seven medical conditions has been accurately 
converted into the Classification of Illness States, that is Gudex assumes that 
she has accurately converted the parameters most easily comparable to the 
disability and distress dimensions of the Rosser Classification. A discussion of 
the acceptability of the conversions of the outcome parameters in each of the 
medical studies follows in the next section, together with an extensive 
sensitivity analysis of those conversions.
A second assumption that Gudex makes is that the subjects analysed in 
each study are representative of all patients undergoing those medical 
procedures. However, as a result of the paucity of adequate outcome data 
available for the seven medical procedures under study, the papers selected as 
a basis for analysis do not all represent the diversity of characteristics present
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in the populations with their respective conditions. The study by Evans et al. 
(1985), for example, which was used to assess the health-related quality of life 
of patients with end-stage renal failure was (according to the authors 
themselves) "..limited by both the nonrepresentativeness and the size of the 
sample of centers and patients studied" (page 557). The 27 patients in the 
study by Boyle et al. (1976), who formed the basis of the health-related quality 
of life assessments of cystic fibrosis patients, had an average age of just under 
20 years. This contrasts with a median age at death of British cystic fibrosis 
patients of 17 years in 1986 [Britton (1989)], the year that the Gudex study was 
formulated. The diagnoses in the study by Collis and Ponseti (1969), which 
Gudex uses to assess the health-related quality of life of untreated scoliotics, 
have been questioned by Dickson (1983). In addition, the assumption Collis 
and Ponseti (1969) make concerning the death rate of untreated scoliotics is at 
variance with the finding of Nilsonne and Lundgren (1968) whose follow-up 
period was 20 years longer. It seems therefore that, in selecting sources of 
information on patient outcomes that are comparable to the Rosser 
Classification, Gudex may have unwittingly used studies which are not 
representative of their wider clinical populations.
A third assumption of the Gudex study is that the improved health-related 
quality of life scores attained by patient groups who have undergone surgery 
or treatment remain constant and do not deteriorate over the duration of 
their extended lives or the stated duration of improvement. However, it is 
likely that for some of the medical conditions studied, the health-related 
quality of life scores will deteriorate over that period. For patients who have 
had shoulder joint replacements, for example, the high incidence of 
loosening after 5 years is likely to have an adverse effect on the postoperative 
health-related quality of life scores. This in turn is likely to reduce the relative 
cost effectiveness of shoulder joint replacement surgery.
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A fourth assumption that Gudex makes is that the Classification of Illness 
States encompasses all the factors that are relevant to the health-related 
quality of life of all the patient groups. However, as a result of its generic 
nature, it has a tendency to include certain factors that are irrelevant to some 
patient groups (the emphasis on employment, for example, with respect to 
elderly patients) and exclude other factors which may arguably contribute to 
one's quality of life (for example, job satisfaction).
Implicit within the Rosser Classification are a number of assumptions. It is 
assumed the health state valuations have been derived from the correct 
number and combination of subjects. The group of 70 subjects used to derive 
the valuations however may be unrepresentative of the general population. 
It is assumed that health status can accurately be measured. This does not 
allow for the fact that difficulties arise when accurately defining health states 
and when ascribing proportionate values to those health states. It is assumed 
that the subjects were both knowledgeable and well informed when assigning 
preference values to the alternative health states. In reality, members of the 
general public often require advice from medically-qualified personnel 
[Mooney (1986)]. It is assumed that the patients amongst the 70 subjects, 
whose preferences form the basis of the Classification, valued the health 
states honestly. This overlooks the possible self-interest the patients may 
have felt in exaggerating their own level of health status [Drummond (1981)]. 
A similar tendency to magnify the scale of a problem may have been the 
result of subjects expressing altruistic concern for a particular illness. It is 
assumed the 70 subjects responded rationally when rating the health states. It 
is assumed that the interview method used in the development of the 
Classification has no bias on the results. In fact, the subjects' responses may 
have been influenced by the exact wording of the health state descriptions 
[Bulpitt and Fletcher (1990)]. Another possibility is that the subjects may not 
have been expressing their true preferences but rather what they thought
CHAPTER 4 100
were the 'right answers' [Thompson et al. (1984)]. Finally, it is assumed that 
the ratio scaling method used to develop the scale is the most appropriate 
method for measuring health state preferences.
The fifth assumption of the Gudex study is that information from studies 
which were performed at different times and in different places can be 
compared in the same league table. Gudex's league table compares converted 
information from the British and overseas medical literature, which covered 
a 17 year time span (1968-1985). As shall be discussed in more detail in 
Chapter 7, it is a methodological error to compare the results from studies 
which were performed at different places and in different years.
The sixth major assumption in the Gudex study is that all the appropriate 
and relevant costs have been taken into account in the cost utility 
calculations. However, we are not told which costs are included in the 
calculations (for example, whether indirect costs are included).
The final assumption of the Gudex study is that future costs and benefits 
should be discounted at a rate of 5% to reflect the subjects' positive marginal 
rate of time preference. A discussion of the acceptability of this assumption 
will follow in the next section of this chapter.
4.4 Sensitivity Analysis of Gudex Study
In this section, the assumptions which underlie Gudex's estimates of the 
benefits which accrue from each medical programme will be varied over a 
range of possible values. If, as a result of our sensitivity analyses the basic 
conclusions of the study remain unchanged, then the confidence with which 
we can use Gudex's cost utility estimates will increase. If, however, those 
conclusions are shown to be sensitive to reasonable variations in the
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assumptions, then doubts will be raised over the overall conclusions of the 
study.
Since the benefits of each medical programme are calculated by 
multiplying health-related quality of life estimates by ranges of potential 
survival periods which have been discounted by 5%, an alteration in any of 
these three variables (the health-related quality of life score, the survival 
period and the discount rate) may affect the QALY and Cost per QALY 
estimates. Sensitivity analyses will be performed on Gudex's assumptions 
about these three variables for each of the seven medical procedures. First, 
sensitivity analyses will be performed on Gudex's health-related quality of life 
and survival estimates for each of the seven medical procedures. This will be 
followed by a sensitivity analysis performed on the 5% discount rate.
4.41 Sensitivity Analysis of Quality of Life and Survival Estimates
(a) CAPD
Gudex estimates the health-related quality of life of patients receiving 
continuous ambulatory peritoneal dialysis (CAPD) by converting the 
information about 81 patients in the study by Evans et al. (1985) into the 
Rosser Classification. These 81 patients were assessed by Evans et al. (1985) 
according to the Karnofsky Index [Karnofsky and Burchenal (1949)] and, 
though it is not stated explicitly, it seems that Gudex ascribes categories from 
the Karnofsky Index into the Rosser Classification as follows:
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Table 4.1: Gudex's Conversion of the Karnofsky Index Categories into the 
Rosser-Kind Classification
Karnofsky Categories Number
of
Patients
Rosser Disability 
Categories
Rosser Distress 
Categories
No complaints; almost 
normal physical activity (A) 39 i-n A
Able to carry out normal 
physical activity at least 
part of the time (B) 20 m A
Only able to carry out 
physical activity 
involving self-care (C) 10 IV B
Requires at least some 
assistance for care of bodily 
needs; may require special 
care; often debilitated (D) 12 V-VI C
Requires institutionalization 
or hospitalization; 
may be moribund (E) 0 VII-VIII D
Gudex then multiplied the proportion of the 81 patients in each Rosser 
Disability/Distress Category by the valuation for that category. In this way, she 
obtained a health-related quality of life score of 0.96 for patients receiving 
CAPD. In her final cost utility calculations, she assumes a survival period of 4 
years, resulting in an estimate of 3.4 QALY's gained per patient (after 
discounting). With an annual cost per patient of £12,866 (1986 prices), Gudex's 
final Cost per QALY estimate per patient is £13,434.
Appendix 20 summarizes a sensitivity analysis of Gudex's conversion of 
the Karnofsky Categories into Rosser Disability/Distress Categories. The 
Appendix illustrates the robustness of Gudex's Cost per QALY estimate for 
CAPD, despite a rigourous testing of the effects of alternative conversions. 
The Cost per QALY estimates in the sensitivity analysis of 14 alternative, 
reasonable scenarios fluctuate over a very narrow range (£13,110-£l4,499). 
This compares favourally to Gudex's estimate of £13,434. In addition, the 
sensitivity analysis of potential survival periods has little effect on the Cost 
per QALY estimates, since the increased cost of treatment and annual QALY's
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gained per patient tend to cancel each other out. The table below illustrates 
the insensitivity of Gudex's Cost per QALY estimate for CAPD; the sensitivity 
analysis has no effect on her cost utility rankings of the seven medical 
procedures.
Table 4.2: Gudex’s Cost Utility Rankings after Sensitivity Analysis of CAPD 
Data
Procedure Cost per QALY
CAPD £13,110-£14,499
Haemodialysis £9,075
Treatment of cystic fibrosis 
with ceftazidime £8,225
Scoliosis surgery - 
idiopathic adolescent £2,619
Kidney transplant £1,413
Shoulder joint replacement £592
Scoliosis surgery - 
neuromuscular illness £194
(b) Haemodialysis
Gudex estimates the health-related quality of life of patients receiving 
haemodialysis by converting the information available in three medical 
studies [Bonney et al. (1978), Evans et al. (1985) and Procci (1980)] into the 
Rosser Classification. The first two of these studies provided information on 
the health-related quality of life of patients on both home and hospital 
haemodialysis, whilst the third study only provided information on the 
health-related quality of life of patients on hospital haemodialysis. In her 
final cost utility calculations, Gudex uses the information in the study by 
Procci (1980) to estimate a health-related quality of life score of 0.94. Assuming 
a survival period of 8 years, an estimate of 6.1 QALY’s gained per patient is
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arrived at (after discounting). With an annual cost per patient of £8,569 (1986 
prices), Gudex's final Cost per QALY estimate per patient is £9,075.
Gudex arrives at a health-related quality of life score of 0.94 for patients on 
hospital haemodialysis by making two sets of conversions of the Procci data. 
The first set of conversions Gudex makes is from the Ruesch Disability Scores 
[Ruesch et al. (1972)], used by Procci to estimate the disability of 16 patients, 
into Rosser Disability Categories. The Disability Scores are categorised as 
follows:
Table 4.3: Gudex’s Conversion of the Ruesch Disability Scores into Rosser 
Disability Categories
Ruesch Disability Score Number of 
Patients
Rosser Disability 
Category
0-20 No Social Disability 0 I
20-49 Minor Social Disability:
can continue as usual with 
home or occupational 
activities
6 n
50-79 Major Social Disability:
must alter work programme, 
if patient can work at all, 
rely on regular outside help
10 m-v
80-109 Total Social Disability:
24 hour full care or 
in an institution
0 VI-VIII
The second set of conversions Gudex makes is from the Social Modifiers 
within the Ruesch Disability Scores, which "reflect the impact that physical or 
behavioral impairment has upon the patient's life" (Gudex (1986); page 27] 
into Rosser Distress Categories. Gudex categorises the Social Modifiers as 
follows (but without any explanation of how this categorisation was decided):
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Table 4.4: Gudex’s Conversion of the Social Modifiers within the Ruesch 
Disability Scores into Rosser Distress Categories
Social Modifier Score Number of 
Patients
Rosser Distress Category
1-5 0 A
6-19 11 B
20-39 3 C
40-55 2 D
Appendix 21 summarizes an extensive sensitivity analysis of the two sets 
of conversions Gudex makes of the Procci data; 40 alternative sets of 
assumptions are presented. Alternative conversions of the Disability Scores 
and Social Modifier Scores into Rosser Disability / Distress Categories have 
little effect on the final Cost per QALY estimate for haemodialysis. Indeed, the 
Cost per QALY estimate only varies between £8,741 and £9,656 as a result of 
the sensitivity analysis, compared to Gudex's estimate of £9,075. In addition, a 
sensitivity analysis of the potential survival periods of between 2 and 10 years 
only leads to a small variation in the Cost per QALY estimate (less than £30). 
This is the result of the recurring annual costs for haemodialysis 
counterbalancing the annual QALY’s gained per patient. The table below 
illustrates how the sensitivity analyses do not alter Gudex's cost utility 
rankings for the seven medical procedures:
Table 4.5: Gudex’s Cost Utility Rankings after Sensitivity Analysis of 
Haemodialysis Data
Procedure Cost per QALY
CAPD £13,434
Haemodialysis £8,741 -£9,656
Treatment of cystic fibrosis 
with ceftazidime £8,225
Scoliosis surgery - 
idiopathic adolescent £2,619
Kidney transplant £1,413
Shoulder joint replacement £592
Scoliosis surgery - 
neuromuscular illness £194
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Gudex also estimates the health-related quality of life of patients receiving 
haemodialysis by converting the information about 634 patients in the study 
by Evans et al. (1985) into the Rosser Classification. By ascribing categories 
from the Karnofsky Index into the Rosser Classification (as described on page 
102), she estimates a health-related quality of life score of 0.97 for the 287 
patients treated with home haemodialysis and a health-related quality of life 
score of 0.95 for the 347 patients treated with hospital haemodialysis. These 
health-related quality of life scores are tabulated in the main body of the 
paper, but do not affect the final cost utility estimate of haemodialysis 
treatment (which Gudex bases on the conversions from the Procci study).
Appendix 22 summarizes a sensitivity analysis of Gudex's conversion of 
the Karnofsky Categories into Rosser Disability/Distress Categories; fourteen 
alternative scenarios are presented. As in Appendix 21, the sensitivity 
analysis illustrates the robustness of Gudex's cost utility estimate for 
haemodialysis treatment. The Cost per QALY estimates vary between £8,659 
and £9,114 for home haemodialysis treatment, and between £8,833 and £9,855 
for hospital haemodialysis treatment. This compares to Gudex's estimate of 
£9,075 for 'haemodialysis' treatment. As in Appendix 21, the sensitivity 
analysis of potential survival periods has little effect on the Cost per QALY 
estimates, and Gudex's cost utility rankings of the seven medical procedures 
is not affected by the exercise.
(c) Renal Transplant
Gudex estimates the health-related quality of life of patients undergoing 
kidney transplantation by converting the information available in two 
medical studies [Procci (1980), Evans et al. (1984)] into the Rosser 
Classification. In her final cost utility calculations, Gudex uses the
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information in the study by Procci (1980) to estimate a health-related quality 
of life score of 0.96. With the additional assumptions of a 10 year survival 
period and a total one-off cost per patient of £10,452 (1986 prices), the final 
Cost per QALY estimate arrived at is £1,413.
Gudex arrives at a health-related quality of life score of 0.96 for patients 
undergoing kidney transplantation by making two sets of conversions of the 
Procci data for 16 patients into the Rosser Classification (the conversions are 
explained on pages 104-105). Appendix 23 tabulates the sensitivity of Gudex's 
Cost per QALY estimate to alternative conversions of the Procci data into the 
Rosser Classification. The sensitivity analysis presents 40 alternative and 
reasonable sets of conversions into the Rosser Classification. The results that 
emerge in the Appendix are quite interesting. For given potential survival 
periods, alternative conversions into the Rosser Categories make little 
difference to the final Cost per QALY estimate. This may be explained by the 
fact that renal transplantation is a procedure in which quality adjustment 
makes almost no difference. If we assume a potential survival period of 10 
years, for example, the alternative conversions into the Rosser Categories 
only lead to a £43 difference in the Cost per QALY estimates (£1,381-£1,424). 
However, a sensitivity analysis of the potential survival periods leads to a 
wide variation in the Cost per QALY estimates. This is the result of the one- 
off cost for a kidney transplant reducing the average annual cost per patient as 
the potential survival period increases. The table below illustrates how the 
assumption of a four year survival period reduces the cost effectiveness of 
kidney transplantation, and alters Gudex's cost utility rankings for the seven 
medical procedures (the pre-sensitivity analysis rankings are shown in 
brackets):
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Table 4.6: Gudex’s Cost Utility Rankings after Sensitivity Analysis of Kidney
Procedure Cost per QALY
CAPD £13,434 (1)
Haemodialysis £9,075 (2)
Treatment of cystic fibrosis 
with ceftazidime £8,225 (3)
Kidney transplant £3,003-£3,101 (5)
Scoliosis surgery - 
idiopathic adolescent £2,619 (4)
Shoulder joint replacement £592 (6)
Scoliosis surgery - 
neuromuscular illness £194 (7)
A sensitivity analysis was also carried out on Gudex’s conversion of the 
Evans data into the Rosser Classification. Evans et al. (1984) had assessed 144 
patients, who had undergone kidney transplantation, according to the 
Karnofsky Index. Gudex ascribed categories from the Karnofsky Index into the 
Rosser Classification according to the procedure described previously (page 
102). Appendix 24 tabulates the sensitivity analysis of Gudex's conversion of 
the Karnofsky Categories into Rosser Disability/Distress Categories. In the 
Appendix, 14 alternative sets of conversions into the Rosser Classification are 
presented. As in Appendix 23, for given survival periods, alternative 
conversions of the Karnofsky Categories into Rosser Disability/Distress 
Categories have little effect on the Cost per QALY estimate for kidney 
transplantation. However, reducing the potential survival periods also 
reduces the cost effectiveness of kidney transplantation. Assuming a survival 
period of 4 years, for example, alters Gudex’s cost utility rankings of the seven 
medical procedures (Table 4.6).
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(d) Upper Limb Joint Replacement Surgery
Gudex estimates the health-related quality of life of patients undergoing 
shoulder joint replacement surgery by converting the patient outcome data in 
three medical studies [Clayton et al. (1982), Cofield (1984) and Neer et al. 
(1982)] into the Rosser Classification. Of these three studies, her final cost 
utility estimate is based on the conversions of the outcome data of 29 
shoulder replacements evaluated by Cofield (1984). This author had evaluated 
29 shoulder replacements in patients with rheumatoid arthritis, 31 shoulder 
replacements in patients with osteoarthritis and 13 shoulder replacements in 
patients with post-traumatic arthritis. Gudex graded the preoperative health- 
related quality of life of the patients in Rosser Categories IV-VC-D since all the 
patients suffered either moderate or severe pain and the range of motion of 
their shoulder joints was significantly impaired. She also estimated the 
postoperative health-related quality of life of the patients by categorising their 
success in an exercise programme into the Rosser Classification as follows:
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Table 4.7: Gudex’s Conversion of Cofield’s Exercise Programme Categories 
into the Rosser-Kind Classification
Cofield’s Exercise Programme 
Categories
Number of 
Shoulders
Rosser Categories
A: Excellent: No or slight pain, patient 
satisfied. Full use of shoulder.
Muscle strength near normal.
Able to do usual work and strenuous 
activity, eg, tennis, golf.
6 IA
B: Satisfactory: Slight or moderate pain 
only with vigorous activity. Patient 
satisfied, good use of shoulder for 
full daily function, minimum of
30% normal muscle strength.
11 H-IHB
C: Unsatisfactory: Above criteria 
not met.
7 IV-VC-D
D: Limited Goals Rehabilitation. 
Successful: No, slight or moderate pain 
only with vigorous activity.
3 IVB
E: Limited Goals Rehabilitation. 
Unsuccessful: Above criteria not met.
2 VD
By multiplying the proportion of the patients who fell into each Rosser 
Disability/Distress Category by the valuation for that category, Gudex obtained 
a postoperative health-related quality of life score of 0.93 for the patients 
suffering from rheumatoid arthritis, a postoperative health-related quality of 
life score of 0.96 for the patients suffering from osteoarthritis and a 
postoperative health-related quality of life score of 0.95 for the patients 
suffering from post-traumatic arthritis.
Her final cost utility calculations are based on the health-related quality of 
life of the osteoarthritis patients. Assuming a joint survival period of 10 years 
and a total one-off cost of £533 (1986 prices) for a shoulder joint replacement, a 
final Cost per QALY estimate of £592 is attained (after discounting).
Appendix 25 summarizes the effects of alternative and reasonable 
assumptions concerning the preoperative health-related quality of life of 
shoulder joint replacement patients, the categorisation of the full exercise 
programme categories into Rosser Categories and the joint replacement
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durations, on the final Cost per QALY estimate. The Appendix is split into 
three sections which tabulate the sensitivity analyses of the outcome data for 
the rheumatoid arthritis, osteoarthritis and post-traumatic arthritis groups 
respectively.
The Appendix illustrates the sensitivity of Gudex's Cost per QALY estimate 
to her assumptions. Amongst the rheumatoid arthritis group, when a joint 
replacement duration of 10 years is assumed, 59 of the 160 examples of the 
sensitivity analysis result in Cost per QALY estimates which are large enough 
to alter Gudex's cost utility rankings of the seven medical procedures. When 
a joint replacement duration of 8 years is assumed, 68 of the 160 examples of 
the sensitivity analysis result in Cost per QALY estimates which are large 
enough to alter Gudex's cost utility rankings of the seven medical procedures. 
When a joint replacement duration of 5 years is assumed, this proportion 
rises to 98 out of the 160 examples. The respective figures for the osteoarthritis 
group are 44, 50 and 70 (out of 132 examples). For the post-traumatic arthritis 
group, the respective figures are 59, 72 and 100 (out of 178 examples).
The sensitivity of Gudex's Cost per QALY estimate for shoulder joint 
replacement surgery can be illustrated with an example from the rheumatoid 
arthritis group. Let us assume that preoperative health-related quality of life 
is graded as Rosser Category IVC-D and that postoperatively, the full exercise 
programme categories are converted into Rosser Categories as follows: A=IB, 
B=II-IIIB, C=IV-VC-D, D=IVB and E=VD. Let us also assume that the duration 
of a joint replacement is 10 years. Despite these very minor changes to 
Gudex's assumptions, the Cost per QALY estimate increases almost fivefold 
to £2,805 and Gudex's cost utility rankings of the seven medical procedures 
are altered as follows (with the pre-sensitivity analysis rankings shown in 
brackets):
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Table 4.8: Gudex's Cost Utility Rankings after Sensitivity Analysis of Shoulder
Procedure Cost per QALY
CAPD £13,434 (1)
Haemodialysis £9,075 (2)
Treatment of cystic fibrosis 
with ceftazidime £8,225 (3)
Shoulder joint replacement £2,805 (6)
Scoliosis surgery - 
idiopathic adolescent £2,619 (4)
Kidney transplant £1,413 (5)
Scoliosis surgery - 
neuromuscular illness £194 (7)
Thus, Gudex's Cost per QALY estimate for shoulder joint replacement 
surgery is shown to be sensitive to her assumptions. This sensitivity is not 
confined to the assumption concerning the duration of the shoulder joint 
(since the cost of the operation occurs on a one-off basis, one would expect the 
cost effectiveness of the medical procedure to increase as the benefits accruing 
from the operation are enjoyed over a longer period). Rather, the Cost per 
QALY estimate is also very sensitive to Gudex’s assumptions concerning 
preoperative health-related quality of life and the conversion of Cofield's full 
exercise programme categories into Rosser Categories.
Gudex also estimated the health-related quality of life of a group of patients 
who had elbow joint replacements, though this medical procedure does not 
feature in her final cost utility 'league table'. The source of patient outcome 
was a study by Soni and Cavendish (1984) who evaluated the success of 80 
elbow joint replacements in 65 patients. Gudex converted the outcome data 
on function and pain into Rosser Categories as follows:
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Table 4.9: Gudex's Conversion of Soni and Cavendish Function Categories
into Rosser Disability Categories
Soni and Cavendish 
Function Categories
Number of 
Elbows- 
Before 
Operation
Number of 
Elbows- 
After 
Operation
Rosser
Disability
Categories
A: Excellent: Stable, good 
range of movement.
0 42 i-n
B: Good: Complications 
requiring revision but 
patient satisfied.
0 15 m
C: Fair: Discomfort but 
could carry out some 
daily activities.
80
9 IV
D: Poor: Poor range of 
motion, patient 
dissatisfied
14 V
Table 4.10: Gudex's Conversion of Soni and Cavendish Pain Grading 
Categories into Rosser Distress Categories
Soni and 
Cavendish
Pain Grading 
Categories
Number of 
Elbows- 
Before 
Operation
Number of
Elbows-
After
Operation
Rosser
Distress
Categories
a. Normal 3 65 A
b. Slight 7 10 B
c. Moderate 27 5 C
d. Severe 43 0 D
As a result of these conversions, Gudex estimated a preoperative health- 
related quality of life score of 0.85 and a postoperative health-related quality of 
life score of 0.98. Assuming a joint survival of 5 to 8 years, she calculated that 
the QALY's gained per patient were 0.5-0.9.
Appendix 26 tabulates a sensitivity analysis of Gudex's conversion of Soni 
and Cavendish's Function Categories into Rosser Disability Categories at the 
preoperative and postoperative stages. The Appendix presents 96 alternative 
sets of conversions of the categories into the Rosser Classification. As in the
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shoulder joint replacement sensitivity analysis, the final Cost per QALY 
estimate is shown to be sensitive to both the conversion into the Rosser 
Classification and the assumed duration of the joint Assuming that an elbow 
joint replacement costs £533 (1986 prices), the extremes in the possible Cost 
per QALY estimates vary thirtyfold.
(e) Ceftazidime Treatment of Cystic Fibrosis
Gudex's estimate of the health-related quality of life of cystic fibrosis 
patients is based on the psychological adjustment of 27 young adults studied 
by Boyle et al. (1976). All the patients in this study had been given a rating 
score according to one of two disease-specific scales, the National Institute of 
Health (NIH) Clinical Score of Taussig et al. (1973) or the Shwachman and 
Kulczycki scale (1958). Gudex argues that these two scores are good indicators 
of general activity and converts them into Rosser Disability Categories as 
follows:
Table 4.11: Gudex's Conversion of Cystic Fibrosis Clinical Scores into Rosser 
Disability Categories
Taussig / Shwachman 
and Kulczycki Score
Number of Patients Rosser Disability 
Category
86-100 5 I
71-85 8 n
56-70 9 m-iv
41-55 4 V-VI
0-40 1 vn
Gudex categorizes both clinical scores into the same Rosser Disability 
Categories, even though the scores are composed of different elements. 
Indeed, Shwachman and Kulczycki consider patient status to be excellent 
when their score is over 85, good when their score is between 71 and 85, mild 
when between 56 and 70, moderate between 41 and 55, and severe when 40 or
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below. Taussig et al., on the other hand, consider patients with NIH scores of 
91 to 100, 81 to 90, 71 to 80, 61 to 70, and less than 60 as having excellent, very 
good, good, fair, and poor prognoses, respectively. It seems therefore that 
Gudex may be mistaken in categorizing both clinical scores into the same 
Rosser Disability Categories (a more detailed discussion of Gudex's 
assumptions concerning the health-related quality of life of cystic fibrosis 
patients follows in the Chapter 5). Boyle et al. also graded the 27 patients in 
terms of daily coping skills which Gudex converts into Rosser Distress 
Categories as follows:
Table 4.12 : Gudex’s Conversion of Boyle et al’s Daily Coping Skills Categories
into Rosser Distress Categories
Boyle et al's Daily 
Coping Skills
Number of Patients Rosser Distress 
Categories
Good 13 B
Fair 6 C
Poor 8 D
After the two sets of conversions, Gudex multiplied the proportion of the 
27 patients who fell into each Rosser Disability/Distress Category by the 
valuation for that category, and obtained a health-related quality of life score 
of 0.91 for cystic fibrosis patients on 'established treatment'. However, Boyle et 
al. do not inform us of the treatment of the 27 subjects, and Gudex does not 
define the term 'established treatment'.
Gudex then makes the assumption that ceftazidime treatment does not 
reduce patient disability, but leads to half the patients in each distress category 
moving up to the next highest distress category. As a result, the average 
health-related quality of life score of the Boyle et al. group of subjects increases 
to 0.94. Combined with the additional assumptions of an annual cost per 
patient of £250 (1986 prices) and a treatment duration of 22 years, the final 
Cost per QALY estimate is £8,225.
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Appendix 27 tabulates a sensitivity analysis of Gudex's conversion of the 
two clinical scores into Rosser Disability Categories. It also tabulates a 
sensitivity analysis of Gudex's conversion of the Daily Coping Skills 
Categories into Rosser Distress Categories for patients on 'established' and 
ceftazidime treatment. Fourteen alternative sets of conversions into the 
Rosser Classification are presented. A more detailed analysis of Gudex's 
assumptions will be discussed in Chapter 5, but what is clear from this 
sensitivity analysis of her conversions into the Rosser Classification is that 
her final Cost per QALY estimate is very sensitive to her assumptions. For 
example, let us assume that the two clinical scores are converted into Rosser 
Disability Categories as follows: 81-100=1, 70-80=11, 50-69=HI-IV, 40-49=V-VI 
and 0-39=VIE. Let us also assume that for patients on 'established' treatment, 
the Daily Coping Skills Categories are converted into Rosser Distress 
Categories as follows: Good=B, Fair=C and Poor=D, and that ceftazidime 
treatment results in all patients in each Distress Category moving up to the 
next highest category. Leaving the assumption of the treatment duration 
unchanged, the Cost per QALY estimate increases to £12,658. This alters 
Gudex's cost utility rankings of the seven medical procedures as follows (with 
the pre-sensitivity analysis rankings shown in brackets):
Table 4.13: Gudex’s Cost Utility Rankings after Sensitivity Analysis of 
Ceftazidime Treatment of Cystic Fibrosis Data (1) 
Procedure Cost per QALY
CAPD £13,434 (1)
Treatment of cystic fibrosis 
with ceftazidime £12,658 (3)
Haemodialysis £9,075 (2)
Scoliosis surgery - 
idiopathic adolescent £2,619 (4)
Kidney transplant £1,413 (5)
Shoulder joint replacement £592 (6)
Scoliosis surgery - 
neuromuscular illness £194 (7)
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Alternatively, let us assume that the two clinical scores are converted into 
Rosser Disability Categories as follows: 86-100=1, 75-85=11, 65-74=ni-IV, 50- 
64=V-VI and 0-49=VII. Let us also assume that for patients on established 
treatment, the Daily Coping Skills Categories Good, Fair and Poor are 
converted into Rosser Distress Categories B, C and D respectively, and that 
ceftazidime treatment results in all patients in each Distress Category moving 
up to the next highest category. Assuming a treatment duration of 23 years, 
the Cost per QALY estimate decreases to £2,278. This alters Gudex's cost utility 
rankings of the seven medical procedures as follows (with the pre-sensitivity 
analysis rankings shown in brackets):
Table 4.14: Gudex's Cost Utility Rankings after Sensitivity Analysis of 
Ceftazidime Treatment of Cystic Fibrosis Data (2)
Procedure Cost per QALY
CAPD £13,434 (1)
Haemodialysis £9,075 (2)
Scoliosis surgery - 
idiopathic adolescent £2,619 (4)
Treatment of cystic fibrosis 
with ceftazidime £2,278 (3)
Kidney transplant £1,413 (5)
Shoulder joint replacement £592 (6)
Scoliosis surgery - 
neuromuscular illness £194 (7)
Thus, Gudex's Cost per QALY estimate for ceftazidime treatment of cystic 
fibrosis is shown to be sensitive not only to her conversions of the outcome 
data into the Rosser Classification, but also her assumption concerning the 
duration of ceftazidime treatment. The sensitivity analysis of her 
assumptions results in Cost per QALY estimates which shift the procedure 
between second and fourth place in the 'league table' of the seven medical 
programmes.
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(f) Treatment for Idiopathic Adolescent Scoliosis
Gudex estimates the health-related quality of life of patients treated for 
idiopathic adolescent scoliosis by converting the outcome data presented by 
Van Grouw et al. (1976) into the Rosser Classification. Van Grouw et al. (1976) 
had evaluated 51 patients, who underwent surgery for idiopathic adolescent 
scoliosis between 1960 and 1966, over an average follow-up period of 10.2 
years. They recorded the experience of activity and pain of these patients 
which Gudex converts into Rosser Disability and Distress categories as 
follows:
Table 4.15 : Gudex's Conversion of Van Grouw et al. Activity Categories into 
Rosser Disability Categories
Van Grouw et al. Activity Categories Number of 
Patients
Rosser Disability 
Categories
I: Indoor activities of a sedentary 
nature which were least strenuous 
such as reading, art or sewing.
3 IV
n 8 IV
in 28 m
IV: Most strenuous activities which 
demanded endurance and placed the 
most significant stresses on the back 
such as skiing, mountain climbing 
and all contact sports.
12 i-n
Table 4.16: Gudex's Conversion of Van Grouw et al. Pain Categories into 
Rosser Distress Categories
Van Grouw et al. Pain Categories Number of 
Patients
Rosser Distress 
Categories
Grade 1: No back symptoms 10 A
Grade 2: Rare annoying backache 12 B
Grade 3: Occasional annoying 
backache
15 C
Grade 4: Frequent but not restrictive 
annoying backache
7 C
Grade 5: Partially restrictive frequent 
to daily backache
6 D
Grade 6: Incapacitating daily back pain 1 D
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By multiplying the proportion of the 51 patients who fell into each Rosser 
Disability/Distress Category by the valuation for that category, Gudex obtains 
an average health-related quality of life score of 0.96.
Gudex also evaluated the outcome data of one other study, which is not 
named or described, and arrives at an average health-related quality of life 
score of 0.97 for treated idiopathic adolescent scoliosis. She does not mention 
how this estimate was calculated, but it is probable that it is the average of the 
health-related quality of life estimates derived from the two studies. The 
QALY’s gained from treatment were calculated by assuming untreated life 
expectancies of 40, 50, 60 and 70 years and assuming that without treatment, 
the average health-related quality of life score would fall to 0.95 at the age of 
46 and to 0.91 at the age of 60.
In her final cost utility calculations, Gudex assumes a treated life 
expectancy of 77 years, and an untreated life expectancy of 60 years. With the 
additional assumption of a total, one-off, cost of treatment of £3,143 (1986 
prices), a final Cost per QALY estimate of £2,619 is obtained.
Appendix 28 tabulates a sensitivity analysis of Gudex's conversion of Van 
Grouw et al's Activity and Pain Categories into Rosser Disability/Distress 
Categories and her assumption concerning untreated life expectancy. The 
Appendix tabulates 19 alternative conversions into the Rosser Classification. 
What emerges from the sensitivity analysis is that alternative conversions of 
the activity and pain categories into Rosser Disability/Distress Categories have 
little effect on Gudex's final Cost per QALY estimate. For example, assuming 
an untreated life expectancy of 60 years, the Cost per QALY estimates in all the 
examples of the sensitivity analysis only vary between £2,686 and £2,883. This 
has no effect on Gudex's cost utility rankings of the seven medical 
procedures. However, varying the life expectancy of untreated patients has a 
noticeable effect on the Gudex's final Cost per QALY estimate. When an 
untreated life expectancy of 50 years is assumed, the Cost per QALY estimates
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in all the examples of the sensitivity analysis vary between £1,267 and £1,367. 
This pushes the treatment for idiopathic adolescent scoliosis down the league 
table as shown below (the pre-sensitivity analysis rankings are shown in 
brackets). In other words, the medical procedure appears more cost effective.
Table 4.17: Gudex's Cost Utility Rankings after Sensitivity Analysis of 
Scoliosis Surgery for Idiopathic Adolescents Data (1)
Procedure Cost per QALY
CAPD £13,434 (1)
Haemodialysis £9,075 (2)
Treatment of cystic fibrosis 
with ceftazidime £8,225 (3)
Kidney transplant £1,413 (5)
Scoliosis surgery - 
idiopathic adolescent £1,267-£1,367 (4)
Shoulder joint replacement £592 (6)
Scoliosis surgery - 
neuromuscular illness £194 (7)
When an untreated life expectancy of 70 years is assumed, the Cost per 
QALY estimates in all the examples of the sensitivity analysis vary between 
£8,495 and £9,244 (Appendix 28). This pushes the treatment for idiopathic 
adolescent scoliosis up the league table as shown below (the pre-sensitivity 
analysis rankings are shown in brackets). In other words, the medical 
procedure appears less cost effective.
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Table 4.18: Gudex’s Cost Utility Rankings after Sensitivity Analysis of
Scoliosis Surgery for Idiopathic Ado escents Data (2)
Procedure Cost per QALY
CAPD £13,434 (1)
Haemodialysis £9,075 (2)
Scoliosis surgery - 
idiopathic adolescent £8,495-£9,244 (4)
Treatment of cystic fibrosis 
with ceftazidime £8,225(3)
Kidney transplant £1,413 (5)
Shoulder joint replacement £592 (6)
Scoliosis surgery - 
neuromuscular illness £194 (7)
Therefore, the cost effectiveness of the treatment of idiopathic adolescent 
scoliosis is very sensitive to the assumption concerning the life expectancy of 
untreated patients. The longer that life expectancy, the shorter the period over 
which the benefits of treatment are enjoyed and hence the less cost effective 
the medical procedure appears.
(g) Scoliosis Secondary to Neuromuscular Illness
When estimating the health-related quality of life of patients operated on 
for scoliosis secondary to neuromuscular illness, Gudex formulates her own 
assumptions, rather than convert outcome data available in the medical 
literature into the Rosser Classification. For patients who forgo the operation, 
a life expectancy of 30 years is assumed, whilst it is assumed that operated 
patients were surgically treated at 14 years of age and have a life expectancy of 
40 years. We are informed that the purpose of the operation is to prevent 
patients, who are already chairbound, from becoming bedridden after 14 years 
of age. Hence, Gudex conveys the alternatives as either 26 years in Rosser
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Category VID (with operation) or 16 years in Rosser Category VIID (without 
operation). As a result of these assumptions, Gudex calculates a gain in 
QALY’s from the operation of 16.2. With a total one-off cost of £3,143 (1986 
prices), the final Cost per QALY gained for scoliosis surgery secondary to 
neuromuscular illness is £194, making the procedure the most cost effective 
of the seven analysed by Gudex.
Appendix 29 summarizes the effects of alternative assumptions about the 
health states of surgically treated and surgically untreated patients and the life 
expectancy of surgically treated patients on the final Cost per QALY estimate. 
In total, 81 alternative sets of assumptions are presented. Once again, Gudex’s 
final Cost per QALY estimate is found to be sensitive to minor alterations in 
her assumptions. For example, if we slightly alter one of her assumptions and 
assume that the health state of patients who forgo the operation falls into 
Rosser Category VI-VIIC-D, the Cost per QALY estimate for surgery increases 
to £1,442. This pushes surgery for scoliosis secondary to neuromuscular 
illness up the 'league table* as shown below (the pre-sensitivity analysis 
rankings are shown in brackets). In other words, the procedure becomes less 
cost effective.
Table 4.19: Gudex’s Cost Utility Rankings after Sensitivity Analysis of 
Scoliosis Surgery for Neuromuscular Illness Data
Procedure Cost per QALY
CAPD £13,434 (1)
Haemodialysis £9,075 (2)
Treatment of cystic fibrosis 
with ceftazidime £8,225 (3)
Scoliosis surgery - 
idiopathic adolescent £2,619 (4)
Scoliosis surgery - 
neuromuscular illness £1,442 (7)
Kidney transplant £1,413 (5)
Shoulder joint replacement £592 (6)
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Therefore, the cost effectiveness of surgery for scoliosis secondary to 
neuromuscular illness is sensitive to Gudex’s assumptions about the health 
states of surgically treated and surgically untreated patients. In addition, the 
life expectancy of surgically treated patients affects the final Cost per QALY 
estimate The shorter that life expectancy, the shorter the period over which 
the benefits of treatment are enjoyed and hence the less cost effective the 
medical procedure appears.
4.42 Sensitivity Analysis of Discount Rate
The discounting process reduces the costs and benefits of health care 
programmes to their present values and allows us to compare the relative 
effectiveness of each programme with alternatives. Typically, this involves 
deflating future costs and benefits by an increasing proportion.
Discounting is necessary to reflect the preferences of individuals and of 
society as a whole for current consumption, that is we tend to place greater 
value on current resources as opposed to future resources. There are several 
possible explanations for this. First, the notion that most of us are naturally 
short-sighted and prefer the option of benefiting from resources in the 
present. Second, people's perception of inflation is likely to erode the value of 
resources over time. Third, even in an inflation-free economy, we can benefit 
from the investment of those resources and the subsequent interest which 
accrues. Fourth, we must allow for the uncertainty surrounding our future 
existence and our future investments. Finally, since consumption is likely to 
increase in the future, the principle of diminishing marginal utility implies 
that greater weight should be placed on current consumption.
Sorkin (1975), Irvin (1978), Warner and Luce (1982) and Drummond et al. 
(1987) outline the procedures required to deal with inflation in the economy 
when discounting future costs and benefits to their current values. The
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general consensus is that future cost and benefit streams should be expressed 
at current levels before discounting. In addition, Sorkin (1975) illustrates how 
productivity changes in the economy affect the calculation of the net effective 
discount rate.
The discounting process has been widely criticised. The problems involved 
in the measurement of the costs and benefits of health care programmes and 
in deciding which costs and benefits should be discounted are well 
documented [Ward (1975), Sorkin (1975), Sassone and Schaffer (1978), Cullis 
and West (1979), Mooney et al. (1980)]. Cullis and West (1979) question the 
entire logic of placing greater weight on the current consumption of health 
care resources. Despite increasing affluence, they argue, the value of health is 
likely to increase in the future. (Unlike other commodities, the demand for 
health care is virtually infinite). The utilitarian hypothesis [Dasgupta and 
Pearce (1978)] emphasizes this generation's responsibility for the welfare of 
future generations. A related criticism is the seemingly callous discounting of 
future health benefits as explained by Drummond et al. (1986). However, 
powerful counter-arguments are presented by Weinstein and Stason (1977) 
and Warner and Luce (1982).
Much disagreement surrounds the choice of an appropriate discount rate 
for health care programmes (the social discount rate). Two alternatives 
prevail: the interest rate that commercial banks charge for business loans and 
the real rate of return on long-term government bonds [Sorkin (1975), 
Drummond et al. (1987)]. Sassone and Schaffer (1978) present arguments for 
setting the social discount rate both below and above the market interest rate. 
However, a public sector discount rate recommended by the UK Treasury 
provides assistance in this technical decision.
The discounting procedure has been applied in a multitude of academic 
papers in the health care field. A striking feature of these applications is the 
range of discount rates that have been employed, though the tendency since
i »
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1980 has been to use a central rate of 5-6% with many papers also using higher 
and lower rates to test the sensitivity of their findings (Table 4.20, page 131). 
The variation that does exist between the discount rates used in the literature 
does not seem to be accounted for by the inflation rate prevailing in the 
economy at the time of the study (Table 4.20, page 131).
To test whether the basic conclusions of the Gudex study are sensitive to 
slight variations in the discount rate, a sensitivity analysis was performed on 
the assumed 5 percent rate. The Cost per QALY estimates for each of the 
seven medical procedures have been recalculated using discount rates 
between 0 percent and 10 percent. This range of discount rates was chosen to 
cover the range previously used in the health care literature (Table 4.20, page 
131). Though a 0 percent discount rate is unusual, and in some senses 
controversial, the recent favour it has found with the Department of Health 
[Parsonage and Neuburger (1991)] supports its inclusion in the sensitivity 
analysis. The discount rate was the sole variable in this sensitivity analysis. 
The health-related quality of life scores, the time horizon of each health 
programme and the annual cost of each health programme were identical to 
those estimated by Gudex.
The effects of alternative discount rates on the relative cost effectiveness of 
each of the medical procedures are displayed in Table 4.21 (page 134). Surgery 
for idiopathic adolescent scoliosis is particularly affected by the exercise. Its 
Cost per QALY increases from £191, assuming a discount rate of 0 percent, to 
£31,430 when a discount rate of 10 percent is applied. (In other words, if a 0 
percent discount rate is used, surgery for idiopathic adolescent scoliosis is the 
second most cost effective of the seven medical procedures. If a 10 percent 
discount rate is used, this procedure becomes the least cost effective). Kidney 
transplant surgery, shoulder joint replacement surgery and scoliosis surgery 
for neuromuscular illness also appear less cost effective when the discount 
rate is increased, though to a lesser degree. The cost effectiveness of CAPD,
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haemodialysis and ceftazidime treatment of cystic fibrosis remain unaffected 
by the exercise.
The effects of the application of alternative discount rates on the Costs per 
QALY for four procedures are illustrated in Figure 4.1 (page 135). These four 
procedures were selected to include the shortest and longest time spans for 
programmes with either recurring costs (CAPD and ceftazidime treatment of 
cystic fibrosis) or costs incurred only at the beginning of the programme 
(kidney transplant surgery and surgery for idiopathic adolescent scoliosis).
The effects of applying alternative discount rates can be explained as 
follows. Discounting converts the future costs and benefits of health care 
programmes to their present values by multiplying them by a weighting 
factor. This weighting factor diminishes the further in the future those costs 
and benefits arise. Let us define the time horizon of a health project as 'n' and 
the weighting factor as 'f'. As n tends to infinity then f tends to zero and as n 
tends to zero then f tends to 1. In other words, f varies inversely between 0 
and 1 depending on the time horizon of the project. It follows from this that 
whatever the discount rate the project analyst decides to use, long-lived 
projects will be penalized because benefits accruing in the distant future will 
add little to the present value of the project. The low weighting factor will 
reduce distant benefits to relatively insignificant levels.
Increases in the discount rate also progressively depreciate the present 
value of future costs and benefits. Let us define the discount rate applied to 
reduce future costs and benefits as 'r'. It follows that whatever the time 
profile of the health project, as r tends to infinity then f tends to zero and as r 
tends to zero then f tends to one. By increasing the discount rate, the project 
analyst is in effect increasing the relative importance of current consumption. 
It is clear that both the time horizon of health projects and the discount rate 
affect the value of the weighting factor. The formula for this factor is
f=(l+r)’n.
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In our sensitivity analysis of Gudex's data, both variations in the time 
profiles of the health care programmes and the application of alternative 
discount rates have noticeable effects on the relative cost effectiveness of the 
seven medical procedures. In the case of surgery for idiopathic adolescent 
scoliosis, benefits occurring in the distant future, particularly 50 years or more 
in the future, add little to present QALY's per patient. As the discount rate is 
increased, future benefits are given progressively less weight and the QALY's 
gained per patient by the procedure fall. Since costs occur on a one-off basis 
and therefore need not be discounted, the Cost per QALY estimate for the 
procedure rises dramatically. Analogous falls occur in the cost effectiveness of 
the kidney transplant, shoulder joint replacement and surgery for 
neuromuscular illness scoliosis procedures, though to a lesser degree since 
the time spans of these programmes are shorter. In the CAPD, Haemodialysis 
and treatment of cystic fibrosis with ceftazidime procedures, costs recur 
annually throughout the period of the programmes and therefore are also 
discounted to present values. The resulting effect on the relative cost 
effectiveness of these programmes of discounting future costs as well as 
future benefits is that the reduced present values will tend to cancel each 
other out. In any case, the time spans of these programmes are shorter than 
that of the surgery for idiopathic adolescent scoliosis, implying that even if 
their costs did all occur on a one-off basis and therefore did not have to be 
discounted, their relative decrease in cost effectiveness would not be quite so 
evident.
A simulation of the data Gudex uses to arrive at her results is shown in 
Figure 4.2 (page 135), comparing Costs per QALY with variations in the 
discount rate. It confirms what we have been arguing. According to the 
simulated data, Costs per QALY increase as the discount rate rises, whatever 
the time span of the health care programme. All curves slope upwards from 
left to right. In other words, increases in the discount rate reduce the present
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value of the benefits of the health care programme (QALY’s). Since the 
simulated data assumes that costs occur on a one-off basis and therefore are 
not discounted, Costs per QALY rise.
If we study the graph in more detail, we can see that Costs per QALY fall 
with increases in survival periods resulting from any of the medical 
procedures, when discount rates below 4.5 percent are applied. However, 
between discount rates of 5 and 6 percent, Costs per QALY become insensitive 
to the length of the survival period. When discount rates greater than 6 
percent are applied, Costs per QALY fall with increases in the survival period 
but only up to a certain point. For long-term survival periods, greater than 35 
years, Costs per QALY increase noticeably.
In other words, the choice of discount rate can discriminate against health 
care programmes with benefits accruing in the more distant future. A low 
discount rate extols the virtues of long-lived projects. The project analyst is, 
in effect, making a value judgment by choosing a low social discount rate. He 
is stating that society is prepared to wait for the benefits of the project. Hence, 
when costs as well as benefits are taken into account, long-lived projects with 
benefits occurring 35, 40 and 50 years into the future appear to be more cost 
effective than short-lived projects at low social discount rates. However, as 
the discount rate increases, progressively less weight is given to future 
benefits (the weighting factor diminishes). The project evaluator, perhaps 
myopically, is stating society’s preference for present over future 
consumption. High discount rates introduce a bias against long-lived projects. 
Hence, the cost effectiveness of health care programmes with benefits 
occurring in the distant future noticeably diminishes.
The above assertions have important implications and should be taken 
into account when projects allocating finite health care resources use discount 
rates to reduce future costs and benefits to their present values. It has been 
shown that the discount rate applied makes a considerable difference.
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Therefore, when the discounting process is employed to evaluate the relative 
cost effectiveness of alternative health care programmes, special 
consideration must be given to selecting the appropriate rate. Whichever rate 
is chosen, a value judgment is in fact being made on our preference for 
current over future consumption.
4.5 Conclusions
This chapter has illustrated the sensitivity of Gudex's final cost utility 
estimates to her assumptions concerning the accruing benefits from each of 
the seven medical procedures studied. Only two of the seven cost utility 
estimates, those for CAPD and Haemodialysis, were shown to be robust after 
sensitivity analyses of the three variables underlying their 'effectiveness' 
calculations (the health-related quality of life score, the survival period / 
treatment duration and the discount rate). Two other cost utility estimates, 
those for shoulder joint replacement surgery and surgery for scoliosis 
secondary to neuromuscular illness, were shown to be sensitive to all three 
variables. The cost utility estimates of renal transplantation, ceftazidime 
treatment of cystic fibrosis and scoliosis surgery for idiopathic adolescents, 
were shown to be sensitive to two of the three variables. Moreover, 
sensitivity analyses of all three variables produced results which altered 
Gudex's cost utility rankings of the seven medical procedures.
Some of the other assumptions underlying Gudex's results, for example 
that the subjects analysed in each study are representative of all patients 
undergoing those medical procedures and that the improved health-related 
quality of life scores attained by patient groups remain constant over the 
duration of their extended lives or the stated duration of improvement, are
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also debatable. A discussion of Gudex's cost estimates will follow later on in 
the thesis (Chapter 6).
This chapter has raised some important doubts about Gudex's results. It 
seems that, in focussing on sources of information on patient outcomes that 
are comparable to the Rosser Classification, she may have inadvertently based 
some of her results on unrepresentative studies [the studies by Evans et al. 
(1985) and Boyle et al. (1976) for example]. Assumptions have been made 
which are not supported by the medical literature. Moreover, no sensitivity 
analysis of her results is presented. The results of this chapter emphasize the 
importance of the accurate measurement of health-related quality of life 
estimates in cost utility calculations.
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TABLE 4.20: EXAMPLES OF ALTERNATIVE DISCOUNT RATES USED IN
PREVIOUS COST BENEFIT ANALYSES OF HEALTH CARE PROGRAMMES
YEAR OF 
STUDY
DISCOUNT 
RATE (%)
INCREASE
IN RETAIL 
PRICE 
INDEX
IN YEAR OF 
STUDY (%)*
HEALTH
CARE
PROGRAMME
REFERENCE
1958 4 3 Hospitalization 
and treatment of 
mental illness
Fein (1958)
1965 4 5 Eradication of 
syphilis
Klarman
(1965)
1966 10 . 4 Birth control Enke (1966)
1971 10 9 Treatment of
pulmonary
tuberculosis
Pole (1971)
1973 4 9 PKU screening 
programme
Steiner and 
Smith (1973)
1980 10 18 New vascular 
grafts
Adar and 
Pliskin (1980)
1980 2,6,10 18 Cancer, motor 
vehicle injuries, 
coronary heart 
disease and stroke
Hartunian 
et al. (1980)
1980 3,7 18 Epilepsy clinics Kriedel (1980)
1980 0-20 18 Treatment for 
end-stage renal 
failure
Roberts et al. 
(1980)
1980 4-15 18 Continuous 
immunization 
programme for 
measles
Ponnighaus
(1980)
1980 5 18 Estrogen use in
postmenopausal
women
Weinstein
(1980)
1980 6,10 18 X-linked recessive 
cardiac and 
humeroperoneal 
neuromuscular 
disease
Wright and 
Elsas (1980)
1981 5 12 Cholesterol 
levels in children
Berwick et al. 
(1981)
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1981 5,7,10 12 Duodenal ulcer 
treatment
Culyer and
Maynard
(1981)
1981 2-10 12 Long term 
domiciliary 
oxygen therapy
Lowson et al. 
(1981)
1981 7,10,15 12 Treatment of 
chronic renal 
failure
Ludbrook
(1981)
1981 5 12 Coronary Artery 
Bypass Graft 
Surgery
Pliskin et al. 
(1981)
1981 10 12 Alcoholism
treatment
programmes
Rundell et al. 
(1981)
1981 14 12 Prenatal detection 
of Down 
syndrome and 
neural tube 
defects in older 
mothers
Sadovnick 
and Baird 
(1981)
1982 5 9 Lead screening Berwick and
Komaroff
(1982)
1982 4,7,10 9 Screening for 
open spina bifida
Henderson
(1982)
1982 6,10,15 9 Second-opinion
programmes
Ruchlin et al. 
(1982)
1982 5 9 Coronary Artery 
Bypass Surgery
Weinstein 
and Stason 
(1982)
1983 5 5 Neonatal 
intensive care of 
very low birth 
weight infants
Boyle et al. 
(1983)
1984 5 5 Experimental 
behaviour 
programme for 
patients with 
chronic 
obstructive 
pulmonary 
disease
Toevs et al. 
(1984)
1985 4,8 6 Thalassemia
disease
prevention
programme
Ostrowsky 
et al. (1985)
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1986 5 3 Various health 
care programmes
Gudex (1986)
1986 0,10 3 North karelia 
hypertension 
programme
Nissinen 
et al. (1986)
1987 0-20 4 Health projects 
in Ghana
Barnum
(1987)
1987 6 4 Multiple
sclerosis
Inman (1987)
1987 5 4 Lithiotripsy Labelle et al. 
(1987)
1987 2 4 Compensation 
of asbestos victims
Siskind (1987)
1988 5 5 Prenatal maternal 
serum alpha-feto 
protein screening
Taplin et al. 
(1988)
.1989 5 8 External costs of 
sedentary life-style
Keeler et al. 
(1989)
1990 4,7,10 9 Prenatal diagnosis 
by amniocentesis
Goldstein and 
Philip (1990)
* Source: 'Economic Trends' - Central Statistical Office
TABLE 4.21; EFFECTS OF ALTERNATIVE DISCOUNT RATES ON THE RELATIVE COST EFFECTIVENESS OF THE
SEVEN MEDICAL PROCEDURES STUDIED BY GUDEX
Survival/
Life
Expectancy
(Years)
Cost per 
QALY
D.R. 0%
Cost per 
QALY
D.R. 2%
Cost per 
QALY
D.R. 4%
Cost per 
QALY
D.R. 6%
Cost per 
QALY
D.R. 8%
Cost per 
QALY
D.R. 10%
CAPD 4 £13,402 £13,385 £13,420 £13,388 £13,400 £13,416
Haemodialysis 8 £9,116 £9,111 £9,114 £9,112 £9,119 £9,125
Ceftazidime
treatment of 
cystic fibrosis
22 £8,333 £8,330 £8,402 £8,361 £8,226 £8,435
Kidney
transplant
10 £1,089 £1,213 £1,342 £1,478 £1,623 £1,772
Shoulder joint
replacement
10 £485 £538 £599 £658 £720 £784
Scoliosis
surgery -
idiopathic
adolescent
60 £191 £563 £1,620 £4,490 £12,088 £31,430
Scoliosis
surgery -
neuromuscular
illness
30 £132 £156 £181 £209 £239 £270
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FIG. 4.1: Relative cost effectiveness of four of the medical procedures 
studied by Gudex as a result of the application of alternative discount rates
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FIG. 4.2: A simulation of the data used by Gudex illustrating the 
relationship between Costs per QALY and the discount rate
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5.1 Introduction
In this chapter, the attempt by Gudex (1986) to use cost per quality adjusted 
life year (QALY) data to calculate the relative cost effectiveness of cystic 
fibrosis treatment with ceftazidime vis-^-vis six other medical procedures is 
analysed further. Of the seven medical procedures studied by Gudex, cystic 
fibrosis treatment with ceftazidime was selected for a more in depth analysis 
because the medical literature revealed a relatively large number of studies in 
this area which could be used as a basis for discussion and comparison. 
Initially, it was hoped that the information in the patient records of the cystic 
fibrosis patients at Ninewells Hospital, Dundee, could also be analysed. 
However, it was decided that the relatively small number of cystic fibrosis 
patients currently receiving treatment at the hospital (eight) would not 
provide us with any conclusive evidence, and hence the information 
available in the published literature forms the basis of discussion.
The chapter is structured as follows. First, Gudex's main arguments are 
outlined and a sensitivity analysis performed on her underlying 
assumptions. This is followed by a discussion of how reasonable these 
assumptions are by considering the placebo controlled trials to date and 
examining how effective antibiotics have in fact been in treating cystic fibrosis 
patients. A discussion of Gudex's cost assumptions for cystic fibrosis 
treatment will follow in a separate chapter (Chapter 6). Finally, in the light of 
the information revealed in the medical literature, some conclusions are 
offerred.
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5.2 Gudex’s Assumptions about the Antibiotic Treatment of Cystic Fibrosis
(a) Gudex's Overall Assumptions
Gudex calculated the Cost per QALY data for the seven different health care 
programmes using a method based on the Rosser-Kind Classification of 
Illness States. Of these seven programmes, the assumptions about the health- 
related quality of life of cystic fibrosis patients were based on a study by Boyle 
et al. (1976), which provided information about the psychological adjustment 
of 27 cystic fibrosis patients aged between 13 and 30 years. Of the 27 patients in 
the study, 22 were evaluated with the National Institute of Health (NIH) 
Clinical Score [Taussig et al. (1973)] and 5 were evaluated with the 
Shwachman-Kulczycki Score [Shwachman and Kulczycki (1958)]. Both scores 
are rated out of 100, but are made up of different parameters. The 
Shwachman-Kulczycki Score weights general activity, physical examination, 
nutrition and X-ray findings equally. The NIH Clinical Score, on the other 
hand, weights the pulmonary component very heavily (75 out of 100) with 
the remainder of the score made up of weight, activity and attitude. Gudex 
converted both scores into Rosser Disability Categories as follows:
Table 5.1: Gudex’s Conversion of Cystic Fibrosis Clinical Scores into Rosser 
Disability Categories
Score Rosser Disability Category
86-100 I
71-85 n
56-70 m-iv
41-55 V-VI
0-40 VII
The Boyle paper also provided information on the daily coping skills of the 
27 patients which Gudex converted into Rosser Distress Categories as follows:
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Table 5.2: Gudex’s Conversion of Boyle et al’s Daily Coping Skills Categories
Boyle et al. Daily Coping Skills Rosser Distress Category
Good B
Fair C
Poor D
Gudex then multiplied the proportion of patients in each Rosser 
disability/distress category by the valuation for that category. In this way, she 
obtained a health-related quality of life score of 0.91 for patients on the 
established treatment for cystic fibrosis. Gudex then assumed that ceftazidime 
had no significant effect on patients' levels of disability. However, she also 
assumed that half the patients in each distress category moved up to the next 
highest category when treated with ceftazidime. This increased the health- 
related quality of life score to 0.94. When the health-related quality of life 
estimates were multiplied by life expectancy assumptions (discounted by 5%), 
ranges of QALY and Cost per QALY data were obtained.
The first point to make is that Gudex's conversion of both the Shwachman 
Score and the NIH score into equivalent Rosser Disability Categories implies 
that the disparate elements which make up the two scores have the same 
overall effect on the disability of cystic fibrosis patients. However, there is 
little evidence that this should be the case. Shwachman and Kulczycki 
consider patient status to be excellent when their score is over 85, good when 
their score is between 71 and 85, mild when between 56 and 70, moderate 
between 41 and 55, and severe when 40 or below. Taussig et al., on the other 
hand, consider patients with NIH scores of 91 to 100, 81 to 90, 71 to 80, 61 to 70. 
and less than 60 as having excellent, very good, good, fair, and poor 
prognoses, respectively. In Gudex's defence, the only study to date to use both 
scores to evaluate the health-related quality of life of cystic fibrosis patients. 
Levy et al. (1984) found that they yield broadly similar results. The authors 
studied the disposition of 12 cystic fibrosis patients to tobramycin in a
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prospective controlled study. The mean Shwachman score of the patients was 
52 (range 25-90), compared to a mean NIH score of 53 (range 42-88).
A second assumption which Gudex makes is that the 27 patients studied by 
Boyle et al. (1976) are representative of all cystic fibrosis patients on 
established treatment (which she does not define). In the Boyle study, the 27 
patients had a mean overall clinical score of 69 (range 35-92). The 22 subjects 
rated by the NIH Score had a mean clinical score of 68 (range 35-92), and the 5 
subjects rated by the Shwachman Score had a mean clinical score of 71 (range 
54-86). Eleven other studies were found which used either the Shwachman 
Score or the NIH score to evaluate the health-related quality of life of cystic 
fibrosis patients. In 7 of these studies [Larsen et al. (1980), Gilbert et al. (1988), 
Strandvik (1988), Pan et al. (1989), Turck et al. (1989), Simmonds et al. (1990) 
and Sivan et al. (1990)], the mean clinical score was higher than that of the 
Boyle study. Of the four studies with lower mean clinical scores than the 
Boyle study [Hyatt et al. (1981), Mclaughlin et al. (1983), Conway et al. (1985) 
and Levy et al. (1984)], the first three were studying cystic fibrosis patients who 
were in relapse at the time of admission to hospital, so they may not be 
representative samples of cystic fibrosis patients on 'established treatment'. It 
is possible therefore that Gudex has focussed on a sample of patients whose 
health-related quality of life, as measured by the two clinical scores, is slightly 
worse than the whole population of cystic fibrosis patients on ’established 
treatment'. As an exercise the eight cystic fibrosis subjects who had been 
screened by Simmonds et al. (1990) for allergic bronchopulmonary 
aspergillosis were used as a representative sample. The mean Shwachman 
score of this group was 82 (range 70-95). When the eight subjects were 
categorized according to the Rosser Classification, the average health-related 
quality of life score rose to 0.94-0.99 (depending on the assumptions about 
distress), compared to 0.91 estimated by Gudex.
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Even if we accept that the two clinical scores have an equivalent overall 
effect on patient disability and that the 27 subjects in the study by Boyle et al. 
(1976) are representative of cystic fibrosis patients on established treatment, it 
may be the case that Gudex's overall results are sensitive to her categorisation 
of the two clinical scores and the coping skills parameter into Rosser 
Disability/Distress categories. The rigorousness of her assumptions were 
therefore tested in an extensive sensitivity analysis (Appendix 27) which 
considered 14 alternative and reasonable sets of conversions. The results of 
this sensitivity analysis are summarized below:
Table 5.3: Examples of Sensitivity Analyses of Gudex’s Quality of Life Score on
Established Cystic Fibrosis Treatmen
Example of Sensitivity Analysis Quality of Life Score on 
Established Treatment
1,2 0.96
9,10 0.95
3,4,5,6 0.94
11 0.87
12 0.86
7,8 0.81
13 0.79
14 0.78
As we can see in the table, Gudex's estimate of the health-related quality of 
life score on established treatment is sensitive to her categorisation of the two 
clinical scores and the coping skills parameters to Rosser Disability/Distress 
Categories.
Having demonstrated that Gudex's initial health-related quality of life 
score on established treatment is contingent on some debatable assumptions, 
the next section will test the sensitivity of her assumptions concerning the 
effects of ceftazidime treatment. The sensitivity of her cost utility result to the 
assumptions that ceftazidime treatment leads to half the patients in each 
Rosser Distress Category moving up to the next highest Distress Category, and
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has no effect on patient disability and survival will be tested. This sensitivity 
analysis will not vary Gudex's pre-treatment conversion of Boyle's clinical 
rating score into Rosser Disability Categories or Gudex's pre-treatment 
conversion of Boyle's coping skills grades into Rosser Distress Categories.
(b) Patient Distress
As explained above, Gudex assumes that ceftazidime treatment leads to 
half the patients in each Rosser Distress Category moving up to the next 
highest Distress Category, resulting in an increase in the average health- 
related quality of life score of the 27 study patients from 0.91 to 0.94. The 
following table summarizes the implications of a sensitivity analysis of the 
possible reductions in patient distress on the cost effectiveness of ceftazidime
treatment.
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Table 5.4: The Implications of Possible Reductions in Patient Distress on 
the Cost Effectiveness of Ceftazidime Treatment
Change in
Daily Coping 
Skills
(Indicator of 
Patient
Distress)
QALY’s 
gained over 
Established 
Treatment
Total Costs 
(Discounted 
at 5%)
Cost per
QALY
GUDEX 0.4 £3,290 £8,225
Good = A/B
Fair = B/C
Poor = C/D
0.26 £3,291 £12,658
Good - A
Fair - B
Poor = C
0.53 £3,291 £6,209
Good = A
Fair =A/B
Poor = B
0.66 £3,291 £4,986
Good = A
Fair = A
Poor = A
0.66 £3,291 £4,986
We can see from the table how sensitive Gudex's Cost per QALY estimate 
is to her assumption concerning the reduction in patient distress. In the 
second example above, assuming that patients in each of the coping skills 
grades only improve by half a Distress Category results in ceftazidime 
treatment appearing less cost effective. This has the effect of altering Gudex's 
cost utility rankings of the seven medical procedures studied as shown below, 
with the pre-sensitivity analysis rankings shown in brackets:
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Table 5.5: Effect of a Smaller Reduction in Patient Distress as a Result of
Procedure Cost per QALY
CAPD £13,434 (1)
Treatment of cystic fibrosis 
with ceftazidime
£12,658 (3)
Haemodialysis £9,075 (2)
Scoliosis surgery - 
idiopathic adolescent
£2,619 (4)
Kidney transplant £1,413 (5)
Shoulder joint replacement £592 (6)
Scoliosis surgery - 
neuromuscular illness
£194 (7)
Assuming greater reductions in patient distress than Gudex does results in 
noticeably more cost effective estimates, but without altering her cost utility 
rankings of the seven medical procedures.
(c) Patient Distress and Patient Disability
Gudex assumes that ceftazidime treatment has no effect on patient 
disability. As an exercise, the assumption that ceftazidime treatment of cystic 
fibrosis improves both patient disability (as measured by the two clinical 
scores) and patient distress was tested. The results of the exercise can be seen 
in the table below.
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Table 5.6: The Implications of Possible Reductions in Patient Distress and
Patient Disability on the Cost Effectiveness of Ceftazidime Treatment
Change in 
Clinical
Score
(Indicator of
Patient
Disability)
Change in
Daily Coping 
Skills
(Indicator of 
Patient
Distress) ;
QALY’s 
gained over 
Established 
Treatment
Total Costs 
(Discounted 
at 5%)
Cost per
QALY
GUDEX 0.4 £3,290 £8,225
0 Good = A/B
Fair = B/C
Poor = C/D
0.26 £3,291 £12,658
0 Good = A
Fair = B
Poor = C
0.53 £3,291 £6,209
0 Good = A
Fair s A/B
Poor = B
0.66 £3,291 £4,986
0 Good - A
Fair = A
Poor = A
0.66 £3,291 £4,986
+2 Good = B
Fair = C
Poor = D
0.26 £3,291 £12,658
+2 Good = A/B
Fair = B/C
Poor = C/D
0.39 £3,291 £8,438
+2 Good = A
Fair = B
Poor = C
0.66 £3,291 £4,986
+2 Good = A
Fair = A/B
Poor = B
0.66 £3,291 £4,986
+2 Good = A
Fair = A
Poor = A
0.79 £3,291 £4,166
+5 Goods B
Fair = C
Poor = D
0.39 £3,291 £8,438
+5 Good = A/B
Fair = B/C
Poor s C/D
0.53 £3,291 £6,209
+5 Good = A
Fair = B
Poor = C
0.66 £3,291 £4,986
+5 Good = A
Fair = A/B
Poor sB
0.79 £3,291 £4,166
+5 Goods A
Fair = A
Poor = A
0.79 £3,291 £4,166
+10 Goods B
Fair = C
Poor = D
0.66 £3,291 £4,986
CHAPTER 5 146
+10 Good = A/B
Fair = B/C
Poor = C/D
0.79 £3,291 £4,166
+10 Good = A
Fair = B
Poor = C
0.92 £3,291 £3,577
+10 Good = A
Fair = A/B
Poor = B
0.92 £3,291 £3,577
+10 Good = A
Fair - A
Poor = A
0.92 £3,291 £3,577
+15 Good = B
Fair = C
Poor = D
0.79 £3,291 £4,166
+15 Good = A/B
Fair = B/C
Poor = C/D
0.92 £3,291 £3,577
+15 Good = A
Fair = B
Poor = C
0.92 £3,291 £3,577
+15 Good = A
Fair = A/B
Poor = B
1.05 £3,291 £3,134
+15 Good = A
Fair = A
Poor = A
1.05 £3,291 £3,134
+20 Good = B
Fair « C
Poor = D
0.79 £3,291 £4,166
+20 Good = A/B
Fair = B/C
Poor = C/D
0.92 £3,291 £3,577
+20 Good = A
Fair « B
Poor = C
1.05 £3,291 £3,134
+20 Good = A
Fair = A/B
Poor - B
1.05 £3,291 £3,134
+20 Good = A
Fair - A
Poor = A
1.05 £3,291 £3,134
Table 5.6 illustrates the sensitivity of Gudex’s cost utility estimate to any 
reduction in patient disability, as well as patient distress. It has been assumed 
that the two clinical scores (which Gudex uses as indicators of patient 
disability) increase by up to 20 points as a result of ceftazidime treatment In 
addition, it has been assumed that patients in each of Boyle et al's Daily 
Coping Skills Categories (which Gudex uses as indicators of patient distress)
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improve by varying degrees as a result of ceftazidime treatment, the best 
possible improvement being all patients in each of the Coping Skills 
Categories moving up to Rosser Distress Category A.
The only example in the table which alters Gudex's pre-sensitivity analysis 
cost utility rankings of the seven medical procedures is the one highlighted in 
the last section. However, the Cost per QALY estimates vary between £3,134 
and £12,658, depending on the assumed reductions in disability and distress. 
In other words, the Cost per QALY estimates vary between 38% and 154% of 
Gudex's original Cost per QALY estimate. For example, assuming that 
antibiotic treatment leads to a 10 point increase in the clinical score results in 
ceftazidime treatment becoming twice as cost effective as originally estimated. 
Even a relatively small increase in the clinical score (an increase of 5 points), 
combined with a marked reduction in patient distress, results in ceftazidime 
treatment becoming twice as cost effective.
(d) Patient Distress, Patient Disability and Survival
In her final analysis, Gudex assumes that ceftazidime treatment lasts for 22 
years, and has no effect on patient survival. As she states in her paper (page 
34), this figure may be too high as it is based on the life expectancy of patients 
in specialised units [Batten (1983), Wilmott et al. (1983)]. It may be more 
sensible to assume an average life expectancy of cystic fibrosis patients of 17 
years [Britton (1989)]. As an exercise, the assumption that ceftazidime 
treatment lasts for 22 years was varied. When it was assumed that ceftazidime 
treatment lasted for either 10 years or 17 years, and did not vary any of 
Gudex's other assumptions, it had very little effect on the cost effectiveness of 
the treatment, since costs and QALY's per case recur annually and hence the 
reduced absolute numbers in both tend to cancel each other out. However,
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when it was assumed that ceftazidime treatment increases life expectancy, as 
well as reducing patient disability and distress, a noticeable effect on its cost 
effectiveness is seen (table 5.7).
As a sensitivity analysis (in brackets), it was also assumed that established 
treatment lasts for 17 years. (Even though this is a more realistic estimate, it is 
still likely to be on the high side.) The effects of a longer life expectancy of up 
to 20 years on the cost effectiveness of ceftazidime treatment are calculated.
Table 5.7: The Implications of Possible Reductions in Patient Distress and 
Patient Disability and Possible Improvements in Life Expectancy on the Cost 
Effectiveness of Ceftazidime Treatment
Change in
Clinical Score 
(Indicator of
Patient
Disability)
Change in Daily 
Coping Skills 
(Indicator of
Patient
Distress)
Average Life 
Expectancy 
from Birth /
Length of
Treatment
Cost per QALY
GUDEX 22 £8,225
0 Good = A/B 22 (17) £12,658 (£12,257)
Fair = B/C 23 (18) £5,196 (£4,790)
Poor = C/D 24 (19) £4,059 (£3,083)
25 (20) £3,118 (£2,343)
0 Good = A 22 (17) £6,209 (£6,264)
Fair = B 23 (18) £4,014 (£3,438)
Poor = C 24 (19) £3,053 (£2,476)
25 (20) £2,499 (£1,972)
0 Good = A 22 (17) £4,986 (£5,034)
Fair = A/B 23 (18) £3,476 (£3,044)
Poor = B 24 (19) £2,717 (£2,254)
25 (20) £2,273 (£1,833)
0 Good = A 22 (17) £4,986 (£5,034)
Fair = A 23 (18) £3,476 (£3,044)
Poor = A 24 (19) £2,717 (£2,254)
25 (20) £2,273 (£1,833)
+2 Good = B 22 (17) £12,658 (£12,257)
Fair = C 23 (18) £5,196 (£4,790)
Poor = D 24 (19) £4,059 (£3,083)
25 (20) £3,118 (£2,343)
+2 Good = A/B 22 (17) £8,438 (£8,291)
Fair = B/C 23 (18) £4,817 (£4,003)
Poor = C/D 24 (19) £3,485 (£2,746)
25 (20) £2,774 (£2,134)
+2 Good = A 22(17) £4,986 (£5,034)
Fair > B 23 (18) £3,476 (£3,044)
Poor =s C 24 (19) £2,717 (£2,254)
25 (20) £2,273 (£1,833)
+2 Good = A 22 (17) £4,986 (£5,034)
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Fair = A/B 23 (18) £3,476 (£3,044)
Poor = B 24 (19) £2,717 (£2,254)
25 (20) £2,273 (£1,833)
+2 Good = A 22(17) £4,166 (£4,146)
Fair = A 23 (18) £3,038 (£2,706)
Poor = A 24 (19) £2,447 (£2.069)
25 (20) £2,085 (£1,703)
+5 Good = B 22 (17) £8,438 (£8,291)
Fair = C 23 (18) £4,817 (£4,003)
Poor = D 24 (19) £3,485 (£2,746)
25 (20) £2,774 (£2,134)
+5 Good = A/B 22 (17) £6,209 (£6,264)
Fair = B/C 23 (18) £4,014 (£3,438)
Poor = C/D 24 (19) £3,053 (£2,476)
25 (20) £2,499 (£1,972)
+5 Good = A 22(17) £4,986 (£5,034)
Fair = B 23 (18) £3,476 (£3,044)
Poor = C 24 (19) £2,717 (£2,254)
* 25 (20) £2,273 (£1,833)
+5 Good = A 22 (17) £4,166 (£4,146)
Fair - A/B 23 (18) £3,038 (£2,706)
Poor = B 24 (19) £2,447 (£2.069)
25 (20) £2,085 (£1,703)
+5 Good - A 22 (17) £4,166 (£4,146)
Fair = A 23 (18) £3,038 (£2,706)
Poor = A 24 (19) £2,447 (£2.069)
25 (20) £2,085 (£1,703)
+10 Good = B 22 (17) £4,986 (£5,034)
Fair = C 23 (18) £3,476 (£3,044)
Poor = D 24 (19) £2,717 (£2,254)
25 (20) £2,273 (£1,833)
+10 Good = A/B 22 (17) £4,166 (£4,146)
Fair = B/C 23 (18) £3,038 (£2,706)
Poor = C/D 24 (19) £2,447 (£2.069)
25 (20) £2,085 (£1,703)
+10 Good = A 22(17) £3377 (£3,568)
Fair = B 23 (18) £2,719 (£2,435)
Poor = C 24 (19) £2,240 (£1,912)
25 (20) £1,925 (£1,598)
+10 Good - A 22 (17) £3377 (£3,568)
Fair = A/B 23 (18) £2,719 (£2,435)
Poor = B 24 (19) £2,240 (£1,912)
25 (20) £1,925 (£1,598)
+10 Good = A 22 (17) £3377 (£3,568)
Fair = A 23 (18) £2,719 (£2,435)
Poor = A 24 (19) £2,240 (£1,912)
25 (20) £1,925 (£1,598)
+15 Good = B 22 (17) £4,166 (£4,146)
Fair = C 23 (18) £3,038 (£2,706)
Poor = D 24 (19) £2,447 (£2.069)
25 (20) £2,085 (£1,703)
+15 Good = A/B 22 (17) £3377 (£3,568)
Fair = B/C 23 (18) £2,719 (£2,435)
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Poor = C/D 24 (19) £2,240 (£1,912)
25 (20) £1,925 (£1,598)
+15 Good = A 22(17) £3,577 (£3,568)
Fair = B 23 (18) £2,719 (£2,435)
Poor = C 24 (19) £2,240 (£1,912)
25 (20) £1,925 (£1,598)
+15 Good = A 22(17) £3,134 (£3,132)
Fair = A/B 23(18) £2,443 (£2,231)
Poor = B 24 (19) £2,054 (£1,767)
25 (20) £1,788 (£1,498)
+15 Good = A 22(17) £3,134 (£3,132)
Fair = A 23(18) £2,443 (£2,231)
Poor = A 24 (19) £2,054 (£1,767)
25 (20) £1,788 (£1,498)
+20 Good = B 22(17) £4,166 (£4,146)
Fair = C 23 (18) £3,038 (£2,706)
Poor = D 24 (19) £2,447 (£2.069)
25 (20) £2,085 (£1,703)
+20 Good = A/B 22(17) £3,577-(£3,568)
Fair = B/C 23 (18) £2,719 (£2,435)
Poor = C/D 24 (19) £2,240 (£1,912)
25 (20) £1,925 (£1,598)
+20 Good = A 22 (17) £3,134 (£3,132)
Fair = B 23 (18) £2,443 (£2,231)
Poor = C 24 (19) £2,054 (£1,767)
25 (20) £1,788 (£1,498)
+20 Good = A 22(17) £3,134 (£3,132)
Fair » A/B 23(18) £2,443 (£2,231)
Poor = B 24 (19) £2,054 (£1,767)
25(20) £1,788 (£1,498)
+20 Good = A 22(17) £3,134 (£3,132)
Fair = A 23(18) £2,443 (£2,231)
Poor = A 24 (19) £2,054 (£1,767)
25 (20) £1,788 (£1,498)
We can see from table 5.7 the sensitivity of Gudex's cost utility estimate to 
any increase in life expectancy. In the first example in table 5.7, the Cost per 
QALY estimate is reduced by three-quarters as a result of a three year increase 
in life expectancy. The Cost per QALY estimates vary between £1,498 and 
£12,658, depending on the assumed reductions in disability and distress and 
the assumed increases in life expectancy. In other words, the Cost per QALY 
estimates vary between 18% and 154% of Gudex's original estimate. As an 
example, let us assume that established treatment lasts for 17 years and that 
ceftazidime treatment extends life expectancy to 18 years, leads to a 10 point
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increase in the clinical score and leads to each patient moving up to the next 
highest distress category. The Cost per QALY of cystic fibrosis treatment with 
ceftazidime falls to £2,435. This has the effect of altering Gudex's cost utility 
rankings as shown below, with the pre-sensitivity analysis rankings given in 
brackets:
Table 5.8: Effect of a Greater Reduction in Patient Distress and Improvements
Procedure Cost per QALY
CAPD £13,434 (1)
Haemodialysis £9,075 (2)
Scoliosis surgery - ,
idiopathic adolescent
£2,619 (4)
Treatment of cystic fibrosis 
with ceftazidime
£2,435 (3)
Kidney transplant £1,413 (5)
Shoulder joint replacement £592 (6)
Scoliosis surgery - 
neuromuscular illness
£194 (7)
5.3 Gudex’s Assumptions Concerning Established Treatment
The last section demonstrated the sensitivity of Gudex's cost utility 
estimate of ceftazidime treatment to a range of assumptions concerning the 
efficacy of ceftazidime treatment relative to that of established treatment. In 
this section Gudex's lack of definition of established treatment and how its 
various possible definitions may lead to different outcomes in terms of costs 
and efficacy will be discussed.
Gudex calculated the health-related quality of life score of cystic fibrosis 
patients on established treatment by converting the information about the 
psychological adjustment of 27 cystic fibrosis subjects [Boyle et al. (1976)] into 
the Rosser-Kind Classification of Illness States. However, we are not told in
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the Boyle paper what treatment the 27 subjects were receiving. It is not clear 
whether Gudex meant physiotherapy in combination with other forms of 
treatment when she used the term established treatment, or whether she 
meant the use of established antibiotics. If it is the former, then the analysis in 
the next section of the placebo-controlled antibiotic trials to date will clarify 
the efficacy of antibiotics relative to established treatment. If it is the latter, the 
same analysis will help us in estimating the efficacy of various antibiotics. 
Alternatively, the term established treatment may refer to an established 
method of treating cystic fibrosis patients with antibiotics. Cystic fibrosis 
patients can be treated using intravenous antibiotics, inhaled antibiotics or 
oral antibiotics. They can be treated at home or in hospital. They can be 
treated as each acute exacerbation occurs or their treatment can be planned 
prospectively. It is in this context that the discussion shall now focus on the 
various methods of treatment used in the main antibiotic trials to date and 
how they have affected the costs and efficacy of treatment.
An important issue which arises when we discuss the various methods of 
treating cystic fibrosis patients with antibiotics is the most effective method of 
delivering the drug. Most of the major antibiotic trials to date have delivered 
the drug intravenously.
Parry et al. (1977) tested the hypothesis that combination therapy with anti­
Pseudomonas drugs is superior to single-drug therapy by randomizing 
patients with acute pulmonary exacerbations to treatment with intravenous 
ticarcillin alone, intravenous gentamicin alone, or the combination. Clinical 
and bacteriologic responses were similar in the three groups of patients. 
Beaudry et al. (1980) randomly assigned 22 children with cystic fibrosis and 
signs of acute lower respiratory infection to receive either cloxacillin or 
carbenicillin plus gentamicin administered intravenously for 10 days. Clinical 
improvement, chest radiograph changes, evidence of airway obstruction, and 
bacteriologic flora of sputum were no different regardless of the regimen
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used. In the study by Martin et al. (1980), 18 children with cystic fibrosis were 
treated with intravenous courses either of gentamicin plus carbenicillin or 
tobramycin plus carbenicillin, with 2 children each receiving 2 courses. There 
was clinical and X-ray improvement in both groups of children, but there was 
no difference between the therapeutic benefit of either regimen. Intravenous 
piperacillin as a single drug was evaluated in an open, noncomparative trial 
and found to produce satisfactory results. In a comparative trial of piperacillin 
versus piperacillin and tobramycin, administered intravenously, there was 
no difference in clinical or bacteriologic results [Prince and Neu (1980)]. Of 24 
exacerbations, Hyatt et al. (1981) treated 15 with oxacillin plus sisomicin and 
carbenicillin, and compared the results with 9 treated with oxacillin alone. 
Again, all the antibiotics were administered intravenously. The difference 
between the failure rate in the treatment group (3/15) and the control group 
(7/9) was found to be statistically significant (p less than 0.015). David et al. 
(1983) evaluated the effect of intravenous ceftazidime on 28 cystic fibrosis 
patients with severe infections. In 20 cases ceftazidime was the sole antibiotic, 
but in the first 8 of the 20 cases it was accompanied by oral flucloxacillin. 
There was an excellent clinical response in 27 courses, judged to be as good as 
the authors' former high dosage carbenicillin and tobramycin combination 
though with much greater patient acceptability. McLaughlin et al. (1983) 
compared 3 intravenous regimens: ticarcillin and tobramycin, azlocillin and 
tobramycin, and azlocillin and placebo. Clinical and bacteriologic responses 
were similar in the three groups. Permin et al. (1983) undertook two open 
randomized cross-over studies comparing ceftazidime to tobramycin and 
ceftazidime and ceftazidime to tobramycin and carbenicillin in 13 and 15 cystic 
fibrosis patients respectively, with chronic bronchopulmonary Pseudomonas 
aeruginosa infection. Patients receiving intravenous ceftazidime showed a 
tendency for greater long-term benefit in lung function as measured at 1 and 2 
months after treatment than patients receiving the other intravenous
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antibiotics. Conway et al. (1985) studied 17 cystic fibrosis patients who were in 
relapse at the time of admission in hospital. Patients were randomly allocated 
to an intravenous antibiotic regime of either netilmicin and ticarcillin or 
tobramycin and ticarcillin. Regular bronchodilator therapy using a nebuliser 
was administered to all patients with evidence of excessive bronchial liability. 
In addition, all patients received physiotherapy four times daily during their 
period of hospital treatment. A significant subjective and objective 
improvement occurred in all patients. Pseudomonas was cleared temporarily 
from the sputum in 11 out of the 30 courses of treatment. There was no 
significant difference between the netilmicin and tobramycin groups, nor 
evidence of sustained renal or otoxicity. In all cases re-appearance of 
Pseudomonas occurred by the follow up visits four weeks later. In an 
evaluation of 30 patients treated intravenously with either ceftazidime or 
ticarcillin and tobramycin, Gold et al. (1985) found no significant differences 
between the 2 groups in terms of clinical responses, pulse rate, respiratory 
rate, white blood count (WBC) or erythrocyte sedimentation rate (ESR), forced 
expiratory volume in 1 second (FEVi) or midexpiratory flow rate (FEF25-75%), 
increase in weight. However, ceftazidime was significantly more effective in 
reducing sputum colony counts of Pseudomonas aeruginosa. The effect was 
more pronounced on nonmucoid than on mucoid strains. Unfortunately, the 
reduction in sputum colony counts achieved by treatment with ceftazidime 
was only transient. Within 1 to 2 months after discharge from the hospital, 
the colony counts had returned to pretreatment concentrations. Krilov et al. 
(1985) administered intravenous imipenem/cilastatin to 19 patients with 
pulmonary exacerbations of cystic fibrosis due to Pseudomonas aeruginosa for 
6 to 10 days. They found that mean Shwachman scores, clinical efficacy scores, 
forced vital capacity (FVC) and FEVi all rose as a result of treatment. 
Strandvik (1988) evaluated the home treatment of 31 cystic fibrosis patients 
with an aminoglycoside and a cephalosporin or a ureidopenicillin for 1 year.
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The mean duration of each intravenous course of therapy was 15.4 days and 
there was an average of 3 courses per patient. The author noted that all 
patients improved clinically. Van der Laag (1988) studied the administration 
of several combinations of intravenous antibiotics to 54 patients and found 
that antibiotic treatment led to good clinical results in 77% of all courses. In a 
recent trial by Steen et al. (1989), 12 cystic fibrosis patients who had developed 
an acute respiratory exacerbation and who had Pseudomonas species isolated 
from their sputum, were given intravenous ciprofloxacin twice daily. 11 of 
the 12 patients showed clinical improvement at the end of the treatment 
period.
In the studies by Penketh et al. (1982) and Wall et al. (1983), the antibiotics 
were inhaled by the patients, resulting in reduced hospital admissions. 
Penketh et al. (1982) found that the administration of inhaled gentamicin and 
carbenicillin in 41 patients over an average period of 21 months substantially 
reduced the frequency of hospital admissions from an average of 1.8 to 1.03 
admissions per patient year. In the study by Wall et al. (1983), 11 cystic fibrosis 
patients chronically infected with Pseudomonas aeruginosa were treated with 
inhaled tobramycin and ticarcillin, twice daily. As a result, the frequency of 
hospital admissions was substantially reduced from 31 in the 89 patient- 
months before the initiation of therapy to only 5 in the same period 
afterwards. Hodson et al. (1981) found the use of aerosol antibiotics to be not 
only time consuming, taking most patients 20 minutes every morning and 
evening, but also an expensive form of treatment. Jensen et al. (1989) argue 
that the administration of antipseudomonal drugs by inhalation has proven 
clinically effective and has the advantage of being convenient for prolonged 
use. They argue that the main difficulties of this kind of therapy include 
technical problems of delivery of properly sized aerosol particles for 
deposition mainly in the lower airways, and uneven distribution of the drug 
within the lungs due to the unequal air exchange. Furthermore, there is a
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potential risk of development of allergy or induction of bacterial resistance 
following inhalation of antibiotics. This could diminish the possibility of 
subsequent parenteral efficacy of the drug. Selection of multiple resistant 
organisms such as Pseudomonas cepacia is another potential risk. These 
advantages and disadvantages of the use of aerosols are also echoed by 
Mouton and Kerrebijn (1990) who add that most antibiotics taste rather badly, 
that it is unknown what quantity of the dose given is deposited in the lungs, 
and whether it reaches the infectious foci, and that hypersensitivity might be 
induced.
Another issue which arises when we discuss the methods of antibiotic 
treatment of cystic fibrosis patients is the best location for that treatment. 
Traditionally, patients requiring intravenous antibiotic treatment have had to 
remain in hospital. However, home therapy is becoming increasingly 
commonplace. Kuzemko (1988) argues that home therapy allows 
administration early in the course of a relapse, thus avoiding hospital 
admission. The risk of cross-infection from hospital patients harbouring 
drug-resistant Pseudomonas aeruginosa strains or other pathogens is 
eliminated. He lists the social benefits of home care therapy as little 
disruption to family life, school, and work hours, the fostering of 
independence from hospital and the continuity of total care in a home 
environment. Possible disadvantages to home care therapy are the additional 
burdens on the family, it may lead to anxiety, if unsuccessful, or to abuse, ie, 
unnecessary treatments, and it may lead to a deterioration in medical 
standards. Home treatment requires intensive cooperation among hospital 
pharmacists providing the intravenous antibiotic mixtures, nurses 
experienced in intravenous antibiotic administration, and physicians 
responsible for the medical care of the patient involved in such a home care 
treatment programme. Gilbert et al. (1988) argue that the advantages of 
hospital treatment are more effective physiotherapy and the reassurance of
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having medical help at hand. The disadvantages of hospital treatment are 
considered to be the disruption and stress it causes even when mothers are 
resident and the financial strains on the patient's family. Patients with cystic 
fibrosis requiring intravenous treatment are often not acutely ill but place a 
great strain on the accommodation, manpower and financial resources of the 
hospital. The authors discuss the effect 40 courses of home intravenous 
antibiotic treatment had on 13 cystic fibrosis patients. They note highly 
significant improvements in weight, respiratory function, and white cell 
count during home treatment. There was no significant difference in weight 
and forced expiratory volume in one second between the end of home 
treatment and the end of hospital treatment while forced vital capacity was 
better after home treatment. All patients preferred home treatment. Most 
families found financial advantages of up to £110 per week because of reduced 
travelling expenses to hospital and because earnings were not lost. All 
families felt some degree of stress during home treatment but only 2 
considered this greater than the stress of a hospital admission. On the basis of 
the cost of inpatient accommodation alone (assumed to be £81.37 per day), 
Gilbert et al. estimated the savings from the home intravenous service at 
£29,098 a year. In the study by Strandvik (1988), discussed above, all 31 patients 
treated with home intravenous antibiotic therapy improved clinically, the 
improvement being similar to that previously reported for in-hospital 
treatment. However, physiotherapy was less well performed at home. Nearly 
all patients could attend school or work during the entire treatment period. 
From an economic perspective, home treatment saved the hospital a mean of
3.5 beds per day for 1 year as well as the cost of the antibiotics themselves. 
Kuzemko and Williams (1986) estimated that the approximate hospital and 
home care costs (excluding antibiotics) in the UK for 30 patients amounted to 
£36,000 and £1,680 respectively. Forty-one home and 41 hospital treatments 
with tobramycin and a semisynthetic penicillin or tobramycin and a
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cephalosporin were matched by Donati et al. (1987) according to sex, age, 
pulmonary function tests, and arterial blood gas values to compare the 
efficacy and benefits of the two types of treatment. Both home and hospital 
treatments resulted in statistically significant improvement in pulmonary 
function. A comparison of these values did not show any statistically 
significant difference between the groups at admission or discharge. 
Furthermore, the mean number of treatment days for both groups, 
individually determined by the primary physician, was equivalent. The 
interval between pulmonary exacerbations for the two groups was not 
significantly different. In addition, 85% of patients receiving treatment at 
home were able to maintain at least some of their school or work activities. 
The charges billed to the 2 groups were significantly different, with a mean 
charge of approximately $10,000 ($600/day) for home care patients and more 
than $18,000 ($l,000/day) for hospitalized patients, resulting in a $370,000 
reduction in charges for 41 home care treatments during the study. These data 
indicate that home therapy is less costly and is as effective as in-hospital 
therapy.
In all the studies discussed above, only three [Penketh et al. (1982), Wall et 
al. (1983), Donati et al. (1987)] planned the antibiotic treatment prospectively. 
In the remaining studies, each acute exacerbation of infection was treated as it 
occurred. The only major study to date which has calculated the differences in 
efficacy between the two modes of treatment is that by Pederson et al. (1987). 
In this study, the annual mortality rate of cystic fibrosis patients with chronic 
Pseudomonas aeruginosa lung infection fell from 10-20% in the years 1970­
1975 to 1-2% in 1985, after the centre studied switched from only treating acute 
exacerbations of infection to administering 2-week intravenous courses every 
3-4 months.
So far it has been demonstrated that Gudex's cost utility estimate of 
ceftazidime treatment of cystic fibrosis is sensitive to a range of assumptions
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concerning the efficacy of of ceftazidime treatment relative to those of 
established treatment. The way in which the lack of definition of the term 
established treatment may itself affect the cost and efficacy of antibiotic 
treatment has also been discussed. In the next section, the acceptability of 
Gudex’s assumptions are further discussed by considering the placebo- 
controlled antibiotic trials to date and examining how effective antibiotics 
have in fact been in treating cystic fibrosis patients.
5.4 Benefits of Placebo-Controlled Studies
To analyse Gudex's assumption that ceftazidime treatment has no effect on 
patient disability and survival and only slightly reduces patient distress, the 
benefits resulting from antibiotic treatment in the placebo controlled 
antibiotic trials of cystic fibrosis were calculated. An extensive literature 
search revealed ten placebo-controlled antibiotic trials dating back to 1977. For 
each of these ten antibiotic trials, information was gathered on the efficacy of 
the active treatment and the improvement or deterioration in parameters 
which constitute components of the Taussig and Shwachman scores was 
noted. Where possible, the precise effects of antibiotic treatment on the two 
clinical scores were estimated, thereby allowing us to make some inferences 
on Gudex's assumptions.
Three of the ten antibiotic trials [Wientzen et al. (1980), Gold et al. (1987) 
and Regelmann et al. (1990)] compared active versus placebo treatment for 
single acute pulmonary exacerbations of cystic fibrosis. In all three trials, 
patients showed evidence of improvement during active treatment.
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(a) Wientzen et al. (1980)
Wientzen et al. (1980) performed a double-blind evaluation of intravenous 
tobramycin therapy versus placebo to test the hypothesis that antibiotic 
therapy was not as important as intensive chest physiotherapy in treatment of 
acute exacerbations. Eleven children were given 2 mg/kg of tobramycin every 
8 hours as a one-hour continuous infusion. Therapy was continued daily 
until the time of discharge from the hospital or until persistence or 
worsening of symptoms required breaking the code. Eleven patients were 
given placebo. The active group fared better. Clinical responses were recorded 
as satisfactory in all eleven children given tobramycin and in seven of the 
eleven given placebo, though it is not stated what constitutes a satisfactory 
clinical response. The interpretation of the results was clouded by the fact that 
patients with more severe disease were randomized to the placebo group.
No patient given placebo demonstrated improvement in pulmonary 
function studies, whereas 4 of 6 children given tobramycin showed a 15% or 
greater improvement in at least 2 of the 3 tests performed [vital capacity (VC), 
forced expiratory volume in 1 second (FEVi) and peak expiratory flow rates 
(PEFR)]. Of these, only vital capacity is a component of the Taussig score. At 
least a 15% improvement in this parameter would lead to at least a 2 or 4 
point improvement in the Taussig score. However, it is also likely that 
tobramycin therapy would have increased FEVi as a percentage of total VC, 
another of the pulmonary function tests. This would also increase the 
Taussig score. This is the best we can do. Without any precise figures, we 
cannot make precise estimates of the improvements in the Shwachman and 
Taussig scores. Chest roentgenograms showed no consistent changes in most 
patients in either group during the course of treatment with placebo or 
tobramycin. Tobramycin treatment was associated with a 1 logarithm or 
greater decrement in Pseudomonas sputum concentrations in the sputum of
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6 of 7 patients, although this occurred in only 2 of 8 patients given placebo. 
Tobramycin treatment was associated with a 2 logarithm or greater decrement 
in Pseudomonas sputum concentrations in the sputum of 3 of 7 patients, 
although this occurred in only 1 of 8 patients given placebo. This parameter 
can perhaps be equated with component I of the Taussig score (sputum 
production and / or cough). As a result tobramycin treatment may have 
increased the Taussig score by 1 in this component as well.
(b) Gold et al. (1987)
Gold et al. (1987) conducted a randomized trial of ceftazidime versus 
placebo in patients with cystic fibrosis hospitalized for acute respiratory 
exacerbations. Sixteen patients were given ceftazidime; fifteen patients were 
given placebo, three of whom dropped out. Active treatment consisted of 200 
mg/kg/day over a 14 day period. There were no significant differences in the 
rate of improvement of symptom score, weight gain, or pulmonary function 
between the two treatment groups. There was no difference in the course 
during the 6-24 months after the study period. The authors argue that, 
intravenous antibiotics are not essential in the management of all acute 
respiratory exacerbations of mild to moderate severity in patients with cystic 
fibrosis.
Results of sputum cultures were similar in both groups; most patients 
were infected with both Pseudomonas aeruginosa and Pseudomonas cepacia. 
The clinical responses after the 16 episodes were treated with ceftazidime 
were all rated as showing improvement in that the patients were discharged 
within 14 days, having returned to their usual state of health. In 10 of the 12 
episodes treated with placebo, clinical responses were also rated as showing 
improvement. When the 16 ceftazidime-treated episodes are compared with
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the 12 placebo-treated episodes (10 cures and 2 failures), no significant 
differences were seen in any outcome measure. The average weight gains 
between admission and discharge in the ceftazidime and placebo groups were 
2.6% and 2.1% respectively, not enough to alter the Taussig score (though 
they may increase the Shwachman Score), but indicating a reduction in 
patient disability. The mean number of days taken to peak improvement in 
clinical scores in the 2 groups were 6.0 and 6.4 days, respectively. No 
differences in the rates of improvement in the total symptom score or in 
scores for cough, dyspnea, or anorexia were observed, implying that 
ceftazidime had no positive effect on patient distress over and above that of 
placebo. Similarly, the rate of improvement in daily spirometry was the same 
in both groups. Analysis of the results of complete pulmonary function tests 
also indicated no statistically significant differences, either in the increments 
in FEVi, FEF25%-75% or FVC or in the proportions of patients with at least a 
10% increase in pulmonary function. The mean percentage change in % 
predicted value of FEVi, FEF25%-75% and FVC was +19%, +27.7% and +17.8% in 
the ceftazidime group, and +11.5%, +22.9% and +4.8% in the placebo group. 
Without knowing the pretreatment percentages, we cannot estimate the 
effects on the Taussig score, but it is clear that ceftazidime did not lead to a 
significant improvement over and above that of the placebo. Bacteriologic 
outcomes differed significantly in the 2 treatment groups. Ceftazidime 
reduced the colony counts of Pseudomonas aeruginosa by more than 3 logio 
cfu/ml in over 55% of episodes. No such change was observed in the placebo 
group. Ceftazidime had no effect on Pseudomonas cepacia. All patients were 
followed up for 6 to 24 months after discharge. The hospitalization rates 
subsequent to the acute exacerbation were similar: 0.96 and 0.79 admissions 
per patient-year in the ceftazidime and placebo groups respectively (p greater 
than 0.1).
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(c) Regelmann et al. (1990)
Regelmann et al. (1990) record the performance of 12 cystic fibrosis patients 
who had been stratified to receive either parenteral tobramycin and ticarcillin 
(n=7) or placebo (n=5), in addition to aerosol therapy and chest physiotherapy. 
Both groups had initially received 4 days of bronchodilating aerosols and 
chest physiotherapy. Treatment (average daily doses of tobramycin and 
ticarcillin were 10.5 mg/kg and 317 mg/kg respectively) lasted 14 days.
The study provides strong evidence of the benefits of antibiotic therapy for 
patients suffering from single acute pulmonary exacerbations of cystic fibrosis. 
Significantly (p less than 0.01) greater improvements were observed in FVC, 
FEVi and FEF25-75% in the antibiotic group compared to the placebo group. In 
the antibiotic group, the FVC improved by 13% predicted, from 77% to 90%; 
the FEVi improved by 16% predicted, from 54% to 70%; and the FEF25-75% 
improved by 20% predicted, from 31% to 51%. This compares with no 
significant changes in FVC, FEVi and FEF25-75 in the placebo group. Antibiotic 
treatment increases the Taussig score by 3 points, solely as a result of the 
improvement in the forced vital capacity parameter. FEVi as a percentage of 
VC increases from 70% before treatment to 78% at the end of the 14-day 
treatment period. This does not increase the Taussig score, but is an indicator 
of reduced patient disability. Likewise, the 20% improvement in FEF25-75% 
does not lead to an increase in the Taussig score, but suggests that antibiotic 
treatment does lead to a reduction in patient disability. The antibiotic group 
showed significantly (p less than 0.01) greater reductions in logio colony­
forming units (cfu) of Pseudomonas aeruginosa per gram of sputum. In each 
of the antibiotic-treated patients, a greater than 99% (greater than 2 logio cfu) 
reduction in the cfu/g sputum of Pseudomonas aeruginosa was observed. 
None of the placebo-treated patients experienced such a reduction. The degree 
of decrease in logio cfu Pseudomonas aeruginosa/g sputum correlated
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significantly (p less than 0.001) with the degree of improvement in FVC, FEVi 
and FEF25-75%. In both groups, there was a significant (p less than 0.0001) 
decrease in quantity of sputum produced by an average of 12.6g/12h, but no 
difference between antibiotic and placebo groups was observed. Sputum 
production and/or cough is component I of the Taussig Score, worth 3 points. 
It may be that both antibiotic treatment and placebo treatment improve the 
Taussig score, but we cannot estimate by how much without any guide-lines. 
A significant (p = 0.0001) increase in weight by 2.6kg (5.3%) was observed in 
both the antibiotic and placebo groups, but no significant difference was 
observed between the 2 groups. This improves the Taussig score by 2 points in 
both groups and also increases the Shwachman Score.
The mean Brasfield score improved by 26% within the antibiotic group, 
compared to 5% within the placebo group, indicating improved X-ray 
findings. This also improves both the Taussig and Shwachman scores.
Table 5.9 (page 175) summarizes the benefits in each of the three studies 
[Wientzen et al. (1980), Gold et al. (1987) and Regelmann et al. (1990)] resulting 
from the treatment of each episode of acute exacerbation as it occurs. All three 
studies showed some improvement during active treatment. In addition, 
they all showed improvement in parameters which affect the Shwachman 
and Taussig scores. It was not clear from any of the three studies, however, if 
antibiotic treatment reduced inpatient stay or improved the survival 
prospects of the patients.
Seven additional placebo controlled antibiotic trials were found in the 
literature. They all report the results of planned prospective treatment of 
cystic fibrosis patients and, as such, they form a distinct group. The earliest of 
these trials was the double blind study by Park et al. (1977).
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(d) Park et al. (1977)
The authors divided 22 cystic fibrosis patients into 2 groups according to 
age, sex and pulmonary status. Group A was given oral cloxacillin (50 
mg/kg/day) and group B, a placebo, over a 12 month period. The remaining 
cystic fibrosis treatment methods remained unchanged. Ten of the eleven 
patients receiving active treatment improved or remained stable and one 
showed deterioration. The respective figures for patients receiving placebo 
treatment were six and five. We are not given any specific data concerning 
sputum volume and colour, cough, physical examinatio, ESR, chest 
radiograph, pulmonary function tests and blood gas analysis, the parameters 
measured by the authors. As a result, we cannot estimate whether antibiotic 
treatment improves the two clinical scores. However, the authors conclude 
that the data indicates that there is less progression of the pulmonary 
component of cystic fibrosis in patients who received continuous cloxacillin.
(e) Loening-Baucke et al. (1979)
Loening-Baucke et al. (1979) recorded the effects of oral administration of 
cephalexin over a 2 year period. Every 4 months, 50 mg/kg/day of cephalexin 
was alternated with placebo in a group of 17 cystic fibrosis patients who served 
as their own control subjects. The authors observed fewer acute respiratory 
infections (48 v 63), respiratory infections requiring antibiotics (25 v 53) and 
respiratory infections requiring hospitalization during the periods that 
patients received cephalexin. Acute respiratory illnesses were defined as 
increased cough and sputum production, decrease in physical activity, with or 
without fever, and / or change in roentgenographic findings in chest. These 
seem to be acceptable indicators of patient disability and distress. Forty-eight
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cases of acute respiratory infections occurred during the periods that patients 
received cephalexin, compared to 63 during the placebo period. This suggests 
a prevention of a deterioration in health status amongst patients receiving 
active treatment. Cephalexin appeared to have the greatest effects upon 
patients initially infected with Staphylococcus aureus with or without 
simultaneous infection with Haemophilus influenzae (p less than 0.05).
More rapid weight gain was observed during cephalexin treatment in 16 of 
the 17 patients. This will have a positive effect on the Shwachman and 
Taussig scores, but we cannot estimate by how much as we are not given any 
absolute figures. The height gain of patients given cephalexin was also greater 
than those given placebo. This will have a positive effect on the Shwachman 
score, but once again any absolute improvements cannot be estimated. The 
initial Shwachman scores were similar in all groups (range 55-85) despite the 
fact that patients initially infected with Pseudomonas aeruginosa (median age
8.6 years) were older than patients not infected with Pseudomonas aeruginosa 
(median age 5.7 years). Patients initially infected with Pseudomonas 
aeruginosa (n=ll) showed a decrease in the total Shwachman score, whereas 
those patients not infected with Pseudomonas aeruginosa (n=6) appeared to 
improve during the 2-year period. These differences were significant (p less 
than 0.05), even though they only represent small changes in the clinical 
score of 3 to 6 points (absolute figures are not shown by authors). We are not 
given any information on the Shwachman scores during the placebo period. 
Without the full absolute figures we cannot calculate the effect of the change 
in the Shwachman score on Gudex's approximations, but it does contradict 
her assumption that antibiotic therapy has no effect on patient disability.
Of the pulmonary function tests performed on 14 patients, 10 remained 
stable. The FVC and FEVi were significantly improved during cephalexin 
treatment in patients infected by Haemophilus influenzae (p less than 0.05). 
Again, without absolute figures, or any information on the placebo group, we
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cannot estimate the effect improved pulmonary functioning has on the 
Taussig or Shwachman scores and hence estimate any effects on Gudex’s 
assumptions.
(f) Hodson et al. (1981)
Hodson et al. (1981) present a placebo controlled antibiotic trial of inhaled 
antibiotics. It was a double-blind randomised cross-over trial of carbenicillin 
and gentamicin versus placebo. The authors randomly allocated 20 patients to 
6 months’ treatment with aerosol antibiotic and 6 months’ treatment with 
placebo. Active treatment consisted of Ig of carbenicillin and 80mg of 
gentamicin, twice daily, for 6 months.
In terms of patient preferences, 14 of the 17 patients who completed the 
trial favoured the antibiotic period and 3 patients were uncertain. The 
assessments of the clinician favoured the antibiotic preparation in 12 cases 
and the placebo in 1; in 4 cases he was uncertain. There were significant 
improvements in FEVi (p less than 0.001), FVC (p less than 0.02)and PEFR (p 
less than 0.001) during the active preparation. No patient showed a significant 
improvement in any of the pulmonary function tests when taking the 
placebo. Furthermore, the frequency of acute hospital admissions was reduced 
during aerosol treatment although the difference was not significant because 
of the small numbers involved
Let us study the pulmonary function test results in more detail. Mean 
FEVi was 92ml per patient for the antibiotic group (1566/17) and 76ml per 
patient for the placebo group (1300/17). Mean FVC was 156ml per patient for 
the antibiotic group (2656/17) and 136ml per patient for the placebo group 
(2314/17). Therefore, mean FEVi was 59% of mean FVC for the antibiotic 
group, and mean FEVI was 56% of mean FVC for the placebo group. This is
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the only data on the benefits of antibiotic treatment which we can use and the 
higher proportion does not change the Taussig score, though it is an indicator 
of reduced patient disability under the antibiotic regimen.
(g) Kun et al. (1984)
Kun et al. (1984) compared the benefits from the twice daily inhalation of 
20mg of nebulised gentamicin over 2 years with the inhalation of a nebulised 
saline mixture in 29 children with cystic fibrosis. The majority of the children 
had minimal or mild lung disease on entry to the study. .
The authors recorded no significant difference in antibiotic usage, days in 
hospital or clinical symptoms between the two regimes, though the subjects 
with Pseudomonas aeruginosa in sputum showed significantly less 
deterioration in lung function over the 2 years while using gentamicin 
aerosol. Antibiotic usage was calculated by the formulation of and conversion 
into an antibiotic score. To obtain an overall antibiotic score, one day's 
therapy of cotrimoxazole (trimethoprim-sulphamethoxazole) or tetracycline 
was scored as 1, oral flucloxacillin combined with amoxycilln or erythromycin 
was scored as 3, oral chloramphenicol as 5 and intravenous antibiotics as 7. 
Clinical symptoms were estimated by the parents of children under the age of 
10 and the patients themselves over that age recording on a continuum scale 
with semantic cues the quality of the cough, the amount of the cough, the 
amount of sputum produced and its type as well as any changes in cough and 
sputum.
Patients on gentamicin showed a slower deterioration in pulmonary 
function. The mean percentage change in FEVi over the 2 years was 0 in the 
gentamicin group and -6 in the saline group. In terms of FEF25-75%, the mean 
percentage change was -2 in the gentamicin group and and -6 in the saline
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group. Hence there was a milder, though not significant, deterioration in 
patient disability in the gentamicin group, though we cannot estimate the 
effect on the Taussig score as we are not given any information on the vital 
capacity of the patients. For those with Pseudomonas aeruginosa on entering 
the study however, there were significant differences between the gentamicin 
and saline regimes (change in FEF25-75, p less than 0.05; change in FEVi, p less 
than 0.02). There was no statistically significant differences for the 21 subjects 
without Pseudomonas aeruginosa at the beginning of the study. There was 
also no significant difference between the 2 treatment regimes in preventing 
the development of Pseudomonas aeruginosa.
(h) Carswell et al. (1987)
Carswell et al. (1987) present a double-blind cross-over comparison of oral 
flucloxacillin and nebulized aminoglycoside versus double placebo. The study 
was composed of 6 children with cystic fibrosis who had persistently had 
Pseudomonas aeruginosa isolated from their respiratory tract. Active 
treatment lasted for a month and consisted of oral flucloxacillin, 25 mg/kg of 
bodyweight/dose and nebulized tobramycin.
The results of the study indicate improved pulmonary function and 
reduced disability at the end of the month of active treatment. We are not 
told the initial FEVi, FVC and PEFR scores. However, we are told that FEVi 
was the only respiratory function testing which was statistically significant. 
Figure 1 in the Carswell et al. paper indicates that FEVi was approximately 
61% at the end of the active period and approximately 57% at the end of the 
placebo period. Assuming FEVi improved during treatment (which we can 
infer from the discussion), the Taussig score might have increased at the end 
of the active treatment simply as a result of the improvement in FEVi as a
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percentage of vital capacity. (Without the absolute figures, this is the best we 
can do). We are also told that all 6 of the peak expiratory flow rates and 5 out 
of 6 of the forced vital capacity changes showed higher values at the end of 
the active treatment period than at the end of the placebo period. The mean 
FVC (standard deviation) and PEFR (standard deviation) at the end of the 
active treatment period were 66.5(28)% predicted and 75.8(36)% predicted 
respectively. The respective figures for the placebo period were 63.8(23)% 
predicted and 72.8(36)% predicted. Assuming the two sets of scores were 
similar prior to the two types of treatment, they will have no effect on the 
Taussig score. However, we can say that patient disability has been reduced as 
the discussion of the Carswell et al. paper states that there .was a significant 
improvement in respiratory function in the treatment group and respiratory 
function is, arguably, one indicator of patient disability: "The trial indicates 
that significant improvement in respiratory function can be produced in 
ambulant children with cystic fibrosis by a regimen of oral flucloxacillin and 
nebulized aminoglycoside" (page 359). In terms of sputum production, 
another parameter within the Taussig Index, no consistent changes were 
detected after nebulised tobramycin.
(i) Jensen et al. (1987)
Jensen et al. (1987) carried out a prospective double-blind placebo- 
controlled study of colistin inhalation. Forty cystic fibrosis patients (20 males 
and 20 females, with a mean age of 14.2 years), who were infected with 
chronic bronchopulmonary Pseudomonas aeruginosa, were treated over a 
period of 3 months. Active inhalation consisted of one million units of 
colistin dissolved in 3 ml of sterile water, twice daily.
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The authors argue that "Colistin treatment was superior to placebo 
treatment in terms of a significantly better clinical symptom score, 
maintenance of pulmonary function and inflammatory parameters" (page 
831). There was a significant difference in the completion rates of the study 
(18 in the active group, 11 in the placebo group).
Mean FVC fell from 86% of normal at the beginning of the study to 79% of 
normal after 90 days for the colistin group. The respective figures for the 
placebo group were 89% and 71%. Therefore, in this study, antibiotic 
treatment slows the deterioration in pulmonary function, rather than leads to 
any improvement. Even though the mean fall in FVC was significantly 
smaller in the colistin treated group as compared to the placebo group (p less 
than 0.05), the reduction in the Taussig score is the same for both groups - the 
Taussig score falls by 2 points in both cases. Mean FEVi fell from 71% at the 
beginning of the study to 60% after 90 days for the colistin group. The 
respective figures for the placebo group were 79% and 62%. The fall in mean 
FEVi was less pronounced in the colistin group, but the difference observed 
was not significant and the Taussig score is not affected by the exercise if FEVi 
is taken as a percentage of FVC. Of the parameters white blood cell count, 
erythrocyte sedimentation rate and orosomucoid, only the change in 
orosomucoid during the study period was significantly in favour of colistin 
treatment. The authors conclude that their study "..illustrates that colistin 
inhalation reduces the deterioration in wellbeing and pulmonary function, 
and also reduced the inflammatory response that otherwise occurs after 
completion of a course of intravenous anti-pseudomonal therapy" (page 837).
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(j) Stead et al. (1987)
The study by Stead et al. (1987) provides strong evidence that antibiotic 
therapy reduces the disability of cystic fibrosis patients. In a crossover trial, 
aerosol ceftazidime was compared with aerosol gentamicin plus carbenicillin 
and with saline (placebo), each given for 4 months to 13 cystic fibrosis patients 
infected with Pseudomonas aeruginosa.
The three alternative treatments were (1) lg of ceftazidime, (2) 80mg (2ml) 
of gentamicin solution and lg of carbenicillin or (3) 3.5% sodium chloride 
solution. Each treatment was given twice a day. The authors were unable to 
demonstrate any difference in efficacy between the 2 antibiotic regimens, but 
both patients on aerosol carbenicillin plus gentamicin and those on 
ceftazidime showed an increase in body weight and improved lung function. 
Also, hospital admissions were less frequent during the study year than 
during the previous year. Of the 13 patients who completed the study, 4 
required a total of 5 admissions to hospital during the study year, compared to
10 requiring a total of 16 similar admissions in the previous year).
The authors show that patients improved their PEF, FEVi and FVC scores 
whilst taking the active preparations compared to pretreatment values and to 
values achieved during the saline period. All but one of the differences were 
statistically significant, the exception being the case of FVC during ceftazidime 
treatment compared with saline. The median FVC of the patients on entry to 
the study was 53% of the predicted value. If we assume that the median and 
mean FVC scores are similar, then the predicted FVC is 4.62 litres (from Table
11 in the Stead et al. paper). Therefore, FVC was 64% of predicted value at the 
end of the ceftazidime period, 63% of predicted value at the end of the 
gentamicin/carbenicillin period and 58% of predicted value at the end of the 
saline period. As a result, the Taussig score increases by 2 points at the end of 
both the ceftazidime and gentamicin/carbenicillin periods and does not
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change during the saline period. There was a 14% increase in peak expiratory 
flow [PEF (litres/min)] during the ceftazidime period and a 13% increase in 
PEF during the gentamicin/carbenicillin period, compared to a 6% increase in 
PEF during the saline period. Though this has no effect on the Taussig score 
(since PEF is not a component of the Taussig score), it is a good indicator that 
antibiotic treatment improves pulmonary function and reduces patient 
disability. Nine of the 13 patients showed at least a 20% increase in mean 
FEVi during one or both antibiotic treatment periods compared to the value 
on entry to the study. FEVi was 53% of vital capacity at the beginning of the 
study, 58% of vital capacity at the end of the ceftazidime period (leading to a 2 
point increase in the Taussig score), 58% of vital capacity at the end of the 
gentamicin/ carbenicillin period (leading to a 2 point increase in the Taussig 
score) and 55% of vital capacity at the end of the saline period (leading to no 
change in the Taussig score). Body weight increased by 2.9kg during the 
ceftazidime period (leading to a 2 point increase in the Taussig score), by 2.8kg 
during the gentamicin/carbenicillin period (leading to a 2 point increase in 
the Taussig score) and by 1.7kg during the saline period (leading to no change 
in the Taussig score). Sputum purulence (colour), arguably an indicator of 
patient distress, was reduced to 2.9 during the ceftazidime period (on a 0-5 
scale), compared with 3.3 during the gentamicin/carbenicillin period and 3.4 
during the saline period. Sputum volume (production), an indicator of both 
disability and distress was reduced to 2.3 during the ceftazidime period (on a 
0-5 scale), compared to 2.4 during the gentamicin/carbenicillin period and 2.9 
during the saline period. Sputum production and/or cough, component I of 
the Taussig score, is given 3 points, so it may be that antibiotic treatment has 
increased the Taussig score in this component as well. (Once again, the 
absence of pre-treatment data precludes a more precise estimate).
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At the end of the study, 8 of the 13 patients stated a preference for 
ceftazidime of the 3 treatments, and 4 preferred gentamicin and carbenicillin. 
One patient had no preference.
Table 5.10 (page 176) summarizes the benefits in each of the seven studies 
[Park et al. (1977), Loening-Baucke et al. (1979), Hodson et al. (1981), Kun et al. 
(1984), Carswell et al. (1987), Jensen et al. (1987) and Stead et al. (1987)] 
resulting from the planned prospective antibiotic treatment of cystic fibrosis. 
In all but one of the seven studies [Kun et al. (1984)], the patients showed 
some improvement during antibiotic treatment. In three of the seven studies 
[Loening-Baucke et al. (1979), Hodson et al. (1981) and Stead et al. (1987)], there 
is evidence that antibiotic treatment reduces patient days in hospital. In five 
of the studies [Loening-Baucke et al. (1979), Hodson et al. (1981), Carswell et al. 
(1987), Jensen et al. (1987) and Stead et al. (1987)], there were improvements in 
parameters which affect the Shwachman and Taussig clinical scores. None of 
the studies indicated any evidence that antibiotic treatment improves the 
survival prospects of cystic fibrosis patients.
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5.5 Summary and Conclusion
In this chapter, it has been demonstrated that Gudex’s cost utility estimate 
of ceftazidime treatment is sensitive to a range of assumptions concerning the 
efficacy of ceftazidime treatment. In addition, there has been a discussion of 
how the lack of definition of the term established treatment may itself affect 
the cost and efficacy of established treatment. In the main body of the chapter, 
the placebo controlled antibiotic trials of cystic fibrosis treatment were 
reviewed which allowed us to estimate how effective antibiotics in fact are in 
treating cystic fibrosis patients. From this analysis and the summary of the 
results/ we can see that there is little evidence for Gudex's assertion that 
antibiotic treatment has no significant effect on patients' level of disability. In 
7 of the 10 studies [Park et al. (1977), Wientzen et al. (1980), Hodson et al. 
(1981), Carswell et al. (1987), Gold et al. (1987), Stead et al. (1987) and 
Regelmann et al. (1990)], there were improvements in the pulmonary 
function tests which make up a large component of the Taussig score, and 
which a recent study by Orenstein et al. (1989) show to be highly significantly 
associated with the quality of well-being of cystic fibrosis patients. Of these 7 
studies, only the study by Gold et al. (1987) showed no significant differences 
between the antibiotic and the placebo groups. In the 3 other studies [Loening- 
Baucke et al. (1979), Kun et al. (1984) and Jensen et al. (1987)], antibiotic 
treatment slowed the deterioration in pulmonary function and there were 
significant differences between the two groups of patients. Indeed, even with 
the limited information we are given in most of the papers, there is strong 
evidence that the two clinical scores increase as a result of antibiotic treatment 
in 3 of the trials [ Wientzen et al. (1980), Stead et al. (1987), Regelmann et al. 
(1990)] and in a subgroup of patients in one other trial [Loening-Baucke et al. 
(1979)]. In defence of Gudex, none of the studies indicated any improvement 
in the survival prospects of the cystic fibrosis patients, which was shown in
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the first section to radically alter the cost effectiveness of cystic fibrosis 
treatment.
The main problem we come across when attempting to convert the data 
we are given in the papers to a generic health-related quality of life score, such 
as the Rosser Valuation Matrix, or even to disease-specific ratings, such as the 
Shwachman and Taussig Scores, is the limited amount of information we 
have to work on. The study by Hodson et al. (1981), for example, only gives 
data on 3 pulmonary function tests (FEVi, FVC and PEFR), and none of these 
are components of the Shwachman Score. A second problem that we face 
when attempting to convert the information we are given into indexes is that 
identical parameters have been presented by different studies in different 
ways which cannot strictly be compared. For example, Wientzen et al. (1980) 
give us information on the improvement in pulmonary function scores, 
whilst Jensen et al. (1987) present the pre-treatment and post-treatment 
percentages. Finally, we have to overcome the problem that the prognostic 
scores available turn continuous variables (such as the pulmonary function 
percentages) into discrete variables, and hence may not adequately reflect any 
real improvement or deterioration in patient health-related quality of life. 
For example, an increase in VC from 69% to 70% would lead to a 2 point 
increase in the Taussig Score, indicating an improvement in patient health- 
related quality of life. However, an increase in VC from 70% to 79% would 
leave the Taussig Score unchanged, indicating that patient health-related 
quality of life remained unchanged. Clearly, a continuous scale would be 
preferable in measuring such parameters. A more detailed discussion of these 
issues will be presented in Chapter 7.
Ideally, we would like information on a number of parameters which 
could easily be converted into Rosser Disability/Distress Categories and which 
would comprehensively measure the health-related quality of life of cystic 
fibrosis patients. Parameters which would reflect patient disability would
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include pulmonary function tests, eg, FVC, FEVi, FEV, PEFR, general activity 
(work/school), weight, oxygen saturation, pulmonary radiograph, sputum 
production, bacterial counts in sputum, infection markers in blood and 
serology. Parameters which would reflect patient distress would include 
cough, sputum production, dyspnea, malaise, appetite and attitude. These 
parameters could be measured on continuous scales and perhaps be given 
appropriate weights. Such information would allow us to make an overall 
assessment of the health-related quality of life of cystic fibrosis patients, and 
assist us in measuring the benefits of antibiotic and other treatments. Where 
studies do use disease-specific scales, such as the Shwachman and Taussig 
clinical scores, researchers should present all the relevant data (pretreatment , 
and posttreatment scores). Not only would this allow us to make a more 
reasonable assessment of the benefits of the studied treatments, but it would 
make it easier for others to convert the information into generic scores (such 
as the Rosser Classification) and hence make cross-programme comparisons 
easier.
Nevertheless, despite the paucity of information, we do have enough data 
to be able to say that antibiotic treatment can have a significant effect on 
patients’ level of disability. The paper by Stead et al. (1987), for example, gives 
us enough information to be able to say that ceftazidime treatment led to at 
least a 5-8 point increase in the Taussig score, and that is solely based on the 
components of the Taussig score which the authors have measured. It is 
probable that, if all the components had been measured, the increase in the 
prognostic score would have been much greater.
In conclusion, it has been shown that there is little evidence to prove 
Gudex’s assumption that ceftazidime treatment has no effect on the disability 
of cystic fibrosis patients, and that her cost utility estimate of cystic fibrosis 
treatment is sensitive to a whole range of assumptions that she makes.
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6.1 Introduction
In the Gudex study, no information is provided about the derivation of the 
cost estimates for each of the seven medical procedures. It is not clear which 
forms of treatment were costed, which costs were included in the final total 
cost estimates and how they were arrived at. This chapter aims to show that 
specifying an exact cost for a medical programme can be misleading when 
researchers do not provide any details about the form of medical treatment 
being costed and the range of costs calculated. The chapter begins with an 
identification of the range of costs a medical programme might incur and 
some of the problems that might arise in the calculation of those costs. A case 
study of the costs of hospital acquired infection is presented to illustrate the 
components usually calculated by the medical and health economics 
literature. The main body of the chapter then presents an analysis of Gudex's 
cost estimate for one of the seven medical procedures, her £250 annual cost 
estimate for the ceftazidime treatment of cystic fibrosis patients. It is shown 
that there are different modes of ceftazidime treatment, each with very 
different cost structures which can affect Gudex’s conclusions.
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6.2 Costs - Identification and Problems
Economists usually use the concept of opportunity cost when estimating 
the costs of a health care programme, that is costs are defined as the benefits 
foregone by investing in a project rather than the simple financial outlay. 
Levin (1975) defines the cost of a health care programme as ’’representing that 
set of social sacrifices associated with any particular choice among social- 
policy alternatives” (page 98). As an illustration, let us consider the example 
of unpaid volunteers in a hospital. Their work may not add to the hospital's
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wage bill, but their labour still represents a true cost of the running of the 
hospital. They contribute to the hospital's output, and their labour is a cost to 
society in the sense that it could have been more productively used in 
another sector during that time or spent on leisure activities. This leads 
economists to divide the costs of a health care programme between direct 
costs and indirect costs. Direct costs represent the resources purchased directly 
to run the health care activity. This category may be subdivided into fixed 
costs which do not vary as output varies, for example, depreciation costs and 
rent, and variable costs which are directly related to output and include wages 
and costs of equipment. Indirect costs represent the element of indirect 
consumption of resources in the production process, for example the value of 
lost earnings by patients who are unable to work. A further category of costs 
are the intangible or psychic costs, defined by Drummond et al. (1987) as "costs 
borne externally to the health sector, patients, and their families" (page 22). 
This refers to the element of pain or grief experienced by patients and their 
families and friends. Economists usually shy away from valuing such costs 
and, as a result, implicitly set them equal to zero across disease groups.
Even after the relevant costs of a health care programme have been 
identified, a number of problems arise when one attempts to value them. 
Warner and Luce (1982) describe the problem facing economists who try to 
measure research and development costs when such costs are an integral 
component of the medical programme. Drummond (1981) describes the 
problems involved in the division of costs when the production process 
produces the joint use of resources (joint production). In addition to these 
rather technical problems, there are other areas of difficulty. For example, 
there is the problem of valuing the time lost by patients and others (such as 
families, friends, volunteers) through illness. The arguments for and against 
using earnings losses as a measure of lost production are presented by 
Drummond et al. (1986). The same authors criticise the common use of
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average hospital costs per day as unrepresentative of a particular treatment or 
department of interest. The further issue of reducing future costs to present 
values was presented in Chapter 4, together with a discussion of the need for 
sensitivity analyses of alternative discount rates.
6.3 Case Study of the Costs of Hospital Acquired Infection
To evaluate the cost components commonly calculated by economists and 
medical researchers, a case study of the costs of hospital acquired infection was 
carried out. A literature search revealed eleven studies which, in one form or 
another, had calculated the cost of nosocomial infection. All eleven had 
measured (at least some of) the direct costs associated with infection, whilst 
only one [Dixon (1985)3 attempted to measure the indirect costs.
Beyt et al. (1985) attempted to audit the bills and medical records of 26 
randomly selected American patients with hospital-acquired infections over a 
six month period. The sites of infection of the selected patients fell into 4 
major groups: urinary tract, lower respiratory, surgical wound infections and 
bacteremia. Additional costs were estimated jointly by an infection control 
practitioner and an infectious disease consultant. The costs included were 
room ’charges' for increased length of stay; medications including antibiotics; 
laboratory tests including culture and sensitivity reports, antibiotic levels and 
toxicity studies; respiratory therapy; x-ray; additional surgical procedures; 
supplies, and other 'charges'. The authors did not calculate any health care 
labour costs, nor any indirect costs due to nosocomial infections. The final 
annual cost of nosocomial infections was estimated at $484,723 for the 270-bed 
acute care general hospital, of which medications and supplies were the most 
significant components.
CHAPTER 6 184
Davies and Cottingham (1979) estimated the costs to the National Health 
Service of nosocomial bacterial infections. The cohort studied was a group of 
345 orthopaedic patients. Of these, 29 patients (8.4%) became infected, 
excluding patients discharged in the first 48 hours. They were then matched 
with control patients from the same cohort. The sites of infection of the 29 
patients were: wound, chest, urinary tract, wound and urinary tract and 
general or three site. The authors calculated total inpatient costs, extra 
microbiology cost, total antibiotic costs, costs of visits to GP’s and costs of 
visits by nurses for each of the patients. Costs attributable to loss of productive 
activity were not calculated. The final estimate of excess costs attributable to 
infection was £775 per infected patient (1978 prices), of which at least 97% was 
accounted for by the increased length of stay.
The study by Dixon (1985) attempts to estimate the economic and financial 
burdens that result from respiratory tract infections in the United States. 
Respiratory tract infections were defined as any acute infection involving the 
upper or lower respiratory tract (for example, otitis media and pneumonia). 
Where possible, noninfectious components of these illnesses and the chronic 
sequelae of some acute infectious diseases were excluded from the analysis. 
The author estimated both direct and indirect costs. The direct costs included 
were hospital 'charges', physician fees, costs of diagnostic tests and the costs of 
antimicrobial treatment. These were estimated at $470 million (1984 prices). 
Of this total sum, physician fees accounted for approximately 9 percent. 
Indirect costs were estimated by calculating the loss in income of employed 
persons who miss work because of infection. The estimated loss in wages 
alone stood at $9 billion per year. The author does not clarify what proportion 
of this total was due to nosocomial respiratory infections, but he states the 
possibility that the indirect loss of income may equal the total direct costs of 
these infections.
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An earlier study by the same author [Dixon (1978)] calculated the overall 
impact of infections on hospital care in the United States. The study divided 
infections into those acquired in the community and those acquired whilst in 
hospital. The incidence of the latter was based on the infection estimates 
reported by National Nosocomial Infections Study (NNIS) hospitals in 1976. 
Pathogens were categorised into 4 groups, whilst the anatomic sites of 
infection were combined into 7 major groups. Using unpublished Center for 
Disease Control studies, the author derived an estimate of 6 million days 
attributable to the prolongation of stay for nosocomial infections. When the 
extra costs of medication, specialised or intensive care and infection isolation 
requirements were considered, a 1977 estimate of $4.8 billion for treating 
infectious diseases was arrived at. This figure included the costs of treating 
community-acquired infections, but excluded physicians fees and all indirect 
costs.
A French study of the costs of hospital acquired infections was carried out 
by Girard et al. (1983). This study calculated the costs of hospital acquired 
infections for 61 neonates. The observed infections were divided into the 
following sites: umbilicus, eye, mouth, nose and upper respiratory tract, 
intestine, urinary tract, and blood. The costs considered by the study were the 
extra inpatient costs resulting from prolonged stay, the costs of additional 
biological and radiological tests, the cost of medical and surgical procedures, 
and the costs of drugs, IV fluids and human milk. No indirect costs were 
calculated by the authors. The additional average costs resulting from 
infection were 6000 French Francs, 93% of which was the consequence of a 
28% increase in the length of stay.
Green and Wenzel (1977) considered the differences in duration of hospital 
stay and hospital bills between matched patients with and without acquired 
postoperative wound infections. Six operation sites were focussed on: 
appendectomy, cholecystectomy, bowel resection, total abdominal
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hysterectomy, caesarean section and coronary artery bypass graft. No mention 
was made of which costs were calculated, although the authors imply that 
only the direct costs to the surgical patient were included. We are told 
however that postoperative wound infections increased the average hospital 
bill from $705.51 to $1,394.48 following appendectomy, from $2,139.12 to 
$2,582.13 following cholecystectomy, from $2,823.58 to $4,414.77 following 
colon resection, from $1,096.44 to $1,885.29 following total abdominal 
hysterectomy, from $775.30 to $1,302.80 following caesarean section and from 
$4,939.82 to $7,542.50 following coronary artery bypass graft.
Haley et al. (1981) estimated the cost of hospital acquired infection in 3 
hospitals that differed in size, administrative characteristics and patients' 
financial status. The infection types included in the study were urinary tract 
infections, bloodstream infections, lower respiratory tract infections, surgical 
wound infections and a group of unspecified 'other' infections. The authors 
divided costs as follows: costs of prolonged hospitalization, antibiotics, 
bacteriologic cultures, other laboratory services, roentgenograms, respiratory 
therapy and miscellaneous services. Physicians' fees and costs attributable to 
loss of productive activity were excluded from the estimates. It should be 
noted that the study did not make a distinction between 'costs' and 'charges'. 
The 3 hospitals showed similar results in terms of prolonged hospitalization 
and increased charges.
An analysis of the characteristics that distinguish high and low cost 
nosocomial infections was carried out by Pinner et al. (1982). Information was 
based on 215 infections in 183 study patients. Of these, 92 were urinary tract 
infections, 5 were bacteremia infections, 29 were lower respiratory tract 
infections, 69 were surgical wound infections and 20 were other infections. 
The cost components included the cost due to routine 'charges' caused by 
extended hospital stay or by hospital transfer and supplementary costs 
attributable to the infection, such as laboratory fees, antibiotic costs and x-rays.
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Health care labour costs and indirect costs were not included in the estimates. 
The authors estimated an average cost per infection of $590.
Rose et al. (1977) report a retrospective study of the hospitalization costs of 
40 patients with hospital-acquired bacteremias at the University of Virginia 
Hospital. A comparison was made with 40, similarly aged, matched and 
uninfected patients. The study focussed on patients with hospital acquired 
bloodstream infections. Only the cost of hospitalization was considered; 
physicians' fees, radiology bills and all indirect costs were excluded. The cost 
of hospital stay for bacteremic patients (mean $6,692) was estimated to be three 
times that of the matched controls.
Scheckler (1980) reports a prospective assessment of the costs of 123 
nosocomial infections in 104 patients over a three-month period. Of the 123 
infections, 65 were urinary tract infections, 26 were surgical wound infections, 
17 were pneumonia infections and 15 occurred in other sites. Scheckler breaks 
down the costs of infections into increased length of stay; diagnostic services, 
including intravenous fluids used to treat the nosocomial infection and 
therapeutic services, such as inhalation therapy, physical therapy, surgery, etc, 
used to treat the infection. Data on physicians' fees were not available; 
therefore they were not recorded. In addition, indirect costs were not taken 
into account. The author calculated an average hospital charge of $636 for 
each nosocomial infection, about half of which was accounted for by 
prolonged length of stay.
The final study found in the literature search which attempted to calculate 
the cost of hospital acquired infection was carried out by Spengler and 
Greenough (1978). This study focussed on 81 patients with nosocomial 
bacteremia. Total room costs and total laboratory charges were included in the 
study, but no labour or indirect costs were taken into account. The authors 
showed an average excess of approximately $3,600 in direct hospital costs for 
infected patients.
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The above studies are typical of cost analyses in the medical literature. The 
indirect and intangible costs of a treatment or an illness are usually ignored, 
and even the full range of direct costs are often not calculated. Apart from the 
identification and valuation problems outlined in the previous section, 
researchers often take a narrow viewpoint at the outset of a study and ignore 
the costs of a programme or an illness to patients and to society. Clearly, many 
of the studies above take the viewpoint of attempting to calculate the costs of 
nosocomial infections to a hospital. Patient and societal concerns, such as 
losses in earnings and productivity, are ignored. In effect, ignoring such costs 
underestimates the true costs of the infections. In addition, a methodological 
error of many American studies is to confuse charges with costs. They are not 
identical and researchers should attempt to use true costs where possible.
6.4 Analysis of Gudex’s Cost Estimate for Antibiotic Treatment of Cystic 
Fibrosis
Gudex estimated the annual cost of ceftazidime treatment for cystic fibrosis 
patients at £250. No information was provided concerning the derivation of 
the cost estimate. Neither was it clear which cost components were included 
in the final estimate. This section attempts to show that this figure may be 
misleading, and that alternative assumptions concerning the mode of 
antibiotic treatment and cost components affect the final cost utility results.
We learnt in Chapter 5 that there are different methods of treating cystic 
fibrosis patients with antibiotics. The antibiotic may be delivered through 
intravenous, inhaled or oral routes. Patients may be treated in hospital or, 
alternatively, at home. Treatment may be planned prospectively or each acute 
exacerbation may be treated as it occurs. What is not clear from the Gudex 
study is which mode of treatment has been used as the basis for cost
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estimation. Clearly, this will affect the final results of the study as each mode 
of treatment has different cost implications.
Few previous studies have estimated the costs of alternative methods of 
treating cystic fibrosis patients with antibiotics. Gilbert et at (1988) estimated a 
saving of £29,098 a year from a home intravenous service, based solely on the 
cost of inpatient accommodation (assumed to be £81.37 per day). They also 
calculated a saving of up to £110 per week for the families of 13 cystic fibrosis 
patients, because of reduced travelling expenses to hospital and because 
earnings were not lost. Kuzemko and Williams (1986) estimated that the 
approximate hospital and home care costs (excluding antibiotics) in the UK 
for 30 patients amounted to £36,000 and £1,680 respectively. Donati et al. 
(1987) estimated significant differences in the charges billed to 41 home 
patients and 41 matched hospital patients. The estimates were $10,000 ($600 
per day) for the home care patients and more than $18,000 ($1,000 per day) for 
the hospitalized patients, resulting in a $370,000 reduction in charges for 41 
home care treatments during the study. The results indicated that home 
therapy was less costly and as effective as in-hospital therapy.
To determine the confidence with which we can use Gudex's results, the 
costs associated with alternative modes of antibiotic treatment were 
compared. The sources of information were the 10 placebo-controlled 
antibiotic studies discussed in Chapter 5 [Park et al. (1977), Loening-Baucke et 
al. (1979), Wientzen et al. (1980), Hodson et al. (1981), Kun et al. (1984), 
Carswell et al. (1987), Gold et al. (1987), Jensen et al. (1987), Stead et al. (1987) 
and Regelmann et al. (1990)]. For each study, a note was made of the 
antibiotic(s) administered, the method of delivering the antibiotic, whether 
patients were treated for each acute exacerbation of infection as it occurred or 
whether treatment was planned prospectively, the average daily dose and 
frequency of treatment, the duration of treatment, the antibiotic costs per 
patient per day/course, the hospital hotel costs per patient per day/course, the
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administration/equipment costs per day/course, total costs per patient per 
day/course and total costs per patient per course/per year.
Daily antibiotic costs and course of treatment antibiotic costs were 
calculated from the July 1990 edition of MIMS. Hospital hotel costs were 
assumed to be £140 per day in 1990 prices (M. Malek, personal 
communication). This figure included the cost of all staff salaries, drugs, 
equipment and overheads such as heating and lighting. Administration / 
equipment costs were calculated using the median figures estimated by Davey 
et al. (1990). This study had comprehensively estimated the recent costs of 
materials used in IV administration. The items costed were IV lines, syringes, 
needles, water for injection, saline, hepflush/hepsal, gloves and mediwipes. 
The cost of a nebuliser was based on the 1991 hospital price for a Medicare 
'Parkneb', and it was assumed that each one was discarded at the end of each 
trial.
Table 6.1 (page 194) summarizes the costs of the 3 trials which compared 
active versus placebo treatment for single acute exacerbations of cystic fibrosis 
[Wientzen et al. (1980), Gold et al. (1987) and Regelmann et al. (1990)]. The 
patients in all three trials were treated intravenously and in hospital. 
Treatment in the latter two trials lasted for 14 days; Wientzen et al. (1980) do 
not clarify the duration of their trial. Only Regelmann et al. (1990) state the 
average bodyweight of their sample of patients (49kg), and this has been used 
as the standard to calculate average daily doses of antibiotics in the other two 
trials. The main difference in costs was in the daily antibiotic costs per patient. 
The daily cost of tobramycin of £10.73 in the study by Wientzen et al. (1980) 
was one ninth of the daily cost of ceftazidime of £97.02 in the study by Gold et 
al. (1987). The total costs per patient per course were £3,365.60 in the Gold et 
al. (1987) study and £2,833.74 in the Regelmann et al. (1990) study. If a 14 day 
duration is also assumed for the study by Wientzen et al. (1980), the total costs 
per patient per course would have been £2,203.74.
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Table 6.2 (page 195) summarizes the costs of antibiotic treatment in the 
seven placebo controlled trials which planned treatment prospectively [Park 
et al. (1977), Loening-Baucke et al. (1979), Hodson et al. (1981), Kun et al. 
(1984), Carswell et al. (1987), Jensen et al. (1987) and Stead et al. (1987)]. The 
patients in all seven trials were treated with either inhaled antibiotics or oral 
antibiotics, or both. All seven trials were located in the homes of the patients. 
The duration of the trials varied between 1 month [Carswell et al. (1987)] and 
2 years [Kun et al. (1984)]. For the studies which reported average daily doses 
of antibiotics in mg/kg and did not report the average bodyweight of their 
patients, the average bodyweight of 49kg reported by Regelmann et al. (1990) 
was used. When all the antibiotic, hospital and administration costs were 
annualized, the range of costs varied between £651.01 for 50 mg/kg/day over a 
12 month period [Park et al. (1977)] and £7,341.71 for lg ceftazidime, twice 
daily over a 4 month period [Stead et al. (1987)], an elevenfold difference.
In terms of planning antibiotic treatment prospectively, oral prophylaxis 
appears to be cheaper than inhaled prophylaxis because equipment costs are 
avoided. The main difference in costs between the treatment of each acute 
exacerbation as it occurs and planned prospective treatment was in the daily 
hospital hotel costs incurred by the former mode of treatment. It must be 
stated at this point however that great care should be taken when making 
such cost comparisons, if no associated evidence is available concerning the 
relative efficacy of the modes of treatment. If planned prospective antibiotic 
treatment were shown to prevent regular episodes of acute exacerbations of 
infection, then there would be a strong case for antibiotic treatment to be 
planned in such a manner. A review of the case records of the six cystic 
fibrosis patients receiving planned prospective treatment in Dundee suggests 
that such treatment is successful in preventing acute exacerbations of 
infection. All six patients had at least one emergency admission in the year 
preceding planned prospective treatment. They were then placed on a course
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of regular treatment with intravenous ceftazidime. Three of the patients also 
received regular nebulized tobramycin. In the one to two years following 
initiation of planned prospective treatment, none of the six patients were 
admitted to hospital for treatment of an acute exacerbation. This suggests that 
planning treatment prospectively is successful in avoiding the hospitalisation 
of cystic fibrosis patients. What this study cannot state however is that regular 
prophylaxis is the most cost effective method of treating cystic fibrosis patients 
with antibiotics. Stronger evidence is required concerning the success of such 
treatment in preventing acute exacerbations of infection before such a 
hypothesis can be proven.
This study has illustrated the variety of methods in which cystic fibrosis 
patients can be treated with antibiotics. Each mode of treatment differs in its 
costs and efficacy. It is clear that, despite the difficulties that exist in comparing 
alternative methods of treatment, Gudex's annual cost estimate of £250 for 
ceftazidime treatment of cystic fibrosis patients is unrealistically low. This 
appears to be the case even after the cost estimate is inflated to 1990 prices 
[which have been used as the basis for the cost estimations in Tables 6.1 (page 
194) and 6.2 (page 195)3. A cost of £250 in 1986 prices is equivalent to a cost of 
£331 in 1990 prices using the Retail Price Index. It is unlikely that antibiotic 
and equipment costs increased by much more than the rise in general prices 
over the years 1986-1990. A cost estimate of £331 is approximately half of the 
lowest annual cost estimate of the placebo controlled trials [Park et al. (1977)] 
and just 4.5% of the highest cost estimate [Stead et al. (1987)].
An increase in the annual cost estimate of ceftazidime treatment of cystic 
fibrosis reduces the relative cost effectiveness of the procedure, if all Gudex's 
other assumptions remain unchanged. However, Chapter 5 concluded that 
Gudex's assumptions concerning the efficacy of ceftazidime treatment were 
sensitive to a whole range of assumptions. Therefore, it would be 
inappropriate to use Gudex's health-related quality of life estimates when
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assessing the cost effectiveness of the procedure. What we can say however is 
that it is unclear how Gudex has arrived at her cost estimate, and that an 
extensive cost analysis of alternative methods of treating cystic fibrosis 
patients with antibiotics has shown this estimate to be unrealistically low. A 
plea is made to researchers to explain how their cost estimates were arrived 
at.
In tables 6.1 and 6.2 (pages 194-195), only the direct costs of antibiotic 
treatment were incorporated into the final cost estimates. As explained in the 
previous section, this underestimates the true costs of treatment to society. 
Most of the cystic fibrosis patients in the placebo controlled studies were 
children or young adults. It is likely that most of them were still in education 
whilst receiving treatment and hence, the cost to society in terms of lost 
earnings or lost productivity would be relatively small. However, other 
indirect costs of treatment were likely to have arisen. For example, the 
parents of the patients may have incurred travelling expenses or lost time 
from their own work whilst attending to the needs of their children. 
Incorporating the indirect costs of antibiotic treatment of cystic fibrosis 
patients into the cost estimates in Tables 6.1 and 6.2 (pages 194-195) would 
widen further the differences with Gudex's own cost estimate and increase
the reservations we have about Gudex's results.
Table 6 J: Cost of Treatment of Each Episode of Acute Exacerbation in Placebo Controlled Antibiotic Trials
of Cystic Fibrosis Treatment
Author Drug Dose Route Frequency Antibiotic
Costs
Per
Patient
Per Day
Hospital
Hotel
Costs
Per
Patient
Per Day
Admin / 
Equip
Costs
Per
Patient
Per Day
Total
Costs
Per
Patient
Per Day
Total
Costs
Per
Patient
Per
Course
Wientzen
etal(1980)
Tobramycin 2 mg/kg Intravenous Every 8 
hours
£10.73* £140 £6.68 £157.41 Not known
Gold
etal(1987)
Ceftazidime 200 mg/kg/ 
day
Intravenous Every 6 hours 
over 14 days
£97.02* £140 £3.38 £240.40 £3,365.60
Regelmann
etal(1990)
Tobramycin
and
Ticarcillin
10.5 mg/kg 
tobramycin, 
317 mg/kg 
ticarcillin
Intravenous Divided doses 
over 14 days
£53.96 £140 £8.45 £202.41 £2,833.74
* Using the average bodyweight of the group of patients studied by Regelmann et al (1990) of 49kg
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7.1 Summary
This thesis has endeavoured to examine the incorporation of health status 
measurement techniques into the economic appraisal of health care 
programmes and the application of such techniques. The increasing use of 
health state utility values and quality adjusted life years in deciding how- 
health care resources should be allocated was analysed. Particular attention 
was focussed on two patient groups, those who had undergone hip and knee 
joint replacement surgery, and results of one important study [Gudex (1986)].
The thesis began by introducing the techniques commonly used in the 
economic appraisal of health care programmes, namely cost analysis, cost 
minimisation analysis, cost benefit analysis, cost effectiveness analysis and 
cost utility analysis (Chapter 1). The position of health status measurement 
within such a framework was explained.
Chapter 2 provided a detailed synopsis and exposition of the techniques 
which have been used to measure health status. Five broad approaches were 
outlined: the willingness to pay approach, decision analytic techniques, the 
use of existing utility values available in the medical literature, a range of 
measurement techniques (the rating scale technique, the standard gamble 
approach, the time trade-off approach, the equivalence method, ratio scaling) 
and the use of health status indices. Examples were provided to illustrate how 
these techniques are used in practise. Particular attention was focussed on one 
health status index, the Rosser-Kind Classification of Illness States, because of 
its prominence in the field of Health Economics and its importance to this 
thesis. The latter part of Chapter 2 explained how cardinal utility values have 
been derived from these health status measurement techniques and used as a 
method of assessing preferences for alternative health states within a single 
weighted measure, the quality adjusted life year.
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In Chapter 3, the Rosser-Kind Classification was used to estimate the 
preoperative and postoperative health-related quality of life of patients who 
had undergone hip and knee joint replacement surgery. This chapter had 
four aims. First, to compare the use of the Rosser-Kind Classification with 
detailed questionnaires as tools of measurement in health-related quality of 
life estimates. Second, to test for the reliability of using retrospective data as 
opposed to prospective data when estimating the improvements in health- 
related quality of life in patients who had undergone hip and knee joint 
replacement surgery. Third, to calculate the scale of change in health-related 
quality of life in the two groups of patients, with QALY’s used as the method 
of estimation. Fourth, to use the results to estimate the time period over 
which the maximum improvements in health-related quality of life are 
achieved. The interviewed patients were divided into two groups, a control 
group and a much larger retrospective group, who were matched in terms of 
age, sex and operation site.
The control group patients were interviewed twice, once prior to their 
operations and once at three months following their operations. Amongst 
these patients, the Rosser-Kind Classification was found to be as good a health 
status indicator as much more detailed questionnaires. In addition, it was 
found that retrospective data could be used with some degree of confidence 
when estimating the improvements in health-related quality of life in 
patients who have had hip replacements. However, such data should only be 
used with caution when estimating the improvements in health-related 
quality of life in patients who have had knee replacements. It was argued that 
further research is required before any generalisations could be made 
concerning the acceptability of retrospective data. A third result from this 
group of patients was that there were significant improvements in health- 
related quality of life following both hip and knee joint replacement surgery.
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The retrospective group of patients were interviewed once only, at three 
months, one year or two years following their operations. Each interview was 
divided into two sections. The first section asked patients about their health- 
related quality of life at that point in time, and the second section asked 
patients about their health-related quality of life prior to their operations. As 
was the case for the control group, there was strong agreement between the 
subjects' estimates of their health-related quality of life (based on the Rosser- 
Kind Classification) and the derived estimates (based on their responses to the 
detailed questionnaires). There were noticeable improvements in the health- 
related quality of life of both sets of patients following surgery, with results 
suggesting that the highest Rosser-Kind rating score is achieved after the first 
year following knee replacement surgery and after the second year following 
hip replacement surgery.
Chapter 4 performed an extensive sensitivity analysis on widely-quoted 
cost utility calculations [Gudex (1986)] for seven medical procedures: CAPD, 
haemodialysis, treatment of cystic fibrosis with ceftazidime, kidney 
transplantation, shoulder joint replacement surgery, scoliosis surgery for 
idiopathic adolescents and scoliosis surgery for neuromuscular illness. 
Gudex's main arguments were outlined and the underlying assumptions of 
her study discussed. The chapter then presented a sensitivity analysis of 
Gudex's conversion of the health outcome data (she had selected from the 
medical literature) into the Rosser-Kind Classification. In addition, her 
assumptions concerning the survival period / life expectancy following each 
of the seven medical procedures and the 5% discount rate used were also 
varied. Only two of the seven cost utility estimates, those for CAPD and 
haemodialysis, were shown to be robust after the three sets of sensitivity 
analyses, whilst the cost utility estimates for shoulder joint replacement 
surgery and surgery for scoliosis secondary to neuromuscular illness were 
shown to be sensitive to all three variables. The cost utility estimates of renal
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transplantation, ceftazidime treatment of cystic fibrosis and scoliosis surgery 
for idiopathic adolescents were shown to be sensitive to two of the three 
variables. Moreover, sensitivity analyses of all three variables produced 
results which altered Gudex's cost utility rankings of the seven medical 
procedures.
Chapter 5 conducted a more in depth analysis of Gudex's cost utility 
estimate for one of the seven medical procedures, cystic fibrosis treatment 
with ceftazidime. After a detailed sensitivity analysis of Gudex's assumptions 
concerning the procedure, the chapter then proceeded to demonstrate that 
these assumptions are not borne out by the medical literature. Rather, the 
placebo controlled antibiotic trials to date suggest improvement in patient 
well-being and reduced patient disability, which contradicts Gudex's 
arguments and radically alters her final cost utility estimate.
Chapter 6 followed on from Chapter 5 by analysing Gudex's cost estimate 
for ceftazidime treatment of cystic fibrosis. The chapter showed that it is 
misleading for researchers to specify exact costs for medical programmes 
when they do not provide corollary information on what exactly is being 
costed. Using the same placebo controlled trials that were analysed in Chapter 
5, it was shown that there are different modes of ceftazidime treatment, each 
with different cost structures which affect Gudex's final cost estimate and her
conclusions.
The thesis raises a number of issues which require more detailed 
discussion. These fall into four broad areas. First, the use of disease-specific 
and generic health status indices within the economic evaluation of health 
care programmes. Second, the implications of discounting future costs and 
benefits to their present values. Third, the use and abuse of the QALY concept 
for allocating scarce health care resources. Fourth, the problems involved in 
collecting original health state utilities. Each of these issues shall be discussed 
in detail, after which will follow a list of lessons which have been learnt from
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the thesis as a whole and which health care evaluators would do well to 
incorporate into their studies.
7.2 Health Status Indices
A number of issues arise when using health status indices or output 
measures in economic evaluations of health care programmes, whether they 
are disease-specific measures, such as the Shwachman and Taussig scores, or 
more generic measures, such as the Rosser Classification and the Karnofsky 
Index of Performance Status.
7.21 Concept of health
It is important to understand that health status measurement is in itself a 
difficult process. By its very nature, it is a complex, multidimensional process 
and it is laden with value judgments. In 1947, the World Health Organization 
defined health as a "state of complete physical, mental and social well-being 
and not merely the absence of disease or infirmity" (WHO, 1947). The English 
dictionary defines health as "a sound state of body or mind; freedom from 
disease; bodily conditions; wish of health and happiness." Using these 
definitions, it is clear that disease-specific scales do not tend to measure health 
status in its complete sense. Neither do they usually claim to. Rather, indices 
such as the Shwachman and Taussig scores are helpful for classifying the 
initial disease of patients as well as providing quantitative estimations of 
outcomes. They are of great benefit to analysts, but they should be used as 
health status 'indicators' and not health status 'measures'. Chapters 4 and 5 
demonstrated that it may be inappropriate to base resource allocation 
decisions on information derived from these disease-specific scales, since it is
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likely to be intermediate output effectiveness data, which cannot easily be 
converted into QALY's. In addition, few general or generic health status 
indices actually cover all aspects of health-related quality of life. Instead, they 
tend to cover those aspects which the authors claim to adequately reflect 
health status or which the confines of the study allowed to be measured. Of 
the health status indices covered in Chapter 2, not only the older measures 
(Karnofsky Index of Performance Status) but also some of the more recent and 
widely-quoted measures (Nottingham Profile, Euroqol Instrument) fail to 
adequately cover all aspects of health-related quality of life: physical health, 
mental health, everyday functioning in social activities, everyday functioning 
in role activities and general perception of well-being. As discussed in 
Chapter 3, the Rosser-Kind Classification also fails to measure some aspects of 
health-related quality of life, such as role fulfilment, and fails to account for 
the dynamics of disease.
7.22 Acceptability of Measures
A second issue which arises for discussion when using health status 
indices in economic evaluations of health care programmes is the 
acceptability and validity of the chosen measure. Spitzer et al. (1981) argue 
that a good health-related quality of life index should have the following 10 
attributes: "It should be simple, which means it should be short, easy to 
understand, to remember, to administer and to record. It should be 
comprehensive, covering an adequate range of the different dimensions of 
quality of life. Its content should be compatible with views of the community 
and the dimensions should be identified empirically from patients, healthy 
people, physicians, and other providers. It should be quantitative. It should be 
applicable in many situations with as few restrictions as possible related to
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factors such as age, sex, occupation and category of chronic disease. It should 
be formally validated before being recommended for wide or general use. It 
must be acceptable to those measuring (particularly clinicians) and to those 
measured. It should be sensitive to changes in the health status of persons 
measured. It should discriminate well among groups of people with 
demonstrably different levels of quality of life. The new index should be 
plausible; the resulting scores should be consistent with other measures of 
health status, clinical status or life stage.'* (Page 587).
Sackett et al. (1977) lay down seven prerequisites for credible health indices. 
First, they should be comprehensive. They should encompass social, 
emotional and physical function. Second, they should be positively orientated 
and be able to identify good or even excellent function. Third, they should be 
generally applicable to free-living populations. Fourth, the indices should be 
sensitive enough to detect important changes in health status or function. 
Fifth, the health status measurements should be able to be made quickly, at 
reasonable cost, and without embarrassment or offence. Sixth, the individual 
and group reproducibility of the health measurements repeated at short 
intervals should be high. Seventh, the measurements should be amenable to 
index construction.
The Rosser-Kind Classification exhibits all the qualities and meets all the 
prerequisites described by Spitzer et al. (1981) and Sackett et al. (1977). It is 
fairly straightforward to understand and record, comprehensive, empirically 
identified, quantitative, widely applicable, validated, acceptable (based on the 
available evidence), able to discriminate between patients with different 
levels of health-related quality of life, plausible, reproducible and amenable to 
index construction. However, a doubt remains over its ability to pick up small 
changes in the health-related quality of life of some patients. For example, a 
person confined to a wheelchair following an accident might slowly improve 
his/her health-related quality of life as defined by the World Health
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Organization, but might also remain confined to Rosser Disability Category 
VI. As discussed in the previous section, the disease-specific scales used in the 
studies, from which Gudex obtained her health outcome information 
(Chapters 4 and 5), are not comprehensive measures of health-related quality 
of life and, by themselves, could not be used to make across-programme 
comparisons.
7.23 Appropriate Subjects
A third issue for discussion is the appropriate number and combination of 
subjects whose preferences form the basis of the valuations for such health 
status indices. Drummond et al. (1987) argue that informed members of the 
general public, who truly understand what health states are like, and 
community representatives, are the appropriate subjects. They do not 
recommend the use of patients as the source of utilities as this method 
restricts the measurement to one health state utility per subject. Of the health 
status indices covered in Chapter 2, only eight [Breslow (1972), Patrick et al. 
(1973), Kaplan et al. (1976), Sackett et al. (1977), Kind et al. (1982), Torrance et 
al. (1982), Bulpitt and Fletcher (1990) and Euroqol Group (1990)] conducted 
initial surveys which assigned preference values to alternative health states. 
In only two of these eight studies [Patrick et al. (1973), Kind et al. (1982)] were 
the subjects medically qualified. The subjects in the remaining studies were 
either randomly selected members of the general public, members of a 
general practice, parents of school children or psychology college students. 
The use of non-medically qualified persons to assign utility values to 
alternative health states has been criticised by Mooney (1986), because such 
persons are likely to have great difficulty in understanding concepts of health. 
If we accept that medically qualified people are in a position to assign utility
CHAPTER 7 205
values to alternative health states, a question remains over the appropriate 
size and composition of the sample of subjects. Doctors and nurses may differ 
between themselves over utility values for alternative health states. Kind et 
al. (1982) found that in their sample, doctors placed relatively less emphasis 
on the importance of death. In their analysis of the relative importance that 
48 British rheumatologists placed on 10 commonly measured clinical 
variables in 50 sets of patient data, Chaput de Saintonge et al. (1988) found 
that the doctors showed little agreement over which patients had improved 
and which had not. It seems therefore that the selection of a sample to make 
utility valuations is of great importance. The size and composition of such a 
sample entails value judgments over whose preferences are appropriate to 
make the valuations. There are no right or wrong answers. Rather, the best 
suggestion would be to test utility valuations over as many subjects as 
possible, including diverse groups of subjects, and over periods of time. If 
these valuations differ greatly, then it should be explicitly stated that a 
judgment has been made that the preference values of a certain group are the 
most appropriate.
7.24 Method of Valuation
A fourth issue for discussion when using health status indices in economic 
evaluations of health care programmes is the method in which preference 
values for alternative health states are obtained. Two main approaches of 
obtaining estimates are available, the questionnaire approach and the 
interview approach. Drummond (1981) argues that one problem with the 
questionnaire approach is that individuals may deliberately overstate their 
valuations if they know the purpose of the exercise. In addition, question 
wording and ordering and extraneous factors may bias responses. The
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interview approach has the advantage of correcting subjects’ 
misunderstandings and inconsistent answers. However, it may place more 
pressure on subjects to respond to questions which they would otherwise fail 
to answer. Questioning or interviewing medically qualified professionals, as 
Rosser and Kind (1978) did to obtain relative preference values for the 
Classification of Illness States, should overcome these problems. 
Nevertheless, it is always difficult to ensure that any one of a number of 
extraneous variables do not systematically bias a subject’s responses.
In the joint replacement study (Chapter 3), the interview approach was 
used as the method of assessing the quality of life of the patients. In each 
interview, the patient was asked a set of previously formulated questions. 
The majority of the questions offerred a number of alternative answers, from 
which the patients were asked to choose one. This approach was selected 
because it was the most convenient, and because it was feared that a 
questionnaire approach would have a lower compliance rate. An attempt was 
made not bias each subject's responses.
7.25 Ordinal and Cardinal Scales
A fifth issue which arises when using health status indices in the 
economic evaluation of health care programmes is the different scaling 
methods of indicating or measuring health status. Essentially, these fall into 
two broad categories: ordinal scales and cardinal scales. Ordinal scales tell us 
that one unit has more of a property than does another unit. In the case of 
health status indices, a person or a group of people deem that one health state 
is better or worse than another health state. (Note, value judgments are 
entailed in this decision). No meaningful numerical inferences can be made 
about the differences between the health states. Cardinal scales do allow us to
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make meaningful numerical inferences about the differences between 
different health states and fall into two categories: interval scales and ratio 
scales. Interval scales tell us that one unit differs by a certain amount of a 
property from another unit. However, no real meaning is assigned to the zero 
or the endpoint on interval scales. Ratio scales do have true zero points and 
allow us to say that one unit has so many times as much of a property as does 
another unit. For example, ratio scales allow us to say that a score of 4 is twice 
as good as a score of 2 and one half as good as a score of 8.
Ideally, we would like health status indices to exhibit the ratio scaling 
quality. This would allow us to make meaningful comparisons between 
alternative health states. However, of all the health status indices covered in 
this thesis, disease-specific as well as generic, only the Rosser-Kind 
Classification of Illness States assigned utility values to alternative health 
states using the ratio scaling method. Most of the remainder are ordinal scales 
which do not allow us to say that a patient with health state a is x times better 
or worse than a patient with health state b. Let us illustrate this point with 
two examples.
The health status index developed by Grogono and Woodgate (1971) was 
described in Chapter 2. It assesses patients with respect to 10 activities, each of 
which receive a score of either 1, 0.5 or 0, representing normal, impaired or 
incapacitated respectively. The results are then transformed into a 0-1 index 
by dividing the total score by 10. Using this index, it is possible to say that a 
score of 1 for each of the functions is better than a score of 0.5, which in turn is 
better than a score of 0. However, we are not able to say how much better a 
normal state is than an impaired state, or how much better an impaired state 
is than an incapacitated state. We certainly cannot say that it is twice as good. 
The reason for this is that the authors have assigned arbitrary values (1, 0.5 
and 0) to three of many possible levels of disability without any prior 
evidence that utility values for these health states conform to an interval or
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ratio scale. Likewise, it may be misleading to quote an overall score using this 
index, since people may make cardinal conclusions from ordinal scale data. 
That is not to say that ordinal scales are of no use to the field of health status 
measurement. They certainly are helpful, but they are not appropriate for 
inclusion in quality adjusted life year data.
A second illustration is the NIH Clinical Score developed by Taussig et al. 
(1973) and described in Chapter 5. This is a disease-specific scale which 
evaluates chronic pulmonary disease in cystic fibrosis patients. It assigns 
patients a score out of 100, three-quarters of which is placed on the pulmonary 
component. The NIH Clinical Score is a good example of an ordinal scale 
which makes value judgments about which attributes contribute to a 
patient's health-related quality of life, weights the relative importance of each 
attribute and adds the ratings for each attribute to form a total score. The scale 
may assist evaluators in concluding that a patient with an NIH score of 70 has 
a better health-related quality of life than a patient with an NIH score of 60. 
However, they are not able to say how much better that quality of life is. That 
would attribute to the scale a property possessed only by ratio and interval 
scales. For health economists who would like to convert information 
available in disease-specific ordinal scales, such as the NIH Clinical Score, into 
quality adjusted life years, this raises many problems. Assumptions have to be 
made concerning the utility weight placed on each increment of the ordinal 
scale, that is to say it has to be stated explicitly that a year of life with an NIH 
Clinical Score of x is equivalent to y quality adjusted life years. More often 
than not, this would be too complex a task, and health economists would find 
it more straightforward to measure the health-related quality of life of 
patients using a ratio-scaled index such as the Rosser-Kind Classification and 
then convert this information into quality adjusted life years.
There are a number of additional assumptions which ordinal health status 
indices or ad hoc numerical scales make. First, many of them simply add
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scores for a number of attributes which are assumed to measure health- 
related quality of life. This implicitly assumes that each attribute is an equally 
important determinant of health-related quality of life. The Shwachman- 
Kulczycki Score, which assesses the health-related quality of life of cystic 
fibrosis patients and was covered in Chapter 5, weights general activity, 
physical examination, nutrition and X-ray findings equally. Of the generic 
health status indices, the Grogono-Woodgate Index [Grogono and Woodgate 
(1971)] assumes equal importance for 10 activities, the Ability Index [Izsak and 
Medalie (1971)] assumes equal importance for 15 activities, the Activities of 
Daily Living Index [Katz and Akpom (1976)] places equal importance on six 
functions and it appears that the Spitzer QL-Index [Spitzer et al. (1981)] 
assumes equal importance for five activities. Other generic health status 
indices assume equal weights for different attributes which are themselves 
subdivided and then combined in different permutations [Torrance et al. 
(1982), Euroqol Group (1990)]. Assuming equal importance for different 
functions in this way is debatable. For example, Grogono and Woodgate (1971) 
argue that physical suffering and recreation are equally important 
determinants of health-related quality of life. It could be argued, in response, 
that physical suffering is by far the greater concern to the patient.
A second assumption which many ordinal health status indices make, and 
which follows on from the first assumption, is that by simply adding the 
scores together for different functions, they assume that each function is 
independent. Though this may be the case, it is more likely that the scores for 
different health functions are highly correlated. For example, with respect to 
the Shwachman-Kulczycki Score, it is quite likely that an improvement in 
the general activity element of the score is associated with an improvement 
in the physical examination element. As a result, a minor fluctuation in a 
patient's health-related quality of life might lead to a spurious inflation or 
deflation of the overall score. Alternatively, a fluctuation in a patient's
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health-related quality of life might not be picked up at all because of the 
limited number of functions chosen to measure it.
In addition to the assumptions of exhaustiveness, equal importance and 
mutual exclusivity, a third assumption of many ordinal health status indices 
is that they can measure changes in continuous variables, using discrete and 
often unequal categories. The example was given in Chapter 5 of the Taussig 
NIH Clinical Score which is divided into a number of categories. The score 
increases by 2 points if the vital capacity of cystic fibrosis patients increases 
from 69% to 70%, but remains unchanged if the vital capacity of the patients 
increases from 70% to 79%. Clearly, this unequal subdivision of categories of 
a scale may not adequately reflect any real improvement or deterioration in 
patient health-related quality of life. Continuous categories of scales or 
categories which are subdivided into equal steps would be preferable in 
measuring such parameters.
Finally, many ordinal health status indices are mistakenly analysed using 
parametric statistical tests, such as means and standard deviations. This was 
Gudex's error when she estimated the mean Shwachman and Taussig score 
for the 27 patients studied by Boyle et al. (1976). Parametric statistical tests 
should not be used as ordinal data only tell us the rank order of scores and 
there is no proof that intervals between the increments on the scales are equal 
in any true sense. This can be illustrated with a quote from Andersen (1990): 
"When steps on a measurement scale are not known to be of equal length, 
values from different patients ought not to be added to form a mean. It is also 
impermissible to estimate the SD. An analogy may illustrate the problem. 
Suppose eight athletes are available for a 4 x 100 m relay for men in the 
Olympics. Their qualifications are constant, but have been measured on an 
ordinal scale only. It is accordingly known that A is less than B is less than C 
is less than D is less than E is less than F is less than G is less than H. The 
team ABCD ought accordingly always to defeat team EFGH, but what are the
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chances of ABCH in competition with DEFG? The tradition in clinical 
research is to symbolize the classes of an ordinal scale with 1-2-3-4-5-6-7-8. 
This rule would make team ABCH the winner, because l + 2 + 3 + 8is less 
than 4 + 5 + 6 + 7. Suppose the seven athletes were Olympic-class track stars 
and the eighth (= H) a 54-year-old overweight smoker with arthritis! Now it is 
likely that team DEFG would win. The reason is that the translation H = 8 
fails to reveal that the distance from G to H is much larger than any other. H 
ought perhaps to be 13 or 127? Calculation of mean and SD from data on an 
ordinal scale requires some translation. No matter which is used, the absence 
of a benchmark means the introduction of some unverifiable assumptions. 
Conclusions accordingly rest upon them. This uncertainty is intolerable, 
because alternatives exist without such problems. The median and fractiles 
(e.g. percentiles or quartiles) should be used to indicate central tendency and 
dispersion whenever data are on ordinal scales." (Pages 179-180).
7.26 Conversion into Generic Scales
The sixth and final issue for discussion which has arisen in the use of 
health status indices in this thesis, and which was touched upon in Chapter 4, 
is the conversion of information from disease-specific scales or ad hoc 
numeric scales into generic health status indices, such as the Rosser-Kind 
Classification.
Across-programme output measures aid health economists by offering 
guidance on the relative benefits to be derived at the margin by putting 
resources into one programme or another [Williams (1989)]. However, 
obtaining information on all medical conditions using such generic outcome 
measures would be a tremendous task, and it is often easier to convert 
information available from disease-specific outcome measures into across-
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programme outcome measures. This conversion process has the advantages 
of avoiding setting up new studies and using large data sets already in 
existence. In addition, it avoids expecting health service professionals to adopt 
a new outcome measure which they are not familiar with and which they 
might perceive to be crude.
In Chapter 4, sensitivity analyses were conducted on Gudex’s conversions 
of data from a number of disease-specific outcome measures into the Rosser- 
Kind Classification. Despite the advantages of the conversion process, and 
appreciating the constraints faced by Gudex, a number of difficulties with this 
approach come to mind. First, it is imperative that the correct disease-specific 
scale is selected as a comprehensive measure of each clinical condition. We 
learnt in Chapter 5 that the Shwachman and Taussig scores are not 
comprehensive measures of health-related quality of life. Under such 
circumstances, health economists or clinicians may have to choose from an 
imperfect set of disease-specific scales. Second, it has to be decided how best to 
convert the information from the disease-specific scales into the generic 
outcome measure. This involves value judgments and, as it was shown in 
Chapter 4, one's final results may be sensitive to alternative and reasonable 
categorisations. In addition, there is a risk that in the conversion process, the 
generic outcome measure may be insensitive to minor changes in clinical 
conditions. The reason for this is that the two types of measures are designed 
with different aims and are likely to emphasize different elements of health- 
related quality of life. Finally, problems may arise when converting 
information from what are usually ordinal disease-specific scales into 
cardinal generic scales. It would be advantageous if the disease-specific scales 
had interval or ratio properties. However, if they have ordinal properties, 
then transformations from such scales into scales where the differences 
between points have real meaning, may lead to statistical errors.
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7.3 Discounting
In Chapter 4, it was shown that the choice of discount rate can affect the 
relative cost effectiveness of medical procedures. Increases in the discount 
rate were shown to progressively depreciate the present value of future costs 
and benefits. When this was combined with a time span factor which also 
tended to place progressively less weight on costs and benefits accruing in the 
future, the importance of the selection of a discount rate for health projects 
was illustrated. It was argued that whichever discount rate a project evaluator 
chooses, a value judgment is in fact being made on the preference for current 
over future consumption. Low discount rates extol the virtues of long-lived 
projects; high discount rates introduce a bias against long-lived projects.
The sensitivity analysis performed on the 5 percent discount rate used by 
Gudex to calculate the relative cost effectiveness of the seven medical 
procedures (Chapter 4) produced some interesting results and illustrated the 
importance of discount rate selection, particularly when two or more projects 
are being compared. Surgery for idiopathic adolescent scoliosis was 
particularly affected by the exercise with its Cost per QALY varying 164-fold 
when the discount rate was varied between 0 percent and 10 percent. This was 
the result of the long time span over which the benefits of the medical 
procedure are enjoyed and the one-off costs per case. The sensitivity analysis 
also had some effect on the relative cost effectiveness of kidney 
transplantation, shoulder joint replacement surgery and scoliosis surgery for 
neuromuscular illness. These are all medical procedures for which benefits 
are enjoyed over a long period of time and for which the costs occur on a one- 
off basis. The remaining three medical procedures studied by Gudex, CAPD, 
haemodialysis and ceftazidime treatment of cystic fibrosis, remained 
unaffected by the exercise, largely because the recurring costs and benefits for 
these procedures tended to cancel each other out.
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In Chapter 3, the discount rate was also shown to affect the final Cost per 
QALY gained for hip and knee joint replacement surgery. The Cost per QALY 
gained for the two types of surgery was shown to vary by over £2,000 when 
discount rates of 0 to 10 percent were applied.
The main issue for discussion which emerges from this section is the 
appropriate discount rate for inclusion in health care projects. Chapter 4 
presented a list of studies, dating from 1958 to 1990, which applied discount 
rates of between 0 percent and 20 percent. This variation did not seem to be 
accounted for by the inflation rate prevailing in the economy at the time of 
the study. In addition, various theories were presented on the correct 
approach project evaluators should take toward the level of discount rates 
they apply. The need for discounting future costs remains relatively 
uncontroversial and the debate in this area tends to revolve around the 
appropriate rate. However, an interesting debate has emerged recently 
concerning not only the appropriate rate at which future health effects should 
be discounted, but also whether future health effects should be discounted at 
all.
Drummond et al. (1987) present some powerful arguments in favour of 
discounting future health effects. They argue that failing to discount future 
health effects, whilst at the same time discounting future costs would lead to 
inconsistencies, quite impossible conclusions and would ignore the 
possibilities of trading health through time. Weinstein and Stason (1977) 
present an example which clarifies these arguments:
"The reason for discounting future life years saved is not that life years can, 
in any sense, be invested to yield more life years as dollars can be invested to 
yield more dollars. Nor is it necessary to assume that life years in the future 
are less valuable than life years today in any absolute utilitarian sense. Rather, 
the reason for discounting future life years is precisely that they are being 
valued relative to dollars and, since a dollar in the future is discounted
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relative to a present dollar, so must a life year in the future be discounted 
relative to a present dollar. Consider the following example that illustrates 
the chain of logic for discounting future health benefits... Suppose that 
Program A saves one year of life expectancy 40 years hence at a present cost of 
$10,000, and that Program B saves one year of life expectancy now at present 
cost of $10,000. Which program should have higher priority? To answer this 
question, consider first a hypothetical Program Al, which can save one year of 
life 40 years hence at a cost of $70,000 borne in 40 years. This result is 
equivalent to Program A because $70,000 in 40 years has a present value (at 5 
per cent) of $10,000 and because the benefits of both programs, A and Al, are 
the same. Now, consider Program' Al, which simply translates both the 
benefits and the costs of Program Al from the future to the present. Provided 
life years are valued the same in relation to dollars in the present as in the 
future, Program Al should be considered to have the same long-run priority 
as Program Al. Finally, consider Program A3, under which both the benefits 
and the costs are reduced proportionately in relation to Program A2 and 
which, therefore, has the same priority. Now, it is clear that Program B is 
preferable to Program A3, since the costs are identical, but the benefits of 
Program B, which accrue at the same point in time as those of A3, are much 
more. Moreover, we have seen that Program A3, which has the same priority 
as Program A, could have been derived from Program A simply by 
discounting the future health benefits. The cost-effectiveness ratio for 
Program A is thus the present value of cost divided by the present value of 
benefit, or $10,000 / (l/(1.05)40), or $70,000 per QALY, which compares 
unfavorably to the $10,000 per QALY ratio for Program B.
Throughout this argument, it is never stated that, in any absolute sense, a 
year of life in the future is less valuable than a year of life in the present. It is 
the discounting of dollar costs, and the assumed constant steady-state relation
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between dollars and health benefits, that mandates the discounting of health 
benefits (i.e., quality-adjusted life years) as well as dollar health costs.
The exact equivalence between Al and A2 that underlies this line of 
reasoning assumes that opportunities for purchasing health benefits for 
dollars do not change over time. If it is expected that technology will improve 
so that it becomes less expensive to save lives, A2 may be somewhat less 
valuable than Ai, suggesting an even higher effective discount rate for life 
years than for dollar costs. If it is expected that environmental or other factors 
will conspire to make lifesaving more expensive - that is, more valuable - in 
the future, a lower discount rate may be in order. Moreover, if it is anticipated 
that societal attitudes will change so that the willingness to pay for lifesaving 
increases with time, a lower discount rate may be appropriate.
Another important caveat is that as we move far into the future, the 
uncertainty about the rate of discount that will obtain at that time increases, 
as does the uncertainty concerning future uses of health resources that will be 
available. Hence, the discount rate should be varied over a range of 
possibilities if the benefits or costs occur in the distant future." (Page 720).
The main argument against discounting future health effects is that it is 
not clear that people value future health effects any less than their present 
health. Indeed, concern for fitness and general health, and the willingness of 
individuals to spend large sums of money on health care, are taken as 
evidence that human beings are naturally concerned about their future 
health. Cullis and West (1979) argue that, as a result, a zero discount rate or 
even a negative rate might be appropriate. This line of thinking has recently 
found support in the Department of Health which has proposed that a zero 
discount rate should be applied to future health benefits [Parsonage and 
Neuburger (1991)].
This writer has no firm opinion about which discount rate should be 
applied to health care programmes, but believes that the recent debate on the
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subject and the results from Chapters 3 and 4 make it imperative that 
sensitivity analyses are performed on the rates selected to discount future 
costs and benefits of health care programmes. These sensitivity analyses 
should preferably include discount rates of 0, 5 and 10 percent. If one’s results 
are shown to be sensitive to alternative discount rates, as Gudex's cost utility 
estimates and the Cost per QALY estimates for hip and knee replacement 
surgery in Chapter 3 are, then it should be made clear by the study. This is 
particularly important when Cost per QALY league tables are presented to 
health authorities and other bodies with exact cost utility estimates for 
medical procedures. A failure to perform a sensitivity analysis and to present 
one's results can be misleading.
7.4 Use of QALY’s
The QALY concept is a brave and powerful attempt to tackle the problem of 
efficiently allocating scarce health care resources. If applied on a 
comprehensive basis to our own National Health Service (NHS), it would 
make explicit, choices and priorities which up until recently have been made 
on a more implicit basis. At present, health care resources in the NHS are 
allocated by a mixture of formal and informal devices [Stevenson (1991)]. 
These include the Resource Allocation Working Party (RAWP) formula 
which divides central government funds between Regional Health 
Authorities and smaller District Health Authorities, and the rationing of 
health care through queues and clinical discretion. The advantage of a QALY- 
based system would be that it would theoretically maximize health output for 
a given budget and would challenge health professionals to devise a better 
system. For the first time, health professionals in the NHS would seriously
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have to consider the implications of the choices that they have usually taken 
for granted.
A QALY-based system would work by allocating health care resources 
according to the relative position of medical procedures on a Cost per QALY 
league table. Theoretically, once all the data collection problems had been 
overcome, the most cost effective procedure, at the top of the league table, 
would be supplied first. The authority or governing body would then proceed 
to work down the league table and place decreasing priority on the less cost 
effective procedures, until the health budget is exhausted. Those procedures 
at the bottom of the league table would fare badly, but would not necessarily 
be overlooked. Stevenson (1991) argues that the gaps would be filled by 
private insurance, voluntary agencies and special government funds.
This writer believes that the QALY concept is a useful tool in aiding 
decision-making in the allocation of scarce health care resources and is 
certainly the direction that the NHS should be considering. However, it is still 
very early days for a wholesale application of the approach. A number of 
issues have been raised by this thesis concerning the QALY approach, which 
require more detailed discussion and which need to be dealt with before the 
QALY concept can be comprehensively applied.
As it was shown in Chapter 4, the Cost per QALY league tables which have 
been constructed have based their results on studies which were performed at 
different times and in different places. Gudex converted information from 
the British and overseas medical literature, which overed a 17 year time span 
(1968-1985), into one league table. This is a methodological error in the sense 
that the relative costs and consequences of medical procedures should only be 
compared in this way if the procedures were performed at the same time and 
in the same location. (In reality, this requirement can never be met and, as a 
result, no two procedures can strictly be compared). The benefits of medical 
programmes are likely to improve over time. For example, the study by Boyle
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et al. (1976) provides the basis of Gudex's health-related quality of life estimate 
for antibiotic treatment of cystic fibrosis. However, the period between 1976 
and 1986, when Gudex's study was written, saw great improvements in the 
life expectancy of cystic fibrosis patients [Britton (1989)]. Likewise, the relative 
costs of alternative medical procedures are likely to vary over time, as a result 
of technological improvements. Socio-economic factors, such as levels of 
income, are likely to differ between nations and between regions within 
nations, implying that the results of studies not performed in the same 
location may be affected by extraneous factors.
It is also important that the benefit estimates included in Cost per QALY 
league tables are derived using the same utility measurement technique. As 
discussed in Chapter 2, different utility methods yield different results. If the 
QALY concept is to be applied on a wide scale basis, then health economists 
and health care professionals will have to arrive at some sort of consensus 
over which measurement technique is the most accurate and most 
appropriate for the exercise. Even after this problem has been overcome, one 
can think of other methodological decisions which would have to be made. 
For example, which costs would be included in the calculations? Would some 
attempt be made to calculate the costs to relatives and friends of patients?
If Cost per QALY data are to form the basis of resource allocation decisions, 
then a continuous revision of the data may be necessary. The relative costs 
and consequences of medical procedures will vary continuously as a result of 
technological changes. A new programme which appears relatively expensive 
may improve its cost effectiveness over time, as a result of factors such as 
economies of scale. Some sort of check in the system may be necessary then to 
prevent discrimination against new procedures and programmes which are 
likely to improve their relative cost effectiveness at a later stage of 
development. This is likely to prove a very difficult task.
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Even if all the data collection problems could be overcome, decision 
makers would still face a number of other problems when they considered 
the final results. Drummond (1989) suggests that a highly summarized 
presentation of data is dangerous in that it suggests quick and easy solutions 
to the decision maker. If this is the case, then decision makers may have to 
become more involved in the data collection process, so that they can become 
more aware of the inaccuracy of the final results. In addition, the final Cost 
per QALY results would reflect averages for each medical procedure, whereas 
a safer proposition might be to present ranges of Cost per QALY figures for 
each procedure. A final problem with a Cost per QALY league table would be 
that it offends against the whole principle of equity within the NHS 
[Stevenson (1991)]. Even if some safeguards were introduced into the system, 
the logical outcome would be that some patients whose treatments had high 
costs per QALY would receive no care at all. Economic efficiency, rather than 
equity, would be the primary concern of the system and, as a result, it would 
arguably be safer to keep the present, imperfect, system.
In summary therefore, a wholesale application of the QALY concept to the 
allocation of scarce health care resources is still a long way off. The data 
requirements for such a system would be tremendous and a number of 
methodological problems would have to be overcome. Even if these 
problems could be tackled, a system based on the QALY concept might require 
decision makers to implement unpopular policies in the name of economic 
efficiency. Certainly, choices will sooner or later have to be made more 
explicit, but it seems that a good starting point would be to consider the QALY 
approach within clinical fields, as suggested by Donaldson et al. (1988). A 
number of lessons could be learnt from such a process which would help 
prevent future problems.
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7.5 Collections of Original Data
Chapters 4 to 6 were constructive in that they taught us a number of 
lessons about using existing data sets as a basis for resource allocation 
decisions. It was shown that converting existing medical information into 
generic health status indices is an informative indicator of the benefits of 
health programmes. However, we learnt that care should be taken to ensure 
that such medical information has been derived from representative patient 
cohorts and, that in the conversion process, realistic categorisations are made. 
In addition, it was learnt that, where time constraints or lack of resources 
deem it necessary to estimate the benefits of health programmes without any 
hard data, specialist clinical advice should be sought. The importance of 
performing sensitivity analyses on all assumptions was discussed. In terms of 
the costs of health programmes, it was argued that researchers should reveal 
the cost components incorporated into their estimates and their methods of 
calculation.
Despite the lessons that can be learnt from working with existing medical 
information, an important conclusion of this thesis must surely be that the 
collection of original data is the most reliable method on which to base 
resource allocation decisions. Collecting original data allows decision makers 
to design studies which avoid many of the problems discussed in Chapters 4 
to 6, such as conversions into generic health status indices. It is particularly 
important that an attempt should be made to collect original data when the 
health-related quality of life of patients is an important outcome, and when 
the existing environment only permits the collection of intermediate output 
effectiveness data.
Despite time constraints, resource constraints and the perceived suspicion 
on the part of health professionals, it is still difficult to understand the paucity 
of studies which have collected original health state utility values. The
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experience of this writer was that, after an initial fear of being intimidated by 
the whole process had been overcome, the vast majority of health 
professionals and patients were keen to cooperate in the joint replacement 
study (Chapter 3), and indeed were very interested in the project. It seems that 
this was the first attempt to measure the health-related quality of life of joint 
replacement patients at the Dundee Royal Infirmary. An initial fear of being 
treated with suspicion did not materialise. Rather, after they had learnt what 
the aims of the study were, the consultants and nurses took an increasing 
interest in its progress over the nine month period of interviews. The 
consultants, in particular, were interested in the results of the study. One 
commented that he was surprised that the health-related quality of life of 
patients who had knee replacement surgery improved after the three month 
period and, after hearing the result, later found that it was confirmed by his 
own experience with patients who had returned for their reviews.
This experience with health professionals leads to two suggestions. First, 
there should be more two-way interaction and communication between 
social scientists and health professionals. Neither group should fear the other. 
Rather, both have a great deal to learn from each other. Health professionals 
appreciate the resource constraints facing the National Health Service, and 
would prefer to play a more important role in the decision-making process. 
Social scientists should not fear working with either health professionals or 
patients. Second, if health state utilities are to be measured on a widescale 
basis, then there is no reason why the health professionals themselves should 
not play a greater role in the measurement process. It was shown in Chapter 3 
that the Rosser-Kind Classification of Illness States is a reliable measure of the 
health-related quality of life of patients who have undergone joint 
replacement surgery. It would take health professionals very little extra time 
to apply such a generic health status index to each of their patients. This 
would avoid employing outsiders to undertake the task. Of course, a number
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of problems would still have to be overcome, such as ensuring that the 
patients are representative of their illness groups, but there is no reason why 
health professionals should not be given a greater role in the health status 
measurement and decision making processes.
7.6 Lessons to be Learnt
To sum up then, a number of issues have been raised by this thesis which 
need more thorough consideration by academics, policy analysts and decision 
makers.
First, in selecting a health status measurement technique to be 
incorporated into an economic evaluation of health care programmes, one 
should try to use one of the health measurement instruments (the rating 
scale, the standard gamble approach, the time trade-off approach, ratio scaling 
and the equivalence method) or one of the cardinal-scaled health status 
indices (e.g. Rosser-Kind Classification of Illness States). These provide 
relatively accurate approaches to the quantitative valuation of health status 
and avoid some of the more difficult value judgments which are 
incorporated into the other techniques.
Second, whichever measurement instrument is chosen to obtain utility 
and ultimately QALY values, the number and combination of subjects whose 
preferences form the basis of the valuations should be stated explicitly. A 
discussion should follow explaining why it is believed that these subjects are 
representative. In addition, the questionnaire or interview approach selected 
should also be defended.
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Third, developing Cost per QALY league tables which compare the results 
of different studies can be misleading and can contain a number of 
methodological errors. A consensus should be reached concerning the most 
accurate and most appropriate measurement technique to be included in such 
studies, and an attempt should be made to avoid timing, location and 
development stage discrepancies. This is likely to prove a very difficult task. 
In the meantime, health economists can begin the process by comparing Cost 
per QALY results within clinical fields.
Fourth, the Rosser-Kind Classification of Illness States is an accurate health 
status measurement technique. However, if it is to become more widely used 
to compare the health-related quality of life of patient undergoing alternative 
medical treatments, then it should at least be borne in mind that it may be 
insensitive in picking up minor fluctuations in the health-related quality of 
life of certain groups of patients. The best solution would be to develop a new 
health status index which overcomes this insensitivity problem, but still 
allows across-programme comparisons to be made.
Fifth, prospective data would be preferable in assessing the health-related 
quality of life of groups of patients. Ideally, follow-up studies should be 
performed to measure the health-related quality of life of patients at later 
stages in life. If retrospective data have to be used, then tests will have to be 
incorporated into the studies to check for any biases in the final results.
Sixth, all assumptions of a study should be made explicit at the outset. It 
should be obvious to the reader which measurement technique was selected, 
how the study was conducted and all analogous assumptions. In particular, 
evidence should be provided to support the assumption of health-related 
quality of life improvement following medical treatment.
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Seventh, whatever the chosen health status measurement technique, 
when estimating the QALY’s gained for each medical procedure, reasonable 
assumptions concerning the survival period / life expectancy of each patient, 
conversions into health status indices and the discount rate should be tested 
using sensitivity analyses. If the final results are shown to be sensitive to such 
analyses, then it might be safer to present them in terms of ranges, rather 
than exact figures.
Eighth, studies which present medical information (such as the placebo 
controlled antibiotic trials encountered in Chapter 5) should present all 
relevant data (pretreatment and posttreatment scores) for each parameter 
evaluated. This would make comparative studies more straightforward.
Ninth, prognostic scores which are used as sources of information for each 
medical condition, should provide comprehensive measures of health- 
related quality of life. They should avoid assuming that all elements are 
independent of each other, and should avoid turning continuous variables 
into discrete variables. In addition, the information they provide should 
easily be convertible into more generic health status indices.
Tenth, all studies should clarify which costs and benefits were included in 
their estimates. If the list of cost and benefit components is less than 
comprehensive, then authors should make some sort of estimate of the likely 
effects of a more comprehensive list.
Eleventh, there should be more interaction and cooperation between social 
scientists and health professionals in the health status measurement process.
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It is hoped that these ideas can help improve health status measurement 
approaches and their inclusion in economic evaluations. Their incorporation 
would be a great step forward for one of the most difficult problems in health 
economics, namely the valuation of health outcome.
227
REFERENCES
Acton, J.P. (1973). Evaluating public programs to save lives. The case of heart 
attacks. Rand Corporation, R-73-02, Santa Monica, California, USA.
Adar, R. and Pliskin, N. (1980). Cost analysis of the utilization of new vascular 
grafts. Metamedicine 1, 213-223.
Anbar, R.D., Lapey, A., Khaw, K.T., Spragg, J., Strieder, D.J., Shaw, L.F., Kelly, 
D.H., and Shannon, D.C. (1990). Does lithium carbonate affect the ion 
transport abnormality in cystic fibrosis? Pediatric Pulmonology 8, 82-88.
Andersen, B. (1990). Methodological errors in medical research. Blackwell 
Scientific Publications, Oxford.
Barnum, H. (1987). Evaluating healthy days of life gained from health 
projects. Social Science and Medicine 24, 833-841.
Batten, J.C. (1983). The adolescent and adult. In Cystic fibrosis (eds M.E. 
Hodson, A.P. Norman and J.C. Batten), pp. 209-218. London.
Beaudry, P.H., Marks, M.I., McDougall, D., Desmond, K., and Rangel, R. (1980). 
Is anti-Pseudomonas therapy warranted in acute respiratory exacerbations in 
children with cystic fibrosis? Journal of Pediatrics' 97 (1), 144-147.
Bergner, M., Bobbitt, R.A., Kressel, S., Pollard, W.E., Gilson, B.S., and Morris, 
J.R. (1976). The Sickness Impact Profile: conceptual formulation and 
methodology for the development of a health status measure. International 
Journal of Health Services 6, 393-415.
Berwick, D.M., Cretin,. S., and Keeler, E. (1981). Cholesterol, children, and 
heart disease: an analysis of alternatives. Pediatrics 68, 721-730.
Berwick, D.M. and Komaroff, M.D. (1982). Cost-effectiveness of lead screening. 
New England Journal of Medicine 306, 1392-1398.
Beyt, B.E., Troxler, S., and Cavaness, J. (1985). Prospective payment and 
infection control. Infection Control 4, 161-164.
Bland, J.M. and Altman, D.G. (February 8, 1986). Statistical Methods for 
assessing agreement between two methods of clinical measurement. Lancet, 
307-310.
Bonney, S., Finkelstein, F.O., Lytton, B., Schiff, M., and Steele, T.E. (1978). 
Treatment of end-stage renal failure in a defined geographic area. Archives of 
Internal Medicine 138, 1510-1513.
228
Bowman, R.R., Guyer, W.D., and Bos, G.D. (1991). Total knee arthroplasty at a 
veterans administration medical center. Clinical Orthopaedics and Related 
Research 269, 51-57.
Boyle, I.R., Di Sant’Agnese, P.A., Sacks, S., Millican, F., and Kulczycki, L.L. 
(1976). Emotional adjustment of adolescents and young adults with cystic 
fibrosis. Journal of Paediatrics 88 (2), 318-326.
Boyle, M.H., Torrance, G.W., Sinclair, J.C., and Horwood, S.P. (1983). 
Economic evaluation of neonatal intensive care of very-low-birth-weight 
infants. New England Journal of Medicine 308 (22), 1330-1337.
Breslow, L. (1972). A quantative approach to the world health organization 
definition of health: physical, mental and social well-being. International 
Journal of Epidemiology 1, 347-355.
Breyer, F. and Fuchs, V.R. (1982). Risk attitudes in health: an exploratory 
study. NBER Working Paper No.875, Cambridge, M.A.
Britton, J.R. (1989). Effects of social class, sex, and region of residence on age at 
death from cystic fibrosis. British Medical Journal 298, 483-487.
Bulpitt, C.J. and Fletcher, A.E. (1990). The measurement of quality of life in 
hypertensive patients: a practical approach. Br J Clin Pharmac 30, 353-364.
Bush, J.W., Chen, M.M., and Patrick, D.L. (1973). Health status index in cost- 
effectiveness: analysis of PKU programme. In Health status indexes (ed. R.L. 
Berg), pp 172-194. Hospital Research and Educational Trust, Chicago.
Buxton, M., Ashby, J., and O'Hanlon, M. (1986). Valuation of health states 
using the time trade-off approach: report of a pilot study relating to health 
states one year after treatment for breast cancer. HERG Discussion Paper No.2., 
Brunel University.
Bywater, E.M. (1981). Adolescents with cystic fibrosis: psychosocial 
adjustment. Archives of Disease in Childhood 56, 538-543.
Carswell, F., Ward, C., Cook, D.A., and Speller, D.C.E. (1987). A controlled trial 
of nebulized aminoglycoside and oral flucloxacillin versus placebo in the 
outpatient management of children with cystic fibrosis. Br J Dis Chest 81, 356­
360.
Chaput de Saintonge, D.M., Kirwan, J.R., Evans, S.J.W., and Crane, G.J. (1988). 
How can we design trials to detect clinically important changes in disease 
severity? Br J Clin Pharmac 26, 355-362.
Clayton, M.L., Ferlic, D.C., and Jeffers, P.D. (1982). Prosthetic arthroplasties of 
the shoulder. Clinical Orthopaedics and Related Research 164, 184-191.
229
Cofield, R.H. (1984). Total shoulder arthroplasty with the Neer prosthesis. 
Journal of Bone and Joint Surgery 66-A (6), 899-906.
Cohen, L.F., di Sant’Agnese, P.A., and Friedlander, J. (1980). Cystic fibrosis and 
pregnancy: A national survey. Lancet 2, 842-844.
Collis, D.K. and Ponseti, I.V. (1969). Long-term follow-up of patients with 
idiopathic scoliosis not treated surgically. Journal of Bone and Joint Surgery 
51-A (3), 425-445.
Conway, S.P., Miller, M.G., Ramsden, C., and Littlewood, J.M. (1985). 
Intensive treatment of pseudomonas chest infection in cystic fibrosis: a 
comparison of tobramycin and ticarcillin, and netilmicin and ticarcillin. Acta 
Paediatr Scand 74, 107-113.
Cullis, J.G. and West, P.A. (1979). The economics of health: an introduction. 
Martin Robertson.
Culyer, A.J. (1978). Measuring health: lessons for Ontario. Ontario Economic 
Council, Toronto, Canada.
Culyer, A.J. and Maynard, A.K. (1981). Cost-effectiveness of duodenal ulcer 
treatment. Social Science and Medicine 15C, 3-11.
Dasgupta, A.K. and Pearce, D.W. (1978). Cost-benefit analysis: theory and 
practice. Macmillan Student Editions.
Davey, P., Dodd, T., Kerr, S., and Malek, M. (1990). Audit of IV antibiotic 
administration. Pharmaceutical Journal , 793-796.
David, T.J. (1989). Intravenous antibiotics at home in children with cystic 
fibrosis. Journal of the Royal Society of Medicine 82, 8-9.
David, T.J., Phillips, B.M., and Connor, P.J. (1983). Ceftazidime - a significant 
advance in the treatment of cystic fibrosis. Journal of Antimicrobial 
Chemotherapy 12 (Suppl A), 337-340.
Davies, T.W. and Cottingham, J. (1979). The cost of hospital infection in 
orthopaedic patients. Journal of Infection 1 (4), 329-338.
Denning, C.R., Park, S., Grece, C.A., and Gilbert, W.M. (1977). Continuous vs 
intermittent oral antibiotics in the management of patients with cystic 
fibrosis. Cystic Fibrosis Club Abstract, 13.
Dickson, R.A. (1983). Scoliosis in the community. British Medical Journal 
286,615-618.
Dixon, R.E. (1978). Effect of infections on hospital care. Annals of Internal 
Medicine 89 (2), 749-753.
230
Dixon, R.E. (1985). Economic costs of respiratory infections in the United 
States. American Journal of Medicine 78 (6B), 45-51.
Donaldson, C., Atkinson, A., Bond, J., and Wright, K. (1988). Should QALYS 
be programme-specific? Journal of Health Economics 7, 239-257.
Donati, M.A., Guenette, G., and Auerbach, H. (1987). Prospective controlled 
study of home and hospital therapy of cystic fibrosis pulmonary disease. 
Journal of Pediatrics 111 (1), 28-33.
Drummond, M.F. (1981). Welfare economics and cost-benefit analysis in 
health care. Scottish Journal of Political Economy 28 (2), 125-145.
Drummond, M.F. (1989). Output measurement for resource allocation 
decisions in health care. Oxford Review of Economic Policy 5 (1), 59-74.
Drummond, M.F., Ludbrook, A., Lowson, K.V., and Steele, A. (1986). Studies 
in economic appraisal in health care, Vol.2. Oxford University Press.
Drummond, M.F., Stoddart, G.L., and Torrance, G.W. (1987). Methods for the 
economic evaluation of health care programmes. Oxford University Press.
Edwards, W. (1977). How to use multiattribute utility measurement for social 
decision making. IEEE Transactions on Systems, Man and Cybernetics 7, 326­
340.
Elstein, A.S., Holzman, G.B., Ravitch, M.M., Metheny, W.A., Holmes, M.M., 
Hoppe, R.B., Rothert, M.L., and Rovner, D.R. (1986). Comparison of 
physicians decisions regarding estrogen replacement therapy for menopausal 
women and decisions derived from a decision analytic model. The American 
Journal of Medicine 80., 246-258.
Enke, S. (1966). The economic aspects of slowing population growth. 
Economic Journal 76, 44-56.
Eraker, S.A. and Sox, H.C. (1981). Assessment of patients preferences for 
therapeutic outcomes. Medical Decision Making 1 (1), 29-39.
Euroqol Group. (1990). Euroqol - a new facility for the measurement of health- 
related quality of life. Health Policy 16 (3), 199-208.
Evans, R.W., Hart, L.G., and Manninen, D.L. (1984). A comparative 
assessment of the quality of life of successful kidney transplant patients 
according to source of graft. Transplantation Proceedings 16 (5), 1353-1358.
Evans, R.W., Manninen, D.L., Garrison, L.P., Hart, L.G., Blagg, C.R., Gutman, 
R.A., Hull, A.R., and Lowrie, E.G. (1985). The quality of life of patients with 
end-stage renal disease. New England Journal of Medicine 312 (9), 553-559.
231
Fein, R. (1958). Economics of mental illness. Basic Books, New York.
Fein, R. (1977). But on the other hand: high blood pressure, economics and 
equity. New England Journal of Medicine 296 (13), 751-753.
Gafni, A. and Torrance, G. (1984). Risk attitudes and time preferences in 
health. Management Science 30 (4), 440-451.
Geddes, D.M. (1988). Antimicrobial therapy against staphlococcus aureus, 
Pseudomonas aeruginosa, and pseudomonas cepacia.Chest 94 (2), 140S-144S.
Gilbert, J., Robinson, T., and Littlewood, J.M. (1988). Home intravenous 
antibiotic treatment in cystic fibrosis. Archives of Disease in Childhood 63, 
512-517.
Girard, R., Fabry, J., Meynet, R., Lambert, D.C., and Sepetjan, M. (1983). Costs 
of nosocomial infection in a neonatal unit. Journal of Hospital Infection 4 
(iv), 361-366. •
Gold, R. (1987). Mild to moderate chest exacerbations: do antibiotics help? 
Pediatr Pulmonology 1 (Suppl 1), 38-39.
Gold, R., Carpenter, S., Heurter, H., Corey, M., and Levison, H. (1987). 
Randomized trial of ceftazidime versus placebo in the management of acute 
respiratory exacerbations in patients with cystic fibrosis. Journal of Pediatrics 
111 (6), 907-913.
Gold, R., Overmeyer, A., Knie, B., Fleming, P.C., and Levison, H. (1985). 
Controlled trial of ceftazidime vs. ticarcillin and tobramycin in the treatment 
of acute respiratory exacerbations in patients with cystic fibrosis. Pediatric 
Infectious Disease 4 (2), 172-177.
Goldstein, H. and Philip, J. (1990). A cost-benefit analysis of prenatal diagnosis 
by amniocentesis in Denmark. Clin Genet 37, 241-263.
Green, J.W. and Wenzel, R.P. (1977). Postoperative wound infection : a 
controlled study of the increased duration of hospital stay and direct cost of 
hospitalization. Annals of Surgery 185, 264-268.
Grogono, A.W. and Woodgate, D.J. (1971). Index for measuring health. Lancet 
2,1024-1026.
Gudex, C. (1986). QALY's and their use by the health service. University Of 
York, Centre For Health Economics, Discussion Paper 20.
Haley, R.W., Schaberg, D.R., Crossley, K.B., Von Allmen, S.D., and McGowan, 
J.E. (1981). Extra charges and prolongation of stay attributable to nosocomial 
infections : a prospective interhospital comparison. American Journal of 
Medicine 70, 51-58.
232
Harris, A.I., Cox, E., and Smith, C.R.W. (1971). Handicapped and impaired in 
Great Britain. HMSO, London.
Hartunian, N.S., Smart, C.N., and Thompson, M.S. (1980). The incidence and 
economic costs of cancer, motor vehicle injuries, coronary heart disease and 
stroke: a comparative analysis. American Journal of Public Health 70, 1249­
1260.
Henderson, J.B. (1982). An economic appraisal of the benefits of screening for 
open spina bifida. Social Science and Medicine 16, 545-560.
Henley, L.D. and Hill, I.D. (1990). Global and specific disease-related 
information needs of cystic fibrosis patients and their families. Pediatrics 85 
(6), 1015-1021.
Hodson, M.E. (1988). Antibiotic treatment: aerosol therapy. Chest 94 (2), 156S- 
160S.
Hodson, M.E., Penketh, A.R.L., and Batten, J.C. (1981). Aerosol carbenicillin 
and gentamicin treatment of Pseudomonas aeruginosa infection in patients 
with cystic fibrosis. Lancet 1, 1137-1139.
Hoiby, N. and Koch, C. (1990). Pseudomonas aeruginosa infection in cystic 
fibrosis and its management. Thorax 45, 881-884.
Hunt, S.M., McEwen, J., and McKenna, S.P. (1985). Measuring health status: a 
new tool for clinicians and epidemiologists. Journal of the Royal College of 
General Practitioners 35, 185-188.
Hutchinson, T.A., Boyd, N.F., Feinstein, A.R., Gonda, A., Hollomby, D., and 
Rowat, B. (1979). Scientific problems in clinical scales, as demonstrated in the 
Karnofsky Index of Performance Status. Journal Of Chronic Diseases 32, 661­
666.
Hyatt, A.C., Chipps, B.E., Kumor, K.M., Mellits, E.D., Lietman, P.S., and 
Rosenstein, B.J. (1981). A double-blind controlled trial of anti-Pseudomonas 
chemotherapy of acute respiratory exacerbations in patients with cystic 
fibrosis. Journal of Pediatrics 99 (2), 307-311.
Inman, R.P. (1987). The economic consequences of debilitating illness: the case 
of multiple sclerosis. Review of Economics and Statistics 69, 651-660.
Irvin, G. (1978). Modern cost-benefit methods. An introduction to financial, 
economic and social appraisal of development projects. Macmillan Press, 
London.
Izsak, F.C. and Medalie, J.H. (1971). Comprehensive follow-up of carcinoma 
patients. Journal Of Chronic Diseases 24, 179-191.
233
Jensen, T., Pederson, S.S., Game, S., Heilmann, C., Hoiby, N., and Koch, C. 
(1987). Colistin inhalation therapy in cystic fibrosis patients with chronic 
Pseudomonas aeruginosa lung infection. Journal of Antimicrobial 
Chemotherapy 19, 831-838.
Jensen, T., Pederson, S.S., Hoiby, N., Koch, C., and Flensborg, E.W. (1989). Use 
of antibiotics in cystic fibrosis: the Danish approach. In Pseudomonas 
aeruginosa infection. Antibiot Chemother (eds N. Hoiby, S.S. Pederson, G.H. 
Shand, G. Doring and I.A. Holder) Vol.42, pp. 237-246. Basel, Karger.
Kahneman, D. and Tversky, A. (1979). Prospect theory: an analysis of decision 
under risk. Econometrica 47 (2), 263-291.
Kannel, W.B. and Gordon, T. (1970). The Framingham Study: an 
epidemiological investigation of cardiovascular disease. Sect 26. Government 
Printing Office, Washington, D.C.
Kaplan, R.M. and Bush, J.W. (1982). Health-related quality of life 
measurement for evaluation research and policy analysis. Health Psychology 
1 (1), 61-80.
Kaplan, R.M., Bush, J.W., and Berry, C.C. (1976). Health status. Types of 
validity and the index of well-being. Health Services Research 11 (4), 478-507.
Kaplan, R.M., Bush, J.W., and Berry, C.C. (1979). Health status index. Category 
rating versus magnitude estimation for measuring levels of well-being. 
Medical Care 17 (5), 501-525.
Karnofsky, D.A., Abelmann, W.H., Craver, L.F., and Burchenal, J.H. (1948). 
The use of the nitrogen mustards in the palliative treatment of carcinoma, 
with particular reference to bronchogenic carcinoma. Cancer, 634-656.
Karnofsky, D.A. and Burchenal, J.H. (1949). The clinical evaluation of chemo­
therapeutic agents in cancer. In Evaluation of chemotherapeutic agents (ed 
C.M. Macleod), pp 191-205. Columbia University Press, New York.
Kattan, M., Mansell, A., Levison, H., Corey, M., and Krastins, I.R.B. (1980). 
Response to aerosol salbutamol, SCH 1000, and placebo in cystic fibrosis. 
Thorax 35, 531-535.
Katz, S. (1987). The Portugal Conference: measuring quality of life and 
functional status in clinical and epidemiological research. Journal of Chronic 
Diseases: Forum For Clinical Epidemiology.
Katz, S. and Akpom, C.A. (1976). A measure of primary sociobiological 
functions. International Journal of Health Services 6, 493-507.
234
Keeler, E.B., Manning, W.G., Newhouse, J.P., Sloss, E.M., and Wasserman, J. 
(1989). The external costs of a sedentary life-style. American Journal of Public 
Health 79, 975-981.
Keeney, R.L. and Raiffa, H. (1976). Decisions with multiple objectives. 
Preferences and value tradeoffs. Wiley Publications, New York.
Kerem, E., Corey, M., Gold, R., and Levison, H. (1990). Pulmonary function 
and clinical course in patients with cystic fibrosis after pulmonary 
colonization with Pseudomonas aeruginosa. Journal of Pediatrics 116 (5), 714­
719.
Kilgus, D.J., Dorey, F.J., Finerman, G.A.M., and Amstutz, H.C. (1991). Patient 
activity, sports participation, and impact loading on the durability of 
cemented total hip replacements. Clinical Orthopaedics and Related Research 
269,25-31.
Kind, P., Rosser, R., and Williams, A. (1982). Valuation of quality of life: some 
psychometric evidence. In The value of life and safety (ed M.W. Jones-Lee), 
pp 159-170. Amsterdam: Elsevier/North Holland.
Klarman, H.E. (1965). Syphilis control programs. In Measuring benefits of 
government investment (ed. R. Dorfman), pp. 367-414. Brookings Institute, 
Washington DC.
Klarman, H.E. (1982). The road to cost-effectiveness analysis. Milbank 
Memorial Fund Quarterly 60 (4), 585-603.
Kriedel, T. (1980). Cost-benefit analysis of epilepsy clinics. Social Science and 
Medicine 14C, 35-39.
Krilov, L.R., Blumer, J.L., Stern, R.C., Hartstein, A.I., Iglewski, B.N., and 
Goldmann, D.A. (1985). Imipenem/Cilastatin in acute pulmonary 
exacerbations of cystic fibrosis. Reviews of Infectious Diseases 7 (3), 482-489.
Kun, P., Landau, L.I., and Phelan, P.D. (1984). Nebulized gentamicin in 
children and adolescents with cystic fibrosis. Aust Paediatr J 20, 43-45.
Kuzemko, J.A. (1988). Home treatment of pulmonary infections in cystic 
fibrosis. Chest 94 (2), 162S-165S.
Kuzemko, J.A. and Williams, K.J. (1986). Home intravenous treatment of 
pulmonary infections in cystic fibrosis. In Cystic fibrosis in children: practical 
and legal aspects of intravenous antibiotic administration in the home (ed. 
T.J. David), pp 29-32. Excerpta Medica, Amsterdam.
235
Labelle, R.J., Churchill, D.N., Martin, S., Isbister, E., and Orovan, W. (1987). 
Economic evaluation of extracorporeal shock wave lithotripsy, percutaneous 
ultrasonic lithotripsy, and standard surgical treatment of urolithiasis - a 
Canadian perspective. Clin Invest Med 10, 86-95.
Larsen, G.L., Barron, R.J., Landay, R.A., Cotton, E.K., Gonzales, M.A., and 
Brooks, J.G. (1980). Intravenous aminophylline in patients with cystic fibrosis. 
Am J Dis Child 134, 1143-1148.
Levin, H.M. (1975). Cost-effectiveness analysis in evaluation research. In 
Handbook of evaluation research (eds M. Guttentag and E.L. Struening) Vol. 
2, pp 89-122. Sage Publications, London.
Levy, J., Smith, A.L., Koup, J.R., Williams-Warren, J., and Ramsey, B. (1984). 
Disposition of tobramycin in patients with cystic fibrosis: A prospective 
controlled study. Journal of Pediatrics 105 (1), 117-123.
Loening-Baucke, V.A., Mischler, E., and Myers, M.G. (1979). A placebo- 
controlled trial of cephalexin therapy in the ambulatory management of 
patients with cystic fibrosis. Journal of Pediatrics 95 (4), 630-637.
Lowson, K.V., Drummond, M.F., and Bishop, J.M. (1981). Costing new 
services: long-term domiciliary oxygen therapy. Lancet i, 1146-1149.
Ludbrook, A. (1981). A cost-effectiveness analysis of the treatment of chronic 
renal failure. Applied Economics 13, 337-350.
McLaughlin, F.J., Matthews, W.J., Strieder, D.J., Sullivan, B., Taneja, A., 
Murphy, P., and Goldmann, D.A. (1983). Clinical and bacteriological responses 
to three antibiotic regimens for acute exacerbations of cystic fibrosis: 
ticarcillin-tobramycin, azlocillin-tobramycin, and azlocillin-placebo. Journal 
of Infectious Diseases 147 (3), 559-567.
McNeil, B.J., Pauker, S.G., Sox, H.C., and Tversky, A. (1982). On the elicitation 
of preferences for alternative therapies. New England Journal of Medicine 306 
(21), 1259-1262.
McNeil, B.J., Weichselbaum, R., and Pauker, S.G. (1978). Fallacy of the five- 
year survival in lung cancer. New England Journal of Medicine 299 (25), 1397­
1401.
McNeil, B.J., Weichselbaum, R., and Pauker, S.G. (1981). Tradeoffs between 
quality and quantity of life in laryngeal cancer. New England Journal of 
Medicine 305 (17), 982-987.
Mantle, D.J. and Norman, A.P. (1966). Life-table for cystic fibrosis. British 
Medical Journal 2, 1238-1241.
236
Martin, A.J., Smalley, C.A., George, R.H., Healing, D.E., and Anderson, C.M. 
(1980). Gentamicin and tobramycin compared in the treatment of mucoid 
Pseudomonas lung infections in cystic fibrosis. Archives of Disease in 
Childhood 55, 604-607.
Mooney, G.H. (1986). Economics, medicine and health care. Harvester Press.
Mooney, G.H., Russell, E.M., and Weir, R.D. (1980). Choices for health care. 
Macmillan Press, London.
Mouton, J.W. and Kerrebijn, K.F. (1990). Antibacterial therapy in cystic 
fibrosis. Medical Clinics of North America 74 (3), 837-850.
Muller, A. and Reutzel, T.J. (1984). Willingness to pay for reduction in fatality 
risk: an exploratory survey. American Journal of Public Health 74 (8), 808-812.
Neer, C.S., Watson, K.C., and Stanton, F.J. (1982). Recent experience in total 
shoulder replacement. Journal of Bone and Joint Surgery 64-A (3), 319-337.
Nelson, J.D. (1985). Management of acute pulmonary exacerbations in cystic 
fibrosis: A critical appraisal. Journal of Pediatrics 106 (6), 1030-1033.
Nilsonne, U. and Lundgren, K.D. (1968). Long-term prognosis in idiopathic 
scoliosis. Acta Orthopaedica Scandinavica 39, 456-465.
Nissinen, A., Tuomilehto, J., Kottke, T.E., and Puska, P. (1986). Cost- 
effectiveness of the North Karelia hypertension program. 1972-1977. Medical 
Care 24, 767-780.
Orenstein, D.M., Nixon, P.A., Ross, E.A., and Kaplan, R.M. (1989). The quality 
of well-being in cystic fibrosis. Chest 95 (2), 344-347.
Ostrowsky, J.T., Lippman, A., and Scriver, C.R. (1985). Cost-benefit analysis of 
a thalassemia disease prevention program. American Journal of Public 
Health 75, 732-736.
Pan, S.H., Canafax, D.M., Le, C.T., Cipolle, R.J., Uden, D.L., and Warwick, W.J. 
(1989). Bronchodilation from intravenous theophylline in patients with cystic 
fibrosis: Results of a blinded placebo-controlled crossover clinical trial. 
Pediatric Pulmonology 6, 172-179.
Park, S., Grece, C.A., and Denning, C.R. (1977). Continuous use of oral 
antibiotics in the management of patients with cystic fibrosis. Am Rev Resp 
Dis 115 (Suppl), 288.
Parry, M.F., Neu, H.C., Merlino, M., Gaerlan, P.F., Ores, C.N., and Denning, 
C.R. (1977). Treatment of pulmonary infections in patients with cystic fibrosis: 
a comparative study of ticarcillin and gentamicin. Journal of Pediatrics 90, 
144-148.
237
Parsonage, M. and Neuburger, H. (1991). Discounting and QALY's. Paper 
presented at Aberdeen Health Economics Study Group.
Patrick, D.L., Bush, J.W., and Chen, M.M. (1973). Toward an operational 
definition of health. Journal of Health and Social Behaviour 14, 6-23.
Pauker, S.G. (1976). Coronary artery surgery: the use of decision analysis. 
Annals of Internal Medicine 85, 8-18.
Pauker, S.G. and McNeil, B.J. (1981). Impact of patient preferences on the 
selection of therapy. Journal of Chronic Disability 34, 77-86.
Pauker, S.P. and Pauker, S.G. (1977). Prenatal diagnosis: a directive approach 
to genetic counselling using decision analysis. Yale Journal of Biology and 
Medicine 50, 275-289.
Pederson, S.S., Jensen, T., Hoiby, N., Kocch, C., and Flensborg, E.W. (1987). 
Management of Pseudomonas aeruginosa lung infection in Danish cystic 
fibrosis patients. Acta Paediatr Scand 76, 955-961.
Penketh, A.R.L., Hodson, M.E., and Batten, J.C. (1982). Long-term use of 
aerosol antibiotics in adults with cystic fibrosis. In Proceedings of the 11th 
Annual Meeting of the European Working Group in Cystic Fibrosis, Brussels, 
Belgium. Belgian Cystic Fibrosis Association, Brussels.
Permin, H., Koch, C., Hoiby, N., Christensen, H.O., Moller, A.F., and Moller, 
S. (1983). Ceftazidime treatment of chronic Pseudomonas aeruginosa 
respiratory tract infection in cystic fibrosis. Journal of Antimicrobial 
Chemotherapy 12 (Suppl A), 313-323.
Pinner, R.W., Haley, R.W., Blumenstein, B.A., Schaberg, D.R., Von Allmen, 
S.D., and McGowan, J.E. (1982). High cost nosocomial infections. Infection 
Control 3 (2), 143-149.
Pliskin, J.S., Shepard, D.S., and Weinstein, M.C. (1980). Utility functions for 
life years and health status. Operations Research 28, 206-224.
Pliskin, J.S., Stason, W.B., Weinstein, M.C., Johnson, R.A., Cohn, P.F., 
McEnany, M.T., and Braun, P. (1981). Coronary artery bypass graft surgery. 
Clinical decision making and cost-effectiveness analysis. Medical Decision 
Making 1 (1), 10-28.
Pole, D. (1971). Mass radiography: a cost-benefit approach. In Problems and 
progress in medical care (ed. G. McLachlan). University Press, Oxford.
Ponnighaus, J.M. (1980). The cost/benefit of measles immunization: a study 
from Southern Zambia. Journal of Tropical Medicine and Hygiene 83, 141-149.
238
Prince, A.S. and Neu, H.C. (1980). Use of piperacillin, a semisynthetic 
penicillin, in the therapy of acute exacerbations of pulmonary disease in 
patients with cystic fibrosis. Journal of Pediatrics 97,148.
Procci, W.R. (1980). A comparison of psychosocial disability in males 
undergoing maintenance haemodialysis or following cadaver 
transplantation. General Hospital Psychiatry 2, 255-261.
Raiffa, H. (1969). Preferences for multiattributed alternatives. Rand 
Corporation, RM-5868-DOT/RC, Santa Monica, California, USA.
Read. J.L., Quinn, R.J., Berwick, D.M., Fineberg, H.V., and Weinstein, M.C. 
(1984). Preferences for health outcomes: comparison of assessment methods. 
Medical Decision Making 4 (3), 315-329.
Regelmann, W.E., Elliott, G.R., Warwick, W.J., and Clawson, C.C. (1990). 
Reduction of sputum Pseudomonas aeruginosa density by antibiotics 
improves lung function in cystic fibrosis more than do bronchodilators and 
chest physiotherapy alone. Am Rev Respir Dis 141, 914-921.
Roberts, S.D., Maxwell, D.R., and Gross, T.L. (1980). Cost-effective care of end- 
stage renal disease: a billion dollar question. Annals of Internal Medicine 92, 
243-248.
Robinson, P. and Sly, P.D. (1990). Placebo-controlled trial of misoprostol in 
cystic fibrosis. Journal of Pediatric Gastroeneterology and Nutrition 11 (1), 37­
40.
Rose, R., Hunting, K,J., Townsend, T.R., and Wenzel, R.P. (1977). 
Morbidity/Mortality and economics of hospital-acquired blood stream 
infections : a controlled study. Southern Medical Journal 70, 1267-1269.
Rosser, R.M. and Kind, P. (1978). A scale of valuations of states of illness: is 
there a social consensus? International Journal of Epidemiology 7 (4), 347-358.
Rosser, R.M. and Watts, V. (1975). A clinical classification of disability and 
distress and its application to the awards made by the courts in personal 
injury cases. New Law Journal 125, 323-328.
Ruchlin, H.S., Finkel, M.L., and McCarthy, E.G. (1982). The efficacy of second- 
opinion consultation programs: a cost-benefit perspective. Medical Care 20: 3­
20.
Ruesch, J., Jospe, S., Peterson, H.W., and Imbeau, S. (1972). Measurement of 
social disability. Comprehensive Psychiatry 13, 507-518.
Rundell, O., Jones, R.K., and Gregory, D. (1981). Practical benefit-cost analysis 
for alcoholism programmes. Alcoholism: Clinical and Experimental Research 
5,497-509.
239
Sackett, D.L., Chambers, L.W., Macpherson, A.S., Goldsmith, C.H., and 
McAuley, R.G. (1977). The development and application of indices of health: 
general methods and a summary of results. American Journal of Public 
Health 67, 423-428.
Sackett, D.L. and Torrance, G.W. (1978). The utility of different health states as 
perceived by the general public. Journal of Chronic Diseases 31, 697-704.
Sadovnick, A.D. and Baird, P.A. (1981). A cost-benefit analysis of prenatal 
detection of Down syndrome and neural tube defects in older mothers. Am J 
Med Genet 10, 367-378.
Sassone, P.G. and Schaffer, W.A. (1978). Cost-benefit analysis. A handbook. 
Academic Press, New York.
Scheckler, W.E. (1980). Hospital costs of nosocomial infections : a prospective 
3-month study in a community hospital. Infection Control 1 (3), 150-152.
Schoemaker, P.J.H. (1980). Experiments on decisions under risk: the expected 
utility hypothesis. Nijhoff Publishing Co., Boston, Mass., USA.
Schoemaker, P.J.H. (1982). The expected utility model: its variants, purposes, 
evidence and limitations. Journal of Economic Literature 20, 529-563.
Shepherd, R.W., Holt, T.L., Thomas, B.J., Kay, L., Isles, A., Francis, P.J., and 
Ward, L.C. (1986). Nutritional rehabilitation in cystic fibrosis: Controlled 
studies of effects on nutritional growth retardation, body protein turnover, 
and course of pulmonary disease. Journal of Pediatrics 109 (5), 788-794.
Shwachman, H. and Kulczycki, L.L. (1958). Long-term study of one hundred 
five patients with cystic fibrosis. American Journal of Diseases of Children 96, 
6-15.
Simmonds, E.J., Littlewood, J.M., and Evans, E.G.V. (1990). Cystic fibrosis and 
allergic bronchopulmonary aspergillosis. Archives of Disease in Childhood 
65,507-511.
Siskind, F.B. (1987). The cost of compensating asbestos victims under the 
Occupational Disease Compensation Act of 1983. Risk Anal 7, 59-69.
Sivan, Y., Arce, P., Eigen, H., Nickerson, B.G., and Newth, C.J.L. (1990). A 
double-blind, randomized study of sodium cromoglycate versus placebo in 
patients with cystic fibrosis and bronchial hyperreactivity. Journal of Allergy 
and Clinical Immunology 85, 649-654.
Smith, A.L. (1986). Antibiotic therapy in cystic fibrosis: Evaluation of clinical 
trials. Journal of Pediatrics 108 (5), 866-870.
240
Soni, R.K. and Cavendish, M.E. (1984). A review of the Liverpool elbow 
prosthesis from 1974 to 1982. Journal of Bone and Joint Surgery 66-B (2), 248­
253.
Sorkin, A.L. (1975). Health economics. D.C. Heath and Company.
Spengler, R.F. and Greenough, W.B. (1978). Hospital costs and mortality 
attributed to nosocomial bacteremias. Journal of the American Medical 
Association 240, 2455-2458.
Spitzer, W.O., Dobson, A.J., Hall, J., Chesterman, E., Levi, J., Shepherd, R., 
Battista, R.N., and Catchlove, B.R. (1981). Measuring the quality of life of 
cancer patients: a concise QL-Index for use by physicians. Journal of Chronic 
Diseases 34, 585-597.
Stafanger, G. and Koch, C. (1989). N-acetylcysteine in cystic fibrosis and 
Pseudomonas aeruginosa infection: clinical score, spirometry and ciliary 
motility. Eur Respir J 2, 234-237.
Stason, W.B. and Weinstein, M.C. (1977). Allocation of resources to manage 
hypertension. New England Journal Of Medicine 296 (13), 732-739.
Stead, R.J., Hodson, M.E., and Batten, J.C. (1987). Inhaled ceftazidime 
compared with gentamicin and carbenicillin in older patients with cystic 
fibrosis infected with Pseudomonas aeruginosa. Br J Dis Chest 81 (3), 272-279.
Steen, H.J., Scott, E.M., Stevenson, M.I., Black, A.E., Redmond, A.O.B., and 
Collier, P.S. (1989). Clinical and pharmacokinetic aspects of ciprofloxacin in 
the treatment of acute exacerbations of pseudomonas infection in cystic 
fibrosis patients. Journal of Antimicrobial Chemotherapy 24, 787-795.
Steiner, K. and Smith, H. (1973). Application of cost benefit analysis to a PKU 
screening program. Inquiry 10, 34.
Stevenson, R. (1991). The Oregon formula: health economists' dream or 
Stalinist nightmare? Archives of Disease in Childhood 66, 990-993.
Strandvik, B. (1988). Antibiotic therapy of pulmonary infections in cystic 
fibrosis. Dosage schedules and duration of treatment. Chest 94 (2), 146S-149S.
Strandvik, B. (1988). Home treatment of pulmonary infections in cystic 
fibrosis. Discussion. Chest 94 (2), 166S.
Strandvik, B., Malmborg, A.S., Alfredson, H., and Ericsson, A. (1983). Clinical 
results and pharmacokinetics of ceftazidime treatment in patients with cystic 
fibrosis. Journal of Antimicrobial Chemotherapy 12 (Suppl A), 283-287.
241
Taplin, S.H., Thompson, R.S., and Conrad, D.A. (1988). Cost-justification 
analysis of prenatal maternal serum alpha-feto protein screening. Medical 
Care 26, 1185-1202.
Taussig, L.M., Kattwinkel, J., Friedewald, W.T., and Di Sant’Agnese, P.A. 
(1973). A new prognostic score and clinical evaluation system for cystic 
fibrosis. Journal of Paediatrics 82 (3), 380-388.
Taussig, L.M., Lobeck, C.C., di Sant’Agnese, P.A., Ackerman, D.R., and 
Kattwinkel, J. (1972). Fertility in males with cystic fibrosis. New England 
Journal of Medicine 287 (12), 586-589.
Thompson, M.S., Read, J.L., and Liang, M. (1984). Feasibility of willingness-to- 
pay measurement in chronic arthritis. Medical Decision Making 4 (2), 195­
215.
Toevs, C.D., Kaplan, R.M., and Atkins, C.J. (1984). The costs and effects of 
behavioral programs in chronic obstructive pulmonary disease. Medical Care 
22, 1088-1100.
Torrance, G.W. (1986). Measurement of health state utilities for economic 
appraisal. Journal of Health Economics 5, 1-30.
Torrance, G.W., Boyle, M.H., and Horwood, S.P. (1982). Application of multi­
attribute utility theory to measure social preferences for health states. 
Operations Research 30 (6), 1043-1069.
Torrance, G.W., Thomas, W.H., and Sackett, D.L. (1972). A utility 
maximization model for evaluation of health care programmes. Health 
Services Research 7 (2), 118-133.
Torrance, G.W. and Zipursky, A. (1984). Cost-effectiveness of ante-partum 
prevention of Rh immunization. Clinics in Perinatology 11 (2), 267-281.
Turck, D., Boute, O., Ythier, H., Gottrand, F., Loeuille, G.A., and Farriaux, J.P. 
(1989). Anomalie de la permeabilite intestinale a l’EDTA-Cr dans la 
mucoviscidose. Arch Fr Pediatr 46, 425-428.
Van der Laag, J. (1988). Antimicrobial therapy against staphlococcus aureus, 
Pseudomonas aeruginosa, and Pseudomonas cepacia. Discussion. Chest 94 
(2), 145S.
Van Grouw, A., Nadel, C.I., Weierman, R.J., and Lowell, H.A. (1976). Long 
term follow-up of patients with idiopathic scoliosis treated surgically. Clinical 
Orthopaedics and Related Research 117, 197-201.
Von Neumann, J. and Morgenstern, O. (1947). Theory of games and economic 
behaviour 2nd. Edn. Princeton University Press.
242
Ward, R.A. (1975). The economics of health resources. Addison-Wesley.
Warner, K.E. and Luce, B.R. (1982). Cost-benefit and cost-effectiveness analysis 
in health care. Principles, practice, and potential. Health Administration 
Press, Ann Arbor, Michigan.
Warwick, W.J. (1982). Prognosis for survival with cystic fibrosis: The effects of 
early diagnosis and cystic fibrosis center care. Acta Paediatr Scand 301 (suppl), 
27-31.
Wall, M.A., Terry, A.B., Eisenberg, J., McNamara, M., and Cohen, R. (1983).
Inhaled antibiotics in cystic fibrosis. Lancet 1,1325.
Weinstein, M.C. (1980). Estrogen use in postmenopausal women - costs, risks 
and benefits. New England Journal of Medicine 303 .(6), 308-316.
Weinstein, M.C. (1981). Economic assessment of medical practices and 
technologies. Medical Decision Making 1 (4), 309-330.
Weinstein, M.C. (1986). Risky choices in medical decision making: a survey. 
The Geneva Papers on Risk and Insurance 11 (4), 197-216.
Weinstein, M.C. and Fineberg, H.V. (1980). Clinical decision analysis. W.B. 
Saunders, Philadelphia.
Weinstein, M.C., Pliskin, J.S., and Stason, W.B. (1977). Coronary artery bypass 
surgery: decision and policy analysis. In Costs, risks and benefits of surgery 
(eds J.P. Bunker, B.A. Barnes and F. Mosteller), pp 342-371. Oxford University 
Press, New York.
Weinstein, M.C. and Quinn, R.J. (1983). Psychological considerations in 
valuing health risk reductions. Journal of Natural Resources 23, 659-673.
Weinstein, M.C. and Stason, W.B. (1976). Hypertension: a policy perspective. 
Harvard University Press, Cambridge, Mass., USA.
Weinstein, M.C. and Stason, W.B. (1977). Foundations of cost-effectiveness 
analysis in health and medical practices. New England Journal of Medicine 
296 (13), 716-721.
Weinstein, M.C. and Stason, W.B. (1982). Cost-effectiveness of coronary artery 
bypass surgery. Circulation 66 (HI), 56-66.
Weintraub, S.J. and Eschenbacher, W.L. (1989). The inhaled bronchodilators 
ipratropium bromide and metaproterenol in adults with CF. Chest 95 (4), 861­
864.
243
Wientzen, R., Prestidge, C.B., Kramer, R.I., McCracken, G.H., and Nelson, J.D. 
(1980). Acute pulmonary exacerbations in cystic fibrosis. Am J Dis Child 134, 
1134-1138.
Williams, A. (1985). Economics of coronary artery bypass grafting. British 
Medical Journal 291, 326-329.
Williams, A. (1989). Comment on ’Should QALYs be programme specific?' 
Journal of Health Economics 8, 485-487.
Wilmott, R.W., Tyson, S.L., Dinwiddie, R., and Matthew, D.J. (1983). Survival 
rates in cystic fibrosis. Archives of Disease in Childhood 58 (10), 835-836.
Wilmott, R.W., Tyson, S.L., and Matthew, D.J. (1985). Cystic fibrosis survival 
rates. The influences of allergy and Pseudomonas aeruginosa. AJDC 139, 669­
671.
World Health Organization (1947). The constitution of the World Health 
Organization. WHO Chron 1, 29.
Wright, M.L. and Elsas, L.J. (1980). Application of benefit-to-cost analysis to an 
X-linked recessive cardiac and humeroperoneal neuromuscular disease. Am J 
Med Genet 6, 315-329.
TECHNICAL APPENDIX

LIST OF APPENDICES
1 Annotated Bibliography of Health Status Measurement
Literature.......................................................................................... 1
2 Hip Joint Replacement Sample - Preoperative
Questionnaire.................................................................................. 13
3 Knee Joint Replacement Sample - Preoperative
Questionnaire.................................................................................. 17
4 Hip Joint Replacement Sample - Postoperative and
Retrospective Questionnaire......................................................... 21
5 Knee Joint Replacement Sample - Postoperative and
Retrospective Questionnaire......................................................... 27
6 Characteristics and Rosser-Kind Estimates of Control
Group Patients................................................................................. 33
7 Control Group - Change in Rating Scores for Individual
Questions for Whole Group.......................................................... 37
8 Control Group - Change in Rating Scores for Individual
Questions for Hip Subgroup......................................................... 39
\ 9 Control Group - Change in Rating Scores for Individual
\ Questions for Knee Subgroup......................................................  41
40 Control Group - Change in Rating Scores for Individual
Questions for Male Subgroup...................................................... 43
11 \ Control Group - Change in Rating Scores for Individual
Questions for Female Subgroup................................................... 45
12 Characteristics and Rosser-Kind Estimates of
Retrospective Group Patients.................... ................................... 47
13 Retrospective Group - Change in Rating Scores for
Individual Questions for Three Month Hip Subgroup..........  58
14 Retrospective Group - Change in Rating Scores for
Individual Questions for One Year Hip Subgroup..................  60
15 Retrospective Group - Change in Rating Scores for
Individual Questions for Two Year Hip Subgroup.................  62
16 Retrospective Group - Change in Rating Scores for
Individual Questions for Three Month Knee Subgroup.......  64
17 Retrospective Group - Change in Rating Scores for
Individual Questions for One Year Knee Subgroup...............  66
18 Hip Patients Matched Between Control and
Retrospective Groups in Terms of Age and Sex......................  68
19 Knee Patients Matched Between Control and
Retrospective Groups in Terms of Age and Sex......................  69
20 Sensitivity Analysis of Gudex's Use of CAPD Data................. 70
21 Sensitivity Analysis of Gudex's Use of Haemodialysis
Data [Procci (1980)].......................................................................... 72
22 Sensitivity Analysis of Gudex's Use of Haemodialysis
Data [Evans et al (1984), Evans et al (1985)]................................ 79
23 Sensitivity Analysis of Gudex's Use of Renal
Transplant Data [Procci (1980)]....................................................  83
24 Sensitivity Analysis of Gudex's Use of Renal
Transplant Data [Evans et al (1984), Evans et al (1985)]........... 90
25 Sensitivity Analysis of Gudex's Use of Shoulder
Joint Replacement Surgery Data [Cofield (1984)]...................... 92
26 Sensitivity Analysis of Gudex's Use of Elbow Joint
x Replacement Surgery Data [Soni and Cavendish (1984)]....... 145
\ •
27 Sensitivity Analysis of Gudex's Use of Ceftazidime
' Treatment of Cystic Fibrosis Data [Boyle et al (1976)].............. 154
28 Sensitivity Analysis of Gudex's Use of Scoliosis Surgery
for Idiopathic Adolescents Data [Van Grouw et al (1976)]...... 156
29 Sensitivity Analysis of Gudex's Use of Scoliosis
Secondary to Neuromuscular Illness Data................................. 159
APPENDIX 1
ANNOTATED BIBLIOGRAPHY OF HEALTH STATUS
MEASUREMENT LITERATURE
1) Acton, J.P. (1973). Evaluating public programs to save lives. The case of 
heart attacks. Rand Corporation, R-73-02, Santa Monica, California, USA.
Application of willingness to pay approach to measure health status in a 
study of life-saving techniques for victims of sudden heart attacks.
2) Bergner, M., Bobbitt, R.A., Kressel, S., Pollard, W.E., Gilson, B.S., and 
Morris, J.R. (1976). The Sickness Impact Profile: conceptual formulation and 
methodology for the development of a health status measure. International 
Journal Of Health Services 6, 393-415.
The Sickness Impact Profile, based on the concept of health-related 
dysfunction, is an outcome measure derived from quantitative estimates of 
changes in the behaviour of respondents. It has 312 items in 14 categories.
3) Boyle, M.H., Torrance, G.W., Sinclair, J.C., and Horwood, S.P. (1983). 
Economic evaluation of neonatal intensive care of very-low-birth-weight 
infants. New England Journal Of Medicine 308 (22), 1330-1337.
Application of cost-utility analysis to neonatal intensive care of very-low- 
birth-weight infants. Utilities are measured by rating scale. Wide range of 
costs taken into account on the cost side.
4) Breslow, L. (1972). A quantative approach to the world health organization 
definition of health: physical, mental and social well-being. International 
Journal Of Epidemiology 1, 347-355.
The self-administered questionnaire of the Alameda County Human 
Population Laboratory yields 3 separate scores for physical, mental and social 
health. It has been used successfully in representative samples of general 
populations.
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hypertensive patients: a practical approach. Br J Clin Pharmac 30, 353-364.
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11) Drummond, M.F., Stoddart, G.L., and Torrance, G.W. (1987). Methods for 
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12) Edwards, W. (1977). How to use multiattribute utility measurement for 
social decision making. IEEE Transactions On Systems, Man And Cybernetics 
7,326-340.
Edwards produces a simplified multiattribute rating technique.
13) Elstein, A.S., Holzman, G.B., Ravitch, M.M., Metheny, W.A., Holmes, 
M.M., Hoppe, R.B., Rothert, M.L., and Rovner, D.R. (1986). Comparison of 
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\ 14) Eraker, S.A. and Sox, H.C. (1981). Assessment of patients preferences for
therapeutic outcomes. Medical Decision Making 1 (1), 29-39.
Standard gamble approach used to analyze patients' responses to hypothetical 
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15) Euroqol Group. (1990). Euroqol - a new facility for the measurement of 
health-related quality of life. Health Policy 16 (3), 199-208.
An early report of the development of a new health status index, the Euroqol 
x instrument. Not a sophisticated index - it only contains six parameters
(mobility, self-care, main activity, social relationships, pain and mood), each 
of which contains three categories.
16) Gafni, A. and Torrance, G. (1984). Risk attitudes and time preferences in 
health. Management Science 30 (4), 440-451.
This paper reviews and explores the application of the concepts of risk 
attitude and time preference to the field of health.
17) Grogono, A.W. and Woodgate, D.J. (1971). Index for measuring health. 
Lancet 2, 1024-1026.
Grogono and Woodgate develop an index to measure health with 10 items 
focussing mainly on physical function.
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An important discussion paper which describes how the cost utility approach 
can be used to allocate health care resources. The calculation of cost utility 
estimates for seven medical procedures illustrate the approach.
18) Gudex, C. (1986). QALY's and their use by the health service. University Of
York, Centre For Health Economics, Discussion Paper 20.
19) Harris, A.I., Cox, E., and Smith, C.R.W. (1971). Handicapped and impaired 
in Great Britain. HMSO, London.
The Harris Index seeks to measure degrees of physical, mental, and sensory 
handicap in the population by measuring subjects.
20) Hunt, S.M., McEwen, J., and McKenna, S.P. (1985). Measuring health 
status: a new tool for clinicians and epidemiologists. Journal of the Royal 
College of General Practitioners 35, 185-188.
The development and characteristics of the Nottingham Health Profile is 
described. This health status index is divided into two parts, each of which is 
weighted to give a total score of 100.
21) Hutchinson, T.A., Boyd, N.F., Feinstein, A.R., Gonda, A., Hollomby, D., 
and Rowat, B. (1979). Scientific problems in clinical scales, as demonstrated in 
the Karnofsky Index of Performance Status. Journal Of Chronic Diseases 32, 
661-666.
An outline of the methodological problems in using ad hoc numeric scales as 
means of measuring health status.
22) Izsak, F.C. and Medalie, J.H. (1971). Comprehensive follow-up of 
carcinoma patients. Journal Of Chronic Diseases 24, 179-191.
Izsak and Medalies' 'Ability Index' integrates 21 items covering physical, 
emotional, social and economic factors to produce a single score measuring 
health. It is modified for each type of cancer.
23) Kahneman, D. and Tversky, A. (1979). Prospect theory: an analysis of 
decision under risk. Econometrica 07 (2), 263-291.
This paper presents a critique of expected utility theory as a descriptive model 
of decision making under risk, and develops an alternative model, called 
prospect theory.
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24) Kaplan, R.M. and Bush, J.W. (1982). Health-related quality of life 
measurement for evaluation research and policy analysis. Health Psychology 
1 (1), 61-80.
Excellent review of the ten years of work by Bush, Kaplan, and colleagues at 
the University of California, San Diego, on health status measurement.
25) Kaplan, R.M., Bush, J.W., and Berry, C.C. (1976). Health status. Types of 
validity and the index of well-being. Health Services Research 11 (4), 478-507.
Kaplan et al construct the Index of Well-being to fulfil the definition of 
content validity by including all levels of function and symptom/problem 
complexes, a clearly defined relation to the death state, and consumer ratings 
of the relative desirability of the function levels.
26) Kaplan, R.M., Bush, J.W., and Berry, C.C. (1979). Health status index. 
Category rating versus magnitude estimation for measuring levels of well­
being. Medical Care 17 (5), 501-525.
Kaplan et al create a health index with two components: level of well-being 
and prognosis, the latter being the probability of attaining a level of well-being 
by a certain time.
27) Karnofsky, D.A., Abelmann, W.H., Craver, L.F., and Burchenal, J.H. (1948). 
The use of the nitrogen mustards in the palliative treatment of carcinoma, 
with particular reference to bronchogenic carcinoma. Cancer, 634-656.
The Karnofsky Index is used to analyze the use of the nitrogen mustards in 
the palliative treatment of carcinoma with particular reference to 
brpnchogenic carcinoma.
28) Karnofsky, D.A. and Burchenal, J.H. (1949). The clinical evaluation of 
chemo-therapeutic agents in cancer. In Evaluation of chemotherapeutic 
agents (ed C.M. Macleod), pp 191-205. Columbia University Press, New York.
An early ad hoc numeric scale to measure health status designed for use in 
cancer research based on an interpretation of health-related quality of life in 
terms of physical ability.
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29) Katz, S. (1987). The Portugal Conference: measuring quality of life and 
functional status in clinical and epidemiological research. Journal Of Chronic 
Diseases: Forum For Clinical Epidemiology.
A thorough review of the issues involved in measuring health-related 
quality of life.
30) Katz, S. and Akpom, C.A. (1976). A measure of primary sociobiological 
functions. International Journal Of Health Services 6, 493-507.
The Katz ADL Index is probably the best example of a scale created for a 
variety of diagnoses to measure health status. It measures the basic 
sociobiological functions of bathing, dressing, toileting, transfer, continence 
and feeding.
31) Keeney, R.L. and Raiffa, H. .(1976). Decisions with multiple objectives. 
Preferences and value tradeoffs. Wiley Publications, New York.
Useful though complicated text on decision analysis. Comprehensive 
coverage of single-attribute and multi-attribute utility theory. Quite 
mathematical and heavy in parts.
32) Kind, P., Rosser, R., and Williams, A. (1982). Valuation of quality of life: 
some psychometric evidence. In The value of life and safety (ed M.W. Jones- 
Lee), pp 159-170. Amsterdam: Elsevier/North Holland.
An outline of a method by which a rough tariff for valuing distress and 
disability might be established in the form of a set of coefficients could be used 
to estimate the compensation due for various states intermediate between fit 
and dead.
33) Klarman, H.E. (1982). The road to cost-effectiveness analysis. Milbank 
Memorial Fund Quarterly 60 (4), 585-603.
The author describes four broad areas which favour cost effectiveness analysis 
over cost benefit analysis: problems in economic valuation, determining 
programme outcomes, calculating programme costs and concern for 
distributional effects.
34) McNeil, B.J., Pauker, S.G., Sox, H.C., and Tversky, A. (1982). On the 
elicitation of preferences for alternative therapies. New England Journal Of 
Medicine 306 (21), 1259-1262. "
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An interesting investigation on how variations in the way information is
presented to patients influence their choices between alternative therapies.
35) McNeil, B.J., Weichselbaum, R., and Pauker, S.G. (1978). Fallacy of the 
five-year survival in lung cancer. New England Journal Of Medicine 299 (25), 
1397-1401.
Standard gamble approach incorporated in study designed to illustrate the 
importance of evaluating therapeutic results with an index that includes 
explicit consideration of patient attitudes toward risk.
36) McNeil, B.J., Weichselbaum, R., and Pauker, S.G. (1981). Tradeoffs between 
quality and quantity of life in laryngeal cancer. New England Journal Of 
Medicine 305 (17), 982-987.
This paper uses the standard gamble and time trade-off approaches to 
measure patients' attitudes toward the quality and quantity of life to develop 
a more precise index of the relative values of alternative treatments.
37) Muller, A. and Reutzel, T.J. (1984). Willingness to pay for reduction in 
fatality risk: an exploratory survey. American Journal Of Public Health 74 (8), 
808-812.
An outline of the practical difficulties of using the willingness to pay 
approach to measure health status.
38) Patrick, D.L., Bush, J.W., and Chen, M.M. (1973). Toward an operational 
definition of health. Journal Of Health And Social Behaviour 14, 6-23.
Patrick et al measure the perceived social values of defined functional levels 
of health. This socially-weighted system of functiort levels was then used in 
the construction of a health status index.
39) Pauker, S.G. (1976). Coronary artery surgery: the use of decision analysis. 
Annals Of Internal Medicine 85, 8-18.
This paper illustrates how decision analysis can be used as an aid in the 
management of individual patients with chronic ischemic heart disease.
40) Pauker, S.G. and McNeil, B.J. (1981). Impact of patient preferences on the 
selection of therapy. Journal Of Chronic Disability 34, 77-86.
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Pauker and McNeil adopt the techniques of utility theory to integrate patient 
preferences with objective survival data. The importance of variations in 
patient attitudes toward survival is illustrated in a typical situation involving 
the choice between medical and surgical therapy.
41) Pauker, S.P. and Pauker, S.G. (1977). Prenatal diagnosis: a directive 
approach to genetic counselling using decision analysis. Yale Journal Of 
Biology And Medicine 50, 275-289.
The decision which prospective parents face concerning mid-trimester 
amniocentesis for prenatal diagnosis was examined by decision analysis.
42) Pliskin, J.S., Shepard, D.S., and Weinstein, M.C. (1980). Utility functions 
for life years and health status. Operations Research 28, 206-224.
Measurement techniques (standard gamble and time trade-off approaches) are 
applied to the treatment decision of whether to prescribe coronary artery 
bypass graft surgery in patients with coronary artery disease.
43) Pliskin, J.S., Stason, W.B., Weinstein, M.C., Johnson, R.A., Cohn, P.F., 
McEnany, M.T., and Braun, P. (1981). Coronary artery bypass graft surgery. 
Clinical decision making and cost-effectiveness analysis. Medical Decision 
Making 1 (1), 10-28.
Decision-analytic techniques used to evaluate the choice between an 
aortocoronary bypass operation and medical management in a set of 
hypothetical patients with coronary artery disease.
44) Raiffa, H. (1969). Preferences for multiattributed alternatives. Rand 
Corporation, RM-5868-DOT/RC, Santa Monica, California, USA.
Useful background text in decision analysis, focussing on the method of 
multiattributed utility functions. .
45) Read. J.L., Quinn, R.J., Berwick, D.M., Fineberg, H.V., and Weinstein, M.C. 
(1984). Preferences for health outcomes: comparison of assessment methods. 
Medical Decision Making 4 (3), 315-329.
This study compared standard gamble, time trade-off, and category scaling 
methods for assessing preferences among hypothetical outcomes of coronary 
artery bypass surgery.
46) Rosser, R.M. and Kind, P. (1978). A scale of valuations of states of illness: is 
there a social consensus? International Journal Of Epidemiology 7 (4), 347-358.
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A ratio scale of valuations of states of illness is derived and applied to health 
indicators and output measures.
47) Rosser, R.M. and Watts, V. (1975). A clinical classification of disability and 
distress and its application to the awards made by the courts in personal 
injury cases. New Law Journal 125, 323-328.
Rosser and Watts measure the willingness to receive as determined by court 
awards for disabilities in order to develop a ratio scale for health states.
48) Sackett, D.L., Chambers, L.W., Macpherson, A.S., Goldsmith, C.H., and 
McAuley, R.G. (1977). The development and application of indices of health: 
general methods and a summary of results. American Journal Of Public 
Health 67, 423-428.
The Health Index from McMaster University measures social, emotional and 
physical function of persons with a wide range of health problems.
\ 49) Sackett, D.L. and Torrance, G.W. (1978). The utility of different health states as perceived by the general public. Journal of Chronic Diseases 31, 697-
704.
This study calculates social utility values for 10 different health states with 
varying physical, social and emotional characteristics, limitations and 
duration.
50) Schoemaker, P.J.H. (1980). Experiments on decisions under risk: the 
expected utility hypothesis. Nijhoff Publishing Co., Boston, Mass., USA.
Thi^ paper illustrates the typical patterns of decision-making under 
uncertainty.
51) Schoemaker, P.J.H. (1982). The expected utility model: its variants, 
purposes, evidence and limitations. Journal Of Economic Literature 20, 529­
563.
This paper reviews the major empirical studies bearing on the expected utility 
model.
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52) Spitzer, W.O., Dobson, A.J., Hall, J., Chesterman, E., Levi, J., Shepherd, R., 
Battista, R.N., and Catchlove, B.R. (1981). Measuring the quality of life of 
cancer patients: a concise QL-Index for use by physicians. Journal Of Chronic 
Diseases 34, 585-597.
The study attempts to provide a new measure, the Spitzer QL-Index, that can 
help physicians assess the relative benefits and risks of various treatments for 
serious illness and of supportive programmes such as palliative care or 
hospice care.
53) Stason, W.B. and Weinstein, M.C. (1977). Allocation of resources to 
manage hypertension. New England Journal Of Medicine 296 (13), 732-739.
Application of cost-utility analysis to hypertension. Hypothetical utilities 
used. Only direct costs are taken into account.
54) Thompson, M.S., Read, J.L., and Liang, M. (1984). Feasibility of 
willingness-to-pay measurement in chronic arthritis. Medical Decision 
Making 4 (2), 195-215.
Application of willingness to pay approach to measure health status to 
patients with chronic arthritis.
55) Torrance, G.W. (1986). Measurement of health state utilities for economic 
appraisal. Journal Of Health Economics 5, 1-30.
An excellent and thorough review of health status measurement for use in 
economic appraisal of health care programmes, with particular emphasis on 
utility measurement.
56) Torrance, G.W., Boyle, M.H., and Horwood, S.P. (1982). Application of 
multi-attribute utility theory to measure social preferences for health states. 
Operations Research 30 (6), 1043-1069.
A presentation of a four-attribute health state classification system designed to 
uniquely categorize the health status of all individuals two years of age and 
over.
57) Torrance, G.W., Thomas, W.H., and Sackett, D.L. (1972). A utility 
maximization model for evaluation of health care programmes. Health 
Services Research 7 (2), 118-133.
The original cost-utility model as first developed. Takes a society-wide view 
of costs though flexible enough to substitute other cost definitions.
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A recent cost-utiiity study. Only direct costs and benefits considered. 
Undertaken from the viewpoint of the health care sector. It does however 
give a listing of cost-utility results from other studies.
58) Torrance, G.W. and Zipursky, A. (1984). Cost-effectiveness of ante-partum
prevention of Rh immunization. Clinics In Perinatology 11 (2), 267-281.
59) Von Neumann, J. and Morgenstern, O. (1947). Theory of games and 
economic behaviour 2nd. Edn. Princeton University Press.
An early text on how the theory of games can be applied to ,economic 
behaviour.
60) Weinstein, M.C. (1980). Estrogen use in postmenopausal women - costs, 
risks and benefits. New England Journal Of Medicine 303 .(6), 308-316.
Application of cost-utility analysis to estrogen therapy. Hypothetical utilities 
used. Only direct costs are taken into account.
\ 61) Weinstein, M.C. (1981). Economic assessment of medical practices and
technologies. Medical Decision Making 1 (4), 309-330.
A review of cost-effectiveness analyses in health care, highlighting some 
common pitfalls and unresolved controversies.
62) Weinstein, M.C. (1986). Risky choices in medical decision making: a 
survey. The Geneva Papers On Risk And Insurance 11 (4), 197-216.
Weinstein outlines the theory and application of decision analysis as a 
prescriptive tool in medical decision making and allocation of health care 
resources.
63) Weinstein, M.C. and Fineberg, H.V. (1980). Clinical decision analysis. W.B. 
Saunders, Philadelphia.
A useful background text on clinical decision analysis.
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64) Weinstein, M.C., Pliskin, J.S., and Stason, W.B. (1977). Coronary artery 
bypass surgery: decision and policy analysis. In Costs, risks and benefits of 
surgery (eds J.P. Bunker, B.A. Barnes and F. Mosteller), pp 342-371. Oxford 
University Press, New York.
Application of cost-utility analysis to coronary artery bypass surgery. 
Hypothetical utilities used. Only direct costs are taken into account.
65) Weinstein, M.C. and Quinn, R.J. (1983). Psychological considerations in 
valuing health risk reductions. Journal Of Natural Resources 23, 659-673.
Weinstein and Quinn discuss to what extent the contextual and psychological 
attributes of a risky decision have sufficient normative status to justify their 
formal inclusion in methods for valuing risk.
66) Weinstein, M.C. and Stason, W.B. (1976).. Hypertension: a policy 
perspective. Harvard University Press, Cambridge, Mass., USA.
Weinstein and Stason use hypertension to demonstrate the usefulness of 
systematic policy analysis in addressing the issues of resource allocation that 
surround a complex, uncertainty-laden medical detection and treatment 
problem.
67) Weinstein, M.C. and Stason, W.B. (1982). Cost-effectiveness of coronary 
artery bypass surgery. Circulation 66 (III), 56-66.
Recent data from the medical literature and other sources were used in an 
analysis of the cost-effectiveness of coronary artery bypass graft surgery in 
symptomatic patients.
68) Williams, A. (1985). Economics of coronary artery bypass grafting. British 
Medical Journal 291, 326-329. ,
Application of cost-utility analysis to coronary artery bypass grafting. Private 
cots ignored. Judgments based on crude data. It does however provide a 
ranking of various procedures in terms of their cost per quality-adjusted life- 
year gained.
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HIPIQINT REPLACEMENT SAMPLE - PREOPERATIVE QUESTIONNAIRE
Title :
Name :
Patient Number :
Address :
Date of birth:
Age:
Sex :
Reason for surgery :
Date of pre-operative interview : 
Time of pre-operative interview : 
Date of operation :
Height:
Weight :
Occupation :
How would you categorize your present state of health according to the 
Rosser Disability/Distress Index ?
Would you describe the pain, stiffness and swelling in your hip as
- non-existent ?
- slight but does not interfere with your daily activities ?
- moderate and occasionally interferes with your daily activities and 
occasionally disturbs your sleep ?
- severe and regularly interferes with your daily activities and regularly 
disturbs your sleep ?
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Would you say that at the present time, the state of the hip about to be 
operated on
- does not affect your performance at work/ability to work ?
- slightly impairs your performance at work/ability to work ?
- severely limits you performance at work/ability to work ?
- means that you are unable to undertake any paid employment ?
Would you say that at the present time, the state of the hip about to be 
operated on
- means that you are able to undertake all housework/household tasks ?
- means that you are able to undertake all housework/household tasks 
except very heavy tasks ?
- means that you are only able to undertake light housework/household
tasks ? .
- means that you are only able to perform a few very simple tasks ?
- means that you are unable to undertake any housework/household tasks 
at all ?
Would you say that at the present time, the state of the hip about to be 
operated on
- does not interfere with your hobbies and leisure activities at all ?
- slightly interferes with your hobbies and leisure activities ?
- severely interferes with your hobbies and leisure activities ?
- completely interferes with your hobbies and leisure activities ?
Would you say that at the present time, the state of the hip about to be 
operated on
- means that you are totally independent of others , e.g., home help, a 
district nurse, family and friends, for all acts of daily living, e.g., washing, 
eating, dressing and moving ?
- means that you occasionally need moderate help from others for acts of 
daily living ?
- means that you regularly need crucial help from others for acts of daily 
living ?
- means that you are totally dependent on others for acts of daily 
living ?
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Would you say that at the present time, the state of the hip about to be 
operated on
- does not restrict your ability to participate in sports, e.g., bowls, tennis, 
athletics, swimming, at all ?
- slightly restricts your ability to participate in sports ?
- severely restricts your ability to participate in sports ?
- completely restricts your ability to participate in sports ?
Would you say that at the present time, the state of the hip about to be 
operated on
- does not interfere with your sleeping patterns at all ?
- slightly interferes with your sleeping patterns ?
- severely interferes with your sleeping patterns ?
- completely interferes with your sleeping patterns ?
Would you say that at the present time, the state of the hip about to be 
operated on
- means that you can walk long distances without assistance and without 
feeling any greater discomfort than you normally would ?
- means that you can only walk short distances without assistance and 
without feeling any greater discomfort than you normally would ?
- means that you are unable to venture out of the house at all without 
assistance and without feeling any greater discomfort than you normally 
would ?
Are you able to sleep on the side about to be operated on without noticeable 
discomfort ?
Are you able to drive/to use public transport without noticeable discomfort ? 
Are you able to bend your knees without noticeable discomfort ?
Are you able to walk up a flight of stairs without noticeable discomfort ?
Are you able to go out shopping without assistance ?
Are you able to sit down on a chair and get up again without assistance and 
without noticeable discomfort ?
Are you able to have a bath/shower without assistance ?
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Can you dress yourself ?
Can you cook a meal without assistance ?
Can you do general housework, e.g., hoovering, dusting, without assistance ?
Do you need assistance when moving around the house because of your 
illness ?
Are you confined to a chair or to a wheelchair because of your illness ?
Are you confined to bed for most or all of the day because of your illness ?
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KNEE JOINT REPLACEMENT SAMPLE -PREOPERATIVE QUESTIONNAIRE
Title :
Name :
Patient Number :
Address :
Date of birth :
Age:
Sex :
Reason for surgery :
Date of pre-operative interview :
Time of pre-operative interview :
Date of operation :
Height:
Weight :
Occupation :
How would you categorize your present state of health according to the 
Rosser Disability/Distress Index ?
Would you describe the pain, stiffness and swelling in your knee as
- non-existent ?
- slight but does not interfere with your daily activities ?
- moderate and occasionally interferes with your daily activities and 
occasionally disturbs your sleep ?
- severe and regularly interferes with your daily activities and regularly 
disturbs your sleep ?
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Would you say that at the present time, the state of the knee about to be 
operated on
- does not affect your performance at work/ability to work ?
- slightly impairs your performance at work/ability to work ?
- severely limits you performance at work/ability to work ?
- means that you are unable to undertake any paid employment or to 
continue any education ?
Would you say that at the present time, the state of the knee about to be 
operated on
- means that you are able to undertake all housework/household tasks ?
- means that you are able to undertake all housework/household tasks 
except very heavy tasks ?
- means that you are only able to undertake light housework/household 
tasks ?
- means that you are only able to perform a few very simple tasks ?
- means that you are unable to undertake any housework/household 
tasks at all ?
Would you say that at the present time, the state of the knee about to be 
operated on
- does not interfere with your hobbies and leisure activities at all ?
- slightly interferes with your hobbies and leisure activities ?
- severely interferes with your hobbies and leisure activities ?
- completely interferes with your hobbies and leisure activities ?
Would you say that at the present time, the state of the knee about to be 
operated on
- means that you are totally independent of others , e.g., home help, a 
district nurse, family and friends, for all acts of daily living, e.g., 
washing, eating, dressing and moving ?
- means that you occasionally need moderate help from others for acts of 
daily living ?
- means that you regularly need crucial help from others for acts of daily 
living ?
- means that you are totally dependent on others for acts of daily living ?
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- does not restrict your ability to participate in sports, e.g., bowls, tennis, 
athletics, swimming, at all ?
- slightly restricts your ability to participate in sports ?
- severely restricts your ability to participate in sports ?
- completely restricts your ability to participate in sports ?
Would you say that at the present time, the state of the knee about to be
operated on
Would you say that at the present time, the state of the knee about to be 
operated on
- does not interfere with your sleeping patterns at all ?
- slightly interferes with your sleeping patterns ?
- severely interferes with your sleeping patterns ?
- completely interferes with your sleeping patterns ?
Would you say that at the present time, the state of the knee about to be 
operated on
- means that you can walk long distances without assistance and without 
feeling any greater discomfort than you normally would ?
- means that you can only walk short distances without assistance and 
without feeling any greater discomfort than you normally would ?
- means that you are unable to venture out of the house at all without 
assistance and without feeling any greater discomfort than you 
normally would ?
Are you able to sleep on the side about to be operated on without noticeable 
discomfort ?
Are you able to drive/to use public transport without noticeable discomfort ? 
Are you able to bend your knees without noticeable discomfort ?
Are you able to walk up a flight of stairs without noticeable discomfort ?
Are you able to go out shopping without assistance ?
Are you able to sit down on a chair and get up again without assistance and 
without noticeable discomfort ?
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Are you able to have a bath/shower without assistance ?
Can you dress yourself ?
Can you cook a meal without assistance ?
Can you do general housework, e.g., hoovering, dusting, without assistance ?
Do you need assistance when moving around the house because of your 
illness ?
Are you confined to a chair or to a wheelchair because of your illness ?
Are you confined to bed for most or all of the day because of your illness ?
APPENDIX 4 21
HIP JOINT REPLACEMENT SAMPLE - POSTOPERATIVE AND
RETROSPECTIVE QUESTIONNAIRE
Title :
Name :
Patient Number :
Address :
Date of birth :
Age:
Sex :
Reason for surgery :
Date of post-operative interview :
Time of post-operative interview :
Date of operation :
Time period between post-operative interview and operation :
Height:
Weight :
Occupation :
How would you categorize your present state of health according to the 
Rosser Disability/Distress Index ?
Would you describe the pain, stiffness and swelling in your hip as
- non-existent ?
- slight but does not interfere with your daily activities ?
- moderate and occasionally interferes with your daily activities and 
occasionally disturbs your sleep ?
- severe and regularly interferes with your daily activities and regularly 
disturbs your sleep ?
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- does not affect your performance at work/ ability to work ?
- slightly impairs your performance at work/ability to work ?
- severely limits you performance at work/ability to work ?
- means that you are unable to undertake any paid employment or to 
continue any education ?
Would you say that at the present time, the state of the hip operated on
Would you say that at the present time, the state of the hip operated on
- means that you are able to undertake all housework/household tasks ?
- means that you are able to undertake all housework/household tasks 
except very heavy tasks ?
- means that you are only able to undertake light housework/household 
tasks ?
- means that you are only able to perform a few very simple tasks ?
- means that you are unable to undertake any housework/household 
tasks at all ?
Would you say that at the present time, the state of the hip operated on
- does not interfere with your hobbies and leisure activities at all ?
- slightly interferes with your hobbies and leisure activities ?
- severely interferes with your hobbies and leisure activities ?
- completely interferes with your hobbies and leisure activities ?
Would you say that at the present time, the state of the hip operated on
- means that you are totally independent of others , e.g., home help, a 
district nurse, family and friends, for all acts of daily living, e.g., 
washing, eating, dressing and moving ?
- means that you occasionally need moderate help from others for acts of 
daily living ?
- means that you regularly need crucial help from others for acts of daily 
living ?
- means that you are totally dependent on others for acts of daily living ?
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- does not restrict your ability to participate in sports, e.g., bowls, tennis, 
athletics, swimming, at all ?
- slightly restricts your ability to participate in sports ?
- severely restricts your ability to participate in sports ?
- completely restricts your ability to participate in sports ?
Would you say that at the present time, the state of the hip operated on
Would you say that at the present time, the state of the hip operated on
- does not interfere with your sleeping patterns at all ?
- slightly interferes with your sleeping patterns ?
- severely interferes with your sleeping patterns ?
- completely interferes with your sleeping patterns ?
Would you say that at the present time, the state of the hip operated on
- means that you can walk long distances without assistance and without 
feeling any greater discomfort than you normally would ?
- means that you can only walk short distances without assistance and 
without feeling any greater discomfort than you normally would ?
- means that you are unable to venture out of the house at all without 
assistance and without feeling any greater discomfort than you normally 
would ?
Are you able to sleep on the side operated on without noticeable discomfort ? 
Are you able to drive/to use public transport without noticeable discomfort ? 
Are you able to bend your knees without noticeable discomfort ?
Are you able to walk up a flight of stairs without noticeable discomfort ?
Are you able to go out shopping without assistance ?
Are you able to sit down on a chair and get up again without assistance and 
without noticeable discomfort ?
Are you able to have a bath/shower without assistance ?
Can you dress yourself ?
Can you cook a meal without assistance ?
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Do you need assistance when moving around the house because of your 
illness ?
Are you confined to a chair or to a wheelchair because of your illness ?
Are you confined to bed for most or all of the day because of your illness ?
Can you do general housework, e.g., hoovering, dusting, without assistance ?
How would you categorize your state of health prior to your operation 
according to the Rosser Disability / Distress Index ?
Would you describe the pain, stiffness and swelling in your hip prior to your 
operation as
- non-existent ? .
- slight but did not interfere with your daily activities ?
- moderate and occasionally interfered with your daily activities and 
occasionally disturbed your sleep ?
- severe and regularly interfered with your daily activities and regularly 
disturbed your sleep ?
Would you say that prior to your operation, the state of the hip operated on
- did not affect your performance at work/ability to work ?
- slightly impaired your performance at work/ability to work ?
- severely limited your performance at work/ability to work ?
- meant that you were unable to undertake any paid employment or to 
continue any education ?
Would you say that prior to your operation, the state of the hip operated on
- meant that you were able to undertake all housework/household tasks ?
- meant that you were able to undertake all housework/household tasks 
except very heavy tasks ?
- meant that you were only able to undertake light housework / household 
tasks ?
- meant that you were only able to perform a few very simple tasks ?
- meant that you were unable to undertake any housework / household 
tasks at all ?
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- did not interfere with your hobbies and leisure activities at all ?
- lightly interfered with your hobbies and leisure activities ?
- severely interfered with your hobbies and leisure activities ?
- completely interfered with your hobbies and leisure activities ?
Would you say that prior to your operation, the state of the hip operated on
Would you say that prior to your operation, the state of the hip operated on
- meant that you were totally independent of others , e.g., home help, a 
district nurse, family and friends, for all acts of daily living, e.g., washing, 
eating, dressing and moving ?
- meant that you occasionally needed moderate help from others for acts 
of daily living ?
- meant that you regularly needed crucial help from others for acts of
daily living ? .
- meant that you were totally dependent on others for acts of daily 
living ?
Would you say that prior to your operation, the state of the hip operated on
- did not restrict your ability to participate in sports, e.g., bowls, tennis, 
athletics, swimming, at all ?
- slightly restricted your ability to participate in sports ?
- severely restricted your ability to participate in sports ?
- completely restricted your ability to participate in sports ?
Would you say that prior to your operation, the state of the hip operated on
- did not interfere with your sleeping patterns at all ?
- slightly interfered with your sleeping patterns ?
- severely interfered with your sleeping patterns ?
- completely interfered with your sleeping patterns ?
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- meant that you could walk long distances without assistance and 
without feeling any greater discomfort than you normally would ?
- meant that you could only walk short distances without assistance and 
without feeling any greater discomfort than you normally would ?
- meant that you were unable to venture out of the house at all without 
assistance and without feeling any greater discomfort than you 
normally would ?
Would you say that prior to your operation, the state of the hip operated on
Were you able to sleep on the side operated on without noticeable 
discomfort?
Were you able to drive/to use public transport without noticeable 
discomfort?
Were you able to bend your knees without noticeable discomfort ?
Were you able to walk up a flight of stairs without noticeable discomfort ? 
Were you able to go out shopping without assistance ?
Were you able to sit down on a chair and get up again without assistance and 
without noticeable discomfort ?
Were you able to have a bath/shower without assistance ?
Could you dress yourself ?
Could you cook a meal without assistance ?
Could you do general housework, e.g., hoovering, dusting, without 
assistance?
Did you need assistance when moving around the house because of your 
illness ?
Were you confined to a chair or to a wheelchair because of your illness ?
Were you confined to bed for most or all of the day because of your illness?
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KNEE JOINT REPLACEMENT SAMPLE - POSTOPERATIVE AND
RETROSPECTIVE QUESTIONNAIRE
Title :
Name :
Patient Number :
Address :
Date of birth :
Age:
Sex:
Reason for surgery :
Date of post-operative interview :
Time of post-operative interview :
Date of operation :
Time period between post-operative interview and operation :
Height:
Weight :
Occupation (or ex-occupation or husband's or parent's occupation) :
How would you categorize your present state of health according to the 
Rosser Disability/Distress Index ? .
Would you describe the pain, stiffness and swelling in your knee as
- non-existent ?
- slight but does not interfere with your daily activities ?
- moderate and occasionally interferes with your daily activities and 
occasionally disturbs your sleep ?
- severe and regularly interferes with your daily activities and regularly 
disturbs your sleep ?
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- does not affect your performance at work/ability to work ?
- slightly impairs your performance at work/ability to work ?
- severely limits you performance at work/ability to work ?
- means that you are unable to undertake any paid employment or to 
continue any education ?
Would you say that at the present time, the state of the knee operated on
Would you say that at the present time, the state of the knee operated on
- means that you are able to undertake all housework/household tasks ?
- means that you are able to undertake all housework/household tasks 
except very heavy tasks ?
- means that you are only able to undertake light housework/household 
tasks ?
- means that you are only able to perform a few very simple tasks ?
- means that you are unable to undertake any housework/household tasks 
at all ?
Would you say that at the present time, the state of the knee operated on
- does not interfere with your hobbies and leisure activities at all ?
- slightly interferes with your hobbies and leisure activities ?
- severely interferes with your hobbies and leisure activities ?
- completely interferes with your hobbies and leisure activities ?
Would you say that at the present time, the state of the knee operated on
- means that you are totally independent of others , e.g., home help, a 
district nurse, family and friends, for all acts of daily living, e.g., washing, 
eating, dressing and moving ?
- means that you occasionally need moderate help from others for acts of 
daily living ?
- means that you regularly need crucial help from others for acts of daily 
living ?
- means that you are totally dependent on others for acts of daily 
living ?
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- does not restrict your ability to participate in sports, e.g., bowls, tennis, 
athletics, swimming, at all ?
- slightly restricts your ability to participate in sports ?
- severely restricts your ability to participate in sports ?
- completely restricts your ability to participate in sports ?
Would you say that at the present time, the state of the knee operated on
Would you say that at the present time, the state of the knee operated on
- does not interfere with your sleeping patterns at all ?
- slightly interferes with your sleeping patterns ?
- severely interferes with your sleeping patterns ?
- completely interferes with your sleeping patterns ?
Would you say that at the present time, the state of the knee operated on
- means that you can walk long distances without assistance and without 
feeling any greater discomfort than you normally would ?
- means that you can only walk short distances without assistance and 
without feeling any greater discomfort than you normally would ?
- means that you are unable to venture out of the house at all without 
assistance and without feeling any greater discomfort than you normally 
would ?
Are you able to sleep on the side operated on without noticeable discomfort ? 
Are you able to drive/to use public transport without noticeable discomfort ? 
Are you able to bend your knees without noticeable discomfort ?
Are you able to walk up a flight of stairs without noticeable discomfort ?
Are you able to go out shopping without assistance ?
Are you able to sit down on a chair and get up again without assistance and 
without noticeable discomfort ?
Are you able to have a bath/shower without assistance ?
Can you dress yourself ?
Can you cook a meal without assistance ?
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Do you need assistance when moving around the house because of your 
illness ?
Are you confined to a chair or to a wheelchair because of your illness ?
Are you confined to bed for most or all of the day because of your illness ?
Can you do general housework, e.g., hoovering, dusting, without assistance ?
How would you categorize your state of health prior to your operation 
according to the Rosser Disability / Distress Index ?
Would you describe the pain, stiffness and swelling in your knee prior to 
your operation as
- non-existent ? .
- slight but did not interfere with your daily activities ?
- moderate and occasionally interfered with your daily activities and 
occasionally disturbed your sleep ?
- severe and regularly interfered with your daily activities and regularly 
disturbed your sleep ?
Would you say that prior to your operation, the state of the knee operated on
- did not affect your performance at work/ability to work ?
- slightly impaired your performance at work/ability to work ?
- severely limited your performance at work/ability to work ?
- meant that you were unable to undertake any paid employment or to 
continue any education ?
Would you say that prior to your operation, the state of the knee operated on
- meant that you were able to undertake all housework/household tasks ?
- meant that you were able to undertake all housework/household tasks 
except very heavy tasks ?
- meant that you were only able to undertake light housework/household 
tasks ?
- meant that you were only able to perform a few very simple tasks ?
- meant that you were unable to undertake any housework/household 
tasks at all ?
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- did not interfere with your hobbies and leisure activities at all ?
- slightly interfered with your hobbies and leisure activities ?
- severely interfered with your hobbies and leisure activities ?
- completely interfered with your hobbies and leisure activities ?
Would you say that prior to your operation, the state of the knee operated on
Would you say that prior to your operation, the state of the knee operated on
- meant that you were totally independent of others , e.g., home help, a 
district nurse, family and friends, for all acts of daily living, e.g., washing, 
eating, dressing and moving ?
- meant that you occasionally needed moderate help from others for acts of 
daily living ?
- meant that you regularly needed crucial help from others for acts of daily 
living ?
- meant that you were totally dependent on others for acts of daily 
living ?
Would you say that prior to your operation, the state of the knee operated on
- did not restrict your ability to participate in sports, e.g., bowls, tennis, 
athletics, swimming, at all ?
- slightly restricted your ability to participate in sports ?
- severely restricted your ability to participate in sports ?
- completely restricted your ability to participate in sports ?
Would you say that prior to your operation, the state of the knee operated on
- did not interfere with your sleeping patterns at all ?
- slightly interfered with your sleeping patterns ?
- severely interfered with your sleeping patterns ?
- completely interfered with your sleeping patterns ?
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- meant that you could walk long distances without assistance and without 
feeling any greater discomfort than you normally would ?
- meant that you could only walk short distances without assistance and 
without feeling any greater discomfort than you normally would ?
- meant that you were unable to venture out of the house at all without 
assistance and without feeling any greater discomfort than you normally 
would ?
Would you say that prior to your operation, the state of the knee operated on
Were you able to sleep on the side operated on without noticeable 
discomfort?
Were you able to drive/to use public transport without noticeable 
discomfort?
Were you able to bend your knees without noticeable discomfort ?
Were you able to walk up a flight of stairs without noticeable discomfort ? 
Were you able to go out shopping without assistance ?
Were you able to sit down on a chair and get up again without assistance and 
without noticeable discomfort ?
Were you able to have a bath/shower without assistance ?
Could you dress yourself ?
Could you cook a meal without assistance ?
Could you do general housework, e.g., hoovering, dusting, without 
assistance?
Did you need assistance when moving around the house because of your 
illness ?
Were you confined to a chair or to a wheelchair because of your illness ?
Were you confined to bed for most or all of the day because of your illness ?
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QUESTIONS FOR WHOLE GROUP
CONTROL GROUP - CHANGE IN RATING SCORES FOR INDIVIDUAL
Question Scale Number of 
Subjects at 
the
Preoperative
Interview
Number of 
Subjects at 
the
Postoperative
Interview
Chisquare
Test (CS)
Pain 1 None 0 8 Chisquare =
2 None-Slight 0 2 59.139
3 Slight 0 18 Significant at
4 Slight-Moderate 0 1 less than the
5 Moderate 11 10 0.001 level
6 Moder-Severe 7 0
7 Severe 26 1
Impairment 1 None •0 5 Chisquare =
of Work 2 None-Slight 0 0 8.153
3 Slight 5 6 Significant at
4 Slight-Severe 4 2 the 0.25 level
5 Severe 8 4
6 Severe-Compl 1 0
7 Complete 26 22
Housework 1 All 2 5 Chisquare =
2 All - All-Heavy 0 0 12.771
3 All but Heavy 5 11 Significant at
4 All-Heavy-Light 4 1 the 0.05 level
5 Light 16 11
6 Light - Few 1 2
7 Few Tasks 16 6
8 Few - None 0 2
9 None 0 0
Interference 1 None 2 11 Chisquare =
With Hobbies 2 None-Slight 0 0 19.099
3 Slight 9 17 Significant at
4 Slight-Severe 1 1 the 0.005
5 Severe 17 8 level
6 Severe-Compl 1 0
7 Complete 13 3
Dependence 1 None 23 24 Chisquare -
On Others 2 None-Occasion 0 1 2.256
3 Occasional 17 12 Significant at
4 Occasional-Reg 0 0 the 0.75 level
5 Regular 4 2
6 Regular - Total 0 0
7 Total 0 0
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Interference 1 None 0 2 Chisquare =
With Sports 2 None-Slight 0 0 9.191
3 Slight 0 4 Significant at
4 Slight-Severe 1 2 the 0.1 level
5 Severe 9 10
6 Severe-Compl 0 0
7 Complete 34 21
Interference 1 None 4 25 Chisquare -
With Sleep 2 None-Slight 0 0 37.904
3 Slight 12 13 Significant at
4 Slight-Severe 4 0 less than the
5 Severe 19 2 0.001 level
6 Severe-Compl 1 0
7 Complete 4 0
Walking 1 Long Distances 0 11 Chisquare =.
2 Long - Short 0 1 33.363
3 Short Distances 9 17 Significant at
4 Short - House 6 7 less than the
5 Confined House 29 4 0.001 level
Sleep on 1 Yes 15 29 CS = 12.392
Side 2 No 29 11 l.t. 0.001 level
Driving/ 1 Yes 12 27 CS = 14.612
Transport 2 No 32 12 l.t. 0.001 level
Bending 1 Yes 12 33 CS = 27.388
Knees 2 No 32 6 l.t. 0.001 level
Stairs 1 Yes 3 32 CS = 47.985
2 No 41 7 l.t. 0.001 level
Shopping 1 Yes 17 29 CS = 11.754
2 No 27 9 l.t. 0.001 level
Chair 1 Yes 6 29 CS = 29.869
Without
Discomfort
2 No . 38 11 l.t. 0.001 level
Bath/ 1 Yes 28 29 CS = 0.755
Shower 2 No 16 11 0.5 level
Dressing 1 Yes 43 40 CS = 0.920
2 No 1 0 0.5 level
Cooking 1 Yes 41 37 CS = 0.015
2 No 3 3 0.95 level
Hoovering/ 1 Yes 28 32 CS = 3.5
Dusting 2 No 16 7 0.1 level
Assistance in 1 Yes 16 9 CS = 1.926
house 2 No 28 31 0.25 level
Confined to 1 Yes 1 0 CS = 0.920
Chair 2 No 43 40 0.5 level
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QUESTIONS FOR HIP SUBGROUP
CONTROL GROUP -CHANGE IN RATING SCORES FOR INDIVIDUAL
Question Scale Number of 
Subjects at 
the
Preoperative
Interview
Number of 
Subjects at 
the
Postoperative
Interview
Chisquare
Test (CS)
Pain 1 None 0 5 Chisquare =
2 None-Slight 0 2 36.596
3 Slight 0 8 Significant at
4 Slight-Moderate 0 0 less than the
5 Moderate 3 7 0.001 level
6 Moder-Severe 5 0
7 Severe 15 0
Impairment 1 None 0 2 Chisquare =
of Work 2 None-Slight 0 0 4.963
3 Slight 2 4 Significant at
4 Slight-Severe 4 2 the 0.5 level
5 Severe 4 2
6 Severe-Compl 1 0
7 Complete 12 11
Housework 1 All 0 2 Chisquare =
2 All - All-Heavy 0 0 10.005
3 All but Heavy 3 8 Significant at
4 All-Heavy-Light 2 0 the 0.1 level
5 Light 10 7
6 Light - Few 0 1
7 Few Tasks 8 3
8 Few - None 0 0
9 None 0 0
Interference 1 None 2 4 Chisquare ~
With Hobbies 2 None-Slight 0 0 19.375
3 Slight 0 11 Significant at
4 Slight-Severe 1 1 less than the
5 Severe 11 4 0.001 level
6 Severe-Compl 0 0
7 Complete 9 2
Dependence 1 None 10 16 Chisquare =
On Others 2 None-Occasion 0 0 4.365
3 Occasional 12 6 Significant at
4 Occasional-Reg 0 0 the 0.25 level
5 Regular 1 0
6 Regular - Total 0 0
7 Total 0 0
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Interference 1 None 0 1 Chisquare =
With Sports 2 None-Slight 0 0 7.601
3 Slight 0 3 1 Significant at
4 Slight-Severe 0 1 the 0.25 level
5 Severe 5 7
6 Severe-Compl 0 0
7 Complete 18 10
Interference 1 None 2 14 Chisquare -
With Sleep 2 None-Slight 0 0 22.656
3 Slight 5 7 Significant at
4 Slight-Severe 3 0 less than the
5 Severe 11 1 0.001 level
6 Severe-Compl 0 0
7 Complete 2 0
Walking 1 Long Distances 0 7 Chisquare =
2 Long - Short 0 1 17.679
3 Short Distances 5 8 Significant at
4 Short - House 4 4 the 0.005
5 Confined House 14 2 level
Sleep on 1 Yes 5 14 CS = 8.091
Side 2 No 18 8 0.005 level
Driving/ 1 Yes 7 18 CS = 13.672
Transport 2 No 16 3 l.t. 0.001 level
Bending I Yes 9 18 CS = 10.047
Knees 2 No 14 3 0.005 level
Stairs 1 Yes 2 19 CS = 29.427
2 No 21 2 l.t. 0.001 level
Shopping 1 Yes 11 18 CS = 7.013
2 No 12 3 0.01 level
Chair 1 Yes 3 18 CS = 21.369
Without
Discomfort
2 No 20 4 l.t. 0.001 level
Bath/ 1 Yes 17 18 CS = 0.407
Shower 2 No 6 4 0.75 level
Dressing 1 Yes 22 22 CS = 0.978
2 No 1 0 0.5 level
Cooking 1 Yes 23 22 CS = 0
2 No 0 0
Hoovering/ 1 Yes 14 19 CS = 5.132
Dusting 2 No 9 2 0.025 level
Assistance in 1 Yes 10 6 CS = 1.289
house 2 No 13 16 0.5 level
Confined to 1 Yes 1 0 CS = 0.978
Chair 2 No 22 22 0.5 level
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QUESTIONS FOR KNEE SUBGROUP
CONTROL GROUP - CHANGE IN RATING SCORES FOR INDIVIDUAL
Question Scale Number of 
Subjects at 
the
Preoperative
Interview
Number of 
Subjects at 
the
Postoperative
Interview
Chisquare
Test (CS)
Pain 1 None 0 3 Chisquare -
2 None-Slight 0 0 26.532
3 Slight 0 10 Significant at
4 Slight-Moderate 0 1 less than the
5 Moderate 8 3 0.001 level
6 Moder-Severe 2 0
7 Severe II 1
Impairment I None 0 3 Chisquare -
of Work 2 None-Slight 0 0 4.020
3 Slight 3 2 Significant at
4 Slight-Severe 0 0 the 0.5 level
5 Severe 4 2
6 Severe-Compl 0 0
7 Complete 14 11
Housework 1 All 2 3 Chisquare =
2 All - All-Heavy 0 0 5.04
3 All but Heavy 2 3 Significant at
4 All-Heavy-Light 2 1 the 0.75 level
5 Light 6 4
6 Light - Few 1 1
7 Few Tasks 8 3
8 Few - None 0 2
9 None 0 0
Interference 1 None 0 7 Chisquare =
With Hobbies 2 None-Slight 0 0 10.724
3 Slight 9 6 Significant at
4 Slight-Severe 0 0 the 0.05 level
5 Severe 6 4
6 Severe-Compl 1 0
7 Complete 4 1
Dependence 1 None 13 8 Chisquare =
On Others 2 None-Occasion 0 1 2.085
3 Occasional 5 6 Significant at
4 Occasional-Reg 0 0 the 0.75 level
5 Regular 3 2
6 Regular - Total 0 0
7 Total 0 0
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Interference 1 None 0 1 Chisquare =
With Sports 2 None-Slight 0 0 2.677
3 Slight 0 1 Significant at
4 Slight-Severe 1 1 the 0.75 level
5 Severe 4 3
6 Severe-Compl 0 0
7 Complete 16 11
Interference 1 None 2 11 Chisquare =
With Sleep 2 None-Slight 0 0 15.614
3 Slight 7 6 Significant at
4 Slight-Severe 1 0 the 0.01 level
5 Severe 8 1
6 Severe-Compl 1 0
7 Complete 2 0
Walking 1 Long Distances 0 4 Chisquare =
2 Long - Short 0 0 15.928
3 Short Distances 4 9 Significant at
• 4 Short - House 2 3 the 0.005
5 Confined House 15 2 level
Sleep on 1 Yes 10 15 CS = 5.372
Side 2 No 11 3 0.025 level
Driving/ 1 Yes 5 9 CS = 2.889
Transport 2 No 16 9 0.1 level
Bending 1 Yes 3 15 CS = 18.594
Knees 2 No 18 3 l.t. 0.001 level
Stairs 1 Yes 1 13 CS = 19.168
2 No 20 5 l.t. 0.001 level
Shopping 1 Yes 6 11 CS = 4.962
2 No 15 6 0.05 level
Chair 1 Yes 3 11 CS = 9.235
Without
Discomfort
2 No 18 7 0.005 level
Bath/ 1 Yes 11 11 CS = 0.300
Shower 2 No 10 7 0.75 level
Dressing 1 Yes 21 18 CS = 0
2 No 0 0
Cooking 1 Yes 18 15 CS = 0.042
2 No 3 3 0.9 level
Hoovering/ 1 Yes 14 13 CS = 0.140
Dusting 2 No 7 5 0.75 level
Assistance in 1 Yes 6 3 CS = 0.774
house 2 No 15 15 0.5 level
Confined to 1 Yes 0 0 CS = 0
Chair 2 No 21 18
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QUESTIONS FOR MALE SUBGROUP
CONTROL GROUP - CHANGE IN RATING SCORES FOR INDIVIDUAL
Question Scale Number of 
Subjects at 
the
Preoperative
Interview
Number of 
Subjects at 
the
Postoperative
Interview
Chisquare
Test(CS)
Pain 1 None 0 4 Chisquare =
2 None-Slight 0 1 26.333
3 Slight 0 6 Significant at
4 Slight-Moderate 0 1 less than the
5 Moderate 5 7 0.001 level
6 Moder-Severe 3 0
7 Severe 11 0
Impairment 1 None 0 3 Chisquare =
of Work 2 None-Slight 0 0 7.895
3 Slight 4 4 Significant at
4 Slight-Severe 4 0 the 0.1 level
5 Severe 4 2
6 Severe-Compl 0 0
7 Complete 7 9
Housework 1 All 2 3 Chisquare =
2 All - All-Heavy 0 0 4.464
3 All but Heavy 4 6 Significant at
4 All-Heavy-Light 2 0 the 0.5 level
5 Light 7 4
6 Light - Few 0 1
7 Few Tasks 4 3
8 Few - None 0 0
9 None 0 0
Interference 1 None 1 3 Chisquare =
With Hobbies 2 None-Slight 0 0 7.743
3 Slight 2 8 Significant at
4 Slight-Severe 1 1 the 0.25 level
5 Severe 9 5
6 Severe-Compl 0 0
7 Complete 6 2
Dependence 1 None 10 13 Chisquare =
On Others 2 None-Occasion 0 0 2.534
3 Occasional 9 5 Significant at
4 Occasional-Reg 0 0 the 0.5 level
5 Regular 0 1
6 Regular - Total 0 0
7 Total 0 0
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Interference 1 None 0 1 Chisquare =
With Sports 2 None-Slight 0 0 4.200
3 Slight 0 2 Significant at
4 Slight-Severe 1 2 the 0.5 level
5 Severe 6 5
6 Severe-Compl 0 0
7 Complete 12 8
Interference 1 None 1 11 Chisquare =
With Sleep 2 None-Slight 0 0 16.833
3 Slight 7 7 Significant at
4 Slight-Severe 2 0 the 0.005
5 Severe 7 1 level
6 Severe-Compl 0 0
7 Complete 2 0
Walking 1 Long Distances 0 6 Chisquare =
2 Long - Short 0 0 13.143
3 Short Distances 5 9 Significant at
4 Short - House 4 2 the 0.005
5 Confined House 10 2 level
Sleep on 1 Yes 7 17 CS = 11.310
Side 2 No 12 2 l.t. 0.001 level
Driving/ 1 Yes 9 14 CS = 3.634
Transport 2 No 10 4 0.1 level
Bending 1 Yes 6 15 CS = 10.087
Knees 2 No 13 3 0.005 level
Stairs 1 Yes 2 15 CS = 19.729
2 No 17 3 l.t. 0.001 level
Shopping 1 Yes 12 13 CS = 0.749
2 No 7 4 0.5 level
Chair 1 Yes 3 16 CS = 17.789
Without
Discomfort
2 No 16 3 l.t. 0.001 level
Bath/ 1 Yes 12 15 CS = 1.152
Shower 2 No 7 4 0.5 level
Dressing 1 Yes 18 19 CS = 1.027
2 No 1 0 0.5 level
Cooking 1 Yes 19 18 CS = 1.027
2 No 0 1 0.5 level
Hoovering/ 1 Yes 15 15 CS = 0.116
Dusting 2 No 4 3 0.75 level
Assistance in 1 Yes 8 5 CS = 1.052
house 2 No 11 14 0.5 level
Confined to 1 Yes 0 0 CS = 0
Chair 2 No 19 19
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QUESTIONS FOR FEMALE SUBGROUP
CONTROL GROUP - CHANGE IN RATING SCORES FOR INDIVIDUAL
Question Scale Number of 
Subjects at 
the
Preoperative
Interview
Number of 
Subjects at 
the
Postoperative
Interview
Chisquare
Test (CS)
Pain 1 None 0 4 Chisquare =
2 None-Slight 0 1 34.160
3 Slight 0 12 Significant at
4 Slight-Moderate 0 0 less than the
5 Moderate 6 3 0.001 level
6 Moder-Severe 4 0
7 Severe 15 1
Impairment 1 None 0 2 Chisquare =
of Work 2 None-Slight 0 0 6.829
3 Slight 1 2 Significant at
4 Slight-Severe 0 2 the 0.25 level
5 Severe 4 2
6 Severe-Compl 1 0
7 Complete 19 13
Housework 1 All 0 2 Chisquare =
2 All - All-Heavy 0 0 12.397
3 All but Heavy 1 5 Significant at
4 All-Heavy-Light 2 1 the 0.1 level
5 Light 9 7
6 Light - Few 1 1
7 Few Tasks 12 3
8 Few - None 0 2
9 None 0 0
Interference 1 None 1 8 Chisquare =
With Hobbies 2 None-Slight 0 0 13.326
3 Slight 7 9 Significant at
4 Slight-Severe 0 0 the 0.01 level
5 Severe 8 3
6 Severe-Compl 1 0
7 Complete 7 1
Dependence 1 None 13 11 Chisquare =
On Others 2 None-Occasion 0 1 2.508
3 Occasional 8 7 Significant at
4 Occasional-Reg 0 0 the 0.5 level
5 Regular 4 1
6 Regular - Total 0 0
7 Total 0 0
APPENDIX 11 46
Interference 1 None 0 1 Chisquare -
With Sports 2 None-Slight 0 0 5.508
3 Slight 0 2 Significant at
4 Slight-Severe 0 0 the 0.25 level
5 Severe 3 5
6 Severe-Compl 0 0
7 Complete 22 13
Interference 1 None 3 14 Chisquare =
With Sleep 2 None-Slight 0 0 21.330
3 Slight 5 6 Significant at
4 Slight-Severe 2 0 less than the
5 Severe 12 1 0.001 level
6 Severe-Compl 1 0
7 Complete 2 0
Walking 1 Long Distances 0 5 Chisquare =
2 Long - Short 0 1 22.201
3 Short Distances 4 8 Significant at
4 Short - House 2 5 less than the
5 Confined House 19 2 0.001 level
Sleep on 1 Yes 8 12 CS = 2.936
Side 2 No 17 9 0.1 level
Driving/ 1 Yes 3 13 CS = 12.530
Transport 2 No 22 8 l.t. 0.001 level
Bending 1 Yes 6 18 CS = 17.420
Knees 2 No 19 3 l.t. 0.001 level
Stairs 1 Yes 1 17 CS = 28.375
2 No 24 4 l.t. 0.001 level
Shopping 1 Yes 5 16 CS = 14.524
2 No 20 5 l.t. 0.001 level
Chair 1 Yes 3 13 CS = 12.530
Without
Discomfort
2 No 22 8 l.t. 0.001 level
Bath/ 1 Yes 16 14 CS = 0.036
Shower 2 No 9 7 0.9 level
Dressing 1 Yes 25 21 CS = 0
2 No 0 0
Cooking 1 Yes 22 19 CS = 0.072
2 No 3 2 0.9 level
Hoovering/ 1 Yes 13 17 CS = 4.217
Dusting 2 No 12 4 0.05 level
Assistance in 1 Yes 8 4 CS = 0.993
house 2 No 17 17 0.5 level
Confined to 1 Yes 1 0 CS = 0.859
Chair 2 No 24 21 0.5 level
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132 M 75 Hip 1 year mA
(0.98)
IHA
(0.98)
IVB
(0.956)
IVB
(0.956)
133 M 68 Hip 1 year IIA
(0.99)
IIA
(0.99)
HD
(0.932)
mD
(0.912)
134 M 70 Hip 2 years IIA
(0.99)
IIA
(0.99)
n-IIIB-C
(0.97175)
n-mB-c
(0.97175)
135 F 52 Knee 1 year IVC
(0.942)
IV-VC
(0.921)
VD
(0.7)
VD
(0.7)
136 F 73 Hip 2 years IVC
(0.942)
IVB-C
(0.949)
VD
(0.7)
VD
(0.7)
137 F 53 Hip 2 years nA
(0.99)
ffiA
(0.98)
VD
(0.7)
VD
(0.7)
138 M 72 Hip 3 months IVC
(0.942)
IVC
(0.942)
mc-D
(0.934)
mc-D
(0.934)
139 M 68 Hip 2 years IA
(1)
IA
(1)
HID
(0.912)
IVD
(0.87)
140 F 62 Hip 2 years IHA
(0.98)
IIIA
(0.98)
VD
(0.7)
VD
(0.7)
141 M 77 Hip 2 years m-IVA
(0.972)
m-IVA
(0.972)
IVD
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IVD
(0.87)
142 M 52 Hip 2 years IV-VB
(0.9455)
IV-VB
(0.9455)
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VD
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143 M 80 Hip 1 year IDA
(0.98)
mA
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(0.912)
144 F 59 Knee 1 year IVC
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IVC
(0.942)
HID
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145 M 62 Hip 2 years VA-B
(0.9405)
IVA-B
(0.96)
IVD
(0.87)
IV-VD
(0.785)
146 F 80 Knee 1 year IVB
(0.956)
IVB
(0.956)
rvc
(0.942)
IVC
(0.942)
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INDIVIDUAL QUESTIONS FOR THREE MONTH HIP SUBGROUP
RETROSPECTIVE GROUP - CHANGE IN RATING SCORES FOR
Question Scale Number of 
Subjects 
at the
Retrospective
Stage
Number of 
Subjects 
at the
Postoperative
Stage
Chisquare
Test(CS)
Pain 1 None 0 4 Chisquare =
2 None-Slight 0 1 36.8
3 Slight 0 9 Significant at
4 Slight-Moderate 0 2 less than the
5 Moderate 1 4 0.001 level
6 Moder-Severe 1 0
7 Severe 18 0
Impairment 1 None 0 0 Chisquare =
of Work 2 None-Slight 0 0 1.032
3 Slight 1 2 Significant at
4 Slight-Severe 0 0 the 0.75 level
5 Severe 4 2
6 Severe-Compl 0 0
7 Complete 15 16
Housework 1 All 0 1 Chisquare =
2 All - All-Heavy 0 0 7.873
3 All but Heavy 4 5 Significant at
4 All-Heavy-Light 0 1 the 0.25 level
5 Light 3 4
6 Light - Few 2 1
7 Few Tasks 6 8
8 Few - None 0 0
9 None 5 0
Interference 1 None 3 6 Chisquare =
With Hobbies 2 None-Slight 0 0 9.555
3 Slight 3 7 Significant at
4 Slight-Severe 0 2 the 0.05 level
5 Severe 5 3
6 Severe-Compl 0 0
7 Complete 9 2
Dependence 1 None 8 15 Chisquare =
On Others 2 None-Occasion 0 0 6.102
3 Occasional 6 4 Significant at
4 Occasional-Reg 0 0 the 0.05 level
5 Regular 6 1
6 Regular - Total 0 0
7 Total 0 0
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Interference 1 None 0 0 Chisquare =
With Sports 2 None-Slight 0 0 8.485
3 Slight 0 2 Significant at
4 Slight-Severe [ 0 1 the 0.05 level
5 Severe 0 4
6 Severe-Compl 0 0
7 Complete 20 13
Interference 1 None 2 9 Chisquare =
With Sleep 2 None-Slight 0 0 15.182
3 Slight 3 8 Significant at
4 Slight-Severe 3 1 the 0.005
5 Severe 9 2 level
6 Severe-Compl 0 0
7 Complete 3 0
Walking 1 Long Distances 2 2 Chisquare =
2 Long - Short 0 0 11.688
3 Short Distances 1 6 Significant at
4 Short - House 1 6 the 0.01 level
5 Confined House 16 6
Sleep on 1 Yes 3 9 CS = 4.792
Side 2 No 17 10 0.05 level
Driving/ 1 Yes 6 10 CS = 1.667
Transport 2 No 14 10 0.25 level
Bending 1 Yes 7 14 CS = 4.912
Knees 2 No 13 6 0.05 level
Stairs 1 Yes 3 13 CS = 10.417
2 No 17 7 0.005 level
Shopping 1 Yes 9 10 CS = 0.1
2 No 11 10 0.9 level
Chair 1 Yes 2 16 CS = 19.798
Without
Discomfort
2 No 18 4 l.t. 0.001 level
Bath/ 1 Yes 12 12 CS = 0
Shower 2 No 8 8
Dressing 1 Yes 18 19 CS = 0.36
2 No 2 1 0.75 level
Cooking 1 Yes 15 18 CS = 1.558
2 No 5 2 0.25 level
Hoovering/ 1 Yes 9 12 CS = 0.902
Dusting 2 No 11 8 0.5 level
Assistance in 1 Yes 8 8 CS = 0
house 2 No 12 12
Confined to 1 Yes 5 1 CS = 3.137
Chair 2 No 15 19 0,1 level
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INDIVIDUAL QUESTIONS FOR ONE YE ARHIP SUBGROUP
RETROSPECTIVE GROUP - CHANGE IN RATING SCORES FOR
Question Scale Number of 
Subjects 
at the
Retrospective
Stage
Number of 
Subjects 
at the
Postoperative
Stage
Chisquare
Test (CS)
Pain 1 None 0 17 Chisquare =
2 None-Slight 0 3 57.675
3 Slight 2 11 Significant at
4 Slight-Moderate 0 3 less than the
5 Moderate 2 2 0.001 level
6 Moder-Severe 0 0
7 Severe 34 2
Impairment 1 None 2 3 Chisquare =
of Work 2 None-Slight 0 0 • 6.809
3 Slight 1 7 Significant at
4 Slight-Severe I 0 the 0.25 level
5 Severe 4 2
6 Severe-Compl 0 0
7 Complete 30 25
Housework 1 All 2 8 Chisquare =
2 All - All-Heavy 0 0 10.044
3 All but Heavy 8 10 Significant at
4 All-Heavy-Light 0 1 the 0.25 level
5 Light 8 10
6 Light - Few 1 1
7 Few Tasks 14 7
8 Few - None 0 0
9 None 5 1
Interference 1 None 2 18 Chisquare =
With Hobbies 2 None-Slight 0 0 22.563
3 Slight 14 14 Significant at
4 Slight-Severe 1 0 less than the
5 Severe 14 5 0.001 level
6 Severe-Compl 0 0
7 Complete 7 1
Dependence 1 None 17 29 Chisquare =
On Others 2 None-Occasion 0 0 8.464
3 Occasional 14 7 Significant at
4 Occasional-Reg 0 0 the 0.05 level
5 Regular 6 2
6 Regular - Total 0 0
7 Total 1 0
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Interference 1 None 0 2 Chisquare =
With Sports 2 None-Slight 0 0 15.079
3 Slight 0 5 Significant at
4 Slight-Severe 0 1 the 0.005
5 Severe 3 9 level
6 Severe-Compl 0 0
7 Complete 35 20
Interference 1 None ■ 7 26 Chisquare =
With Sleep 2 None-Slight 0 0 27.834
3 Slight 9 10 Significant at
4 Slight-Severe 4 0 less than the
5 Severe 17 2 0.001 level
6 Severe-Compl 0 0
7 Complete 1 0
Walking 1 Long Distances 0 12 Chisquare -
2 Long - Short 0 4 48.923
3 Short Distances 3 16 Significant at
4 Short - House • 3 3 less than the
5 Confined House 32 3 0.001 level
Sleep on 1 Yes 13 26 CS = 8.901
Side 2 No 25 12 0.005 level
Driving/ 1 Yes 12 31 CS = 19.335
Transport 2 No 26 7 l.t. 0.001 level
Bending 1 Yes 14 32 CS = 17.843
Knees 2 No 24 6 l.t. 0.001 level
Stairs 1 Yes 5 33 CS = 41.263
2 No 33 5 l.t. 0.001 level
Shopping 1 Yes 18 29 CS = 6.747
2 No 20 9 0.01 level
Chair 1 Yes 7 33 CS = 35.678
Without
Discomfort
2 No 31 5 l.t. 0.001 level
Bath/ 1 Yes 20 30 CS = 5.846
Shower 2 No 18 8 0.025 level
Dressing 1 Yes 35 38 CS = 3.123
2 No 3 0 0.1 level
Cooking 1 Yes 30 37 CS = 6.176
2 No 8 1 0.025 level
Hoovering/ 1 Yes 20 29 CS = 4.653
Dusting 2 No 18 9 0.05 level
Assistance in 1 Yes 16 7 CS = 5.050
house 2 No 22 31 0.025 level
Confined to 1 Yes 3 1 CS = 1.056
Chair 2 No 35 37 0.5 level
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INDIVIDUAL QUESTIONS FOR TWO YEAR HIP SUBGROUP
RETROSPECTIVE GROUP - CHANGE IN RATING SCORES FOR
Question Scale Number of 
Subjects 
at the
Retrospective
Stage
Number of 
Subjects 
at the
Postoperative
Stage
Chisquare
Test(CS)
Pain 1 None 0 29 Chisquare =
2 None-Slight 0 1 89.397
3 Slight 0 15 Significant at
4 Slight-Moderate 1 3 less than the
5 Moderate 6 7 0.001 level
6 Moder-Severe 3 1
7 Severe 48 2
Impairment 1 None 1 13 Chisquare =
of Work 2 None-Slight 0 o • 20.596
3 Slight 6 9 Significant at
4 Slight-Severe 1 1 less than the
5 Severe 11 1 0.001 level
6 Severe-Compl 0 1
7 Complete 35 30
Housework 1 All 2 14 Chisquare =
2 All - All-Heavy 0 0 18.925
3 All but Heavy 13 20 Significant at
4 All-Heavy-Light 2 3 the 0.005
5 Light 20 12 level
6 Light - Few 1 0
7 Few Tasks 17 8
8 Few - None 0 0
9 None 2 0
Interference 1 None 11 34 Chisquare =
With Hobbies 2 None-Slight 0 0 32.306
3 Slight 14 18 Significant at
4 Slight-Severe 1 0 less than the
5 Severe 18 2 0.001 level
6 Severe-Compl 0 0
7 Complete 13 3
Dependence 1 None 31 46 Chisquare =
On Others 2 None-Occasion 0 2 13.065
3 Occasional 20 8 Significant at
4 Occasional-Reg 0 0 the 0.025
5 Regular 6 2 level
6 Regular - Total 0 0
7 Total 1 0
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Interference 1 None 0 4 Chisquare =
With Sports 2 None-Slight 0 1 18.168
3 Slight 1 11 Significant at
4 Slight-Severe 1 1 the 0.005
5 Severe 7 10 level
6 Severe-Compl 0 0
7 Complete 42 25
Interference 1 None 2 43 Chisquare =
With Sleep 2 None-Slight 0 1 72.132
3 Slight 15 11 Significant at
4 Slight-Severe 8 0 less than the
5 Severe 28 3 0.001 level
6 Severe-Compl 0 0
7 Complete 5 0
Walking 1 Long Distances 0 26 Chisquare =
2 Long - Short 1 1 68.681
3 Short Distances 8 23 Significant at
4 Short - House ' 3 4 less than the
5 Confined House 46 4 0.001 level
Sleep on 1 Yes 13 50 CS = 47.560
Side 2 No 45 8 l.t. 0.001 level
Driving/ 1 Yes 21 47 CS = 26.958
Transport 2 No 37 9 l.t. 0.001 level
Bending 1 Yes 31 51 CS = 18.234
Knees 2 No 27 6 l.t. 0.001 level
Stairs 1 Yes 7 47 CS = 57.183
2 No 51 10 l.t. 0.001 level
Shopping 1 Yes 26 46 CS = 15.079
2 No 31 11 l.t. 0.001 level
Chair 1 Yes 8 46 CS = 50.031
Without
Discomfort
2 No 50 12 l.t. 0.001 level
Bath/ 1 Yes 40 47 CS = 2.253
Shower 2 No 18 11 0.25 level
Dressing 1 Yes 54 58 CS = 4.143
2 No 4 0 0.05 level
Cooking 1 Yes 53 56 CS = 1.883
2 No 4 1 0.25 level
Hoovering/ 1 Yes 34 48 CS = 8.515
Dusting 2 No 23 9 0.005 level
Assistance in 1 Yes 16 11 CS = 1.213
house 2 No 41 46 0.5 level
Confined to 1 Yes 2 0 CS = 2.036
Chair 2 No 55 57 0.25 level
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INDIVIDUAL QUESTIONS FOR THREE MONTH KNEE SUBGROUP
RETROSPECnVEOROUP - CHANGE IN RATING SCORES FOR
Question Scale Number of 
Subjects 
at the
Retrospective
Stage
Number of 
Subjects 
at the
Postoperative
Stage
Chisquare
Test (CS)
Pain 1 None 0 1 Chisquare =
2 None-Slight 0 1 10.455
3 Slight 0 3 Significant at
4 Slight-Moderate 0 0 the 0.05 level
5 Moderate 1 3
6 Moder-Severe 0 0
7 Severe 9 2
Impairment 1 None 0 0 Chisquare =
of Work 2 None-Slight 0 0 2.0
3 Slight 0 1 Significant at
4 Slight-Severe 1 0 the 0.5 level
5 Severe 0 0
6 Severe-Compl 0 0
7 Complete 9 9
Housework 1 All 0 0 Chisquare = 0
2 All - All-Heavy 0 0
3 All but Heavy 2 2
4 All-Heavy-Light 0 0
5 Light 4 4
6 Light - Few 0 0
7 Few Tasks 4 4
8 Few - None 0 0
9 None 0 0
Interference 1 None 3 4 Chisquare -
With Hobbies 2 None-Slight 0 0 2.254
3 Slight 5 4 Significant at
4 Slight-Severe 0 0 the 0.75 level
5 Severe 1 0
6 Severe-Compl 0 0
7 Complete 0 1
Dependence 1 None 6 5 Chisquare =
On Others 2 None-Occasion 0 1 2.232
3 Occasional 3 4 Significant at
4 Occasional-Reg 0 0 the 0.75 level
5 Regular 1 0
6 Regular - Total 0 0
7 Total 0 0
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Interference 1 None 0 0 Chisquare =
With Sports 2 None-Slight 0 0 2.222
3 Slight 0 2 Significant at
4 Slight-Severe 0 0 the 0.25 level
5 Severe 0 0
6 Severe-Compl 0 0
7 Complete 10 8
Interference 1 None 0 5 Chisquare =
With Sleep 2 None-Slight 0 0 13.143
3 Slight 3 4 Significant at
4 Slight-Severe 1 0 the 0.025
5 Severe 6 0 level
6 Severe-Compl 0 0
7 Complete 0 1
W alking 1 Long Distances 0 1 Chisquare =
2 Long - Short 0 0 13.333
3 Short Distances 0 3 Significant at
4 Short - House O' 4 the 0.005
5 Confined House 10 2 level
Sleep on 1 Yes 6 7 CS = 0.220
Side 2 No 4 3 0.75 level
Driving/ 1 Yes 0 2 CS = 2.222
Transport 2 No 10 8 0.25 level
Bending 1 Yes 0 7 CS = 10.769
Knees 2 No 10 3 0.005 level
Stairs 1 Yes 0 6 CS = 8.571
2 No 10 4 0.005 level
Shopping 1 Yes 3 3 cs = o
2 No 7 7
Chair 1 Yes 1 7 CS = 7.5
Without
Discomfort
2 No 9 3 0.01 level
Bath/ 1 Yes 7 8 CS = 0.267
Shower 2 No 3 2 0.75 level
Dressing 1 Yes 9 9 cs = o
2 No 1 1
Cooking 1 Yes 8 10 CS = 2.222
2 No 2 0 0.25 level
Hoovering/ 1 Yes 4 5 CS = 0.202
Dusting 2 No 6 5 0.75 level
Assistance in 1 Yes 3 3 CS = 0
house 2 No 7 7
Confined to 1 Yes 0 0 CS = 0
Chair 2 No 10 10
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INDIVIDUAL QUESTIONS FOR ONE YEAR KNEE SUBGROUP
RETROSPECTIVE GROUP - CHANGE IN RATING SCORES FOR
Question Scale Number of 
Subjects 
at the
Retrospective
Stage
Number of 
Subjects 
at the
Postoperative
Stage
Chisquare
Test(CS)
Pain 1 None 0 13 Chisquare =
2 None-Slight 0 0 53.338
3 Slight 0 15 Significant at
4 Slight-Moderate 1 1 less than the
5 Moderate 3 2 0.001 level
6 Moder-Severe 0 0
7 Severe 28 1
Impairment 1 None 2 6 Chisquare =
of Work 2 None-Slight 0 0 8.095
3 Slight I 6 Significant at
4 Slight-Severe I 0 the 0.1 level
5 Severe 4 2
6 Severe-Compl 0 0
7 Complete 24 18
Housework 1 All 1 4 Chisquare =
2 All - All-Heavy 0 0 9.133
3 All but Heavy 4 8 Significant at
4 All-Heavy-Light 0 1 the 0.25 level
5 Light 13 13
6 Light - Few 0 0
7 Few Tasks 10 6
8 Few - None 0 0
9 None 4 0
Interference 1 None 7 16 Chisquare =
With Hobbies 2 None-Slight 0 0 20.459
3 Slight 2 11 Significant at
4 Slight-Severe 0 0 less than the
5 Severe 14 3 0.001 level
6 Severe-Compl 0 0
7 Complete 8 2
Dependence 1 None 17 28 Chisquare -
On Others 2 None-Occasion 0 0 11.022
3 Occasional 8 4 Significant at
4 Occasional-Reg 0 0 the 0.005
5 Regular 7 0 level
6 Regular - Total 0 0
7 Total 0 0
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Interference 1 None 0 1 Chisquare =
With Sports 2 None-Slight 0 0 11.478
3 Slight 1 9 Significant at
4 Slight-Severe 0 1 the 0.025
5 Severe 2 2 level
6 Severe-Compl 0 0
7 Complete 29 17
Interference 1 None 4 22 Chisquare = .
With Sleep 2 None-Slight 0 0 29.795
3 Slight 9 9 Significant at
4 Slight-Severe 2 1 less than the
5 Severe 14 0 0.001 level
6 Severe-Compl 0 0
7 Complete 3 0
Walking 1 Long Distances 0 14 Chisquare =
2 Long - Short 0 3 29.930
3 Short Distances 5 8 Significant at
4 Short - House 4- 2 less than the
5 Confined House 23 5 0.001 level
Sleep on 1 Yes 9 28 CS = 23.127
Side 2 No 23 4 l.t. 0.001 level
Driving/ 1 Yes 9 23 CS = 12.250
Transport 2 No 23 9 l.t. 0.001 level
Bending 1 Yes 2 28 CS = 42.416
Knees 2 No 30 4 l.t. 0.001 level
Stairs 1 Yes 2 20 CS = 22.442
2 No 30 12 l.t. 0.001 level
Shopping 1 Yes 14 24 CS = 6.478
2 No 18 8 0.025 level
Chair 1 Yes 6 25 CS = 22.585
Without
Discomfort
2 No 26 7 l.t. 0.001 level
Bath/ 1 Yes 20 27 CS = 3.925
Shower 2 No 12 5 0.05 level
Dressing 1 Yes 29 32 CS = 3.148
2 No 3 0 0.1 level
Cooking 1 Yes 27 31 CS = 2.943
2 No 5 1 0.1 level
Hoovering/ 1 Yes 19 25 CS = 2.618
Dusting 2 No 13 7 0.25 level
Assistance in 1 Yes 11 5 CS = 3.0
house 2 No 21 27 0.1 level
Confined to 1 Yes 4 0 CS = 4.267
Chair 2 No 28 32 0.05 level
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APPENDIX 19 69
KNEE PATIENTS MATCHED BETWEEN CONTROL AND
RETROSPECTIVE GROUPS IN TERMS OF AGE AND SEX
Control Group 
(No Z Sex / Age at 
Operation)
Matched
Three Months
Retrospective
Group
(No / Sex / Age at 
Operation)
First Matched
One Year
Retrospective
Group
(No / Sex / Age at 
Operation)
Second Matched 
One Year 
Retrospective 
Group
(No / Sex / Age at 
Operation)
1) F 69 9) F 68 106) F 69 124) F 69
3) F 72 97) F 69 26) F 73 86) F 70
10) F 82 27) F 82 1) F 76 *
13) M 66 * 60) F 68 64) M 69
15) F 52 32) F 51 13) F 47 63) F 49
16) F 81 * 146) F 80 *
17) F 65 41) F 68 6) F 64 21) F 69
19) F 80 131) F 78 80) F 80 *
22) F 82 77) F 82 79) F 76 *
24) F 59 * 51) F 57 103) F 56
27) M 58 * 18) M 59 23) F 58
28) F 75 112) F 74 90) F 74 *
30) M 66 * 117) F 68 125) M 68
32) F 76 ♦ 115) F 74 *
34) M 61 * 25) F 58 89) M 59
35) M 67 * 98) M 72 108) M 72
36) F 87 ♦ * *
37) M 65 * 104) F 63 *
40) F 52 130) F 51 54) F 55 135) F 52
43) F 79 42) F 78 30) F 78 *
44) F 63 * 17) F 63 *
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SENSITIVITY ANALYSIS. QF GUDEX’S USE OF CAPD DATA
Conversion
of Karnofsky
Index into
Rosser
Disability/
Distress
Categories
Survival
(Years)
QALY’s 
Gained per 
Patient 
(Discounted 
at 5%)
Total Costs 
(Discounted 
at 5%)
Cost per
QALY
A = I-ILA 2 1.65 £23,923 £14,499
B = IIIB 4 3.16 £45,623 £14,438
C = IVC 6 4.52 £65,304 £14,448
D = V-VID 8 5.75 £83,156 £14,462
e = vn-vniD 10 6.87 £99,347 £14,461
a = i-ha 2 1.73 £23,923 £13,828
B = HI-IVA 4 3.30 £45,623 £13,825
C = VB 6 4.72 £65,304 £13,836 •
D = VIC 8 6.01 £83,156 £13,836
e = vii-vuid 10 7.18 £99,347 £13,837
A = I-IIA 2 1.73 £23,923 £13,828
B = III-IVB 4 3.30 £45,623 £13,825
C = VC 6 4.72 £65,304 £13,836
D = VIC 8 6.01 £83,156 £13,836
e = vn-vinD 10 7.18 £99,347 £13,837
A = I-IIA 2 1.73 £23,923 £13,828
B = IIIB 4 3.30 £45,623 £13,825
C = IV-VC 6 4.72 £65,304 £13,836
D = VIC 8 6.01 £83,156 £13,836
E = VII-VinD 10 7.18 £99,347 £13,837
A = LA 2 1.75 £23,923 £13,670
b = h-ihb 4 3.33 £45,623 £13,701
C = IV-VB 6 4.77 £65,304 £13,691
D = VIC 8 6.08 £83,156 £13,677
e = vn-vmD 10 7.26 £99,347 £13,684
A = LA 2 1.75 £23,923 £13,670
b = n-mB 4 3.33 £45,623 £13,701
C = IV-VC 6 4.77 £65,304 £13,691
D = VIC 8 6.08 £83,156 £13,677
e = vn-vniD 10 7.26 £99,347 £13,684
A = I-ILA 2 1.75 £23,923 £13,670
b = mA 4 3.33 £45,623 £13,701
C = IV-VB 6 4.77 £65,304 £13,691
D = VIC 8 6.08 £83,156 £13,677
E = VII-VIIID 10 7.26 £99,347 £13,684
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a = i-ha 2 1.77 £23,923 £13.516
B = IIIB 4 3.37 £45,623 £13,538
C = IVB 6 4.82 £65,304 £13,549
D == V-VIC 8 6.14 £83,156 £13,543
e = vn-vmD 10 7.34 £99,347 £13,535
A = IA 2 1.79 £23,923 £13,365
B = H-IHA 4 3.40 £45,623 £13,419
C = IVB 6 4.87 £65,304 £13,409
D = V-VIC 8 6.20 £83,156 £13,412
E = VH-VIHD 10 7.41 £99,347 £13,407
A = IA 2 1.79 £23,923 £13,365
B = II-IHB 4 3.40 £45,623 £13,419
c = rvc 6 4.87 £65,304 £13,409
D = V-VIC 8 6.20 £83,156 £13,412
E = VH-VHID 10 7.41 £99,347 £13,407
A = IA 2 1.80 £23,923 £13,291
B = II-IHB 4 3.44 £45,623 £13,263
C = IVC 6 4.92 • £65,304 £13,273
D = VC 8 6.27 £83,156 £13,263
E = VI-VIIID 10 7.49 £99,347 £13,264
A = I-HA 2 1.80 £23,923 £13,291
b — iha 4 3.44 £45,623 £13,263
C = IVB 6 4.92 £65,304 £13,273
D = VC 8 6.27 £83,156 £13,263
E = VI-VIIID 10 7.49 £99,347 £13,264
A = I-IIA 2 1.80 £23,923 £13,291
B = HIB 4 3.44 £45,623 £13,263
C = IVC 6 4.92 £65,304 £13,273
D = VC 8 6.27 £83,156 £13,263
E = VI-VIHD 10 7.49 £99,347 £13,264
A = IA 2 1.82 £23,923 £13,145
b = n-niA 4 3.48 £45,623 £13,110
C = IVB 6 4.97 £65,304 £13,140
D = VC 8 6.33 £83,156 £13,137
E = VI-VIIID 10 7.57 £99,347 £13,124
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PROCCI (1980)
SENSITIVITY ANALYSIS OF GUDEX’S USE OF HAEMODIALYSIS DATA
Conversion
of Social
Disability
Scores into
Rosser
Disability
Categories
Conversion 
of Social 
Modifiers 
into
Rosser
Distress
Categories
Survival
(Years)
QALY’s 
Gained per 
Patient 
(Discounted 
at 5%)
Total Costs 
(Discounted 
at 5%)
Cost per 
QALY
0-20 = I 1-5 = A 2 1.65 £15,933 £9,656
20-49 = n 6-19 = B 4 3.16 £30,386 £9,616
50-54 = in 20-39 = C 6 4.52 £43,494 £9,623
55-64 = IV 40-55 =D 8 5.75 £55,383 £9,632
65-74 = V 
75-89 = VI 
90-99 = VH 
100-109=VIII
10 6.87 £66,167 £9,631
0-20 = I 1-9 = A 2 1.67 £15,933 £9,541
20-49 = n 10-19 = B 4 3.19 £30,386 £9,525
50-54 = m 20-39 = C 6 4.57 £43,494 £9,517
55-64 = IV 40-55 =D 8 5.82 £55,383 £9,516
65-74 = V 
75-89 = VI 
90-99 = vn 
100-109=VHI
10 6.95 £66,167 £9,520
0-20 = I 1-9 = A 2 1.67 £15,933 £9,541
20-49 = H 10-24 = B 4 3.19 £30,386 £9,525
50-54 = m 25-39 = C 6 4.57 £43,494 £9,517
55-64 = IV 40-55 =D 8 5.82 £55,383 £9,516
65-74 = V 
75-89 = VI 
90-99 = vn 
100-109=vni
10 6.95 £66,167 £9,520
0-20 = I 1-5 = A 2 1.67 £15,933 £9,541
20-49 = n 6-19 = B 4 3.19 £30,386 £9,525
50-59 = m 20-39 = C 6 4.57 £43,494 £9,517
60-69 = IV 40-55 =D 8 5.82 £55,383 £9,516
70-74 = V 
75-89 = VI 
90-99 = vn 
100-109=Vni
10 6.95 £66,167 £9,520
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0-20 = I 1-9 = A 2 1.67 £15,933 £9,541
20-49 = n 10-19 = B 4 3.19 £30,386 £9,525
50-59 = HI 20-39 = C 6 4.57 £43,494 £9,517
60-69 = IV 40-55 =D 8 5.82 £55,383 £9,516
70-74 = V 
75-89 = VI 
90-99 = vn 
100-109=Vm
10 6.95 £66,167 £9,520
0-20 = I 1-9 = A 2 1.67 £15,933 £9,541
20-49 = n 10-24 = B 4 3.19 £30,386 £9,525
50-59 = HI 25-39 = C 6 4.57 £43,494 £9,517
60-69 = IV 40-55 =D 8 5.82 £55,383 £9,516
70-74 = V 
75-89 = VI 
90-99 = VII 
100-109=vm
10 6.95 £66,167 £9,520
0-20 = I 1-5 = A 2 1.75 £15,933 £9,105
20-39 = H 6-19 = B 4 3.33 • £30,386 £9,125
40-59 = HI 20-39 = C 6 4.77 £43,494 £9,118
60-69 = IV 40-55 =D 8 6.08 £55,383 £9,109
70-79 = V 
80-89 = VI 
90-99 = VII 
100-109=VIII
10 7.26 £66,167 £9,114
0-20 = I 1-9 = A 2 1.75 £15,933 £9,105
20-39 = n 10-19 = B 4 3.33 £30,386 £9,125
40-59 = ni 20-39 = C 6 4.77 £43,494 £9,118
60-69 = IV 40-55 =D 8 6.08 £55,383 £9,109
70-79 = V 
80-89 = VI 
90-99 = VII 
100-109=VIII
10 7.26 £66,167 £9,114
0-20 = I 1-9 = A 2 1.75 £15,933 £9,105
20-39 = n 10-24 = B 4 3.33 £30,386 £9,125
40-59 = HI 25-39 = C 6 4.77 £43,494 £9,118
60-69 = IV 40-55 =D 8 6.08 £55,383 £9,109
70-79 = V 
80-89 = VI 
90-99 = VH 
100-109=VHI
10 7.26 £66,167 £9,114
0-20 = I 1-5 = A 2 1.75 £15,933 £9,105
20-39 = H 6-19 = B 4 3.33 £30,386 £9,125
40-54 = HI 20-39 = C 6 4.77 £43,494 £9,118
55-69 = IV 40-55 =D 8 6.08 £55,383 £9,109
70-79 = V 
80-89 = VI 
90-99 = VII 
100-109=vm
10 7.26 £66,167 £9,114
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0-20 = I 1-9 = A 2 1.75 £15,933 £9,105
20-39 = n 10-19 = B 4 3.33 £30,386 £9,125
40-54 = HI 20-39 = C 6 4.77 £43,494 £9,118
55-69 = IV 40-55 =D 8 6.08 £55,383 £9,109
70-79 = V 
80-89 = VI 
90-99 = vn 
100-109=VHI
TO 7.26 £66,167 £9,114
0-20 = I 1-9 = A 2 1.75 £15,933 £9,105
20-39 = H 10-24 = B 4 3.33 £30,386 £9,125
40-54 = HI 25-39 = C 6 4.77 £43,494 £9,118
55-69 = IV 40-55 =D 8 6.08 £55,383 £9,109
70-79 = V 
80-89 = VI 
90-99 = VH 
100-109=VHI
10 7.26 £66,167 £9,114
0-20 = I 1-5 = A 2 1.75 £15,933 £9,105
20-44 = H 6-19 = B 4 3.33 £30,386 £9,125 ■
45-54 = HI 20-39 = C 6 4.77 £43,494 £9,118
55-64 = IV 40-55 =D 8 6.08 £55,383 £9,109
65-79 = V 
80-89 = VI 
90-99 = VH 
100-109=VHI
10 7.26 £66,167 £9,114
0-20 = I 1-9 = A 2 1.75 £15,933 £9,105
20-44 = H 10-19 = B 4 3.33 £30,386 £9,125
45-54 = HI 20-39 = C 6 4.77 £43,494 £9,118
55-64 = IV 40-55 =D 8 6.08 £55,383 £9,109
65-79 = V 
80-89 = VI 
90-99 = VH 
100-109=Vni
10 7.26 £66,167 £9,114
0-20 = I 1-9 = A 2 1.75 £15,933 £9,105
20-44 = H 10-24 = B 4 3.33 £30,386 £9,125
45-54 = HI 25-39 = C 6 4.77 £43,494 £9,118
55-64 = IV 40-55 =D 8 6.08 £55,383 £9,109
65-79 = V 
80-89 = VI 
90-99 = VH 
100-109=VHI
10 7.26 £66,167 £9,114
0-20 = I 1-5 = A 2 1.75 £15,933 £9,105
20-49 = H 6-19 = B 4 3.33 £30,386 £9,125
50-64 = HI 20-39 = C 6 4.77 £43,494 £9,118
65-69 = IV 40-55 =D 8 6.08 £55,383 £9,109
70-79 = V 
80-89 = VI 
90-99 = VII 
100-109=VHI
10 7.26 £66,167 £9,114
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0-20 = I 1-9 = A 2 1.75 £15,933 £9,105
20-49 = H 10-19 = B 4 3.33 £30,386 £9,125
50-64 = HI 20-39 = C 6 4.77 £43,494 £9,118
65-69 = IV 40-55 =D 8 6.08 £55,383 £9,109
70-79 = V 
80-89 = VI 
90-99 = VII 
100-109=VIII
10 7.26 £66,167 £9,114
0-20 = I 1-9 = A 2 1.75 £15,933 £9,105
20-49 = n 10-24 = B 4 3.33 £30,386 £9,125
50-64 = HI 25-39 = C 6 4.77 £43,494 £9,118
65-69 = IV 40-55 =D 8 6.08 £55,383 £9,109
70-79 = V 
80-89 = VI 
90-99 = vn 
100-109=VHI
10 7.26 £66,167 £9,114
0-20 = I 1-5 = A 2 1.75 £15,933 £9,105
20-49 = n 6-19 = B 4 3.33 • £30,386 £9,125
50-59 = m 20-39 = C 6 4.77 £43,494 £9,118
60-64 = IV 40-55 =D 8 6.08 £55,383 £9,109
65-79 = V 
80-89 = VI 
90-99 = vn 
100-109=Vni
10 7.26 £66,167 £9,114
0-20 = I 1-9 = A 2 1.75 £15,933 £9,105
20-49 = n 10-19 = B 4 3.33 £30,386 £9,125
50-59 = HI 20-39 = C 6 4.77 £43,494 £9,118
60-64 = IV 40-55 =D 8 6.08 £55,383 £9,109
65-79 = V 
80-89 = VI 
90-99 = vn 
100-109=Vni
10 7.26 £66,167 £9,114
0-20 = I 1-9 = A 2 1.75 £15,933 £9,105
20-49 = n 10-24 = B 4 3.33 £30,386 £9,125
50-59 = m 25-39 = C 6 4.77 £43,494 £9,118
60-64 = IV 40-55 =D 8 6.08 £55,383 £9,109
65-79 = V 
80-89 = VI 
90-99 = vn 
100-109=VUI
10 7.26 £66,167 £9,114
0-20 = I 1-5 = A 2 1.77 £15,933 £9,002
20-44 = n 6-19 = B 4 3.37 £30,386 £9,017
45-59 = m 20-39 = C 6 4.82 £43,494 £9,024
60-74 = IV 40-55 =D 8 6.14 £55,383 £9,020
75-79 = V 
80-89 = VI 
90-99 = VII 
100-109=VIII
10 7.34 £66,167 £9,015
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0-20 = I 1-9 = A 2 1.77 £15,933 £9,002
20-44 = 11 10-19 = B 4 3.37 £30,386 £9,017
45-59 = KT 20-39 = C 6 4.82 £43,494 £9,024
60-74 = IV 40-55 =D 8 6.14 £55,383 £9,020
75-79 = V 
80-89 = VI 
90-99 = VII 
100-109=VHI
10 7.34 £66,167 £9,015
0-20 = I 1-9 = A 2 1.77 £15,933 £9,002
20-44 = 11 10-24 = B 4 3.37 £30,386 £9,017
45-59 = m 25-39 = C 6 4.82 £43,494 £9,024
60-74 = IV 40-55 =D 8 6.14 £55,383 £9,020
75-79 = V 
80-89 = VI 
90-99 = vn 
100-109=vni
10 7.34 £66,167 £9,015
0-20 = 1 1-5 = A 2 1.77 £15,933 £9,002
20-54 = n 6-19 = B 4 3.37 £30,386 £9,017
55-59 = DI 20-39 =C 6 4.82 £43,494 £9,024
60-69 = IV 40-55 =D 8 6.14 £55,383 £9,020
70-79 = V 
80-89 = VI 
90-99 = VII 
100-109=vm
10 7.34 £66,167 £9,015
0-20 = I 1-9 = A 2 1.77 £15,933 £9,002
20-54 = n 10-19 = B 4 3.37 £30,386 £9,017
55-59 = HI 20-39 = C 6 4.82 £43,494 £9,024
60-69 = IV 40-55 =D 8 6.14 £55,383 £9,020
70-79 = V 
80-89 = VI 
90-99 = VII 
100-109=vm
10 7.34 £66,167 £9,015
0-20 = I 1-9 = A 2 1.77 £15,933 £9,002
20-54 = n 10-24 = B 4 3.37 £30,386 £9,017
55-59 = m 25-39 = C 6 4.82 £43,494 £9,024
60-69 = IV 40-55 =D 8 6.14 £55,383 £9,020
70-79 = V 
80-89 = VI 
90-99 = VII 
100-109=Vm
10 7.34 £66,167 £9,015
0-20 = I 1-9 = A 2 1.77 £15,933 £9,002
20-49 = n 10-24 = B 4 3.37 £30,386 £9,017
50-54 = m 25-44 = C 6 4.82 £43,494 £9,024
55-64 = IV 45-55 =D 8 6.14 £55,383 £9,020
65-74 = V 
75-89 = VI 
90-99 = VII 
100-109=VIII
10 7.34 £66,167 £9,015
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0-20 = I 1-9 = A 2 1.79 £15,933 £8,901
20-39 = n 10-24 = B 4 3.40 £30,386 £8,937
40-54 = ni 25-44 = C 6 4.87 £43,494 £8,931
55-69 = IV 45-55 =D 8 6.20 £55,383 £8,933
70-79 = V 
80-89 = VI 
90-99 = VII 
100-109=VIII
10 7.41 £66,167 £8,929
0-20 = I 1-9 = A 2 1.79 £15,933 £8,901
20-44 = H 10-24 = B 4 3.40 £30,386 £8,937
45-54 = El 25-44 = C 6 4.87 £43,494 £8,931
55-64 = IV 45-55 =D 8 6.20 £55,383 £8,933
65-79 = V 
80-89 = VI 
90-99 = vn 
100-109=VIII
10 7.41 £66,167 £8,929
0-20 = I 1-5 = A 2 1.79 £15,933 £8,901
20-54 = H 6-19 = B 4 3.40 • £30,386 £8,937
55-64 = HI 20-39 = C 6 4.87 £43,494 £8,931
65-74 = IV 40-55 =D 8 6.20 £55,383 £8,933
75-79 = V 
80-89 = VI 
90-99 = VII 
100-109=VIII
10 7.41 £66,167 £8,929
0-20 = I 1-9 = A 2 1.79 £15,933 £8,901
20-54 = n 10-19 = B 4 3.40 £30,386 £8,937
55-64 = HI 20-39 = C 6 4.87 £43,494 £8,931
65-74 = IV 40-55 =D 8 6.20 £55,383 £8,933
75-79 = V 
80-89 = VI 
90-99 = VII 
100-109=VHI
10 7.41 £66,167 £8,929
0-20 = I 1-9 = A 2 1.79 £15,933 £8,901
20-54 = n 10-24 = B 4 3.40 £30,386 £8,937
55-64 = m 25-39 = C 6 4.87 £43,494 £8,931
65-74 = IV 40-55 =D 8 6.20 £55,383 £8,933
75-79 = V 
80-89 = VI 
90-99 = vn 
100-109=Vm
10 7,41 £66,167 £8,929
0-20 = I 1-9 = A 2 1.79 £15,933 £8,901
20-49 = n 10-24 = B 4 3.40 £30,386 £8,937
50-59 = m 25-44 = C 6 4.87 £43,494 £8,931
60-69 = IV 45-55 =D 8 6.20 £55,383 £8,933
70-74 = V 
75-89 = VI 
90-99 = VII 
100-109=VIII
10 7.41 £66,167 £8,929
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0-20 = I 1-9 = A 2 1.80 £15,933 £8,852
20-39 = n 10-24 = B 4 3.44 £30,386 £8,833
40-59 = HI 25-44 = C 6 4.92 £43,494 £8,840
60-69 = IV 45-55 =D 8 6.27 £55,383 £8,833
70-79 = V 
80-89 = VI 
90-99 = VII 
100-109=VIII
10 7.49 £66,167 £8,834
0-20 = I 1-9 = A 2 1.80 £15,933 £8,852
20-44 = 11 10-24 = B 4 3.44 £30,386 £8,833
45-59 = HI 25-44 = C 6 4.92 £43,494 £8,840
60-74 = IV 45-55 =D 8 6.27 £55,383 £8,833
75-79 = V 
80-89 = VI 
90-99 = vn 
100-109=VHI
10 7.49 £66,167 £8,834
0-20 = I 1-9 = A 2 1.80 £15,933 £8,852
20-54 = H 10-24 = B 4 3.44 £30,386 £8,833
55-59 = m 25-44 = C 6 4.92 £43,494 £8,840
60-69 = IV 45-55 =D 8 6.27 £55,383 £8,833
70-79 = V 
80-89 = VI 
90-99 = vn 
100-109=Vni
10 7.49 £66,167 £8,834
0-20 = I 1-9 = A 2 1.80 £15,933 £8,852
20-49 = n 10-24 = B 4 3.44 £30,386 £8,833
50-64 = HI 25-44 = C 6 4.92 £43,494 £8,840
65-69 = IV 45-55 =D 8 6.27 £55,383 £8,833
70-79 = V 
80-89 = VI 
90-99 = vn 
100-109=Vni
10 7.49 £66,167 £8,834
0-20 = I 1-9 = A 2 1.80 £15,933 £8,852
20-49 = n 10-24 = B 4 3.44 £30,386 £8,833
50-59 = m 25-44 = C 6 4.92 £43,494 £8,840
60-64 = IV 45-55 =D 8 6.27 £55,383 £8,833
65-79 = V 
80-89 = VI 
90-99 = vn 
100-109=vni
10 7.49 £66,167 £8,834
0-20 = I 1-9 = A 2 1.82 £15,933 £8,754
20-54 = n 10-24 = B 4 3.48 £30,386 £8,732
55-64 = HI 25-44 = C 6 4.97 £43,494 £8,751
65-74 = IV 45-55 =D 8 6.33 £55,383 £8,749
75-79 = V 
80-89 = VI 
90-99 = vn 
100-109=VUI
10 7.57 £66,167 £8,741
APPENDIX 22 79
EVANS ET AL (1984). EVANS ET AL (1985) - HOME HAEMODIALYSIS
SENSITIVITY ANALYSIS OF GUDEX’S USE OF HAEMODIALYSIS DATA
Conversion
of Karnofsky
Index into
Rosser
Disability/
Distress
Categories
Survival
(Years)
QALY’s
Gained per 
Patient 
(Discounted 
at 5%)
Total Costs 
(Discounted 
at 5%)
Cost per
QALY ‘
A = I-IIA 2 1.75 £15,933 £9,105
B = IIIB 4 3.33 £30,386 £9,125
C = IVC 6 4.77 £43,494 £9,118
D = V-VID 8 6.08 £55,383 £9,109
e = vn-vniD 10 7.26 £66,167 £9,114
a = i-ha 2 1.79 £15,933 £8,901
B = III-IVA 4 3.40 £30,386 • £8,937
C = VB ‘6 4.87 £43,494 £8,931
D = VIC 8 6.20 £55,383 £8,933
E = VH-VIIID 10 7.41 £66,167 £8,929
A = I-IIA 2 1.79 £15,933 £8,901
b = ni-rvB 4 3.40 £30,386 £8,937
C = VC 6 4.87 £43,494 £8,931
D = VIC 8 6.20 £55,383 £8,933
e = vn-vniD 10 7.41 £66,167 £8,929
A = I-IIA 2 1.79 £15,933 £8,901
B = niB 4 3.40 £30,386 £8,937
C = IV-VC 6 4.87 £43,494 £8,931
D = VIC 8 6.20 £55,383 £8,933
E = Vn-VIIID 10 7.41 £66,167 £8,929
A = IA 2 1.80 £15,933 £8,852
b = n-niB 4 3.44 £30,386 £8,833
C = IV-VB 6 4.92 £43,494 £8,840
D = VIC 8 6.27 £55,383 £8,833
E = VII-VHID 10 7.49 £66,167 £8,834
A = IA 2 1.80 £15,933 £8,852
b = n-inB 4 3.44 £30,386 £8,833
C = IV-VC 6 4.92 £43,494 £8,840
D = VIC 8 6.27 £55,383 £8,833
E = VII-VUID 10 7.49 £66,167 £8,834
a = i-ha 2 1.80 £15,933 £8,852
b = niB 4 3.44 £30,386 £8,833
C = IVB 6 4.92 £43,494 £8,840
D = V-VIC 8 6.27 £55,383 £8,833
e = vn-vniD 10 7.49 £66,167 £8,834
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A = I-HA 2 1.80 £15,933 £8,852
B = IIIA 4 3.44 £30,386 £8,833
C = IV-VB 6 4.92 £43,494 £8,840
D = VIC 8 6.27 £55,383 £8,833
e = vn-vniD 10 7.49 £66,167 £8,834
A = LA 2 1.82 £15,933 £8,754
b = n-niA 4 3.48 £30,386 £8,732
C = IVB 6 4.97 £43,494 £8,751
D = V-VIC 8 6.33 £55,383 £8,749
e = vn-vniD 10 7.57 £66,167 £8,741
A = LA 2 1.82 £15,933 £8,754
b = n-mB 4 3.48 £30,386 £8,732
C = IVC 6 4.97 £43,494 £8,751
D = V-VIC 8 6.33 £55,383 £8,749
e = vn-vniD 10 7.57 £66,167 £8,741
A = LA 2 1.82 £15,933 £8,754
B = n-IHB 4 3.48 £30,386 £8,732
C = IVC 6 4.97 £43,494 £8,751
D = VC 8 6.33 £55,383 £8,749
E = vi-vniD 10 7.57 £66,167 £8,741
a = i-nA 2 1.82 £15,933 £8,754
b = iua 4 3.48 £30,386 £8,732
C = LVB 6 4.97 £43,494 £8,751
D = VC 8 6.33 £55,383 £8,749
E = VI-VIHD 10 7.57 £66,167 £8,741
A = I-nA 2 1.82 £15,933 £8,754
b = inB 4 3.48 £30,386 £8,732
C = IVC 6 4.97 £43,494 £8,751
D = VC 8 6.33 £55,383 £8,749
E = VI-VHID 10 7.57 £66,167 £8,741
A = IA 2 1.84 £15,933 £8,659
b = n-niA 4 3.51 £30,386 £8,657
C = IVB 6 5.02 £43,494 £8,664
D = VC 8 6.40 £55,383 £8,654
E = VI-VinD 10 7.64 £66,167 £8,661
APPENDIX 22 8 1
EVANS ET At (1984), EVANS.,ET At (1985) - HOSPITAL HAEMODIALYSIS
Conversion
of Kamofsky
Index into
Rosser
Disability/
Distress
Categories
Survival
(Years)
QALY’s 
Gained per 
Patient 
(Discounted 
at 5%)
Total Costs 
(Discounted 
at 5%)
Cost per
QALY
A = I-IIA 2 1.62 £15,933 £9,835
B = IHB 4 3.09 £30,386 £9,834
C = IVC 6 4.42 £43,494 £9,840
D = V-VID 8 5.62 £55,383 £9,855
E = VII-VIIID 10 6.72 £66,167 £9,846
A = I-HA 2 1.71 £15,933 £9,318
B = HI-IVB 4 3.26 £30,386 £9,321
C-VC 6 4.67 £43,494 • £9,313
D = VIC 8 5.95 £55,383 £9,308
E = VH-VHID 10 7.10 £66,167 £9,319
A = I-IIA 2 1.71 £15,933 £9,318
B = IIIB 4 3.26 £30,386 £9,321
C = IV-VC 6 4.67 £43,494 £9,313
D = VIC 8 5.95 £55,383 £9,308
E = VII-VIIID 10 7.10 £66,167 £9,319
A - IA 2 1.73 £15,933 £9,210
B = H-IHB 4 3.30 £30,386 £9,208
C = IV-VB 6 4.72 £43,494 £9,215
D = VIC 8 6.01 £55,383 £9,215
E = Vn-VIHD 10 7.18 £66,167 £9,215
A = IA 2 1.73 £15,933 £9,210
B = H-HIB 4 3.30 £30,386 £9,208
C = IV-VC 6 4.72 £43,494 £9,215
D = VIC 8 6.01 £55,383 £9,215
E = VH-VIHD 10 7.18 £66,167 £9,215
A = I-HA 2 1.73 £15,933 £9,210
B = HI-IVA 4 3.30 £30,386 £9,208
C = VB 6 4.72 £43,494 £9,215
D = VIC 8 6.01 £55,383 £9,215
E = Vn-VIIID 10 7.18 £66,167 £9,215
A = I-HA 2 1.73 £15,933 £9,210
B = HI A 4 3.30 £30,386 £9,208
C = IV-VB 6 4.72 £43,494 £9,215
D = VIC 8 6.01 £55,383 £9,215
E = VII-VIIID 10 7.18 £66,167 £9,215
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A = IA 2 1.77 £15,933 £9,002
B = H-HIA 4 3.37 £30,386 £9,017
C = IVB 6 4.82 £43,494 £9,024
D = V-VIC 8 6.14 £55,383 £9,020
E = VII-VIIID 10 7.34 £66,167 £9,015
A = IA 2 1.77 £15,933 £9,002
B = H-IHB 4 3.37 £30,386 £9,017
C = IVC 6 4.82 £43,494 £9,024
D = V-VIC 8 6.14 £55,383 £9,020
E = VH-VHID 10 7.34 £66,167 £9,015
A = I-HA 2 1.77 £15,933 £9,002
B = HIB 4 3.37 £30,386 £9,017
C = IVB 6 4.82 £43,494 £9,024
D = V-VIC 8 6.14 £55,383 £9,020
E = Vn-VHID 10 7.34 £66,167 £9,015
A = I-HA 2 1.79 £15,933 £8,901
B = HIB 4 3.40 £30,386 £8,937
C = IVC 6 4.87 £43,494 £8,931
D = VC 8 6.20 £55,383 £8,933
E = VI-VHID 10 7.41 £66,167 £8,929
A = IA 2 1.80 £15,933 £8,852
B = H-IHA 4 3.44 £30,386 £8,833
C = IVB 6 4.92 £43,494 £8,840
D = VC 8 6.27 £55,383 £8,833
E = VI-VHID 10 7.49 £66,167 £8,834
A = IA 2 1.80 £15,933 £8,852
B = H-IHB 4 3.44 £30,386 £8,833
c = rvc 6 4.92 £43,494 £8,840
D = VC 8 6.27 £55,383 £8,833
E = VI-VHID 10 7.49 £66,167 £8,834
A = I-HA 2 1.80 £15,933 £8,852
B = IIIA 4 3.44 £30,386 £8,833
C = IVB 6 4.92 £43,494 £8,840
D = VC 8 6.27 £55,383 £8,833
E = VI-VHID 10 7.49 £66,167 £8,834
APPENDIX 23 83
PROCCI (1980)
SENSITIVITY ANALYSIS OF GUDEX'S USE OF RENAL TRANSPLANT DATA
Conversion
of Social
Disability
Scores into
Rosser
Disability
Categories
Conversion 
of Social 
Modifiers 
into
Rosser
Distress
Categories
Survival
(Years)
QALY’s 
Gained per 
Patient 
(Discounted 
at 5%)
Total Costs 
(Discounted 
at 5%)
Cost per 
QALY
0-20 = I 1-9 = A 2 1.77 £10,452 £5,905
20-39 = H 10-24 = B 4 3.37 £10,452 £3,101
40-59 = m 25-34 = C 6 4.82 £10,452 £2,168
60-69 = IV 35-55 =D 8 6.14 £10,452 £1,702
70-79 = V
80-89 = VI 
90-99 = vn 
100-109=vni
10 7.34 £10,452 £1,424
0-20 = I 1-9 = A 2 1.77 £10,452 £5,905
20-39 = n 10-24 = B 4 3.37 £10,452 £3,101
40-54 = m 25-34 = C 6 4.82 £10,452 £2,168
55-69 = IV 35-55 =D 8 6.14 £10,452 £1,702
70-79 = V
80-89 = VI 
90-99 = vn 
100-109=Vm
10 7.34 £10,452 £1,424
0-20 = I 1-9 = A 2 1.77 £10,452 £5,905
20-44 = n 10-24 = B 4 3.37 £10,452 £3,101
45-54 = DI 25-34 = C 6 4.82 £10,452 £2,168
55-64 = IV 35-55 =D 8 6.14 £10,452 £1,702
65-79 = V
80-89 = VI 
90-99 = vn 
100-109=Vni
10 7.34 £10,452 £1,424
0-20 = I 1-9 = A 2 1.77 £10,452 £5,905
20-49 = n 10-24 = B 4 3.37 £10,452 £3,101
50-54 = ni 25-34 = C 6 4.82 £10,452 £2,168
55-64 = IV 35-55 =D 8 6.14 £10,452 £1,702
65-74 = V
75-89 = VI 
90-99 = VII 
100-109=vni
10 7.34 £10,452 £1,424
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0-20 = I 1-5 = A 2 1.79 £10,452 £5,839
20-39 = n 6-19 = B 4 3.40 £10,452 £3,074
40-59 = m 20-39 = C 6 4.87 £10,452 £2,146
60-69 = IV 40-55 =D 8 6.20 £10,452 £1,686
70-79 = V
80-89 = VI 
90-99 = VII 
100-109=VHI
10 7.41 £10,452 £1,411
0-20 = I 1-9 = A 2 1.79 £10,452 £5,839
20-39 = n 10-19 = B 4 3.40 £10,452 £3,074
40-59 = HI 20-39 = C 6 4.87 £10,452 £2,146
60-69 = IV 40-55 =D 8 6.20 £10,452 £1,686
70-79 = V
80-89 = VI 
90-99 = vn 
100-109=Vni
10 7.41 £10,452 £1,411
0-20 = I 1-5 = A 2 1.79 £10,452 £5,839
20-39 = H 6-19 = B 4 3.40 £10,452 £3,074
40-54 = HI 20-39 = C 6 4.87 £10,452 £2,146
55-69 = IV 40-55 =D 8 6.20 £10,452 £1,686
70-79 = V
80-89 = VI 
90-99 - vn 
100-109=VIII
10 7.41 £10,452 £1,411
0-20 = I 1-9 = A 2 1.79 £10,452 £5,839
20-39 = n 10-19 = B 4 3.40 £10,452 £3,074
40-54 = m 20-39 = C 6 4.87 £10,452 £2,146
55-69 = IV 40-55 =D 8 6.20 £10,452 £1,686
70-79 = V
80-89 = VI 
90-99 = vn 
100-109=vm
10 7.41 £10,452 £1,411
0-20 = I 1-9 = A 2 1.79 £10,452 £5,839
20-39 = n 10-24 = B 4 3.40 £10,452 £3,074
40-54 = m 25-39 = C 6 4.87 £10,452 £2,146
55-69 = IV 40-55 =D 8 6.20 £10,452 £1,686
70-79 = V 
80-89 = VI 
90-99 = vn 
100-109=Vni
10 7.41 £10,452 £1,411
0-20 = I 1-5 = A 2 1.79 £10,452 £5,839
20-44 = n 6-19 = B 4 3.40 £10,452 £3,074
45-54 = HI 20-39 = C 6 4.87 £10,452 £2,146
55-64 = IV 40-55 =D 8 6.20 £10,452 £1,686
65-79 = V 
80-89 = VI 
90-99 = vn 
100-109=VIII
10 7.41 £10,452 £1,411
APPENDIX 23 85
0-20 = I 1-9 = A 2 1.79 £10,452 £5,839
20-44 = 11 10-19 = B 4 3.40 £10,452 £3,074
45-54 = HI 20-39 = C 6 4.87 £10,452 £2,146
55-64 = IV 40-55 =D 8 6.20 £10,452 £1,686
65-79 = V
80-89 = VI 
90-99 = VII 
100-109=VHI
10 7.41 £10,452 £1,411
0-20 = I 1-9 = A 2 1.79 £10,452 £5,839
20-44 = n 10-24 = B 4 3.40 £10,452 £3,074
45-54 = El 25-39 = C 6 4.87 £10,452 £2,146
55-64 = IV 40-55 =D 8 6.20 £10,452 £1,686
65-79 = V
80-89 = VI 
90-99 = VII 
100-109=VHI
10 7.41 £10,452 £1,411
0-20 = I 1-5 = A 2 1.79 £10,452 £5,839
20-44 = n 6-19 = B 4 • 3.40 £10,452 £3,074
45-59 = El 20-39 = C 6 4.87 £10,452 £2,146
60-74 = IV 40-55 =D 8 6.20 £10,452 £1,686
75-79 = V
80-89 = VI 
90-99 = VII 
100-109=VUI
10 7.41 £10,452 £1,411
0-20 = I 1-9 = A 2 1.79 £10,452 £5,839
20-54 = n 10-24 = B 4 3.40 £10,452 £3,074
55-59 = HI 25-34 = C 6 4.87 £10,452 £2,146
60-69 = IV 35-55 =D 8 6.20 £10,452 £1,686
70-79 = V
80-89 = VI 
90-99 = VII 
100-109=vm
10 7.41 £10,452 £1,411
0-20 = I 1-5 = A 2 1.79 £10,452 £5,839
20-49 = n 6-19 = B 4 3.40 £10,452 £3,074
50-54 = HI 20-39 = C 6 4.87 £10,452 £2,146
55-64 = IV 40-55 =D 8 6.20 £10,452 £1,686
65-74 = V
75-89 = VI 
90-99 = VII 
100-109=VHI
10 7.41 £10,452 £1,411
0-20 = I 1-9 = A 2 1.79 £10,452 £5,839
20-49 = H 10-19 = B 4 3.40 £10,452 £3,074
50-54 = m 20-39 = C 6 4.87 £10,452 £2,146
55-64 = IV 40-55 =D 8 6.20 £10,452 £1,686
65-74 = V 
75-89 = VI 
90-99 = VII 
100-109=VIII
10 7.41 £10,452 £1,411
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0-20 = I 1-9 = A 2 1.79 £10,452 £5,839
20-49 = H 10-24 = B 4 3.40 £10,452 £3,074
50-54 = HI 25-39 = C 6 4.87 £10,452 £2,146
55-64 = IV 40-55 =D 8 6.20 £10,452 £1,686
65-74 = V
75-89 = VI 
90-99 = VII 
100-109=Vni
10 7.41 £10,452 £1,411
0-20 = I 1-5 = A 2 1.79 £10,452 £5,839
20-49 = n 6-19 = B 4 3.40 £10,452 £3,074
50-64 = III 20-39 = C 6 4.87 £10,452 £2,146
65-69 = IV 40-55 =D 8 6.20 £10,452 £1,686
70-79 = V
80-89 = VI 
90-99 = vn 
100-109=Vni
10 7.41 £10,452 £1,411
0-20 = 1 1-9 = A 2 1.79 £10,452 £5,839
20-49 = n 10-24 = B 4 3.40- £10,452 £3,074
50-64 = ffl 25-34 = C 6 4.87 £10,452 £2,146
65-69 = IV 35-55 =D 8 6.20 £10,452 £1,686
70-79 = V
80-89 = VI 
90-99 = VII 
100-109=VHI
10 7.41 £10,452 £1,411
0-20 = I 1-5 = A 2 1.79 £10,452 £5,839
20-49 = n 6-19 = B 4 3.40 £10,452 £3,074
50-59 = m 20-39 = C 6 4.87 £10,452 £2,146
60-64 = IV 40-55 =D 8 6.20 £10,452 £1,686
65-79 = V 
80-89 = VI 
90-99 = vn 
100-109=vni
10 7.41 £10,452 £1,411
0-20 = 1 1-9 = A 2 1.79 £10,452 £5,839
20-49 = n 10-19 = B 4 3.40 £10,452 £3,074
50-59 = m 20-39 = C 6 4.87 £10,452 £2,146
60-64 = IV 40-55 =D 8 6.20 £10,452 £1,686
65-79 = V 
80-89 = VI 
90-99 = vn 
100-109=vni
10 7.41 £10,452 £1,411
0-20 = I 1-9 = A 2 1.79 £10,452 £5,839
20-49 = n 10-24 = B 4 3.40 £10,452 £3,074
50-59 = HI 25-34 = C 6 4.87 £10,452 £2,146
60-64 = IV 35-55 =D 8 6.20 £10,452 £1,686
65-79 = V 
80-89 = VI 
90-99 = vn 
100-109=vni
10 7.41 £10,452 £1,411
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0-20 = I 1-5 = A 2 1.79 £10,452 £5,839
20-49 = H 6-19 = B 4 3.40 £10,452 £3,074
50-59 = HI 20-39 = C 6 4.87 £10,452 £2,146
60-69 = IV 40-55 =D 8 6.20 £10,452 £1,686
70-74 = V
75-89 = VI 
90-99 = VH 
100-109=VHI
10 7.41 £10,452 £1,411
0-20 = I 1-9 = A 2 1.79 £10,452 £5,839
20-49 = H 10-19 = B 4 3.40 £10,452 £3,074
50-59 = HI 20-39 = C 6 4.87 £10,452 £2,146
60-69 = IV 40-55 =D 8 6.20 £10,452 £1,686
70-74 = V
75-89 = VI 
90-99 = VH 
100-109=VHI
10 7.41 £10,452 £1,411
0-20 = I 1-9 = A 2 1.79 £10,452 £5,839
20-49 = H 10-24 = B 4 ‘ 3.40 £10,452 £3,074
50-59 = HI 25-34 = C 6 4.87 £10,452 £2,146
60-69 = IV 35-55 =D 8 6.20 £10,452 £1,686
70-74 = V
75-89 = VI 
90-99 = VII 
100-109=VHI
10 7.41 £10,452 £1,411
0-20 = I 1-9 = A 2 1.80 £10,452 £5,807
20-39 = H 10-24 = B 4 3.44 £10,452 £3,038
40-59 = m 25-39 = C 6 4.92 £10,452 £2,124
60-69 = IV 40-55 =D 8 6.27 £10,452 £1,667
70-79 = V
80-89 = VI 
90-99 = VH 
100-109=VIII
10 7.49 £10,452 £1,395
0-20 = 1 1-9 = A 2 1.80 £10,452 £5,807
20-44 = H 10-19 = B 4 3.44 £10,452 £3,038
45-59 = HI 20-39 = C 6 4.92 £10,452 £2,124
60-74 = IV 40-55 =D 8 6.27 £10,452 £1,667
75-79 = V
80-89 = VI 
90-99 = VH 
100-109=VHI
10 7.49 £10,452 £1,395
0-20 = 1 1-9 = A 2 1.80 £10,452 £5,807
20-44 = H 10-24 = B 4 3.44 £10,452 £3,038
45-59 = HI 25-39 = C 6 4.92 £10,452 £2,124
60-74 = IV 40-55 =D 8 6.27 £10,452 £1,667
75-79 = V 
80-89 = VI 
90-99 = VII 
100-109=VHI
10 7.49 £10,452 £1,395
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0-20 = I 1-9 = A 2 1.80 £10,452 £5,807
20-44 = 11 10-24 = B 4 3.44 £10,452 £3,038
45-59 = m 25-34 = C 6 4.92 £10,452 £2,124
60-74 = IV 35-55 =D 8 6.27 £10,452 £1,667
75-79 = V
80-89 = VI 
90-99 = vn 
100-109=VIII
10 7.49 £10,452 £1,395
0-20 = I 1-5 = A 2 1.80 £10,452 £5,807
20-54 = n 6-19 = B 4 3.44 £10,452 £3,038
55-59 = DI 20-39 = C 6 4.92 £10,452 £2,124
60-69 = IV 40-55 =D 8 6.27 £10,452 £1,667
70-79 = V
80-89 = VI 
90-99 = vn 
100-109=vni
10 7.49 £10,452 £1,395
0-20 = 1 1-9 = A 2 1.80 £10,452 £5,807
20-54 = n 10-19 = B 4 3.44 £10,452 £3,038-
55-59 = HI 20-39 = C 6 4.92 £10,452 £2,124
60-69 = IV 40-55 =D 8 6.27 £10,452 £1,667
70-79 = V
80-89 = VI 
90-99 = VII 
100-109=Vni
10 7.49 £10,452 £1,395
0-20 = I 1-9 = A 2 1.80 £10,452 £5,807
20-54 = n 10-24 = B 4 3.44 £10,452 £3,038
55-59 = HI 25-39 = C 6 4.92 £10,452 £2,124
60-69 = IV 40-55 =D 8 6.27 £10,452 £1,667
70-79 = V
80-89 = VI 
90-99 = vn 
100-109=VUI
10 7.49 £10,452 £1,395
0-20 = I 1-5 = A 2 1.80 £10,452 £5,807
20-54 = n 6-19 = B 4 3.44 £10,452 £3,038
55-64 = m 20-39 = C 6 4.92 £10,452 £2,124
65-74 = IV 40-55 =D 8 6.27 £10,452 £1,667
75-79 = V 
80-89 = VI 
90-99 = vn 
100-109=VIII
10 7.49 £10,452 £1,395
0-20 = I 1-9 = A 2 1.80 £10,452 £5,807
20-54 = n 10-19 = B 4 3.44 £10,452 £3,038
55-64 = m 20-39 = C 6 4.92 £10,452 £2,124
65-74 = IV 40-55 =D 8 6.27 £10,452 £1,667
75-79 = V 
80-89 = VI 
90-99 = vn 
100-109=VIII
10 7.49 £10,452 £1,395
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0-20 = I 1-9 = A 2 1.80 £10,452 £5,807
20-54 = H 10-24 = B 4 3.44 £10,452 £3,038
55-64 = DI 25-34 = C 6 4.92 £10,452 £2,124
65-74 = IV 35-55 =D 8 6.27 £10,452 £1,667
75-79 = V
80-89 = VI 
90-99 = vn 
100-109=Vni
10 7.49 £10,452 £1,395
0-20 = I 1-9 = A 2 1.80 £10,452 £5,807
20-49 = n 10-19 = B 4 3.44 £10,452 £3,038
50-64 = in 20-39 = C 6 4.92 £10,452 £2,124
65-69 = IV 40-55 =D 8 6.27 £10,452 £1,667
70-79 = V
80-89 = VI 
90-99 = vn 
100-109=Vm
10 7.49 £10,452 £1,395
0-20 = I 1-9 = A 2 1.80 £10,452 £5,807
20-49 = n 10-24 = B 4 3.44 £10,452 • £3,038
50-64 = m 25-39 = C 6 4.92 £10,452 £2,124
65-69 = IV 40-55 =D 8 6.27 £10,452 £1,667
70-79 = V
80-89 = VI 
90-99 = vn 
ioo-i09=vni
10 7.49 £10,452 £1,395
0-20 = I 1-9 = A 2 1.80 £10,452 £5,807
20-49 = n 10-24 = B 4 3.44 £10,452 £3,038
50-59 = m 25-39 = C 6 4.92 £10,452 £2,124
60-64 = IV 40-55 =D 8 6.27 £10,452 £1,667
65-79 = V 
80-89 = VI 
90-99 = vn 
100-109=vni
10 7.49 £10,452 £1,395
0-20 = 1 1-9 = A 2 1.80 £10,452 £5,807
20-49 = n 10-24 = B 4 3.44 £10,452 £3,038
50-59 = m 25-39 = C 6 4.92 £10,452 £2,124
60-69 = IV 40-55 =D 8 6.27 £10,452 £1,667
70-74 = V 
75-89 = VI 
90-99 = vn 
100-109=Vni
10 7.49 £10,452 £1,395
0-20 = I 1-9 = A 2 1.82 £10,452 £5,743
20-54 = n 10-24 = B 4 3.48 £10,452 £3,003
55-64 = HI 25-39 = C 6 4.97 £10,452 £2,103
65-74 = IV 40-55 =D 8 6.33 £10,452 £1,651
75-79 = V 
80-89 = VI 
90-99 = vn 
100-109=Vni
10 7.57 £10,452 £1,381
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EVANS ET AL (1984). EVANS ET AL (1985)
SENSITIVITY ANALYSIS QE GUPEX'S USE OF RENAL TRANSPLANT DATA
Conversion
of Kamofsky
Index into
Rosser
Disability/
Distress
Categories
Survival
(Years)
QALYs
Gained per 
Patient 
(Discounted 
at 5%)
Total Costs 
(Discounted 
at 5%)
Cost per QALY
A = I-IIA 2 1.75 £10,452 £5,973
B=mB 4 3.33 £10,452 £3,139
C = IVC 6 4.77 £10,452 £2,191
D = V-VID 8 6.08 £10,452 £1,719
e = vn-vniD 10 7.26 £10,452 £1,440
A = I-IIA 2 1.79 £10,452 £5,839
B = HI-IVB 4 3.40 £10,452 £3,074 •
C = VC 6 4.87 £10,452 £2,146
D = VIC 8 6.20 £10,452 £1,686
E = VII-VIIID 10 7.41 £10,452 £1,411
A = IA 2 1.80 £10,452 £5,807
b = h-ihb 4 3.44 £10,452 £3,038
C = IV-VB 6 4.92 £10,452 £2,124
D = VIC 8 6.27 £10,452 £1,667
E = VII-VIIID 10 7.49 £10,452 £1,395
A = LA 2 1.80 £10,452 £5,807
b = h-ihb 4 3.44 £10,452 £3,038
c = IV-VC 6 4.92 £10,452 £2,124
D = VIC 8 6.27 £10,452 £1,667
E = VII-VIIID 10 7.49 £10,452 £1,395
A = I-HA 2 1.80 £10,452 £5,807
B = ni-IVA 4 3.44 £10,452 £3,038
C = VB 6 4.92 £10,452 £2,124
D = VIC 8 6.27 £10,452 £1,667
E = VH-VIIID 10 7.49 £10,452 £1,395
A = I-HA 2 1.80 £10,452 £5,807
B = IHA 4 3.44 £10,452 £3,038
C = IV-VB 6 4.92 £10,452 £2,124
D = VIC 8 6.27 £10,452 £1,667
E = VH-VIIID 10 7.49 £10,452 £1,395
A = I-HA 2 1.80 £10,452 £5,807
B = IIIB 4 3.44 £10,452 £3,038
C = IV-VC 6 4.92 £10,452 £2,124
D-VIC 8 6.27 £10,452 £1,667
E = VH-VHID 10 7.49 £10,452 £1,395
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A = IA 2 1.82 £10,452 £5,743
b = h-hia 4 3.48 £10,452 £3,003
C = IVB 6 4.97 £10,452 £2,103
D = V-VIC 8 6.33 £10,452 £1,651
e = vh-vhid 10 7.57 £10,452 £1,381
A = IA 2 1.82 £10,452 £5,743
b = 11-ihb 4 3.48 £10,452 £3,003
C = IVC 6 4.97 £10,452 £2,103
D = V-VIC 8 6.33 £10,452 £1,651
E = VII-VHID 10 7.57 £10,452 £1,381
A = I-IIA 2 1.82 £10,452 £5,743
B = HIB 4 3.48 £10,452 £3,003
C = IVB 6 4.97 £10,452 £2,103
D = V-VIC 8 6.33 £10,452 £1,651
E = VH-VHID 10 7.57 £10,452 £1,381
a = i-ha 2 1.82 £10,452 £5,743
b = iha 4 3.48 £10,452 £3,003
C = IVB 6 4.97 £10,452 • £2,103
D = VC 8 6.33 £10,452 £1,651
E = VI-VIHD 10 7.57 £10,452 £1,381
A = I-HA 2 1.82 £10,452 £5,743
b = ihb 4 3.48 £10,452 £3,003
C = IVC 6 4.97 £10,452 £2,103
D = VC 8 6.33 £10,452 £1,651
E = VI-VIHD 10 7.57 £10,452 £1,381
A = IA 2 1.84 £10,452 £5,680
B = H-IHA 4 3.51 £10,452 £2,978
C = IVB 6 5.02 £10,452 £2,082
D = VC 8 6.40 £10,452 £1,633
E = VI-VIHD 10 7.64 £10,452 £1,368
A = IA 2 1.84 £10,452 £5,680
B = H-HIB 4 3.51 £10,452 £2,978
c = rvc 6 5.02 £10,452 £2,082
D = VC 8 6.40 £10,452 £1,633
E = VI-VHID 10 7.64 £10,452 £1,368
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SENSITIVITY ANALYSIS OF GUDEX’S USE OF SHOULDER JOINT
REPLACEMENT SURGERY DATA
COFIELD (1984) - RHEUMATOID ARTHRITIS
Conversion 
of Full 
Exercise 
Programme 
Categories 
into Rosser 
Categories - 
Postoperative
Sensitivity 
Analysis of 
Preoperative 
Rosser 
Categories
Duration 
of Joint 
(Years)
QALY’s 
Gained per 
Patient- 
Discounted 
at 5%
Total Costs Cost per 
QALY
A = IA me 5 0.15 £533 £3,553
B = IB 8 0.22 £533 £2,423
C = 1HB 10 0.26 £533 £2,050
D = IHA
E = IVB
15 0.35 £533 £1,523
A = LA III-IVC 5 0.18 £533 £2,961
B = IB 8 0.26 £533 £2,050
C = IIIB 10 0.32 £533 £1,666
D = IILA
E = IVB
15 0.43 £533 £1,240
A = IA IVC 5 0.21 £533 £2,538
B = IB 8 0.31 £533 £1,719
C = HIB 10 0.37 £533 £1,441
D = IHA
E = IVB
15 0.50 £533 £1,066
A = IA mc-D 5 0.24 £533 £2,221
B = IB 8 0.36 £533 £1,481
C=IHB 10 0.43 £533 £1,240
D = HIA
E = IVB
15 0.58 £533 £919
A = IA III-IVC 5 0.25 £533 £2,132
B = IB 8 0.37 £533 £1,441
C = IHB 10 0.44 £533 £1,211
D = IIIA
E = IVB
15 0.60 £533 £888
A = IA IV-VC 5 0.30 £533 £1,777
B = IB 8 0.45 £533 £1,184
C = HIB 10 0.53 £533 £1,006
D = HIA
E = IVB
15 0.72 £533 £740
A = IA hi-ivc-d 5 0.30 £533 £1,777
B = IB 8 0.45 £533 £1,184
C = IHB 10 0.54 £533 £987
D = HIA
E = IVB
15 0.73 £533 £730
APPENDIX 25 93
A = IA
B = IB
C = IIIB
D = IIIA
E = IVB
mD 5
8
10
15
0.34
0.50
0.60
0.81
£533
£533
£533
£533
£1,568
£1,066
£888
£658
A = IA IVC-D 5 0.36 £533 £1,481
B = IB 8 0.54 £533 £987
C = IIIB 10 0.65 £533 £820
D = HIA
E = IVB
15 0.87 £533 £613
A = IA VC 5 0.39 £533 £1,367
B = IB 8 0.58 £533 £919
C = HIB 10 0.69 £533 £772
D = HIA
E = IVB
15 0.93 £533 £573
A = IA iii-ivd 5 0.43 £533 £1,240
B = IB 8 0.64 £533 £833
c = mB 10 0.76 £533 ’ £701
d = niA
E = IVB
15 1.03 £533 £517
A = IA hi-vc-d 5 0.48 £533 £1,110
B = IB 8 0.71 £533 £751
C = IIIB 10 0.85 £533 £627
D = IHA
E = IVB
15 1.14 £533 £468
A = IA IVD 5 0.52 £533 £1,025
B = IB 8 0.78 £533 £683
C = fflB 10 0.93 £533 £573
D = IIIA
E = IVB
15 1.25 £533 £426
A = IA IV-VC-D 5 0.59 £533 £903
B = IB 8 0.89 £533 £599
c = niB 10 1.06 £533 £503
D = IHA
E = IVB
15 1.42 £533 £375
A = IA III-VD 5 0.70 £533 £761
B = IB 8 1.05 £533 £508
C = IHB 10 1.26 £533 £423
d = iiia
E = IVB
15 1.69 £533 £315
A = IA VC-D 5 0.82 £533 £650
B = IB 8 1.23 £533 £433
C = HIB 10 1.47 £533 £363
d = iha
E = IVB
15 1.97 £533 £271
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A = IA IV-VD 5 0.89 £533 £599
B = IB 8 1.32 £533 £404
C = IHB 10 1.58 £533 £337
D = mA
E = IVB
15 2.13 £533 £250
A = IA VD 5 1.26 £533 £423
B = IB 8 1.87 £533 £285
C = IIIB 10 2.24 £533 £238
D = fflA
E = IVB
15 3.01 £533 £177
A = IA me 5 0.06 £533 £8,883
B = IIB 8 0.09 £533 £5,922
C = IVC 10 0.11 £533 £4,845
D = mc
E = VC
15 0.15 £533 £3,553
A = IA IVC 5“ 0.12 £533 £4,442
B = IIB 8 0.18 £533 £2,961
C = IVC 10 0.22 £533 £2,423
D=mc
E = VC
15 0.29 £533 £1,838
A = IA ni-vc 5 0.16 £533 £3,331
B = HB 8 0.24 £533 £2,221
C = IVC 10 0.29 £533 £1,838
D = mc
E = VC
15 0.39 £533 £1,367
A = IA m-ivc-D 5 0.22 £533 £2,423
B = HB 8 0.32 £533 £1,666
C = IVC 10 0.39 £533 £1,367
D = mc
E = VC
15 0.52 £533 £1,025
A = IA IVC-D 5 0.28 £533 £1,904
B = IIB 8 0.41 £533 £1,300
C = IVC 10 0.49 £533 £1,088
D = mc
E = VC
15 0.66 £533 £808
A = IA iii-ivd 5 0.34 £533 £1,568
B = IIB 8 0.51 £533 £1,045
C = IVC 10 0.61 £533 £874
D = mc
E = VC
15 0.82 £533 £650
A = IA IVD 5 0.43 £533 £1,240
B = IIB 8 0.65 £533 £820
c = rvc 10 0.77 £533 £692
D = mc 15 1.04 £533 £513
E = VC
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A = IA IV-VC-D 5 0.52 £533 £1,025
B = IIB 8 0.78 £533 £683
c = rvc 10 0.93 £533 £573
D = mc
E = VC
15 1.25 £533 £426
A = IA VC-D 5 0.74 £533 £720
B = HB 8 1.10 £533 £485
c = rvc 10 1.31 £533 £407
D = mc
E = VC
15 1.76 £533 £303
A = IA VD 5 1.17 £533 £456
B = IIB 8 1.75 £533 £305
C = IVC 10 2.08 £533 £256
D = mc
E = VC
15 2.80 £533 £190
A = IA me 5 0.06 £533 £8,883
b = n-niA 8 0.09 £533 £5,922
C = IHB-C 10 0.11 £533 • £4,845
D = IVB-C
E = VC
15 0.15 £533 £3,553
A = IA IVC 5 0.12 £533 £4,442
B = n-IIIA 8 0.18 £533 £2,961
c = mB-c 10 0.22 £533 £2,423
D = IVB-C
E = VC
15 0.29 £533 £1,838
A = IA ni-vc 5 0.16 £533 £3,331
B = H-IIIA 8 0.24 £533 £2,221
c = ihb-c 10 0.29 £533 £1,838
D = IVB-C
E = VC
15 0.39 £533 £1,367
A = IA m-ivc-D 5 0.22 £533 £2,423
B = II-fflA 8 0.32 £533 £1,666
c = niB-c 10 0.39 £533 £1,367
D = IVB-C
E = VC
15 0.52 £533 £1,025
A = IA IVC-D 5 0.28 £533 £1,904
B = n-mA 8 0.41 £533 £1,300
c = iiib-c 10 0.49 £533 £1,088
D = IVB-C
E = VC
15 0.66 £533 £808
A = IA ni-ivD 5 0.34 £533 £1,568
b = n-niA 8 0.51 £533 £1,045
c = hib-c 10 0.61 £533 £874
D = IVB-C
E = VC
15 0.82 £533 £650
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A = IA IVD 5 0.43 £533 £1,240
B = II~niA 8 0.65 £533 £820
c = mB-c 10 0.77 £533 £692
D = IVB-C
E = VC
15 1.04 £533 £513
A = IA IV-VC-D 5 0.52 £533 £1,025
b = n-niA 8 0.78 £533 £683
c = mB-c 10 0.93 £533 £573
D = IVB-C
E = VC
15 1.25 £533 £426
A = IA VC-D 5 0.74 £533 £720
b = n-mA 8 1.10 £533 £485
c = ihb-c 10 1.31 £533 £407
D = IVB-C 
E=VC
15 1.76 £533 £303
A = IA VD 5 1.17 £533 £456
B = II-IIIA 8 1.75 £533 £305
C = IIIB-C 10 2.08 £533 £256
D = IVB-C
E = VC
15 2.80 £533 £190
A = IA ni-ivc 5 0.05 £533 £10,660
B = UB 8 0.07 £533 £7,614
C = IHB 10 0.08 £533 £6,663
D = IVB
E = VD
15 0.11 £533 £4,845
A = IA mc-D 5 0.11 £533 £4,845
B = IIB 8 0.17 £533 £3,135
C = IIIB 10 0.20 £533 £2,665
D = IVB
E = VD
15 0.27 £533 £1,974
A = IA IV-VC 5 0.17 £533 £3,135
B = HB 8 0.25 £533 £2,132
C = HIB 10 0.30 £533 £1,777
D = IVB
E = VD
15 0.40 £533 £1,333
A = IA HID 5 0.21 £533 £2,538
B = HB 8 0.31 £533 £1,719
C=IIIB 10 0.37 £533 £1,441
D = IVB
E = VD
15 0.50 £533 £1,066
A = IA VC 5 0.26 £533 £2,050
B = IIB 8 0.39 £533 £1,367
C = IHB 10 0.46 £533 £1,159
D - IVB
E = VD
15 0.62 £533 £860
, ■!- ■ L i-c:
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A = IA
B = HB 
c = hib
D = IVB
E = VD
HI-VC-D 5
8
10
15
0.35
0.52
0.62
0.83
£533
£533
£533
£533
£1,523
£1,025
£860
£642
A = IA IV-VC-D 5 0.46 £533 £1,159
B = HB 8 0.69 £533 £772
C = IIIB 10 0.83 £533 £642
D = IVB
E = VD
15 1.11 £533 £480
A = IA III-VD 5 0.57 £533 £935
B = HB 8 0.86 £533 £620
c = mB 10 1.02 £533 £523
D = IVB
E = VD
15 1.38 £533 £386
A = IA IV-VD 5 0.76 £533 £701
B = IIB 8 1.13 £533 £472
c = mB 10 1.35 £533' £395
D = IVB
E = VD
15 1.82 £533 £293
A = IA VD 5 1.13 £533 £472
B = HB 8 1.68 £533 £317
C = HIB 10 2.01 £533 £265
D = IVB
E = VD
15 2.70 £533 £197
A = IA HI-IVC 5 0.004 £533 £133,250
B = IIB 8 0.006 £533 £88,833
C=IHD 10 0.008 £533 £66,625
D = IVB
E = VD
15 0.010 £533 £53,300
A = IA mc-D 5 0.07 £533 £7,614
B = IIB 8 0.10 £533 £5,330
C = IHD 10 0.12 £533 £4,442
D = IVB
E = VD
15 0.17 £533 £3,135
A = IA IV-VC 5 0.13 £533 £4,100
B = HB 8 0.19 £533 £2,805
c = mD 10 0.22 £533 £2,423
D = IVB
E = VD
15 0.30 £533 £1,777
A = IA HID 5 0.16 £533 £3,331
B = HB 8 0.25 £533 £2,132
c = hid 10 0.29 £533 £1,838
D = IVB
E = VD
15 0.39 £533 £1,367
APPENDIX 25 98
A = IA
B = HB 
c = mD
D = IVB
E = VD
VC 5
8
10
15
0.22
0.32
0.39
0.52
£533
£533
£533
£533
£2,423
£1,666
£1,367
£1,025
A = IA ffl-VC-D 5 0.30 £533 £1,777
B = IIB 8 0.45 £533 £1,184
C = HID 10 0.54 £533 £987
D = IVB
E = VD
15 0.73 £533 £730
A = IA IV-VC-D 5 0.42 £533 £1,269
B = HB 8 0.63 £533 £846
C=IHD 10 0.75 £533 £711
D = IVB
E = VD
15 1.01 £533 £528
A = IA III-VD 5 0.53 £533 £1,006
B = IIB 8 0.79 £533 £675
c = mD 10 0.95 £533 £561
D = IVB
E = VD
15 1.27 £533 £420
A = IA IV-VD 5 0.71 £533 £751
B = IIB 8 1.07 £533 £498
c = hid 10 1.27 £533 £420
D = IVB
E = VD
15 1.71 £533 £312
A = IA VD 5 1.08 £533 £494
B = IIB 8 1.62 £533 £329
c = hid 10 1.93 £533 £276
D = IVB
E = VD
15 2.59 £533 £206
A = IA III-IVC 5 0.004 £533 £133,250
B = fflB 8 0.006 £533 £88,833
C = IVC 10 0.008 £533 £66,625
D = VB-C
E = VD
15 0.010 £533 £53,300
A = IA mc-D 5 0.07 £533 £7,614
B = fflB 8 0.10 £533 £5,330
C = IVC 10 0.12 £533 £4,442
D = VB-C
E = VD
15 0.17 £533 £3,135
A = IA IV-VC 5 0.13 £533 £4,100
B = fflB 8 0.19 £533 £2,805
C=IVC 10 0.22 £533 £2,423
D = VB-C
E = VD
15 0.30 £533 £1,777
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A = IA HID 5 0.16 £533 £3,331
B = IIIB 8 0.25 £533 £2,132
C = IVC 10 0.29 £533 £1,838
D = VB-C
E = VD
15 0.39 £533 £1,367
A = IA VC 5 0.22 £533 £2,423
B = IIIB 8 0.32 £533 £1,666
C = IVC 10 0.39 £533 £1,367
D = VB-C
E = VD
15 0.52 £533 £1,025
A = IA ni-vc-D 5 0.30 £533 £1,777
B = IIIB 8 0.45 £533 £1,184
C = IVC 10 0.54 £533 £987
D = VB-C
E = VD
15 0.73 £533 £730
A = IA IV-VC-D 5 0.42 £533 £1,269
B = IIIB 8 0.63 £533 £846
c = rvc io- 0.75 £533 £711
D = VB-C
E = VD
15 1.01 £533 £528
A = IA III-VD 5 0.53 £533 £1,006
B = HIB 8 0.79 £533 £675
C = IVC 10 0.95 £533 £561
D = VB-C
E = VD
15 1.27 £533 £420
A = IA IV-VD 5 0.71 £533 £751
B = IIIB 8 1.07 £533 £498
C = IVC 10 1.27 £533 £420
D = VB-C
E = VD
15 1.71 £533 £312
A = IA VD 5 1.08 £533 £494
b = niB 8 1.62 £533 £329
c = rvc 10 1.93 £533 £276
D = VB-C
E = VD
15 2.59 £533 £206
A = IB ni-ivc 5 0.004 £533 £133,250
B = IHB 8 0.006 £533 £88,833
C = IVC 10 0.008 £533 £66,625
D = IV-VB-C
E = VC-D
15 0.010 £533 £53,300
A = IB mc-D 5 0.07 £533 £7,614
B = IIIB 8 0.10 £533 £5,330
C = IVC 10 0.12 £533 £4,442
D = IV-VB-C
E = VC-D
15 0.17 £533 £3,135
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A-IB
B = IIIB 
C-IVC
D = IV-VB-C
E = VC-D
IV-VC 5
8
10
15
0.13
0.19
0.22
0.30
£533
£533
£533
£533
£4,100
£2,805
£2,423
£1,777
A-IB ihd 5 0.16 £533 £3,331
b = iiib 8 0.25 £533 £2,132
C-IVC 10 0.29 £533 £1,838
D = IV-VB-C
E = VC-D
15 0.39 £533 £1,367
A-IB VC 5 0.22 £533 £2,423
B - IIIB 8 0.32 £533 £1,666
C-IVC 10 0.39 £533 £1,367
D = IV-VB-C
E = VC-D
15 0.52 £533 £1,025
A-IB ni-vc-D 5 0.30 £533 £1,777
B -IIIB 8 0.45 £533 £1,184
C-IVC 10 • 0.54 £533 £987
D = IV-VB-C
E = VC-D
15 0.73 £533 £730
A-IB IV-VC-D 5 0.42 £533 £1,269
B - IIIB 8 0.63 £533 £846
C-IVC 10 0.75 £533 £711
D = IV-VB-C
E = VC-D
15 1.01 £533 £528
A-IB III-VD 5 0.53 £533 £1,006
B - HIB 8 0.79 £533 £675
C-IVC 10 0.95 £533 £561
D = IV-VB-C
E = VC-D
15 1.27 £533 £420
A-IB IV-VD 5 0.71 £533 £751
b = hib 8 1.07 £533 £498
C-IVC 10 1.27 £533 £420
D = IV-VB-C
E = VC-D
15 1.71 £533 £312
A-IB VD 5 1.08 £533 £494
B-HIB 8 1.62 £533 £329
c = rvc 10 1.93 £533 £276
D - IV-VB-C
E = VC-D
15 2.59 £533 £206
A-IA mc-D 5 0.03 £533 £17,767
B-HC 8 0.04 £533 £13,325
c = in-vc-d 10 0.05 £533 £10,660
D - IVB
E = VD
15 0.06 £533 £8,883
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A = LA IV-VC 5 0.08 £533 £6,663
b = hc 8 0.12 £533 £4,442
c = in-vc-d 10 0.15 £533 £3,553
D = IVB
E = VD
15 0.20 £533 £2,665
A = IA mD 5 0.12 £533 £4,442
B = HC 8 0.18 £533 £2,961
c = m-vc-D 10 0.22 £533 £2,423
D = IVB
E = VD
15 0.29 £533 £1,838
A = IA VC 5 0.17 £533 £3,135
B = nc 8 0.26 £533 £2,050
c = m-vc-D 10 0.31 £533 £1,719
D = IVB
E = VD
15 0.42 £533 £1,269
A = IA m-vc-D 5 0.26 £533 £2,050
B = nc 8 0.39 £533 £1,367
c = m-vc-D •10 0.46 £533 £1,159
D = IVB
E = VD
15 0.62 £533 £860
A = LA IV-VC-D 5 0.38 £533 £1,403
B = nc 8 0.56 £533 £952
c = m-vc-D 10 0.67 £533 £796
D = rVB
E = VD
15 0.90 £533 £592
A = IA III-VD 5 0.49 £533 £1,088
B = nc 8 0.73 £533 £730
c = m-vc-D 10 0.87 £533 £613
D = IVB
E = VD
15 1.17 £533 £456
A = IA IV-VD 5 0.67 £533 £796
B = nc 8 1.00 £533 £533
c = m-vc-D 10 1.20 £533 £444
D = IVB
E = VD
15 1.61 £533 £331
A = IA VD 5 1.04 £533 £513
B = nc 8 1.55 £533 £344
c = m-vc-D 10 1.85 £533 £288
D = IVB
E = VD
15 2.49 £533 £214
A = IA mc-D 5 0.03 £533 £17,767
B = n-IHA-B 8 0.04 £533 £13,325
C = IV-VC-D 10 0.05 £533 £10,660
D = IVB-C
E = VC-D
15 0.06 £533 £8,883
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A = IA IV-VC 5 0.08 £533 £6,663
B = H-IIIA-B 8 0.12 £533 £4,442
C = IV-VC-D 10 0.15 £533 £3,553
D = IVB-C
E = VC-D
15 0.20 £533 £2,665
A = LA HID 5 0.12 £533 £4,442
B = n-mA-B 8 0.18 £533 £2,961
C = IV-VC-D 10 0.22 £533 £2,423
D = IVB-C
E = VC-D
15 0.29 £533 £1,838
A = IA VC 5 0.17 £533 £3,135
b = n-mA-B 8 0.26 £533 £2,050
C = IV-VC-D 10 0.31 £533 £1,719
D = IVB-C
E = VC-D
15 0.42 £533 £1,269
A = IA hi-vc-d 5 0.26 £533 £2,050
B = II-HIA-B 8 0.39 £533 £1,367
C = IV-VC-D 10 • 0.46 £533 £1,159
D = IVB-C
E = VC-D
15 0.62 £533 £860
A = IA IV-VC-D 5 0.38 £533 £1,403
b = n-mA-B 8 0.56 £533 £952
C = IV-VC-D 10 0.67 £533 £796
D = IVB-C
E = VC-D
15 0.90 £533 £592
A = IA III-VD 5 0.49 £533 £1,088
b = n-inA-B 8 0.73 £533 £730
C = IV-VC-D 10 0.87 £533 £613
D = IVB-C
E = VC-D
15 1.17 £533 £456
A = IA IV-VD 5 0.67 £533 £796
B = II-IIIA-B 8 1.00 £533 £533
C = IV-VC-D 10 1.20 £533 £444
D = IVB-C
E = VC-D
15 1.61 £533 £331
A = IA VD 5 1.04 £533 £513
B = H-IHA-B 8 1.55 £533 £344
C = IV-VC-D 10 1.85 £533 £288
D = IVB-C
E = VC-D
15 2.49 £533 £214
A = IA ni-ivc-D 5 0.04 £533 £13,325
B = HB 8 0.06 £533 £8,883
C = IV-VC-D 10 0.08 £533 £6,663
D = IVB
E = VD
15 0.10 £533 £5,330
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A = IA
B = HB
C = IV-VC-D
D = IVB
E = VD
IVC-D 5
8
10
15
0.10
0.16
0.19
0.25
£533
£533
£533
£533
£5,330
£3,331
£2,805
£2,132
A = IA III-IVD 5 0.17 £533 £3,135
B = HB 8 0.25 £533 £2,132
C = IV-VC-D 10 0.30 £533 £1,777
D = IVB
E = VD
15 0.40 £533 £1,333
A = LA IVD 5 0.26 £533 £2,050
B = HB 8 0.39 £533 £1,367
C = IV-VC-D 10 0.46 £533 £1,159
D = IVB
E = VD
15 0.62 £533 £860
A = IA IV-VC-D 5 0.35 £533 £1,523
B = HB 8 0.52 £533 £1,025
C = IV-VC-D ‘ 10 0.62 £533 £860
D = IVB
E = VD
15 0.83 £533 £642
A = IA VC-D 5 0.56 £533 £952
B = HB 8 0.84 £533 £635
C = IV-VC-D 10 1.00 £533 £533
D = IVB
E = VD
15 1.35 £533 £395
A = IA VD 5 1.00 £533 £533
B = HB 8 1.49 £533 £358
C = IV-VC-D 10 1.78 £533 £299
D = IVB
E = VD
15 2.39 £533 £223
A = IA m-ivc-D 5 0.04 £533 £13,325
B = IHA 8 0.06 £533 £8,883
C = IV-VC-D 10 0.08 £533 £6,663
D = IVB
E = VD
15 0.10 £533 £5,330
A = IA IVC-D 5 0.10 £533 £5,330
b = hia 8 0.16 £533 £3,331
C = IV-VC-D 10 0.19 £533 £2,805
D = IVB
E = VD
15 0.25 £533 £2,132
A = IA III-IVD 5 0.17 £533 £3,135
B = IIIA 8 0.25 £533 £2,132
C = IV-VC-D 10 0.30 £533 £1,777
D = IVB
E = VD
15 0.40 £533 £1,333
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A = IA
B=HIA
C = IV-VC-D
D = IVB
E = VD
IVD 5
8
10
15
0.26
0.39
0.46
0.62
£533
£533
£533
£533
£2,050
£1,367
£1,159
£860
A = IA IV-VC-D 5 0.35 £533 £1,523
B = IHA 8 0.52 ‘ £533 £1,025
C = IV-VC-D 10 0.62 £533 £860
D = IVB
E = VD
15 0.83 £533 £642
A = IA VC-D 5 0.56 £533 £952
B = IUA 8 0.84 £533 £635
C = IV-VC-D 10 1.00 £533 £533
D = IVB
E = VD
15 1.35 £533 £395
A = IA VD 5 1.00 £533 £533
b = niA 8 1.49 £533 £358
C = IV-VC-D 10 1.78 £533 £299
D = IVB
E = VD
15 2.39 £533 £223
A = IB m-ivc-D 5 0.04 £533 £13,325
B = II-mB 8 0.06 £533 £8,883
C = IV-VC-D 10 0.08 £533 £6,663
D = IVB
E = VD
15 0.10 £533 £5,330
A = IB IVC-D 5 0.10 £533 £5,330
B = n-mB 8 0.16 £533 £3,331
C = IV-VC-D 10 0.19 £533 £2,805
D = IVB
E = VD
15 0.25 £533 £2,132
A = IB m-ivD 5 0.17 £533 £3,135
b = n-mB 8 0.25 £533 £2,132
c = IV-VC-D 10 0.30 £533 £1,777
D = IVB
E = VD
15 0.40 £533 £1,333
A = IB IVD 5 0.26 £533 £2,050
b = n-mB 8 0.39 £533 £1,367
C = IV-VC-D 10 0.46 £533 £1,159
D = IVB
E = VD
15 0.62 £533 £860
A = IB IV-VC-D 5 0.35 £533 £1,523
b = n-mB 8 0.52 £533 £1,025
C = IV-VC-D 10 0.62 £533 £860
D = IVB
E = VD
15 0.83 £533 £642
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A = IB VC-D 5 0.56 £533 £952
B = n-IIIB 8 0.84 £533 £635
C = IV-VC-D 10 1.00 £533 £533
D = IVB
E = VD
15 1.35 £533 £395
A = IB VD 5 1.00 £533 £533
b = n-niB 8 1.49 £533 £358
C = IV-VC-D 10 1.78 £533 £299
D = IVB
E = VD
15 2.39 £533 £223
A = IA ffl-IVC-D 5 0.04 £533 £13,325
B = fflB-C 8 0.06 £533 £8,883
C = IV-VC-D 10 0.08 £533 £6,663
D = IVB-C
E = VC-D
15 0.10 £533 £5,330
A = IA IVC-D 5 0.10 £533 £5,330
B = HIB-C 8 0.16 £533 £3,331
C = IV-VC-D 10 0.19 £533 £2,805
D = IVB-C
E = VC-D
15 0.25 £533 £2,132
A = LA ni-ivD 5 0.17 £533 £3,135
B = IHB-C 8 0.25 £533 £2,132
C = IV-VC-D 10 0.30 £533 £1,777
D = IVB-C
E = VC-D
15 0.40 £533 £1,333
A = LA IVD 5 0.26 £533 £2,050
B = fflB-C 8 0.39 £533 £1,367
C = IV-VC-D 10 0.46 £533 £1,159
D = IVB-C
E = VC-D
15 0.62 £533 £860
A = IA IV-VC-D 5 0.35 £533 £1,523
B = HIB-C 8 0.52 £533 £1,025
C = IV-VC-D 10 0.62 £533 £860
D = IVB-C
E = VC-D
15 0.83 £533 £642
A = IA VC-D 5 0.56 £533 £952
B = niB-C 8 0.84 £533 £635
C = IV-VC-D 10 1.00 £533 £533
D = IVB-C
E = VC-D
15 1.35 £533 £395
A = IA VD 5 1.00 £533 £533
B = mB-C 8 1.49 £533 £358
C = IV-VC-D 10 1.78 £533 £299
D = IVB-C
E = VC-D
15 2.39 £533 £223
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A = IB bi-ivc-d 5 0.04 £533 £13,325
B = HB-C 8 0.06 £533 £8,883
C = IIIB-C 10 0.08 £533 £6,663
D = IV-VC
E = VIC-D
15 0.10 £533 £5,330
A = IB IVC-D 5 0.10 £533 £5,330
B = HB-C 8 0.16 £533 £3,331
c = mB-c 10 0.19 £533 £2,805
D = IV-VC
E = VIC-D
15 0.25 £533 £2,132
A = IB bi-ivd 5 0.17 £533 £3,135
B = BB-C 8 0.25 £533 £2,132
c = ihb-c 10 0.30 £533 £1,777
D = IV-VC
E = VIC-D
15 0.40 £533 £1,333
A = IB IVD 5 0.26 £533 £2,050
B = BB-C 8 0.39 £533 £1,367
C = IBB-C 10- 0.46 £533 £1,159
D = IV-VC
E = VIC-D
15 0.62 £533 £860
A = IB IV-VC-D 5 0.35 £533 £1,523
B = BB-C 8 0.52 £533 £1,025
c = ibb-c 10 0.62 £533 £860
D = IV-VC
E = VIC-D
15 0.83 £533 £642
A = IB VC-D 5 0.56 £533 £952
B = BB-C 8 0.84 £533 £635
C = IBB-C 10 1.00 £533 £533
D = IV-VC
E = VIC-D
15 1.35 £533 £395
A = IB VD 5 1.00 £533 £533
B = HB-C 8 1.49 £533 £358
C = IIIB-C 10 1.78 £533 £299
D = IV-VC
E = VIC-D
15 2.39 £533 £223
A = IA IVC-D 5 0.06 £533 £8,883
B = mc 8 0.09 £533 £5,922
C = IV-VC-D 10 0.11 £533 £4,845
D = IVB
E = VD
15 0.15 £533 £3,553
A = IA bi-ivd 5 0.13 £533 £4,100
B = BIC 8 0.19 £533 £2,805
C = IV-VC-D 10 0.22 £533 £2,423
D = IVB
E = VD
15 0.30 £533 £1,777
APPENDIX 25 107
A = IA IVD 5 0.22 £533 £2,423
B = inc 8 0.32 £533 £1,666
C = IV-VC-D 10 0.39 £533 £1,367
D = IVB
E = VD
15 0.52 £533 £1,025
A = IA IV-VC-D 5 0.30 £533 £1,777
B = IHC 8 0.45 £533 £1,184
C = IV-VC-D 10 0.54 £533 £987
D = IVB
E = VD
15 0.73 £533 £730
A = IA VC-D 5 0.52 £533 £1,025
B = mc 8 0.78 £533 £683
C = IV-VC-D 10 0.93 £533 £573
D = IVB
E = VD
15 1.25 £533 £426
A = IA VD 5 0.95 £533 £561
B = mc 8 1.42 £533 £375
C = IV-VC-D 10 1.70 £533 £314
D = IVB
E = VD
15 2.28 £533 £234
A = IA IVC-D 5 0.06 £533 £8,883
B = IIC 8 0.09 £533 £5,922
C = IVB-C 10 0.11 £533 £4,845
D = VB-C
E = VIC-D
15 0.15 £533 £3,553
A = IA HI-IVD 5 0.13 £533 £4,100
B = nc 8 0.19 £533 £2,805
C = IVB-C 10 0.22 £533 £2,423
D = VB-C
E = VIC-D
15 0.30 £533 £1,777
A = IA IVD 5 0.22 £533 £2,423
b = hc 8 0.32 £533 £1,666
C = IVB-C 10 0.39 £533 £1,367
D = VB-C
E = VIC-D
15 0.52 £533 £1,025
A = IA IV-VC-D 5 0.30 £533 £1,777
B = IIC 8 0.45 £533 £1,184
C = IVB-C 10 0.54 £533 £987
D = VB-C
E = VIC-D
15 0.73 £533 £730
A = IA VC-D 5 0.52 £533 £1,025
B = nc 8 0.78 £533 £683
C = IVB-C 10 0.93 £533 £573
D = VB-C
E = VIC-D
15 1.25 £533 £426
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A = LA VD 5 0.95 £533 £561
B = HC 8 1.42 £533 £375
C = IVB-C 10 1.70 £533 £314
D = VB-C
E = VIC-D
15 2.28 £533 £234
A = IB m-vc-D 5 0.04 £533 £13,325
b = mB-c 8 0.06 £533 £8,883
c = VC-D 10 0.08 £533 £6,663
D = V-VIB-C
E = V-VIC-D
15 0.10 £533 £5,330
A = IB IV-VC-D 5 0.16 £533 £3,331
B = HIB-C 8 0.24 £533 £2,221
C = VC-D 10 0.29 £533 £1,838
D = V-VIB-C
E = V-VIC-D
15 0.38 £533 £1,403
A = IB III-VD 5 0.27 £533 £1,974
B = HIB-C 8 0.41 £533 £1,300
C = VC-D •io 0.48 £533 £1,110
D = V-VIB-C
E = V-VIC-D
15 0.65 £533 £820
A = IB IV-VD 5 0.45 £533 £1,184
B = HIB-C 8 0.68 £533 £784
C = VC-D 10 0.81 £533 £658
D = V-VIB-C
E = V-VIC-D
15 1.09 £533 £489
A = IB VD 5 0.82 £533 £650
B = HIB-C 8 1.23 £533 £433
C = VC-D 10 1.47 £533 £363
D = V-VIB-C
E = V-VIC-D
15 1.97 £533 £271
A = IA HI-VC-D 5 0.04 £533 £13,325
b = n-mB 8 0.06 £533 £8,883
C = IVC 10 0.08 £533 £6,663
D = V-VIB-C 
E=IVD
15 0.10 £533 £5,330
A = IA IV-VC-D 5 0.16 ’ £533 £3,331
b = n-mB 8 0.24 £533 £2,221
C = IVC 10 0.29 £533 £1,838
D = V-VIB-C
E = rVD
15 0.38 £533 £1,403
A = IA III-VD 5 0.27 £533 £1,974
b = n-mB 8 0.41 £533 £1,300
c = rvc 10 0.48 £533 £1,110
D = V-VIB-C
E = IVD
15 0.65 £533 £820
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A = IA IV-VD 5 0.45 £533 £1,184
b = n-mB 8 0.68 £533 £784
C-IVC 10 0.81 £533 £658
D = V-VIB-C 
E-IVD
15 1.09 £533 £489
A-IA VD 5 0.82 £533 £650
b = n-mB 8 1.23 £533 £433
C-IVC 10 1.47 £533 £363
D = V-VIB-C 
E-IVD
15 1.97 £533 £271
A-IB III-VC-D 5 0.04 £533 £13,325
b = hb 8 0.06 £533 £8,883
C = VD 10 0.08 £533 £6,663
D = IVB
E = V-VIC-D
15 0.10 £533 £5,330
A-IB IV-VC-D 5 0.16 £533 £3,331
B = IIB 8 0.24 £533 £2,221
C = VD 10 0.29 £533 £1,838
D = IVB
E = V-VIC-D
15 0.38 £533 £1,403
A-IB III-VD 5 0.27 £533 £1,974
B-HB 8 0.41 £533 £1,300
C = VD 10 0.48 £533 £1,110
D = IVB
E = V-VIC-D
15 0.65 £533 £820
A = IB IV-VD 5 0.45 £533 £1,184
B-HB 8 0.68 £533 £784
C = VD 10 0.81 £533 £658
D - IVB
E = V-VIC-D
15 1.09 £533 £489
A-IB VD 5 0.82 £533 £650
B-HB 8 1.23 £533 £433
C = VD 10 1.47 £533 £363
D-IVB
E = V-VIC-D
15 1.97 £533 £271
A-IB VC-D 5 0.04 £533 £13,325
b-hic 8 0.06 £533 £8,883
C- VD 10 0.08 £533 £6,663
D-VIC
E = VID
15 0.10 £533 £5,330
A-IB VD 5 0.48 £533 £1,110
B = fflC 8 0.71 £533 £751
C-VD 10 0.85 £533 £627
D-VIC
E-VID
15 1.14 £533 £468
APPENDIX 25 110
COHELD (1984) - OSTEOARTHRITIS
Conversion 
of Full
Exercise 
Programme 
Categories 
into Rosser 
Categories - 
Postoperative
Sensitivity 
Analysis of 
Preoperative 
Rosser 
Categories
Duration 
of Joint 
(Years)
QALY’s 
Gained per 
Patient- 
Discounted 
at 5%
Total Costs Cost per 
QALY
A = LA me 5 0.15 £533 £3,553
B = IB 8 0.22 £533 £2,423
C = IIIB 
d = iha
E = IVB
10 0.26 £533 £2,050
A = IA mc-D 5 0.24 £533 £2,221
B = IB • 8 0.36 £533 £1,481
c = mB 
d = iha
E = IVB
10 0.43 £533 £1,240
A = IA m-ivc-D 5 0.30 £533 £1,777
B = IB 8 0.45 £533 £1,184
C = IIIB 
d = mA
E = IVB
10 0.54 £533 £987
A = IA VC 5 0.39 £533 £1,367
B = IB 8 0.58 £533 £919
C = IHB 
d = hia
E = IVB
10 0.69 £533 £772
A = LA IVD 5 0.52 £533 £1,025
B = IB 8 0.78 £533 £683
C = IHB 
d = iha
E = IVB
10 0.93 £533 £573
A = IA IV-VC-D 5 0.61 £533 £874
B = IB 8 0.90 £533 £592
C = IIIB
D = mA
E = IVB
10 1.08 £533 £494
A = LA VC-D 5 0.82 £533 £650
B = IB 8 1.23 £533 £433
c = ms
D = mA
E = IVB
10 1.47 £533 £363
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A = IA VD 5 1.26 £533 £423
B = IB 8 1.87 £533 £285
C-HIB 
d = niA
E - IVB
10 2.24 £533 £238
A = IA me 5 0.15 £533 £3,553
B = H-IHA 8 0.22 £533 £2,423
C = IIIB-C
D - IVB-C 
E-VC
10 0.26 £533 £2,050
A = IA mc-D 5 0.24 £533 £2,221
B = H-IHA 8 0.36 £533 £1,481
c = mB-c
D = IVB-C 
E-VC
10 0.43 £533 £1,240
A-LA IH-IVC-D 5 0.30 £533 £1,777
b-h-hia 8 0.45 £533 £1,184
c-ihb-c
D = IVB-C 
E-VC
10 0.54 £533 £987
A-IA VC 5 0.39 £533 £1,367
B = H-HIA 8 0.58 £533 £919
C-IHB-C
D = IVB-C
E = VC
10 0.69 £533 £772
A-IA IVD 5 0.52 £533 £1,025
B = H-HIA 8 0.78 £533 £683
C-HIB-C
D = IVB-C
E-VC
10 0.93 £533 £573
A-IA IV-VC-D 5 0.61 £533 £874
B = H-IHA 8 0.90 £533 £592
C = HIB-C
D = IVB-C
E = VC
10 1.08 £533 £494
A-IA VC-D 5 0.82 £533 £650
B-H-HIA 8 1.23 £533 £433
C-IHB-C
D = IVB-C 
E-VC
10 1.47 £533 £363
A-IA VD 5 1.26 £533 £423
B = H-IHA 8 1.87 £533 £285
C = HIB-C
D = IVB-C 
E-VC
10 2.24 £533 £238
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A = IA ni-ivc 5 0.13 £533 £4,100
B = IIB 8 0.20 £533 £2,665
c = mB
D = IVB
E = VD
10 0.24 £533 £2,221
A = IA III-VC 5 0.20 £533 £2,665
B = HB 8 0.31 £533 £1,719
C-IHB
D = IVB
E = VD
10 0.37 £533 . £1,441
A = IA in? 5 0.29 £533 £1,838
B-HB 8 0.44 £533 £1,211
C = IIIB
D = IVB
E = VD
10 0.53 £533 £1,006
A = IA III-IVD 5 0.39 £533 £1,367
B = nB 8 0.58 £533 £919
c = hib
D = IVB
E = VD
• 10 0.69 £533 £772
A = IA IV-VC-D 5 0.55 £533 £969
B = IIB 8 0.82 £533 £650
c = niB
D = IVB
E = VD
10 0.98 £533 £544
A = IA VC-D 5 0.78 £533 £683
B = IIB 8 1.16 £533 £459
c = niB
D = IVB
E = VD
10 1.39 £533 £383
A = IA VD 5 1.21 £533 £440
B = HB 8 1.81 £533 £294
c = mB
D = IVB
E = VD
10 2.16 £533 £247
A = IA ni-ivc 5 0.13 £533 £4,100
B = HB 8 0.20 £533 £2,665
c = rvc
D = mc
E = VC
10 0.24 £533 £2,221
A = IA ni-vc 5 0.20 £533 £2,665
B = IIB 8 0.31 £533 £1,719
c = rvc
D = mc
E = VC
10 0.37 £533 £1,441
APPENDIX 25 113
A = IA IHD 5 0.29 £533 £1,838
B = IIB 8 0.44 £533 £1,211
C = IVC
D = mc
E = VC
10 0.53 £533 £1,006
A = IA HI-IVD 5 0.39 £533 £1,367
B = IIB 8 0.58 £533 £919
C = IVC
D = mc
E = VC
10 0.69 £533 £772
A —• I.A IV-VC-D 5 0.55 £533 £969
B = HB 8 0.82 £533 £650
C = IVC
D = mc
E = VC
10 0.98 £533 £544
A = IA VC-D 5 0.78 £533 £683
B = HB 8 1.16 £533 £459
C = IVC 
d = ihc
E = VC
10 1.39 £533 £383
A = IA VD 5 1.21 £533 £440
B = HB 8 1.81 £533 £294
C = IVC
D = mc
E = VC
10 2.16 £533 £247
A = IA IVC 5 0.12 £533 £4,442
B = IIB 8 0.18 £533 £2,961
C = IHD
D = IVB
E = VD
10 0.22 £533 £2,423
A = IA IV-VC 5 0.21 £533 £2,538
B = IIB 8 0.32 £533 £1,666
C = IHD
D = IVB
E = VD
10 0.38 £533 £1,403
A = IA IVC-D 5 0.28 £533 £1,904
B = HB 8 0.41 £533 £1,300
C = IHD
D = IVB
E = VD
10 0.49 £533 £1,088
A — IA HI-VC-D 5 0.39 £533 £1,367
B = IIB 8 0.58 £533 £919
C = IHD
D = IVB
E = VD
10 0.69 £533 £772
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A = IA IV-VC-D 5 0.52 £533 £1,025
B = IIB 8 0.78 £533 £683
C = IHD
D = IVB
E = VD
10 0.93 £533 £573
A = IA VC-D 5 0.74 £533 £720
B = IIB 8 1.10 £533 £485
c = hid
D = IVB
E = VD
10 1.31 £533 £407
A = IA VD 5 1.17 £533 £456
B = IIB 8 1.75 £533 £305
c = iiid
D = IVB
E = VD
10 2.08 £533 £256
A = IA IVC 5 0.12 £533 £4,442
B = IIIB 8 0.18 £533 £2,961
C = IVC
D = VB-C
E = VD
10 0.22 • £533 £2,423
A = IA IV-VC 5 0.21 £533 £2,538
b = ikb 8 0.32 £533 £1,666
C = IVC
D = VB-C
E = VD
10 0.38 £533 £1,403
A = IA IVC-D 5 0.28 £533 £1,904
b = niB 8 0.41 £533 £1,300
C = IVC
D = VB-C
E = VD
10 0.49 £533 £1,088
A = IA m-vc-D 5 0.39 £533 £1,367
b = iiib 8 0.58 £533 £919
C = IVC
D = VB-C
E = VD
10 0.69 £533 £772
A = IA IV-VC-D 5 0.52 £533 £1,025
B = IHB 8 0.78 £533 £683
C = IVC
D = VB-C
E = VD
10 0.93 £533 £573
A = IA VC-D 5 0.74 £533 £720
b = niB 8 1.10 £533 £485
C = IVC
D = VB-C
E = VD
10 1.31 £533 £407
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A = IA VD 5 1.17 £533 £456
B = HIB 8 1.75 £533 £305
C = IVC
D = VB-C
E = VD
10 2.08 £533 £256
A = IB IVC 5 0.12 £533 £4,442
B = IIIB 8 0.18 £533 £2,961
C = IVC
D = IV-VB-C
E = VC-D
10 0.22 £533 £2,423
A = IB IV-VC 5 0.21 £533 £2,538
B = IIIB 8 0.32 £533 £1,666
C = IVC
D = IV-VB-C
E = VC-D
10 0.38 £533 £1,403
A = IB IVC-D 5 0.28 £533 £1,904
B = IIIB 8 0.41 £533 £1,300
C = IVC
D = IV-VB-C
E = VC-D
10 • 0.49 £533 £1,088
A = IB HI-VC-D 5 0.39 £533 £1,367
B = IIIB 8 0.58 £533 £919
C = IVC
D = IV-VB-C
E = VC-D
10 0.69 £533 £772
A = IB IV-VC-D 5 0.52 £533 £1,025
b = hib 8 0.78 £533 £683
C = IVC
D = IV-VB-C
E = VC-D
10 0.93 £533 £573
A = IB VC-D 5 0.74 £533 £720
B = HIB 8 1.10 £533 £485
C = IVC
D = IV-VB-C
E = VC-D
10 1.31 £533 £407
A = IB VD 5 1.17 £533 £456
B = IHB 8 1.75 £533 £305
C = IVC
D = IV-VB-C
E = VC-D
10 2.08 £533 £256
A = IA me 5 0.02 £533 £26,650
B = HB 8 0.03 £533 £17,767
C = IV-VC-D
D = IVB
E = VD
10 0.03 £533 £17,767
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A-IA mc-D 5 0.11 £533 £4,845
B = IIB 8 0.17 £533 £3,135
C = IV-VC-D
D - IVB
E- VD
10 0.20 £533 £2,665
A = IA III-IVC-D 5 0.17 £533 £3,135
B = nB 8 0.26 £533 £2,050
C = IV-VC-D
D-IVB
E-VD
10 0.31 £533 £1,719
A-IA VC 5 0.26 £533 £2,050
B -IIB 8 0.39 £533 £1,367
C = IV-VC-D
D-IVB
E-VD
10 0.46 £533 £1,159
A-IA IVD 5 0.39 £533 £1,367
B-UB 8 0.58 £533 £919
C = IV-VC-D
D - IVB
E-VD
10 0.69 £533 £772
A-IA III-VD 5 0.57 £533 £935
B-IIB 8 0.86 £533 £620
C = IV-VC-D
D - IVB
E = VD
10 1.02 £533 £523
A-IA VD 5 1.13 £533 £472
B-IIB 8 1.68 £533 £317
C = IV-VC-D 
D-IVB
E = VD
10 2.01 £533 £265
A-IA me 5 0.02 £533 £26,650
B-nc 8 0.03 £533 £17,767
c - in-vc-d 
D-IVB
E = VD
10 0.03 £533 £17,767
A-IA mc-D 5 0.11 £533 £4,845
B-nc 8 0.17 £533 £3,135
c - in-vc-D 
D-IVB
E-VD
10 0.20 £533 £2,665
A-IA m-ivc-D 5 0.17 £533 £3,135
B-nc 8 0.26 £533 £2,050
c = in-vc-d
D-IVB
E-VD
10 0.31 £533 £1,719
APPENDIX 25 117
A = IA VC 5 0.26 £533 £2,050
B = nc 8 0.39 £533 £1,367
c = ih-vc-d
D = IVB
E = VD
10 0.46 £533 £1,159
A — IA IVD 5 0.39 £533 £1,367
B = nc 8 0.58 £533 £919
c = m-vc-D
D = IVB
E = VD
10 0.69 > £533 £772
A = IA III-VD 5 0.57 £533 £935
b = hc 8 0.86 £533 £620
c = m-vc-D
D = IVB
E = VD
10 1.02 £533 £523
A = IA VD 5 1.13 £533 £472
b = hc 8 1.68 £533 £317
c = m-vc-D
D = IVB
E = VD
io • 2.01 £533 £265
A = IA me 5 0.02 £533 £26,650
B = IHA 8 0.03 £533 £17,767
C = IV-VC-D
D - IVB
E = VD
10 0.03 £533 £17,767
A = IA mc-D 5 0.11 £533 £4,845
B = HIA 8 0.17 £533 £3,135
C = IV-VC-D
D = IVB
E = VD
10 0.20 £533 £2,665
A = IA m-ivc-D 5 0.17 £533 £3,135
B = IHA 8 0.26 £533 £2,050
C = IV-VC-D
D = IVB
E = VD
10 0.31 £533 £1,719
A = IA VC 5 0.26 £533 £2,050
B = mA 8 0.39 £533 £1,367
C = IV-VC-D
D = IVB
E = VD
10 0.46 : £533 £1,159
A = IA IVD 5 0.39 £533 £1,367
B = mA 8 0.58 £533 £919
C = IV-VC-D
D = IVB
E = VD
10 0.69 £533 £772
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A-IA III-VD 5 0.57 £533 £935
B-IIIA 8 0.86 £533 £620
C = IV-VC-D
D-IVB
E-VD
10 1.02 £533 £523
A-IA VD 5 1.13 £533 £472
B = IIIA 8 1.68 £533 £317
C = IV-VC-D
D-IVB
E-VD
10 2.01 £533 £265
A-IA me 5 0.02 £533 £26,650
B = HIB-C 8 0.03 £533 £17,767
C = IV-VC-D
D - IVB-C
E - VC-D
10 0.03 £533 £17,767
A-IA mc-D 5 0.11 £533 £4,845
B-HIB-C 8 0.17 £533 £3,135
C = IV-VC-D
D = IVB-C
E = VC-D
10 • 0.20 £533 £2,665
A-IA III-IVC-D 5 0.17 £533 £3,135
B = HIB-C 8 0.26 £533 £2,050
C = IV-VC-D
D = IVB-C
E - VC-D
10 0.31 £533 £1,719
A-IA VC 5 0.26 £533 £2,050
B = HIB-C 8 0.39 £533 £1,367
C = IV-VC-D
D = IVB-C
E = VC-D
10 0.46 £533 £1,159
A-IA IVD 5 0.39 £533 £1,367
B = HIB-C 8 0.58 £533 £919
C = IV-VC-D
D = IVB-C
E = VC-D
10 0.69 £533 £772
A-IA III-VD 5 0.57 £533 £935
B = HIB-C 8 0.86 £533 £620
C = IV-VC-D
D = IVB-C
E = VC-D
10 1.02 £533 £523
A-IA VD 5 1.13 £533 £472
B = IIIB-C 8 1.68 £533 £317
C - IV-VC-D
D = IVB-C
E - VC-D
10 2.01 £533 £265
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A = IA me 5 0.02 £533 £26,650
B = nc 8 0.03 £533 £17,767
C = IVB-C
D = VB-C
E = VIC-D
10 0.03 £533 £17,767
A = IA mc-D 5 0.11 £533 £4,845
B = HC 8 0.17 £533 £3,135
C = IVB-C
D = VB-C
E = VIC-D
10 0.20 £533 £2,665
A = IA m-ivc-D 5 0.17 £533 £3,135
B = nc 8 0.26 £533 £2,050
C = IVB-C
D = VB-C
E = VIC-D
10 0.31 £533 £1,719
A = IA VC 5 0.26 £533 £2,050
B = HC 8 0.39 £533 £1,367
C = IVB-C
D = VB-C
E = VIC-D
10 0.46 £533 £1,159
A = IA IVD 5 0.39 £533 £1,367
B = nc 8 0.58 £533 £919
C = IVB-C
D = VB-C
E = VIC-D
10 0.69 £533 £772
A = IA III-VD 5 0.57 £533 £935
B = HC 8 0.86 £533 £620
C = IVB-C
D = VB-C
E = VIC-D
10 1.02 £533 £523
A = IA VD 5 1.13 £533 £472
B = nc 8 1.68 £533 £317
C = IVB-C
D = VB-C
E = VIC-D
10 2.01 £533 £265
A = IB me 5 0.02 £533 £26,650
B = UB-C 8 0.03 £533 £17,767
C-IUB-C
D = IV-VC
E = VIC-D
10 0.03 £533 £17,767
A = IB mc-D 5 0.11 £533 £4,845
B = HB-C 8 0.17 £533 £3,135
C = IIIB-C
D = IV-VC
E = VIC-D
10 0.20 £533 £2,665
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A-IB IH-IVC-D 5 0.17 £533 £3,135
B = HB-C 8 0.26 £533 £2,050
C = IHB-C
D = IV-VC
E = VIC-D
10 0.31 £533 £1,719
A-IB VC 5 0.26 £533 £2,050
B = HB-C 8 0.39 £533 £1,367
C-IHB-C
D = IV-VC
E - VIC-D
10 0.46 £533 £1,159
A-IB IVD 5 0.39 £533 £1,367
B - HB-C 8 0.58 £533 £919
C-IHB-C
D = IV-VC
E = VIC-D
10 0.69 £533 £772
A-IB III-VD 5 0.57 £533 £935
B = HB-C 8 0.86 £533 £620
C-IHB-C
D = IV-VC
E = VIC-D
io • 1.02 £533 £523
A-IB VD 5 1.13 £533 £472
B = HB-C 8 1.68 £533 £317
C-IHB-C
D = IV-VC
E = VIC-D
10 2.01 £533 £265
A-IA me 5 0.02 £533 £26,650
B = H-HIA-B 8 0.03 £533 £17,767
C = IV-VC-D
D = IVB-C
E = VC-D
10 0.03 £533 £17,767
A-IA mc-D 5 0.11 £533 £4,845
B - II-HIA-B 8 0.17 £533 £3,135
C = IV-VC-D
D - IVB-C
E - VC-D
10 0.20 £533 £2,665
A-IA m-ivc-D 5 0.17 £533 £3,135
B = H-HIA-B 8 0.26 £533 £2,050
C - IV-VC-D
D = IVB-C
E = VC-D
10 0.31 £533 £1,719
A-IA VC 5 0.26 £533 £2,050
B = H-HIA-B 8 0.39 £533 £1,367
C = IV-VC-D
D - IVB-C
E - VC-D
10 0.46 £533 £1,159
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A = IA IVD 5 0.39 £533 £1,367
B = H-HIA-B 8 0.58 £533 £919
C = IV-VC-D
D = IVB-C
E = VC-D
10 0.69 £533 £772
A = IA III-VD 5 0.57 £533 £935
B = II-HIA-B 8 0.86 £533 £620
C = IV-VC-D
D = IVB-C
E = VC-D
10 1.02 £533 £523
A = IA VD 5 - 1.13 £533 £472
B = II-IIIA-B 8 1.68 £533 £317
C = IV-VC-D
D = IVB-C
E = VC-D
10 2.01 £533 £265
A = IA IVC 5 0.03 £533 £17,767
B = mc 8 0.05 £533 £10,660
C = IV-VC-D
D = IVB
E = VD
• 10 0.06 £533 £8,883
A = IA IV-VC 5 0.13 £533 £4,100
B = inc 8 0.19 £533 £2,805
C = IV-VC-D
D = IVB
E = VD
10 0.22 £533 £2,423
A = IA IVC-D 5 0.19 £533 £2,805
B = HIC 8 0.28 £533 £1,904
C = IV-VC-D
D = IVB
E = VD
10 0.34 £533 £1,568
A = IA III-VC-D 5 0.30 £533 £1,777
B = inc 8 0.45 £533 £1,184
C = IV-VC-D
D = IVB
E = VD
10 0.54 £533 £987
A = IA IV-VC-D 5 0.43 £533 £1,240
B = nic 8 0.65 £533 £820
C = IV-VC-D
D = IVB
E = VD
10 0.77 £533 £692
A = IA VC-D 5 0.65 £533 £820
B = mc 8 0.97 £533 £549
C = IV-VC-D
D = IVB
E = VD
10 1.16 £533 £459
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A = IA VD 5 1.08 £533 £494
B = inc 8 1.62 £533 £329
C = IV-VC-D
D = IVB
E = VD
10 1.93 £533 £276
A = IB IVC 5 0.03 £533 £17,767
B = II-HIB 8 0.05 £533 £10,660
C = IV-VC-D
D = IVB
E = VD
10 0.06 £533 £8,883
A = IB IV-VC 5 0.13 £533 £4,100
b = n-inB 8 0.19 £533 £2,805
C = IV-VC-D
D = IVB
E = VD
10 0.22 £533 £2,423
A = IB IVC-D 5 0.19 £533 £2,805
B = II-IHB 8 0.28 £533 £1,904
C = IV-VC-D
D = IVB
E = VD
io • 0.34 £533 £1,568
A = IB m-vc-D 5 0.30 £533 £1,777
B = II-IIIB 8 0.45 £533 £1,184
C = IV-VC-D
D = IVB
E = VD
10 0.54 £533 £987
A = IB IV-VC-D 5 0.43 £533 £1,240
B = II-IIIB 8 0.65 £533 £820
C = IV-VC-D
D = IVB
E = VD
10 0.77 £533 £692
A = IB VC-D 5 0.65 £533 £820
B = n-mB 8 0.97 £533 £549
C = IV-VC-D
D = IVB
E = VD
10 1.16 £533 £459
A = IB VD 5 1.08 £533 £494
b = n-mB 8 1.62 £533 £329
C = IV-VC-D
D = IVB
E = VD
10 1.93 £533 £276
A = IA IVC 5 0.03 £533 £17,767
b = n-mB 8 0.05 £533 £10,660
C = IVC
D = V-VIB-C
E = VID
10 0.06 £533 £8,883
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A = IA IV-VC 5 0.13 £533 £4,100
b = n-mB 8 0.19 £533 £2,805
C = IVC
D = V-VIB-C
E = VID
10 0.22 £533 £2,423
A = IA IVC-D 5 0.19 £533 £2,805
b = n-niB 8 0.28 £533 £1,904
C = IVC
D = V-VIB-C
E = VID
10 0.34 £533 £1,568
A = IA m-vc-D 5 0.30 £533 £1,777
b = n-mB 8 0.45 £533 £1,184
C = IVC
D = V-VIB-C
E = VID
10 0.54 £533 £987
A = IA IV-VC-D 5 0.43 £533 £1,240
b = n-mB 8 0.65 £533 £820
C = IVC
D = V-VIB-C
E = VID
• 10 0.77 £533 £692
A = IA VC-D 5 0.65 £533 £820
b = n-niB 8 0.97 £533 £549
C = IVC
D = V-VIB-C
E = VID
10 1.16 £533 £459
A = IA VD 5 1.08 £533 £494
B = U-IUB 8 1.62 £533 £329
C = IVC
D = V-VIB-C
E = VID
10 1.93 £533 £276
A = IB IV-VC 5 0.04 £533 £13,325
B = HIB-C 8 0.06 £533 £8,883
C = VC-D
D = V-VIB-C
E = V-VIC-D
10 0.07 £533 £7,614
A = IB IVC-D 5 0.10 £533 £5,330
B = IUB-C 8 0.16 £533 £3,331
C = VC-D
D = V-VIB-C
E = V-VIC-D
10 0.19 £533 £2,805
A = IB m-vc-D 5 0.22 £533 £2,423
B = mB-c 8 0.32 £533 £1,666
C = VC-D
D = V-VIB-C
E = V-VIC-D
10 0.39 £533 £1,367
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A - IB IV-VC-D 5 0.35 £533 £1,523
B = IIIB-C 8 0.52 £533 £1,025
C = VC-D
D = V-VIB-C
E = V-VIC-D
10 0.62 £533 £860
A = IB IV-VD 5 0.63 £533 £846
B = niB-C 8 0.94 £533 £567
C = VC-D
D = V-VIB-C
E = V-VIC-D
10 1.12 £533 £476
A = IB VC 5 0.04 £533 £13,325
B = nB 8 0.06 £533 £8,883
C = VD
D = IVB
E = V-VIC-D
10 0.08 £533 £6,663
A = IB IVD 5 0.17 £533 £3,135
B = KB 8 0.26 £533 £2,050
C = VD
D = IVB
E = V-VIC-D
10 • 0.31 £533 £1,719
A = IB III-VD 5 0.36 £533 £1,481
B = KB 8 0.53 £533 £1,006
C-VD
D = IVB
E = V-VIC-D
10 0.64 £533 £833
A = IB VD 5 0.91 £533 £586
B = KB 8 1.36 £533 £392
C = VD
D = IVB
E = V-VIC-D
10 1.62 £533 £329
A = IB IVD 5 0.04 £533 £13,325
B = mc 8 0.06 £533 £8,883
C = VD
D = VIC
E = VID
10 0.08 £533 £6,663
A = IB VC-D 5 0.35 £533 £1,523
B = mc 8 0.52 £533 £1,025
C = VD
D = VIC
E = VID
10 0.62 £533 £860
A = IB VD 5 0.78 £533 £683
B = mc 8 1.16 £533 £459
C = VD
D = VIC
E-VID
10 1.39 £533 £383
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COFIELD (1984) - POST-TRAUMATIC ARTHRITIS
Conversion 
of Full 
Exercise 
Programme 
Categories 
into Rosser 
Categories - 
Postoperative
Sensitivity 
Analysis of 
Preoperative 
Rosser 
Categories
Duration 
of Joint 
(Years)
QALYs 
Gained per 
Patient- 
Discounted 
at 5%
Total Costs Cost per 
QALY
A = IA me 5 0.15 £533 £3,553
B = IB 8 0.22 £533 £2,423
C = IHB 10 0.26 £533 £2,050
D = mA
E = IVB
15 0.35 £533 £1,523
A = LA m-ivc 5 0.18 £533 £2,961
B = IB 8 0.26 £533 £2,050
c = hib 10 0.32 £533 £1,666
D = niA
E = IVB
15 0.43 £533 £1,240
A = LA IVC 5 0.21 £533 £2,538
B = IB 8 0.31 £533 £1,719
C = IHB 10 0.37 £533 £1,441
D = mA
E = IVB
15 0.50 £533 £1,066
A = IA mc-D 5 0.24 £533 £2,221
B = IB 8 0.36 £533 £1,481
c = mB 10 0.43 £533 £1,240
D = mA
E = IVB
15 0.58 £533 £919
A = LA m-ivc 5 0.25 £533 £2,132
B = IB 8 0.37 £533 £1,441
c = mB 10 0.44 £533 £1,211
D = HIA
E = LVB
15 0.60 £533 £888
A = IA IV-VC 5 0.30 £533 £1,777
B = IB 8 0.45 £533 £1,184
c = mB 10 0.53 £533 £1,006
D = niA
E = IVB
15 0.72 £533 £740
A = IA m-ivc-D 5 0.30 £533 £1,777
B = IB 8 0.45 £533 £1,184
c = mB 10 0.54 £533 £987
D = niA
E = LVB
15 0.73 £533 £730
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A = IA
B = IB 
c = niB 
d = iha
E = IVB
HID 5
8
10
15
0.34
0.50
0.60
0.81
£533
£533
£533
£533
£1,568
£1,066
£888
£658
A = IA IVC-D 5 0.36 £533 £1,481
B = IB 8 0.54 £533 £987
C = IIIB 10 0.65 £533 £820
D = IIIA
E = IVB
15 0.87 £533 £613
A = IA VC 5 0.39 £533 £1,367
B = IB 8 0.58 £533 £919
c = iiib 10 0.69 £533 £772
d = iha
E = IVB
15 0.93 £533 £573
A = IA m-ivD 5 0.43 £533 £1,240
B = IB 8 0.64 £533 £833
c = hib 10 0.76 £533 £701
d = hia
E = IVB
15 1.03 £533 £517
A = IA HI-VC-D 5 0.48 £533 £1,110
B = IB 8 0.71 £533 £751
C = IIIB 10 0.85 £533 £627
D = HIA
E = IVB
15 1.14 £533 £468
A = IA IVD 5 0.52 £533 £1,025
B = IB 8 0.78 £533 £683
C = IHB 10 0.93 £533 £573
D = HIA
E = IVB
15 1.25 £533 £426
A = IA IV-VC-D 5 0.59 £533 £903
B = IB 8 0.89 £533 £599
C=IHB 10 1.06 £533 £503
d = iha
E = IVB
15 1.42 £533 £375
A = IA III-VD 5 0.70 £533 £761
B = IB 8 1.05 £533 £508
c = hib 10 1.26 £533 £423
d = iha
E = IVB
15 1.69 £533 £315
A = IA VC-D 5 0.82 £533 £650
B = IB 8 1.23 £533 £433
C = IIIB 10 1.47 £533 £363
D = niA
E = IVB
15 1.97 £533 £271
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A = IA IV-VD 5 0.89 £533 £599
B = IB 8 1.32 £533 £404
C-HIB 10 1.58 £533 £337
d = iha
E = IVB
15 2.13 £533 £250
A = IA VD 5 1.26 £533 £423
B = IB 8 1.87 £533 £285
c = hib 10 2.24 £533 £238
D = IIIA
E = IVB
15 3.01 £533 £177
A = IA HI-IVC 5 0.13 £533 £4,100
B = HB 8 0.20 £533 £2,665
C = HIB 10 0.24 £533 £2,221
D = IVB
E = VD
15 0.32 £533 £1,666
A = IA ni-vc 5 0.20 £533 £2,665
b = hb 8 0.31 £533 £1,719
c = hib 10 0.37 £533 £1,441
D = IVB
E = VD
15 0.49 £533 £1,088
A = IA ihd 5 0.29 £533 £1,838
B = HB 8 0.44 £533 £1,211
c = ihb 10 0.53 £533 £1,006
D = IVB 
E-VD
15 0.71 £533 £751
A = IA HI-IVD 5 0.39 £533 £1,367
B = HB 8 0.58 £533 £919
c = niB 10 0.69 £533 £772
D = IVB
E = VD
15 0.92 £533 £579
A = IA IV-VC-D 5 0.55 £533 £969
B = HB 8 0.82 £533 £650
c = niB 10 0.98 £533 £544
D = IVB
E = VD
15 1.32 £533 £404
A = IA VC-D 5 0.78 £533 £683
B = HB 8 1.16 £533 £459
c = mB 10 1.39 £533 £383
D = IVB
E = VD
15 1.87 £533 £285
A = IA VD 5 1.21 £533 £440
B - HB 8 1.81 £533 £294
c = hib 10 2.16 £533 £247
D = IVB 15 2.91 £533 £183
E = VD
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A-IA ni-ivc 5 0.13 £533 £4,100
B = nB 8 0.20 £533 £2,665
C-IVC 10 0.24 £533 £2,221
D-mc
E-VC
15 0.32 £533 £1,666
A-IA ffl-VC 5 0.20 £533 £2,665
B = nB 8 0.31 £533 £1,719
C-IVC 10 0.37 £533 £1,441
D-mc
E-VC
15 0.49 £533 £1,088
A-IA TTTD 5 0.29 £533 £1,838
B-UB 8 0.44 £533 £1,211
C-IVC 10 0.53 £533 £1,006
D = inc
E-VC
15 0.71 £533 £751
A-IA ni-ivD 5 0.39 £533 £1,367
B-IIB 8 0.58 £533 £919
C-IVC io • 0.69 £533 £772
D-mc
E-VC
15 0.92 £533 £579
A-IA IV-VC-D 5 0.55 £533 £969
B-HB 8 0.82 £533 £650
C-IVC 10 0.98 £533 £544
D-mc
E-VC
15 1.32 £533 £404
A-IA VC-D 5 0.78 £533 £683
B-IIB 8 1.16 £533 £459
C = IVC 10 1.39 £533 £383
D-mc
E-VC
15 1.87 £533 £285
A-IA VD 5 1.21 £533 £440
B-IIB 8 1.81 £533 £294
C-IVC 10 2.16 £533 £247
D-mc
E = VC
15 2.91 £533 £183
A-IA III-IVC 5 0.13 £533 £4,100
b-n-mA 8 0.20 £533 £2,665
c = mB-c 10 0.24 £533 £2,221
D = IVB-C
E = VC
15 0.32 £533 £1,666
A-IA ffl-VC 5 0.20 £533 £2,665
B-H-IIIA 8 0.31 £533 £1,719
C = fflB-C 10 0.37 £533 £1,441
D = IVB-C 
E-VC
15 0.49 £533 £1,088
APPENDIX 25 129
A-IA HID 5 0.29 £533 £1,838
B-H-IHA 8 0.44 £533 £1,211
c = mB-c 10 0.53 £533 £1,006
D = IVB-C
E = VC
15 0.71 £533 £751
A-IA HI-IVD 5 0.39 £533 £1,367
b = n-niA 8 0.58 £533 £919
C-fflB-C 10 0.69 £533 £772
D - IVB-C 
E-VC
15 0.92 £533 £579
A-IA IV-VC-D 5 0.55 £533 £969
B = n-IHA 8 0.82 £533 £650
C-fflB-C 10 0.98 £533 £544
D = IVB-C 
E-VC
15 1.32 £533 £404
A-IA VC-D 5 0.78 £533 £683
B - H-fflA 8 1.16 £533 £459
C-IHB-C 10 1.39 £533 £383
D - IVB-C 
E-VC
15 1.87 £533 £285
A-IA VD 5 1.21 £533 £440
b = n-niA 8 1.81 £533 £294
C-fflB-C 10 2.16 £533 £247
D = IVB-C 
E-VC
15 2.91 £533 £183
A-IB HI-IVC 5 0.13 £533 £4,100
B = HB-C 8 0.20 £533 £2,665
C — fflB-C 10 0.24 £533 £2,221
D = IV-VC
E = VIC-D
15 0.32 £533 £1,666
A-IB IH-VC 5 0.20 £533 £2,665
B - HB-C 8 0.31 £533 £1,719
C-fflB-C 10 0.37 £533 £1,441
D - IV-VC
E - VIC-D
15 0.49 £533 £1,088
A-IB HID 5 0.29 £533 £1,838
B = HB-C 8 0.44 £533 £1,211
C-IHB-C 10 0.53 £533 £1,006
D = IV-VC
E = VIC-D
15 0.71 £533 £751
A-IB HI-IVD 5 0.39 £533 £1,367
B = HB-C 8 0.58 £533 £919
C-fflB-C 10 0.69 £533 £772
D = IV-VC
E = VIC-D
15 0.92 £533 £579
APPENDIX 25 130
A-IB IV-VC-D 5 0.55 £533 £969
B = HB-C 8 0.82 £533 £650
C = IIIB-C 10 0.98 £533 £544
D = IV-VC
E = VIC-D
15 1.32 £533 £404
A-IB VC-D 5 0.78 £533 £683
B = HB-C 8 1.16 £533 £459
C = IHB-C 10 1.39 £533 £383
D = IV-VC
E = VIC-D
15 1.87 £533 £285
A-IB VD 5 1.21 £533 £440
B = HB-C 8 1.81 £533 £294
C = IHB-C 10 2.16 £533 £247
D - IV-VC
E = VIC-D
15 2.91 £533 £183
A-IA me 5 0.06 £533 £8,883
B-HB 8 0.09 £533 £5,922
C-IHD 10 0.11 £533 £4,845
D-IVB
E-VD
15 0.15 £533 £3,553
A-IA IVC 5 0.12 £533 £4,442
B-HB 8 0.18 £533 £2,961
C-IHD 10 0.22 £533 £2,423
D-IVB
E-VD
15 0.29 £533 £1,838
A-IA HI-VC 5 0.16 £533 £3,331
B-HB 8 0.24 £533 £2,221
C-IHD 10 0.29 £533 £1,838
D-IVB
E-VD
15 0.39 £533 £1,367
A-IA m-ivc-D 5 0.22 £533 £2,423
B-HB 8 0.32 £533 £1,666
C-IHD 10 0.39 £533 £1,367
D-IVB
E-VD
15 0.52 £533 £1,025
A-IA IVC-D 5 0.28 £533 £1,904
B-HB 8 0.41 £533 £1,300
C-HID 10 0.49 £533 £1,088
D-IVB
E-VD
15 0.66 £533 £808
A-IA hi-ivd 5 0.34 £533 £1,568
B-HB 8 0.51 £533 £1,045
C-IHD 10 0.61 £533 £874
D-IVB 15 0.82 £533 £650
E-VD
APPENDIX 25 131
A = IA IVD 5 0.43 £533 £1,240
B = IIB 8 0.65 £533 £820
C = IHD 10 0.77 £533 £692
D = IVB
E = VD
15 1.04 £533 £513
A = IA IV-VC-D 5 0.52 £533 £1,025
B = HB 8 0.78 £533 £683
C=IHD 10 0.93 £533 £573
D - IVB
E = VD
15 1.25 £533 £426
A = IA VC-D 5 0.74 £533 £720
B = HB 8 1.10 £533 £485
C = IHD 10 1.31 £533 £407
D = IVB
E = VD
15 1.76 £533 £303
A = IA VD 5 1.17 £533 £456
B = HB 8 1.75 £533 £305
C = HID 10 2.08 • £533 £256
D = IVB
E = VD
15 2.80 £533 £190
A = IA me 5 0.06 £533 £8,883
b = niB 8 0.09 £533 £5,922
C = IVC 10 0.11 £533 £4,845
D = VB-C
E = VD
15 0.15 £533 £3,553
A = IA IVC 5 0.12 £533 £4,442
B = IIIB 8 0.18 £533 £2,961
C = IVC 10 0.22 £533 £2,423
D = VB-C
E = VD
15 0.29 £533 £1,838
A = IA m-vc 5 0.16 £533 £3,331
B = HIB 8 0.24 £533 £2,221
C = IVC 10 0.29 £533 £1,838
D = VB-C
E = VD
15 0.39 £533 £1,367
A = IA m-ivc-D 5 0.22 £533 £2,423
b = hib 8 0.32 £533 £1,666
C = IVC 10 0.39 £533 £1,367
D = VB-C
E = VD
15 0.52 £533 £1,025
A = IA IVC-D 5 0.28 £533 £1,904
B = HIB 8 0.41 £533 £1,300
c = rvc 10 0.49 £533 £1,088
D = VB-C 15 0.66 £533 £808
E = VD
APPENDIX 25 132
A = IA
B = IIIB 
c = rvc
D = VB-C
E = VD
III-IVD 5
8
10
15
0.34
0.51
0.61
0.82
£533
£533
£533
£533
£1,568
£1,045
£874
£650
A = IA IVD 5 0.43 £533 £1,240
B = niB 8 0.65 £533 £820
C = IVC 10 0.77 £533 £692
D = VB-C
E = VD
15 1.04 £533 £513
A = IA IV-VC-D 5 0.52 £533 £1,025
B = IIIB 8 0.78 £533 £683
c = rvc 10 0.93 £533 £573
D = VB-C
E = VD
15 1.25 £533 £426
A = IA VC-D 5 0.74 £533 £720
b = niB 8 1.10 £533 £485
c = rvc 10 1.31 £533 * £407
D = VB-C
E = VD
15 1.76 £533 £303
A = IA VD 5 1.17 £533 £456
B = IIIB 8 1.75 £533 £305
c = rvc 10 2.08 £533 £256
D = VB-C
E = VD
15 2.80 £533 £190
A = IB me 5 0.06 £533 £8,883
b = heb 8 0.09 £533 £5,922
c = rvc 10 0.11 £533 £4,845
D = IV-VB-C
E = VC-D
15 0.15 £533 £3,553
A = IB IVC 5 0.12 £533 £4,442
B = IIIB 8 0.18 £533 £2,961
C = IVC 10 0.22 £533 £2,423
D = IV-VB-C
E = VC-D
15 0.29 £533 £1,838
A = IB m-vc 5 0.16 £533 £3,331
B = IIIB 8 0.24 £533 £2,221
c = rvc 10 0.29 £533 £1,838
D = IV-VB-C
E = VC-D
15 0.39 £533 £1,367
A = IB ni-ivc-D 5 0.22 £533 £2,423
b = ihb 8 0.32 £533 £1,666
c = rvc 10 0.39 £533 £1,367
D = IV-VB-C
E = VC-D
15 0.52 £533 £1,025
APPENDIX 25 133
A = IB
B = IIIB
C = IVC
D = IV-VB-C
E = VC-D
IVC-D 5
8
10
15
0.28
0.41
0.49
0.66
£533
£533
£533
£533
£1,904
£1,300
£1,088
£808
A = IB • HI-IVD 5 0.34 £533 £1,568
B = IIIB 8 0.51 £533 £1,045
C = IVC 10 0.61 £533 £874
D = IV-VB-C
E = VC-D
15 0.82 £533 £650
A = IB IVD 5 0.43 £533 £1,240
B = IIIB 8 0.65 £533 £820
C = IVC 10 0.77 £533 £692
D = IV-VB-C
E = VC-D *
15 1.04 £533 £513
A = IB IV-VC-D 5 0.52 £533 £1,025
B = IIIB 8 0.78 £533 £683
C = IVC 10 0.93 £533 £573
D = IV-VB-C
E = VC-D
15 1.25 £533 £426
A = IB VC-D 5 0.74 £533 £720
B = IIIB 8 1.10 £533 £485
C = IVC 10 1.31 £533 £407
D = IV-VB-C
E = VC-D
15 1.76 £533 £303
A = IB VD 5 1.17 £533 £456
B = IIIB 8 1.75 £533 £305
c = rvc 10 2.08 £533 £256
D = IV-VB-C
E = VC-D
15 2.80 £533 £190
A = IA me 5 0.06 £533 £8,883
b = n-mB 8 0.09 £533 £5,922
c = rvc 10 0.11 £533 £4,845
D = V-VIB-C
E = VID
15 0.15 £533 £3,553
A = IA IVC 5 0.12 £533 £4,442
b = n-mB 8 0.18 £533 £2,961
c = rvc 10 0.22 £533 £2,423
D = V-VIB-C
E = VID
15 0.29 £533 £1,838
A = LA ni-vc 5 0.16 £533 £3,331
b = n-mB 8 0.24 £533 £2,221
C = IVC 10 0.29 £533 £1,838
D = V-VIB-C
E = VID
15 0.39 £533 £1,367
APPENDIX 25 134
A-IA III-IVC-D 5 0.22 £533 £2,423
B - II-mB 8 0.32 £533 £1,666
C-IVC 10 0.39 £533 £1,367
D = V-VIB-C 
E-VID
15 0.52 £533 £1,025
A-IA IVC-D 5 0.28 £533 £1,904
B = II-IIIB 8 0.41 £533 £1,300
C-IVC 10 0.49 £533 £1,088
D = V-VIB-C 
E-VID
15 0.66 £533 £808
A-IA m-iVD 5 0.34 £533 £1,568
B = II-mB 8 0.51 £533 £1,045
C-IVC 10 0.61 £533 £874
D = V-VIB-C 
E-VID
15 0.82 £533 £650
A-IA IVD 5 0.43 £533 £1,240
b = n-mB 8 0.65 £533 £820
C-IVC 10 0.77 £533 £692
D - V-VIB-C
E = VID
15 1.04 £533 £513
A-IA IV-VC-D 5 0.52 £533 £1,025
b - n-mB 8 0.78 £533 £683
C-IVC 10 0.93 £533 £573
D - V-VIB-C 
E-VID
15 1.25 £533 £426
A-IA VC-D 5 0.74 £533 £720
b - n-mB 8 1.10 £533 £485
C-IVC 10 1.31 £533 £407
D - V-VIB-C
E = VID
15 1.76 £533 £303
A-IA VD 5 1.17 £533 £456
b = n-niB 8 1.75 £533 £305
C-IVC 10 2.08 £533 £256
D - V-VIB-C
E = VID
15 2.80 £533 £190
A-IA me 5 0.06 £533 £8,883
B-nc 8 0.09 £533 £5,922
C = IVB-C 10 0.11 £533 £4,845
D-VB-C
E = VIC-D
15 0.15 £533 £3,553
A-IA IVC 5 0.12 £533 £4,442
B-nc 8 0.18 £533 £2,961
C - IVB-C 10 0.22 £533 £2,423
D-VB-C
E = VIC-D
15 0.29 £533 £1,838
APPENDIX 25 135
A = IA HI-VC 5 0.16 £533 £3,331
B = nc 8 0.24 £533 £2,221
C = IVB-C 10 0.29 £533 £1,838
D = VB-C
E = VIC-D
15 0.39 £533 £1,367
A = IA m-ivc-D 5 0.22 £533 £2,423
B = HC 8 0.32 £533 £1,666
C = IVB-C 10 0.39 £533 £1,367
D = VB-C
E = VIC-D
15 0.52 £533 £1,025
A = IA IVC-D 5 0.28 £533 £1,904
B = nc 8 0.41 £533 £1,300
C = IVB-C 10 0.49 £533 £1,088
D = VB-C
E = VIC-D
15 0.66 £533 £808
A = IA HI-IVD 5 0.34 £533 £1,568
B = nc 8 0.51 £533 £1,045
C = IVB-C 10 0.61 £533 • £874
D = VB-C
E = VIC-D
15 0.82 £533 £650
A = IA IVD 5 0.43 £533 £1,240
B = HC 8 0.65 £533 £820
C = IVB-C 10 0.77 £533 £692
D = VB-C
E = VIC-D
15 1.04 £533 £513
A = IA IV-VC-D 5 0.52 £533 £1,025
B = HC 8 0.78 £533 £683
C = IVB-C 10 0.93 £533 £573
D = VB-C
E = VIC-D
15 1.25 £533 £426
A = IA VC-D 5 0.74 £533 £720
B = nc 8 1.10 £533 £485
C = IVB-C 10 1.31 £533 £407
D = VB-C
E = VIC-D
15 1.76 £533 £303
A = IA VD 5 1.17 £533 £456
B = nc 8 1.75 £533 £305
C = IVB-C 10 2.08 £533 £256
D = VB-C
E = VIC-D
15 2.80 £533 £190
A = IA HI-IVC 5 0.004 £533 £133,250
B = HB 8 0.006 £533 £88,833
C = IV-VC-D 10 0.008 £533 £66,625
D = IVB
E = VD
15 0.010 £533 £53,300
APPENDIX 25 136
A-IA mc-D 5 0.07 £533 £7,614
B-IIB 8 0.10 £533 £5,330
C = IV-VC-D 10 0.12 £533 £4,442
D-IVB
E-VD
15 0.17 £533 £3,135
A-IA IV-VC 5 0.13 £533 £4,100
B-HB 8 0.19 £533 £2,805
C = IV-VC-D 10 0.22 £533 £2,423
D -IVB 
E-VD
15 0.30 £533 £1,777
A-IA hid 5 0.16 £533 £3,331
B-HB 8 0.25 £533 £2,132
C = IV-VC-D 10 0.29 £533 £1,838
D-IVB
E-VD
15 0.39 £533 £1,367
A-IA VC 5 0.22 £533 £2,423
b-hb 8 0.32 £533 £1,666
C = IV-VC-D 10 0.39 £533 £1,367'
D -IVB 
E-VD
15 0.52 £533 £1,025
A-IA m-vc-D 5 0.30 £533 £1,777
B-HB 8 0.45 £533 £1,184
C = IV-VC-D 10 0.54 £533 £987
D-IVB
E-VD
15 0.73 £533 £730
A-IA IV-VC-D 5 0.42 £533 £1,269
B-UB 8 0.63 £533 £846
C = IV-VC-D 10 0.75 £533 £711
D-IVB
E-VD
15 1.01 £533 £528
A-IA III-VD 5 0.53 £533 £1,006
B-HB 8 0.79 £533 £675
C = IV-VC-D 10 0.95 £533 £561
D-IVB
E-VD
15 1.27 £533 £420
A-IA IV-VD 5 0.71 £533 £751
B-HB 8 1.07 £533 £498
C = IV-VC-D 10 1.27 £533 £420
D-IVB
E-VD
15 1.71 £533 £312
A-IA VD 5 1.08 £533 £494
B-IIB 8 1.62 £533 £329
C - IV-VC-D 10 1.93 £533 £276
D-IVB
E-VD
15 2.59 £533 £206
APPENDIX 25 137
A-IA m-ivc 5 0.004 £533 £133,250
B-nc 8 0.006 £533 £88,833
c = m-vc-D 10 0.008 £533 £66,625
D-IVB
E-VD
15 0.010 £533 £53,300
A-IA mc-D 5 0.07 £533 £7,614
B-nc 8 0.10 £533 £5,330
c = m-vc-D 10 0.12 £533 £4,442
D-IVB
E-VD
15 0.17 £533 £3,135
A-IA IV-VC 5 0.13 £533 £4,100
B-nc 8 0.19 £533 £2,805
c = m-vc-D 10 0.22 £533 £2,423
D-IVB
E-VD
15 0.30 £533 £1,777
A-IA nrD 5 0.16 £533 £3,331
B-nc 8 0.25 £533 £2,132
c = m-vc-D 10 0.29 £533 • £1,838
D-IVB
E-VD
15 0.39 £533 £1,367
A-IA VC 5 0.22 £533 £2,423
B-nc 8 0.32 £533 £1,666
c = m-vc-D 10 0.39 £533 £1,367
D-IVB
E-VD
15 0.52 £533 £1,025
A-IA m-vc-D 5 0.30 £533 £1,777
B-nc 8 0.45 £533 £1,184
c = m-vc-D 10 0.54 £533 £987
D-IVB
E-VD
15 0.73 £533 £730
A-IA IV-VC-D 5 0.42 £533 £1,269
B-nc 8 0.63 £533 £846
c - m-vc-D 10 0.75 £533 £711
D-IVB
E-VD
15 1.01 £533 £528
A-IA III-VD 5 0.53 £533 £1,006
B-nc 8 0.79 £533 £675
c = m-vc-D 10 0.95 £533 £561
D-IVB
E-VD
15 1.27 £533 £420
A-IA IV-VD 5 0.71 £533 £751
B-nc 8 1.07 £533 £498
c - m-vc-D 10 1.27 £533 £420
D-IVB
E-VD
15 1.71 £533 £312
APPENDIX 25 138
A = IA VD 5 1.08 £533 £494
b = hc 8 1.62 £533 £329
C = III-VC-D 10 1.93 £533 £276
D = IVB
E = VD
15 2.59 £533 £206
A = IA III-IVC 5 0.004 £533 £133,250
B = IHA 8 0.006 £533 £88,833
C = IV-VC-D 10 0.008 £533 £66,625
D = IVB
E = VD
15 0.010 £533 £53,300
A = IA HIC-D 5 0.07 £533 £7,614
b = niA 8 0.10 £533 £5,330
C = IV-VC-D 10 0.12 £533 £4,442
D = IVB
E = VD
15 0.17 £533 £3,135
A = IA IV-VC 5 0.13 £533 £4,100
b = niA 8 0.19 £533 £2,805
C = IV-VC-D 10 0.22 £533 £2,423 •
D = IVB
E = VD
15 0.30 £533 £1,777
A = IA hid 5 0.16 £533 £3,331
B = IIIA 8 0.25 £533 £2,132
C = IV-VC-D 10 0.29 £533 £1,838
D = IVB
E = VD
15 0.39 £533 £1,367
A = IA VC 5 0.22 £533 £2,423
B = IHA 8 0.32 £533 £1,666
C = IV-VC-D 10 0.39 £533 £1,367
D = IVB
E = VD
15 0.52 £533 £1,025
A = IA ni-vc-D 5 0.30 £533 £1,777
B = IIIA 8 0.45 £533 £1,184
C = IV-VC-D 10 0.54 £533 £987
D = IVB
E = VD
15 0.73 £533 £730
A = IA IV-VC-D 5 0.42 £533 £1,269
b = iha 8 0.63 £533 £846
C = IV-VC-D 10 0.75 £533 £711
D = IVB
E = VD
15 1.01 £533 £528
A = IA III-VD 5 0.53 £533 £1,006
B = niA 8 0.79 £533 £675
C = IV-VC-D 10 0.95 £533 £561
D = IVB
E = VD
15 1.27 £533 £420
APPENDIX 25 139
A = IA IV-VD 5 0.71 £533 £751
B=IHA 8 1.07 £533 £498
C = IV-VC-D 10 1.27 £533 £420
D = IVB
E = VD
15 1.71 £533 . £312
A = IA VD 5 1.08 £533 £494
b = niA 8 1.62 £533 £329
C = IV-VC-D 10 1.93 £533 £276
D = IVB
E = VD
15 2.59 £533 £206
A = IA III-IVC 5 0.004 £533 £133,250
B = H-IIIA-B 8 0.006 £533 £88,833
C = IV-VC-D 10 0.008 £533 £66,625
D = IVB-C
E = VC-D
15 0.010 £533 £53,300
A = IA mc-D 5 0.07 £533 £7,614
B = n-IHA-B 8 0.10 £533 £5,330
C = IV-VC-D 10 0.12 £533 ' £4,442
D = IVB-C
E = VC-D
15 0.17 £533 £3,135
A = IA IV-VC 5 0.13 £533 £4,100
B = n-IHA-B 8 0.19 £533 £2,805
C = IV-VC-D 10 0.22 £533 £2,423
D = IVB-C
E = VC-D
15 0.30 £533 £1,777
A = IA mD 5 0.16 £533 £3,331
B = n-HIA-B 8 0.25 £533 £2,132
C = IV-VC-D 10 0.29 £533 £1,838
D = IVB-C
E = VC-D
15 0.39 £533 £1,367
A = IA VC 5 0.22 £533 £2,423
B = n-IHA-B 8 0.32 £533 £1,666
C = IV-VC-D 10 0.39 £533 £1,367
D = IVB-C
E = VC-D
15 0.52 £533 £1,025
A = IA hi-vc-d 5 0.30 £533 £1,777
B = n-HIA-B 8 0.45 £533 £1,184
C = IV-VC-D 10 0.54 £533 £987
D = IVB-C
E = VC-D
15 0.73 £533 £730
A = IA IV-VC-D 5 0.42 £533 £1,269
B = n-IHA-B 8 0.63 £533 £846
C = IV-VC-D 10 0.75 £533 £711
D = IVB-C
E = VC-D
15 1.01 £533 £528
APPENDIX 25 140
A = IA
B = n-fflA-B
C = IV-VC-D
D = IVB-C
E = VC-D
III-VD 5
8
10
15
0.53
0.79
0.95
1.27
£533
£533
£533
£533
£1,006
£675
£561
£420
A = IA IV-VD 5 0.71 £533 £751
B = n-HIA-B 8 1.07 £533 £498
C = IV-VC-D 10 1.27 £533 £420
D = IVB-C
E = VC-D
15 1.71 £533 £312
A = IA VD 5 1.08 £533 £494
B = H-IHA-B 8 1.62 £533 £329
C = IV-VC-D 10 1.93 £533 £276
D = IVB-C
E = VC-D
15 2.59 £533 £206
A = IB mc-D 5 0.03 £533 £17,767
B = n-IHB 8 0.04 £533 £13,325
C = IV-VC-D 10 0.05 £533 £10,660
D = IVB
E = VD
15 0.06 £533 £8,883
A = IB IV-VC 5 0.08 . £533 £6,663
b = n-mB 8 0.12 £533 £4,442
C = IV-VC-D 10 0.15 £533 £3,553
D = IVB
E = VD
15 0.20 £533 £2,665
A = IB IHD 5 0.12 £533 £4,442
B = H-IHB 8 0.18 £533 £2,961
C = IV-VC-D 10 0.22 £533 £2,423
D = IVB
E = VD
15 0.29 £533 £1,838
A = IB VC 5 0.17 £533 £3,135
B = n-IHB 8 0.26 £533 £2,050
C = IV-VC-D 10 0.31 £533 £1,719
D = IVB
E = VD
15 0.42 £533 £1,269
A = IB m-vc-D 5 0.26 £533 £2,050
B = n-mB 8 0.39 £533 £1,367
C = IV-VC-D 10 0.46 £533 £1,159
D = IVB
E = VD
15 0.62 £533 £860
A = IB IV-VC-D 5 0.38 £533 £1,403
b = n-niB 8 0.56 £533 £952
C = IV-VC-D 10 0.67 £533 £796
D = IVB
E = VD
15 0.90 £533 £592
APPENDIX 25 141
A = IB
B = II-HIB
C = IV-VC-D
D = IVB
E = VD
III-VD 5
8
10
15
0.49
0.73
0.87
1.17
£533
£533
£533
£533
£1,088
£730
£613
£456
A = IB IV-VD 5 0.67 £533 £796
B = II-IIIB 8 1.00 £533 £533
C = IV-VC-D 10 1.20 £533 £444
D = IVB
E = VD
15 1.61 £533 £331
A = IB VD 5 1.04 £533 £513
b = n-mB 8 1.55 £533 £344
C = IV-VC-D 10 1.85 £533 £288
D = IVB
E = VD
15 2.49 £533 £214
A = IA mc-D 5 0.03 £533 £17,767
B = mB-C 8 0.04 £533 £13,325
C = IV-VC-D 10 0.05 £533 £10,660
D = IVB-C
E = VC-D
15
•
0.06 £533 £8,883
A = IA IV-VC 5 0.08 £533 £6,663
B = mB-C 8 0.12 £533 £4,442
C = IV-VC-D 10 0.15 £533 £3,553
D = IVB-C
E = VC-D
15 0.20 £533 £2,665
A = IA mD 5 0.12 £533 £4,442
B - IIIB-C 8 0.18 £533 £2,961
C = IV-VC-D 10 0.22- £533 £2,423
D = IVB-C
E = VC-D
15 0.29 £533 £1,838
A = IA VC 5 0.17 £533 £3,135
B = mB-C 8 0.26 £533 £2,050
C = IV-VC-D 10 0.31 £533 £1,719
D = IVB-C
E = VC-D
15 0.42 £533 £1,269
A = IA m-vc-D 5 0.26 £533 £2,050
B = IUB-C 8 0.39 £533 £1,367
C = IV-VC-D 10 0.46 £533 £1,159
D = IVB-C
E = VC-D
15 0.62 £533 £860
A = IA IV-VC-D 5 0.38 £533 £1,403
B = HIB-C 8 0.56 £533 £952
C = IV-VC-D 10 0.67 £533 £796
D = IVB-C
E = VC-D
15 0.90 £533 £592
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A = IA
B = IHB-C
C = IV-VC-D
D = IVB-C
E = VC-D
III-VD 5
8
10
15
0.49
0.73
0.87
1.17
£533
£533
£533
£533
£1,088
£730
£613
£456
A = IA IV-VD 5 0.67 £533 £796
B = mB-C 8 1.00 £533 £533
C = rv-VC-D 10 1.20 £533 £444
D = IVB-C
E = VC-D
15 1.61 £533 £331
A = IA VD 5 1.04 £533 £513
B = IHB-C 8 1.55 £533 £344
C = IV-VC-D 10 1.85 £533 £288
D = IVB-C
E = VC-D
15 2.49 £533 £214
A = IA IH-IVC-D 5 0.04 £533 £13,325
B = mc 8 0.06 £533 £8,883
C = IV-VC-D 10 0.08 £533 £6,‘663
D = IVB
E = VD
15 0.10 £533 £5,330
A = IA IVC-D 5 0.10 £533 £5,330
B = mc 8 0.16 £533 £3,331
C = IV-VC-D 10 0.19 £533 £2,805
D = IVB
E = VD
15 0.25 £533 £2,132
A = LA HI-IVD 5 0.17 £533 £3,135
B = mc 8 0.25 £533 £2,132 •
C = IV-VC-D 10 0.30 £533 £1,777
D = IVB
E = VD
15 0.40 £533 £1,333
A = IA IVD 5 0.26 £533 £2,050
B = mc 8 0.39 £533 £1,367
C = IV-VC-D 10 0.46 £533 £1,159
D = IVB
E = VD
15 0.62 £533 £860
A = IA IV-VC-D 5 0.35 £533 £1,523
B = mc 8 0.52 £533 £1,025
C = IV-VC-D 10 0.62 £533 £860
D = IVB
E = VD
15 0.83 £533 £642
A = IA VC-D 5 0.56 £533 £952
B = mc 8 0.84 £533 £635
C = IV-VC-D 10 1.00 £533 £533
D = IVB
E = VD
15 1.35 £533 £395
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A-IA VD 5 1.00 £533 £533
B = mc 8 1.49 £533 £358
C = IV-VC-D 10 1.78 £533 £299
D = IVB 
E-VD
15 2.39 £533 £223
A = IB IVC-D 5 0.06 £533 £8,883
B = niB-c 8 0.09 £533 £5,922
C = VC-D 10 0.11 £533 £4,845
D = V-VIB-C
E = V-VIC-D
15 0.15 £533 £3,553
A-IB ni-IVD 5 0.13 £533 £4,100
B = IIIB-C 8 0.19 £533 £2,805
C = VC-D 10 0.22 £533 £2,423
D = V-VIB-C
E = V-VIC-D
15 0.30 £533 £1,777
A-IB IVD 5 0.22 £533 £2,423
B = IIIB-C 8 0.32 £533 £1,666
C = VC-D 10 0.39 £533 • £1,367
D = V-VIB-C
E = V-VIC-D
15 0.52 £533 £1,025
A-IB IV-VC-D 5 0.30 £533 £1,777
B = HIB-C 8 0.45 £533 £1,184
C = VC-D 10 0.54 £533 £987
D - V-VIB-C
E - V-VIC-D
15 0.73 £533 £730
A-IB VC-D 5 0.52 £533 £1,025
B = HIB-C 8 0.78 £533 £683
C = VC-D 10 0.93 £533 £573
D = V-VIB-C
E = V-VIC-D
15 1.25 £533 £426
A-IB VD 5 0.95 £533 £561
B-IKB-C 8 1.42 £533 £375
C = VC-D 10 1.70 £533 £314
D = V-VIB-C
E = V-VIC-D
15 2.28 £533 £234
A-IB HI-IVD 5 0.04 £533 £13,325
B-HB 8 0.06 £533 £8,883
C = VD 10 0.07 £533 £7,614
D-IVB
E = V-VIC-D
15 0.09 £533 £5,922
A-IB IVD 5 0.13 £533 £4,100
B-HB 8 0.19 £533 £2,805
C = VD 10 0.23 £533 £2,317
D-IVB
E = V-VIC-D
15 0.31 £533 £1,719
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A = IB
B = HB
C = VD
D = IVB
E = V-VIC-D
IV-VC-D 5
8
10
15
0.22
0.32
0.39
0.52
£533
£533
£533
£533
£2,423
£1,666
£1,367
£1,025
A = IB VC-D 5 0.43 £533 £1,240
B = HB 8 0.65 £533 £820
C = VD 10 0.77 £533 £692
D = IVB
E = V-VIC-D
15 1.04 £533 £513
A = IB IV-VD 5 0.50 £533 £1,066
B = IIB 8 0.74 £533 £720
C = VD 10 0.89 £533 £599
D = IVB
E = V-VIC-D
15 1.19 £533 £448
A = IB VD 5 0.87 £533 £613
B = HB 8 1.29 £533 £413
C = VD 10 1.54 £533 £346
D = IVB
E = V-VIC-D
15 2.08 £533 £256
A = IB HI-VC-D 5 0.04 £533 £13,325
b = hic 8 0.06 £533 £8,883
C = VD 10 0.08 £533 £6,663
D = VIC
E = VID
15 0.10 £533 £5,330
A = IB IV-VC-D 5 0.16 £533 £3,331
B = mc 8 0.24 £533 £2,221
C = VD 10 0.29 £533 £1,838
D = VIC
E = VID
15 0.38 £533 £1,403
A = IB III-VD 5 0.27 £533 £1,974
B = mc 8 0.41 £533 £1,300
C = VD 10 0.48 £533 £1,110
D = VIC
E = VID
15 0.65 £533 £820
A = IB IV-VD 5 0.45 £533 £1,184
B = mc 8 0.68 £533 £784
C = VD 10 0.81 £533 £658
D = VIC
E = VID
15 1.09 £533 £489
A = IB VD 5 0.82 £533 £650
B = mc 8 1.23 £533 £433
C = VD 10 1.47 £533 £363
D = VIC
E = VID
15 1.97 £533 £271
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SENSITIVITY ANALYSIS OF GUPEVS USE OF ELBOW IOINT REPLACEMENT
SURGERY. DAT A
SQNI AND CAVENDISH (1984)
Conversion 
of Function 
Categories 
into Rosser 
Disability 
Categories - 
Pre operative
Conversion 
of Function 
Categories 
into Rosser 
Disability 
Categories - 
Postoperative
Duration 
of Joint 
(Years)
QALYs 
Gained per 
Patient- 
Discounted 
at 5%
Total Costs Cost per 
QALY
A = I A = I 5 0.26 £533 £2,050
B = n 
c-D = m
B = n 
c = m
D = IV
8 0.39 £533 £1,367
A = I A = I 5 0.30 £533 £1,777
B = n
C-D = III-IV
B = n 
c = m
D = IV
8 0.45 £533 £1,184
A = i-n A = I 5 0.35 £533 £1,523
B = m 
c-d = iv
B = n 
c = m
D = rv
8 0.52 £533 £1,025
A = I A = I 5 0.48 £533 £1,110
B = n
c-d = m-v
B = n 
c = m
D = IV
8 0.71 £533 £751
a = i-u A = I 5 0.82 £533 £650
b = in-rv
C-D = V
B = n 
c = m
D = IV
8 1.23 £533 £433
A = I A = I 5 1.08 £533 £494
B = n
c-d = ni-vi
B = n 
c=m 
d = iv
8 1.62 £533 £329
A = i-n A = I 5 1.34 £533 £398
B = m
C-D = IV-VI
B = n 
c = m
D = IV
8 2.00 £533 £267
a = i-n A = I 5 1.82 £533 £293
B = ffl-IV
C-D = V-VI
B = n 
c = m
D = IV
8 2.71 £533 £197
A = I A = I 5 0.22 £533 £2,423
B = n 
c-d = in
B = n 
c = m
D = IV-V
8 0.32 £533 £1,666
- *
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A = I
B = II
c-D=m-iv
A = I
B = n 
c = m
D = IV-V
5
8
0.26
0.39
£533
£533
£2,050
£1,367
A = i-n A = I 5 0.30 £533 £1,777
B = III
C-D = IV
B = n 
c = m
D = IV-V
8 0.45 £533 £1,184
A = I A = I 5 0.43 £533 £1,240
B = n
c-d = m-v
B = n 
c = m
D = IV-V
8 0.65 £533 £820
A = I-II A = l 5 0.78 £533 £683
b = m-rv
C-D = V
B = n 
c = m
D = IV-V
8 1.16 £533 £459
A = I A = I 5 1.04 £533 £513
B = n
c-d = in-vi
B = n 
c = m
D = IV-V
8 1.55 £533 •£344
A = i-n A = I 5 1.30 £533 £410
B = m
C-D = IV-VI
B = n 
c = m
D = IV-V
8 1.94 £533 £275
A = i-n A = I 5 1.78 £533 £299
b = m-iv
C-D = V-VI
B = n 
c = m
D = IV-V
8 2.65 £533 £201
A = l A = I 5 0.22 £533 £2,423
B = n 
c-d = in
B = n 
c = m
D = IV-VI
8 0.32 £533 £1,666
A = I A = I 5 0.26 £533 £2,050
B = n
c-d = m-iv
B = n 
c = m
D = IV-VI
8 0.39 £533 £1,367
A = i-n A = I 5 0.30 £533 £1,777
B = m
C-D = IV
B = II 
c=m
D = IV-VI
8 0.45 £533 £1,184
A = I A = I 5 0.43 £533 £1,240
B = n
c-d = m-v
B = n 
c = m
D = IV-VI
8 0.65 £533 £820
a = i-u A = I 5 0.78 £533 £683
b = m-iv
C-D = V
B = n 
c = m
D = rv-vi
8 1.16 £533 £459
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A = I 
b = h
c-d = in-vi
A = I
B = n 
c = m
D = IV-VI
5
8
1.04
1.55
£533
£533
£513
£344
A = i-n A = I 5 1.30 £533 £410
B = m
C-D = IV-VI
B = n 
c = m
D = IV-VI
8 1.94 £533 £275
A = i-n A = I 5 1.78 £533 £299
b = m-iv
C-D = V-VI
B = n 
c = m
D = rv-VI
8 2.65 £533 £201
A = I A = I 5 0.22 £533 £2,423
B = n 
c-d = in
B = n-in 
c = iv
D = V
8 0.32 £533 £1,666
A = I A = I 5 0.26 £533 £2,050
B = n
c-d = in-rv
b = n-ni
C = IV
D = V
8 0.39 £533 £1,367
A = i-n A = I 5 0.30 £533 £1,777
B = m
C-D = IV
b = n-ni 
c = rv
D = V
8 0.45 £533 £1,184
A = I A = I 5 0.43 £533 £1,240
B = n
c-d = in-v
b = n-m
C = IV
D = V
8 0.65 £533 £820
A = i-n A = I 5 0.78 £533 £683
b = m-iv
C-D = V
b = n-m 
c = rv
D = V
8 1.16 £533 £459
A = I A = I 5 1.04 £533 £513
B = n
c-d = in-vi
B = n-m 
C-IV
D = V
8 1.55 £533 £344
A = i-n A = I 5 1.30 £533 £410
B = m
C-D = IV-VI
B = n-m
C = IV
D = V
8 1.94 £533 £275
A = i-n A = I 5 1.78 £533 £299
b = m-iv
C-D = V-VI
B = n-in
C = IV
D = V
8 2.65 £533 £201
A = I A = I 5 0.22 £533 £2,423
B = n 
c-D = m
B = n 
c = m-iv
D = V
8 0.32 £533 £1,666
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A = I 
b = h
c-d = in-iv
A = I 
b = h 
c = m-iv
D = V
5
8
0.26
0.39
£533
£533
£2,050
£1,367
A = i-n A = I 5 0.30 £533 £1,777
B = m
C-D = IV
B = n
C = III-IV
D = V
8 0.45 £533 £1,184
A = I A = I 5 0.43 £533 £1,240
B = n
c-d = m-v
B = n 
c = m-iv
D = V
8 0.65 £533 £820
A = i-n A = I 5 0.78 £533 £683
B = m-iv
C-D = V
B = n 
c = m-iv
D = V
8 1.16 £533 £459
A = I A = I 5 1.04 £533 £513
B = n
c-d = m-vi
B = n 
c = m-iv
D = V
8 1.55 £533 •£344
A = I-II A = I 5 1.30 £533 £410
B = m
C-D = IV-VI
B = n 
c = m-iv
D = V
8 1.94 £533 £275
A = i-n A = I 5 1.78 £533 £299
b = m-iv
C-D = V-VI
B = n 
c = m-iv
D = V
8 2.65 £533 £201
A = I A = I 5 0.17 £533 £3,135
B = n 
c-d = in
b = n-m 
c = rv
D = V-VI
8 0.26 £533 £2,050
A = I A = I 5 0.22 £533 £2,423
B = n
c-d = m-rv
B = n-m 
c = rv
D = V-VI
8 0.32 £533 £1,666
A = i-n A = I 5 0.26 £533 £2,050
b = hi
C-D = IV
B = n-m 
c = rv
D = V-VI
8 0.39 £533 £1,367
A = I A = I 5 0.39 £533 £1,367
B = n
c-d = m-v
b = n-ni
C = IV
D = V-VI
8 0.58 £533 £919
A = i-n A = I 5 0.74 £533 £720
b = in-iv
C-D = V
B = n-m
C = IV
D = V-VI
8 1.10 £533 £485
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A = I
B = n
C-D = III-VI
A = I 
b = n-m
C = IV
D = V-VI
5
8
1.00
1.49
£533
£533
£533
£358
A = I-II A = I 5 1.26 £533 £423
B = m
C-D = IV-VI
B = n-in
C = IV
D = V-VI
8 1.87 £533 £285
a = i-u A = I 5 1.73 £533 £308
b = m-iv
C-D = V-VI
b = n-ni 
c = rv
D = V-VI
8 2.59 £533 £206
A = I A = I 5 0.17 £533 £3,135
B = n 
c-D = m
B = n 
c = m-iv
D = V-VI
8 0.26 £533 £2,050
A = I A = I 5 0.22 £533 £2,423
B = n
c-d = m-iv
B = n 
c = m-iv
D = V-VI
8 0.32 £533 £1,666
A = I-II A = I 5 0.26 £533 £2,050
B = m
C-D = IV
B = n 
c = m-iv
D = V-VI
8 0.39 £533 £1,367
A = I A = I 5 0.39 £533 £1,367
b = h
c-d = m-v
B = n 
c = m-iv
D = V-VI
8 0.58 £533 £919
A = i-n A = I 5 0.74 £533 £720
b = m-iv
C-D = V
B = n 
c = m-iv
D = V-VI
8 1.10 £533 £485
A = I A = I 5 1.00 £533 £533
B = n
c-d = ni-vi
B = n 
c = m-rv
D = V-VI
8 1.49 £533 £358
a = i-n A = I 5 1.26 £533 £423
B = m
C-D = IV-VI
B = n 
c = m-iv
D = V-VI
8 1.87 £533 £285
a = i-ii A = I 5 1.73 £533 £308
b = m-iv
C-D = V-VI
B = n 
c = m-rv
D = V-VI
8 2.59 £533 £206
A = I A = I 5 0.13 £533 £4,100
B = n
C-D = in
B = n 
c = m-v
D = VI
8 0.19 £533 £2,805
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A = I
B = n
c-D=m-iv
A = I
B = n 
c = m-v
D = VI
5
8
0.17
0.26
£533
£533
£3,135
£2,050
A = i-n A = I 5 0.22 £533 £2,423
B = m
C-D = IV
B = n 
c = m-v
D = VI
8 0.32 £533 £1,666
A = I A = I 5 0.35 £533 £1,523
B = II
c-d = m-v
B = n 
c = m-v
D = VI
8 0.52 £533 £1,025
A = i-n A = I 5 0.69 £533 £772
b = m-iv
C-D = V
B = n 
c = m-v
D = VI
8 1.03 £533 £517
A = I A = I 5 0.95 £533 £561
B = n
C-D = III-VI
B = n 
c = m-v
D = VI
8 1.42 £533 • £375
a = i-n A = I 5 1.21 £533 £440
B = m
C-D = IV-VI
B = n 
c = m-v
D = VI
8 1.81 £533 £294
A = i-n A = I 5 1.69 £533 £315
b = m-rv
C-D = V-VI
B = n 
c = m-v
D = VI
8 2.52 £533 £212
A = I a = i-u 5 0.13 £533 £4,100
B = n 
c-d = in
B = m 
c = rv
D = V-VI
8 0.19 £533 £2,805
A = I a = i-u 5 0.17 £533 £3,135
B = n
C-D = III-IV
B = m
C = IV
D = V-VI
8 0.26 £533 £2,050
a = i-u A = i-n 5 0.22 £533 £2,423
B = m
C-D = IV
B = m
C = IV
D = V-VI
8 0.32 £533 £1,666
A = I A = I-II 5 0.35 £533 £1,523
B = n
c-d = m-v
B = m
C = IV
D = V-VI
8 0.52 £533 £1,025
a = i-u A = I-II 5 0.69 £533 £772
b = m-iv
C-D = V
B = m 
c = rv
D = V-VI
8 1.03 £533 £517
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A = I
B = II
c-d = in-vi
A = i-n
B = m
C = IV
D = V-VI
5
8
0.95
1.42
£533
£533
£561
£375
A = I-II A = I-II 5 1.21 £533 £440
B = IH
C-D = IV-VI
B = m
C = IV
D = V-VI
8 1.81 £533 £294
A = I-II A = i-n 5 1.69 £533 £315
B = in-iv
C-D = V-VI
B = m
C = IV
D = V-VI
8 2.52 £533 £212
A = I A = I 5 0.09 £533 £5,922
B = n 
c-d = in
B = n-m 
c = rv-v
D = VI
8 0.13 £533 £4,100
A = I A = I 5 0.13 £533 £4,100
B = n
C-D = III-IV
B = n-m 
c = IV-V
D = VI
8 0.19 £533 £2,805
A = I-II A = I 5 0.17 £533 £3,135
B = m
C-D = IV
B = n-in
C = IV-V
D = VI
8 0.26 £533 £2,050
A = I A = I 5 0.30 £533 £1,777
B = n
c-d = m-v
b = n-ni
C = IV-V
D = VI
8 0.45 £533 £1,184
A = i-n A = I 5 0.65 £533 £820
b = m-iv
C-D = V
B = n-m
C = IV-V
D = VI
8 0.97 £533 £549
A = I A = I 5 0.91 £533 £586
B = n
c-d = in-vi
..........
O
U
Q
8 1.36 £533 £392
a = i-n A = I 5 1.17 £533 £456
B = m
C-D = rv-vi
B = n-m
C = IV-V
D = VI
8 1.75 £533 £305
A = i-n A = I 5 1.65 £533 £323
b = m-rv
C-D = V-VI
B = n-m
C = IV-V
D = VI
8 2.46 £533 £217
A = I A = I 5 0.09 £533 £5,922
B = n 
c-d = in
B = n-iv
C = V
D = VI
8 0.13 £533 £4,100
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A = I
B = n
c-D = in-iv
A = I 
b = n-rv 
c = V
D = VI
5
8
0.13
0.19
£533
£533
£4,100
£2,805
A = I-II A = I 5 0.17 £533 £3,135
B = ni
C-D = IV
B = n-rv 
c = V
D = VI
8 0.26 £533 £2,050
A = I A = I 5 0.30 £533 £1,777
B = II
c-d = m-v
b = h-iv 
c = V
D = VI
8 0.45 £533 £1,184
A = i-n A = I 5 0.65 £533 £820
b = m-rv 
C-D=V
B = n-rv 
c = V
D = VI
8 0.97 £533 £549
A = I A = l 5 0.91 £533 £586
B = II
C-D = III-VI
B = n-rv
C = V
D = VI
8 1.36 £533 ‘ £392
A = I-II A = I 5 1.17 £533 £456
B = m
C-D = IV-VI
B = n-iv
C = V
D = VI
8 1.75 £533 £305
A = i-n A = I 5 1.65 £533 £323
b = m-iv
C-D = V-VI
b = n-iv
C = V
D = VI
8 2.46 £533 £217
A = I A = i-n 5 0.09 £533 £5,922
B = n 
c-d = in
B = m-iv
C = V
D = VI
8 0.13 £533 £4,100
A = I A = i-n 5 0.13 £533 £4,100
B = n
c-D=m-iv
B = m-iv
C = V
D = VI
8 0.19 £533 £2,805
A = i-n A = i-n 5 0.17 £533 £3,135
b = ui
C-D = IV
b = in-iv 
c = V
D = VI
8 0.26 £533 £2,050
A = I a = i-h 5 0.30 £533 £1,777
B = n
c-d = in-v
b = m-iv 
c = V
D = VI
8 0.45 £533 £1,184
a = i-u A = I-II 5 0.65 £533 £820
b = m-iv
C-D = V
b = m-iv
C = V
D = VI
8 0.97 £533 £549
APPENDIX 26 153
A = I
B = n
c-d = in-vi
A = I-II 
b = m-iv
C = V
D = VI
5
8
0.91
1.36
£533
£533
£586
£392
A = I-II A = i-n 5 1.17 £533 £456
B = m
C-D = IV-VI
b = m-iv
C = V
D = VI
8 1.75 £533 £305
A = I-II A = i-n 5 1.65 £533 £323
b = hi-iv
C-D = V-VI
b = m-rv 
c = V
D = VI
8 2.46 £533 £217
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OF CYSTIC FIBROSIS DATA
B.QYLE ET AL Q976)
SENSITIVITY ANALYSIS OFGUDEVS USE OF CEFTAZIDIME TREATMENT
Conversion 
of Clinical 
Score into 
Rosser 
Disability 
Categories
Conversion 
of Daily 
Coping
Skills into
Rosser
Distress
Categories -
Established
Treatment
Conversion 
of Daily 
Coping
Skills into
Rosser
Distress
Categories -
Ceftazidime
Treatment
Average
Life
Expectancy
From
Birth
QALY’s
Gained
Over
Established
Treatment
Total
Costs 
(Discoun­
ted at 5%)
Cost per 
QALY
76-100=1 Good=A/B Good=A 22 0.26 £3,291 £12,658
65 -75=11 Fair=C Fair=B 23 0.58 £3,372 £5,814
45-64=III-IV
35-44=V-VI
0-34=VU
Poor=D Poor=C 24
25
0.88
1.17
£3,450
£3,523
£3,876
£2,986
76-100=1 Good=B Good=A 22 0.26 £3,291 £12,658
65 -75=11 Fair=C Fair=B 23 0.58 £3,372 £5,814
45-64=HI-IV
35-44=V-VI
o-34=vn
Poor=D Poor=C 24
25
0.88
1.17
£3,450
£3,523
£3,876
£2,986
81-100=1 Good=A/B Good=A 22 0.26 £3,291 £12,658
70-80=11 Fair=C Fair=B 23 0.58 £3,372 £5,814
50-69=m-IV
40-49=V-VI
0-39=VH
Poor=D Poor=C 24
25
0.87
1.16
£3,450
£3,523
£3,966
£3,037
81-100=1 Good=B Good=A 22 0.26 £3,291 £12,658
70-80=11 Fair=C Fair=B 23 0.58 £3,372 £5,814
50-69=m-IV
40-49=V-VI
0-39=VH
Poor=D Poor=C 24
25
0.87
1.16
£3,450
£3,523
£3,966
£3,037
81-100=1 Good=A/B Good=A 22 0.26 £3,291 £12,658
65-80=11 Fair=C Fair=B 23 0.58 £3,372 £5,814
50-64=IH-IV
40-49=V-VI
0-39=VU
Poor=D Poor=C 24
25
0.87
1.16
£3,450
£3,523
£3,966
£3,037
81-100=1 Good=B Good=A 22 0.26 £3,291 £12,658
65-80=11 Fair=C Fair=B 23 0.58 £3,372 £5,814
50-64=HI-IV
40-49=V-VI
0-39=VH
Poor=D Poor=C 24
25
0.87
1.16
£3,450
£3,523
£3,966
£3,037
86-100=1 Good=A/B Good=A 22 1.18 £3,291 £2,789
75-85=11 Fair=C Fair=B 23 1.48 £3,372 £2,278
65-74=IH-IV
50-64=V-VI
o-49=vn
Poor=D Poor=C 24
25
1.76
2.02
£3,450
£3,523
£1,960
£1,744
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86-100=1 Good=B Good=A 22 1.18 £3,291 £2,789
75-85=11 Fair=C Fair=B 23 1.48 £3,372 £2,278
65-74=IH-IV Poor=D Poor=C 24 1,76 £3,450 £1,960
50-64=V-VI
0-49=VH
25 2.02 £3,523 £1,744
86-100=1 Good=A/B Good=A 22 0.26 £3,291 £12,658
65-85=33 Fair=C Fair=B 23 0.58 £3,372 £5,814
50-64=m-IV Poor=D Poor=C 24 0.88 £3,450 £3,920
35-49=V-VI 
0-34=VII
25 1.17 £3,523 £3,011
86-100=1 Good=B Good=A 22 0.26 £3,291 £12,658
65-85=11 Fair=C Fair=B 23 0.58 £3,372 £5,814
50-64=m-IV Poor=D Poor=C 24 0.88 £3,450 £3,920
35-49=V-VI 
0-34=vn
25 1.17 £3,523 £3,011
91-100=1 Good=A/B Good=A 22 0.79 £3,291 £4,166
75-90=11 Fair=C Fair=B 23 1.09 £3,372 £3,094
60-74=m-IV Poor=D Poor=C 24 1.38 £3,450 £2,500
45-59=V-VI
0-44=VII
25 1.66 £3,523 £2,122
91-100=1 Good=B Good=A 22 0.92 £3,291 £3,577
75-90=31 Fair=C Fair=B 23 1.22 £3,372 £2,764
60-74=m-IV Poor=D Poor=C 24 1.51 £3,450 £2,285
45-59=V-VI
0-44=VH
25 1.79 £3,523 £1,968
96-100=1 Good=A/B Good=A 22 1.32 £3,291 £2,493
85-95=11 Fair=C Fair=B 23 1.61 £3,372 £2,094
70-84=HI-IV Poor=D Poor=C 24 1.88 £3,450 £1,835
50-69=V-VI
0-49=VH
25 2.14 £3,523 £1,646
96-100=1 Good=B Good=A 22 1.45 £3,291 £2,270
85-95=11 Fair=C Fair=B 23 1.74 £3,372 £1,938
70-84=HI-IV Poor=D Poor=C 24 2.01 £3,450 £1,716
50-69=V-VI
0-49=VH
25 2.28 £3,523 £1,545
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IDIOPATHIC ADOLESCENTS DATA
VAN GROUW ET AL (1976)
SENSITIVITY ANALYSIS OF GUDEX’S USE OF SCOLIOSIS SURGERY FOR
Conversion 
of Activity 
Categories 
into Rosser 
Disability 
Categories
Conversion 
of Pain 
Categories 
into Rosser 
Distress 
Categories
Life
Expectancy
of
Untreated
Patients
(Years)
QALY’s 
Gained per 
Patient 
(Discounted 
at 5%)
Total Costs 
(Discounted 
at 5%)
Cost per 
QALY
i = vi-vn 1 = A 40 4.28 £3,143 £734
n = v 2 = B 50 2.30 £3,143 £1,367
m = iv 3 = B 60 1.09 £3,143 £2,883
rv = n 4 = C
5- C
6- D
70 0.34 £3,143 £9,244
1 = VI 1 = A 40 4.32 £3,143 • £728
n = iv 2-B 50 2.33 £3,143 £1,349
m = m 3-C 60 1.10 £3,143 £2,857
rv = n 4- C
5- D
6- D
70 0.35 £3,143 £8,980
I = V-VI 1 =A 40 4.37 £3,143 £719
n = rv 2-B 50 2.35 £3,143 £1,337
m = in 3-C 60 1.11 £3,143 £2,832
rv = n 4- C
5- D
6- D
70 0.35 £3,143 £8,980
1 = V 1 = A 40 4.42 £3,143 £711
n = rv 2-B 50 2.38 £3,143 £1,321
m = rv 3-C 60 1.12 £3,143 £2,806
rv = i-n 4- C
5- D
6- D
70 0.35 £3,143 £8,980
1 = VI 1 = A 40 4.42 £3,143 £711
n = iv 2-B 50 2.38 £3,143 £1,321
m=m 3-B 60 1.12 £3,143 £2,806
iv = n 4- C
5- C
6- D
70 0.35 £3,143 £8,980
1 = V 1 = A 40 4.46 £3,143 £705
n = m 2-B 50 2.40 £3,143 £1,310
m = m 3-C 60 1.14 £3,143 £2,757
iv = i-n 4- C
5- D
6- D
70 0.36 £3,143 £8,731
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1 = V 
n = rv 
m = m 
iv = i-n
1 = A
2 = B
3 = C
4 = C
5 = D
6 = D
40
50
60
70
4.46
2.40
1.14
0.36
£3,143
£3,143
£3,143
£3,143
£705
£1,310
£2,757
£8,731
I = V-VI 1 = A 40 4.46 £3,143 £705
n = rv 2 = B 50 2.40 £3,143 £1,310
m = m 3 = B 60 1.14 £3,143 £2,757
rv = n 4 = C
5 = C
6 = D
70 0.36 £3,143 £8,731
I = IV 1 = A 40 4.51 £3,143 £697
n = ni 2 = B 50 2.43 £3,143 £1,293
m«in 3 = C 60 1.15 £3,143 £2,733
V = I-II 4 = C
5 = D
6 = D
70 0.36 £3,143 £8,731
1 = V 1 = A 40 4.51 £3,143 £697
n = rv 2 = B 50 2.43 £3,143 £1,293
m = m 3 = B 60 1.15 £3,143 £2,733
V = I-II 4 = C
5 = C
6 = D
70 0.36 £3,143 £8,731
1 = V 1 = A 40 4.51 £3,143 £697
n = rv 2 = B 50 2.43 £3,143 £1,293
m = iv 3 = B 60 1.15 £3,143 £2,733
rv = i-n 4 = C
5 = C
6 = D
70 0.36 £3,143 £8,731
i = ni 1 = A 40 4.56 £3,143 £689
n = m 2 = B 50 2.45 £3,143 £1,283
m = n 3 = C 60 1.16 £3,143 £2,709
IV = 1 4 = C
5 = D
6 = D
70 0.37 £3,143 £8,495
I = IV I = A 40 4.56 £3,143 £689
n = m 2 = B 50 2.45 £3,143 £1,283
m = n 3 = C 60 1.16 £3,143 £2,709
rv = i 4 = C
5 = D
6=D
70 0.37 £3,143 £8,495
I = IV 1 =A 40 4.56 £3,143 £689
n = iv 2 = B 50 2.45 £3,143 £1,283
m = n 3 = C 60 1.16 £3,143 £2,709
rv = i 4 = C
5 = D
6 = D
70 0.37 £3,143 £8,495
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I = IV 
n = m 
m = m 
iv = i-n
1 = A
2 = B
3 = B
4 = C
5 = C
6 = D
40
50
60
70
4.56
2.45
1.16
0.37
£3,143
£3,143
£3,143
£3,143
£689
£1,283
£2,709
£8,495
1 = V 1 = A 40 4.56 £3,143 £689
n = m 2 = B 50 2.45 £3,143 £1,283
m = in 3 = B 60 1.16 £3,143 £2,709
iv = i-n 4 = C
5 = C
6 = D
70 0.37 £3,143 £8,495
i = ni 1 = A 40 4.61 £3,143 £682
n = m 2 = B 50 2.48 £3,143 £1,267
m = n 3 = B 60 1.17 £3,143 £2,686
IV = I 4 = C
5 = C
6 = D
70 0.37 £3,143 £8,495
I = IV 1 = A 40 4.61 £3,143 £682
n = m 2 = B 50 2.48 £3,143 £1,267
m = n 3 = B 60 1.17 £3,143 £2,686
IV = I 4 = C
5 = C
6 = D
70 0.37 £3,143 £8,495
I = IV 1 = A 40 4.61 £3,143 £682
n = iv 2 = B 50 2.48 £3,143 £1,267
m = n 3 = B 60 1.17 £3,143 £2,686
IV = I 4 = C
5 = C
6 = D
70 0.37 £3,143 £8,495
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NEUROMUSCULAR ILLNESS DATA
SENSITIVITY ANALYSIS OF GUDEX’S USE QF SCOLIOSIS SECOND ARY TO
Health
State with
Operation
in terms of
Rosser
Disability/
Distress
Categories
Health
State
without
Operation
in terms of
Rosser
Disability/
Distress
Categories
Life
Expectancy
With
Operation
QALY’s
Gained
Per Patient 
(Discounted 
at 5%)
Total Costs 
(Discounted 
at 5%)
Cost per 
QALY
VC VIC 30 2.38 £3,143 £1,321
40 5.57 £3,143 £564
VC VIC-D 30 6.07 £3,143 £518
40 9.25 £3,143 £340
VC VID 30 9.75 £3,143 £322
40 12.94 £3,143 £243
VC VI-VIIC 30 6.07 £3,143 £518
40 9.25 £3,143 £340
VC VI-VIIC-D 30 11.94 £3,143 £263
40 15.12 £3,143 £208
VC VI-VIID 30 17.81 £3,143 £176
40 20.99 £3,143 £150
VC VIIC 30 9.75 £3,143 £322
40 12.94 £3,143 £243
VC VIIC-D 30 17.81 £3,143 £176
40 20.99 £3,143 £150
VC VIID 30 25.86 £3,143 £122
40 29.04 £3,143 £108
VC-D VIC 30 1.30 £3,143 £2,418
40 4.13 £3,143 £761
VC-D VIC-D 30 4.99 £3,143 £630
40 7.82 £3,143 £402
VC-D VID 30 8.67 £3,143 £363
40 11.50 £3,143 £273
VC-D VI-VIIC 30 4.99 £3,143 £630
40 7.82 £3,143 £402
VC-D vi-vnc-D 30 10.85 £3,143 £290
40 13.68 £3,143 £230
VC-D VI-VIID 30 16.72 £3,143 £188
40 19.55 £3,143 £161
VC-D VIIC 30 8.67 £3,143 £363
40 11.50 £3,143 £273
VC-D VIIC-D 30 16.72 £3,143 £188
40 19.55 £3,143 £161
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VC-D VIID 30
40
24.78
27.61
£3,143
£3,143
£127
£114
VD VIC 30 0.22 £3,143 £14,286
40 2.69 £3,143 £1,168
VD VIC-D 30 3.90 £3,143 £806
40 6.38 £3,143 £493
VD VID 30 7.59 £3,143 £414
40 10.06 £3,143 £312
VD VI-VIIC 30 3.90 £3,143 £806
40 6.38 £3,143 £493
VD vi-vhc-d 30 9.77 £3,143 £322
40 12.25 £3,143 £257
VD VI-VIID 30 15.64 £3,143 £201
40 18.12 £3,143 £173
VD VIIC 30 7.59 £3,143 £414
40 10.06 £3,143 £312
VD VIIC-D 30 15.64 £3,143 £201
40 18.12 £3,143 £173
VD VIID 30 23.69 £3,143 £133
40 26.17 £3,143 £120
V-VIC VIC 30 1.19 £3,143 £2,641
40 3.99 £3,143 £788
V-VIC VIC-D 30 4.88 £3,143 £644
40 7.67 £3,143 £410
V-VIC VID 30 8.56 £3,143 £367
40 11.36 £3,143 £277
V-VIC VI-VIIC 30 4.88 £3,143 £644
40 7.67 £3,143 £410
V-VIC vi-vhc-d 30 10.75 £3,143 £292
40 13.54 £3,143 £232
V-VIC VI-VIID 30 16.61 £3,143 £189
40 19.41 £3,143 £162
V-VIC VIIC 30 8.56 £3,143 £367
40 11.36 £3,143 £277
V-VIC VIIC-D 30 16.61 £3,143 £189
40 19.41 £3,143 £162
V-VIC VIID 30 24.67 £3,143 £127
40 27.46 £3,143 £114
V-VIC-D VIC 30 £3,143
40 0.82 £3,143 £3,814
V-VIC-D VIC-D 30 2.49 £3,143 £1,262
40 4.51 £3,143 £697
V-VIC-D VID 30 6.18 £3,143 £509
40 8.19 £3,143 £384
V-VIC-D VI-VIIC 30 2.49 £3,143 £1,262
40 4.51 £3,143 £697
V-VIC-D VI-VHC-D 30 8.36 £3,143 £376
40 10.38 £3,143 £303
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V-VIC-D VI-VIID 30
40
14.23
16.25
£3,143
£3,143
£221
£193
V-VIC-D VIIC 30 6.18 £3,143 £509
40 8.19 £3,143 £384
V-VIC-D VIIC-D 30 14.23 £3,143 £221
40 16.25 £3,143 £193
V-VIC-D VIID 30 22.28 £3,143 £141
40 24.30 £3,143 £129
V-VID VIC-D 30 0.11 £3,143 £28,573
40 1.35 £3,143 £2,328
V-VID VID 30 3.79 £3,143 £829
40 5.03 £3,143 £625
V-VID VI-VIIC 30 0.11 £3,143 £28,573
40 1.35 £3,143 £2,328
V-VID vi-vuc-d 30 5.98 £3,143 £526
40 7.22 £3,143 £435
V-VID VI-VIID 30 11.85 £3,143 £265
40 13.08 £3,143 £240
V-VID VIIC 30 3.79 £3,143 £829
40 5.03 £3,143 £625
V-VID VIIC-D 30 11.85 £3,143 £265
40 13.08 £3,143 £240
V-VID VIID 30 19.90 £3,143 £158
40 21.14 £3,143 £149
VIC VIC-D 30 3.68 £3,143 £854
40 6.09 £3,143 £516
VIC VID 30 7.37 £3,143 £426
40 9.78 £3,143 £321
VIC VI-VIIC 30 3.68 £3,143 £854
40 6.09 £3,143 £516
VIC VI-VIIC-D 30 9.55 £3,143 £329
40 11.96 £3,143 £263
VIC VI-VIID 30 15.42 £3,143 £204
40 17.83 £3,143 £176
VIC VIIC 30 7.37 £3,143 £426
40 9.78 £3,143 £321
VIC VIIC-D 30 15.42 £3,143 £204
40 17.83 £3,143 £176
VIC VIID 30 23.47 £3,143 £134
40 25.88 £3,143 £121
VIC-D VID 30 3.68 £3,143 £854
40 4.89 £3,143 £643
VIC-D VI-VIIC 30 £3,143
40 1.20 £3,143 £2,619
VIC-D VI-VIIC-D 30 5.87 £3,143 £535
40 7.07 £3,143 £445
VIC-D VI-VIID 30 11.74 £3,143 £268
40 12.94 £3,143 £243
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VIC-D VIIC 30
40
3.68
4.89
£3,143
£3,143
£854
£643
VIC-D viic-d 30 11.74 £3,143 £268
40 12.94 £3,143 £243
VIC-D VIID 30 19.79 £3,143 £159
40 20.99 £3,143 £150
VID VI-VHC-D 30 2.18 £3,143 £1,442
40 2.18 £3,143 £1,442
VID VI-VIID 30 8.05 £3,143 £390
40 8.05 £3,143 £390
VID VIIC-D 30 8.05 £3,143 £390
40 8.05 £3,143 £390
VID VIID 30 16.10 £3,143 £195
40 16.10 £3,143 £195
VI-VIIC VI-VHC-D 30 5.87 £3,143 £535
40 7.07 £3,143 £445
VI-VIIC VI-VIID 30 11.74 £3,143 £268 .
40 12.94 £3,143 £243
VI-VIIC VIIC 30 3.68 £3,143 £854
40 4.89 £3,143 £643
VI-VIIC VIIC-D 30 11.74 £3,143 £268
40 12.94 £3,143 £243
VI-VIIC VIID 30 19.79 £3,143 £159
40 20.99 £3,143 £150
VI-VIIC-D VI-VIID 30 5.87 £3,143 £535
40 5.16 £3,143 £609
VI-VIIC-D VIIC-D 30 5.87 £3,143 £535
40 5.16 £3,143 £609
VI-VIIC-D VIID 30 13.92 £3,143 £226
40 13.21 £3,143 £238
VI-VIID VIID 30 8.05 £3,143 £390
40 5.42 £3,143 £579
